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Zusammenfassung 
Beschreibung der Technologie und der Komparatoren 
Die Roboterassistierte Chirurgie ist eine Form der minimal-invasiven Chirur-
gie, bei der die Instrumente nicht unmittelbar durch die ChirurgInnen, son-
dern durch einen Telemanipulator gesteuert werden. Durch den Telemanipu-
lator werden die Hand- und Fingerbewegungen an einen ferngesteuerten Ro-
boter übermittelt; damit können die Objekte manipuliert werden. Der Robo-
ter besitzt ein höheres Maß an Geschicklichkeit in der Manipulation im Ver-
gleich zur Laparoskopie, wodurch eine Operation auf sehr engem Raum im 
Körper ermöglicht wird (dies wäre sonst nur durch offene Chirurgie möglich), 
mit dem Ziel, die klinischen Ergebnisse und den Ressourcenverbrauch zu ver-
bessern. 
Bislang wurden 22 Robotersysteme entwickelt, von denen sich 13 allerdings 
noch in der Entwicklungsphase befinden, sieben sind derzeit kommerziell er-
hältlich (da Vinci SI®, da Vinci SP®, da Vinci XI®, da Vinci X®, Freehand v1.2, 
Surgenius Beta und SenhanceTM Surgical System), eins ist nur für For-
schungszwecke verfügbar und eins ist nur für den transoralen und transana-
len Einsatz. Ziel der derzeit verfügbaren Robotersysteme ist es, Technologien 
zur Unterstützung der ChirurgInnen bereitzustellen und somit eine weitere 
minimal-invasive Operationstechnik zu bieten, und nicht die ChirurgInnen zu 
ersetzen. Die Roboterassistierte Chirurgie ist aber (zurzeit) deutlich kosten-
intensiver als herkömmliche Operationstechniken (offene oder laparoskopi-
sche Chirurgie).  
Gesundheitsproblem 
In diesem Bericht stehen Indikationen für Operationen im Bereich des Tho-
rax- und des Bauchraumes im Zentrum.  
b Zu den Indikationen im Bereich des Thorax gehören Erkrankungen 
der Lunge, der Brustwand und des Zwerchfells (häufig bösartige 
Krebserkrankungen). In dem Bericht wurden die folgenden Verfahren 
im Bereich des Thorax untersucht: Lobektomie, Lungensegmentie-
rung und Mediastinalchirurgie.  
b Zu den Indikationen im Bereich des Bauchraumes gehören die gutar-
tigen und bösartigen Erkrankungen der Bauchorgane, des gesamten 
Magen-Darm-Traktes, der endokrinen Organe, der Bauchwand und 
des Peritoneums. Die Verfahren der Viszeralchirurgie, die in den Be-
richt einbezogen wurden, sind: Antireflux-Chirurgie/ Fundoplikatio, 
Ösophagektomie/ Ösophagus-Chirurgie, Heller Myotomie, Gastrekto-
mie, Bariatrische Chirurgie, Dünndarmresektion, Kolektomie, Rekt-
umresektion, Cholezystektomie, Leberresektion/ Hepatektomie und 
Hernienchirurgie. 
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Methoden 
Für die Bewertung der Wirksamkeit und Sicherheit wurde eine systematische 
Literatursuche in mehreren Datenbanken (Cochrane CENTRAL Register of 
Controlled Trials, Embase über Elsevier und Ovid Medline), ergänzt um eine 
Hand- und Scopus-Suche, durchgeführt.  
Klinische Leitlinien wurden in der UptoDate Datenbank, durch eine Handsu-
che und durch Rücksprache mit klinischen Experten identifiziert.  
Darüber hinaus wurde eine Suche nach laufenden Studien in den folgenden 
Datenbanken durchgeführt:  
b ClincalTrials.gov  
b EU Register für klinische Studien (EU-CTR) 
b WHO International Clinical Trials Registry Platform (ICTRP).  
Das Cochrane Risk of Bias Tool wurde für die Qualitätsbewertung von rando-
misierten kontrollierten Studien (RCTs) und das Tool ROBINS-I für die Be-
wertung von nicht-randomisierten Studien verwendet.  
Zur Bewertung der Wirksamkeit und Sicherheit wurden RCTs mit zumindest 
zehn PatientInnen herangezogen. Wenn keine relevanten RCTs identifiziert 
werden konnten, wurden prospektive, nicht-randomisierte kontrollierte Stu-
dien mit mindestens zehn PatientInnen eingeschlossen. Potenziell relevante 
Studien wurden nach Studiendesign dann eingeschlossen, wenn sie auch Er-
gebnisse zu Wirksamkeit, Sicherheit oder perioperativen Ergebnissen und 
Ressourcenverbrauch berichteten. Es gab keine Einschränkung hinsichtlich 
der PatientInnenpopulationen; alle Studien mit PatientInnen mit Indikatio-
nen im Bereich des Thorax- oder des Bauchraumes wurden eingeschlossen.  
Ergebnisse 
Verfügbare Evidenz 
Die systematische Literatursuche identifizierte keine RCTs zu Indikationen im 
Bereich des Thorax. Es wurden drei nicht-randomisierte kontrollierte Studien 
zu Lobektomie/Lungensegmentierung und eine zu Mediastinalchirurgie ein-
geschlossen.  
Thorax (insgesamt 114 PatientInnen mit Roboterassistierter Intervention): 
b 3 nRCTs (215 PatientInnen, davon 100 in der Interventionsgruppe) 
verglichen Roboterassistierte Lobektomie mit VATS (Videoassisierte 
thorakoskopischer) Lobektomie, 
b 1 nRCT (36 PatientInnen, davon 14 in der Interventionsgruppe) ver-
glich Roboterassistierte mediastinale Massereduktion mit offener 
Sternotomie. 
Zu Indikationen im Bereich des Bauchraumes, insbesondere im Bereich der 
Speiseröhre, wurden fünf RCTs (sechs Publikationen) zu Antireflux-Chirur-
gie/ Fundoplikatio und Ösophagektomie identifiziert. Keine RCTs konnten zu 
Heller Myotomie gefunden werden, daher wurden zwei nicht-randomisierte 
kontrollierte Studien eingeschlossen.  
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Ösophagus (insgesamt 170 PatientInnen mit Roboterassistierter Intervention): 
b 4 RCTs (160 PatientInnen, davon 79 in der Interventionsgruppe) ver-
glichen Roboterassistierte (laparoskopische) Fundoplikatio mit lapa-
roskopischer Fundoplikatio, 
b 1 RCT (109 PatientInnen, davon 54 in der Interventionsgruppe) ver-
glich Roboterassistierte (laparoskopische) Ösophagektomie mit of-
fener Ösophagektomie, 
b 2 prospektive nRCT (92 PatientInnen, davon 37 in der Interven-
tionsgruppe) verglichen Roboterassistierte Myotomie mit partieller 
Fundoplikatio ( 1 Studie mit laparoskopischer Fundoplikatio). 
Drei RCTs wurden zu Magenoperationen (zwei zu Gastrektomie und eine zu 
Bariatrie) und sieben RCTs zu Darmoperationen (eins zu Kolektomie, eins zu 
Rektopexie und fünf zu Rektumresektion) identifiziert. Im Bereich der Gallen-
blase/ Leber/ Milz konnten vier RCTs zu Cholezystektomie, und keine RCTs 
zur Leberresektion und Hernienreparatur identifiziert werden. Somit wurden 
zu Leberresektion zwei und zu Hernienreparatur eine nicht-randomisierte 
kontrollierte Studie eingeschlossen. 
Magen (insgesamt 80 PatientInnen mit Roboterassistierter Intervention): 
b 2 RCTs (474 PatientInnen, davon 255 in der Interventionsgruppe) ver-
glichen Roboterassistierte Gastrektomie mit laparoskopischer oder of-
fener Gastrektomie, 
b 1 RCT (50  PatientInnen, davon 25 in der Interventionsgruppe) ver-
glich Roboterassistierten laparoskopischen Roux-en-Y-Magenbypass 
(RYGB) mit  laparoskopischen RYGB. 
Darm (insgesamt 486 PatientInnen mit Roboterassistierter Intervention):  
b 1 RCT (71 PatientInnen, davon 35 in der Interventionsgruppe) ver-
glich Roboterassistierte Kolektomie mit laparoskopischer Kolektomie, 
b 5 RCTs (866 PatientInnen, davon 435 in der Interventionsgruppe) ver-
glichen Roboterassistierte Rektumresektion mit laparoskopischer 
Rektumresektion, 
b 1 RCT (30 PatientInnen, davon 16 in der Interventionsgruppe) ver-
glich Roboterassistierte Rektopexie mit laparoskopischer Rektopexie. 
Gallenblase (insgesamt 173 PatientInnen mit Roboterassistierter Interven-
tion), Leber (insgesamt 104 PatientInnen mit Roboterassistierter Interven-
tion) und Hernie (16 PatientInnen mit Roboterassistierter Intervention): 
b 4 RCTs (317 PatientInnen, davon 173 in der Interventionsgruppe) ver-
glichen Roboterassistierte Cholezystektomie mit laparoskopischer 
Cholezystektomie, 
b 2 nRCT (162 PatientInnen, davon 104 in der Interventionsgruppe) ver-
glichen Roboterassistierte (partielle) Hepatektomie mit  laparos-
kopischer Hepatektomie, 
b 1 nRCT (32 PatientInnen, davon 16 in der Interventionsgruppe) ver-
glich Roboterassistierte Hernienreparatur mit laparoskopischer 
Hernienreparatur. 
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Alle RCTs berichteten über Wirksamkeitsendpunkte, mit einer Ausnahme. Für 
die Bewertung der Sicherheit wurden dieselben Studien verwendet, zusätz-
lich eine weitere Studie. Alle prospektiven, nicht randomisierten kontrollier-
ten Studien (nRCTs), die als Nachweis für die Wirksamkeit identifiziert wur-
den, berichteten auch Sicherheitsendpunkte. 
Klinische Wirksamkeit & Sicherheit 
Die Vielfalt der unterschiedlichen Operationen, kombiniert mit dem Mangel 
an zuverlässiger Evidenz zu fast allen Indikationen, bereiten Schwierigkeiten 
bei der Analyse und Berichterstattung der Ergebnisse. Folgende Endpunkte 
wurden – auch basierend auf Erwartungen an die Roboterassistierte Chirur-
gie – analysiert: 
Mortalität: 3-, 5-Jahresüberleben 
Morbidität:  
b 3-, 5-Jahres DFS/ krankheitsfreies Überleben 
b Intraoperative Komplikationsrate 
b Postoperative Komplikationsrate 
Lebensqualität: 
b Funktionalität 
b Postoperative Schmerzen  
Ressourcenverbrauch: 
b Spitalsaufenthaltsdauer 
b Wiederaufnahmen 
b Bedarf an Transfusionen 
Aussagen zur Wirksamkeit waren nicht für alle, sondern nur für einen Teil der 
Endpunkte bei vier Verfahren (Ösophagektomie, Gastrektomie, Rektumresek-
tion, Cholezystektomie) möglich, wobei die Evidenzqualität als niedrig oder 
höchstens moderat eingestuft wurde. Die relevanten Endpunkte wurden in 
den meisten Studien entweder nicht berichtet, nicht gemessen oder zeigten 
keine statistisch signifikanten Unterschiede. Es werden daher hier nur jene 
Endpunkte berichtet, die – wenngleich mit Unsicherheit behaftet – Unter-
schiede zeigten 
b Ösophagektomie: die Roboterassistierte Chirurgie verbessert wahr-
scheinlich die postoperative Morbidität/Lebensqualität und reduziert 
postoperative Komplikationen im Vergleich zur offenen Chirurgie 
(Evidenzqualität: moderat). Intraoperative Komplikationen dürften 
durch Roboterassistierte Chirurgie im Vergleich zur offenen Chirurgie 
reduziert werden (Evidenzqualität: niedrig). 
b Gastrektomie: die Roboterassistierte Chirurgie dürfte postoperative 
Komplikationen im Vergleich zur konventionellen Laparoskopie re-
duzieren (Evidenzqualität: niedrig). 
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b Rektumresektion: die Roboterassistierte Chirurgie dürfte die Sexual-
funktion verbessern, aber Schlafstörungen im Vergleich zur konven-
tionellen Laparoskopie verschlimmern (Evidenzqualität: niedrig); 
Roboterassistierte Chirurgie dürfte postoperative Komplikationen 
zwischen 30 Tagen und sechs Monaten verringern, aber intraopera-
tive Komplikationen erhöhen (Evidenzqualität: niedrig). 
b Cholezystektomie: die Roboterassistierte Chirurgie dürfte intraopera-
tive Komplikationen und postoperative Komplikationen nach 30 Ta-
gen im Vergleich zur Laparoskopie reduzieren (Evidenzqualität: nied-
rig).  
Bei allen anderen Endpunkten sowie Verfahren ist die Wirksamkeit der Robo-
terassistierten Chirurgie im Vergleich zur offenen Operation oder Laparosko-
pie  
b entweder unsicher (die Qualität der Evidenz wurde als sehr niedrig be-
wertet und daher sind die Ergebnisse unsicher),  
b unbekannt (der Endpunkt wurde in der Studie einbezogen, aber die 
Studie berichtete keine relative Häufigkeit des Ereignisses aufgrund 
fehlender Daten in der Kontrollgruppe, daher konnte kein relativer Ef-
fekt berechnet werden)  
b oder die vorhandene Evidenz berichtete nicht über die Endpunkte.  
Tabelle 1 gibt einen Überblick über die Ergebnisse zu den wichtigsten Wirk-
samkeits- und Sicherheitsendpunkten der einzelnen Verfahren. 
Laufende Studien 
Die Suche in Datenbanken für klinische Studien ergab viele laufende oder ge-
plante Studien zum Einsatz der Roboterchirurgie im Bereich des Thorax- und 
Viszeralchirurgie.  
Die Verfahren mit den meisten laufenden Studien sind Rektumresektion (17 
Studien), Gastrektomie (14 Studien), Hernienreparatur (acht Studien) und 
Ösophagektomie (sechs Studien). Weiters wurden vier Studien zu Lobekto-
mie/ Lungensegmentierung, eine Studie zu Antireflux-Chirurgie/ Fundoplika-
tion, drei Studien zu Kolektomie, zwei Studien zu Cholezystektomie und zwei 
zu Leberresektion/ Hepatektomie gefunden. Die meisten Studien sind RCTs, 
die die Roboterassistierte Chirurgie mit Laparoskopie oder offener Operation 
vergleichen. Die laufenden oder geplanten Studien rekrutieren zwischen 20 
und 5.000 PatientInnen und werden voraussichtlich zwischen 2019 und 2024 
abgeschlossen sein. 
Es ist hervorzuheben, dass es einige besonders große Studien gibt, von denen 
erwartet werden kann, dass sie weitere und relevantere Evidenz liefern. Ins-
besondere, da in fünf Studien voraussichtlich mehr als 1.000 PatientInnen auf-
genommen werden. Die ersten Ergebnisse dieser laufenden Studien könnten 
ab 2021 vorliegen. 
Allerdings wurden nicht für alle in diesem Bericht berücksichtigten Indikati-
onen/ Verfahren laufende Studien identifiziert, z.B. konnten keine Studien zur 
Mediastinalchirurgie, der Heller Myotomie/ Ösophagus-Chirurgie, der Bariat-
rischen Chirurgie oder der Dünndarmresektion identifiziert werden. 
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Schlussfolgerung  
Zu neun der 13 Verfahren im Bereich des Thorax- und des Bauchraumes gibt 
es keine ausreichende Evidenz, um den Nutzen der Roboterassistierten Chi-
rurgie gegenüber Laparoskopie und offener Chirurgie feststellen zu können. 
In der Ösophagektomie hat die Roboterassistierte Chirurgie im Vergleich zur 
offenen Chirurgie wahrscheinlich (Evidenzqualität: moderat) Zusatznutzen in 
Bezug auf Lebensqualität und postoperative Komplikationen. Jedoch konnte 
in der Gastrektomie kein Zusatznutzen im Vergleich zur offenen Chirurgie ge-
zeigt werden; im Vergleich zur laparoskopischen Gastrektomie kann es Zu-
satznutzen in Bezug auf postoperative Komplikationen durch den Einsatz der 
Roboterassistierten Chirurgie geben. Die (qualitativ moderate) Evidenz legt 
nahe, dass die Roboterassistierte Cholezystektomie Komplikationen reduzie-
ren kann. Die Evidenz zur Roboterassistierten Rektumresektion zeigt jedoch 
kein einheitliches Bild; einige Endpunkte weisen auf eine Verbesserung und 
andere auf eine Verschlechterung in Bezug auf Lebensqualität, postoperative- 
und intraoperative Komplikationen hin. Zu mehreren Verfahren stand nur ein 
einziger (oder kein) RCT zur Verfügung; demzufolge sind weitere Studien er-
forderlich.  
Einige der Studien berücksichtigten Kostenaspekte und die meisten berichte-
ten über deutlich höhere Kosten im Zusammenhang mit Roboterassistierten 
Operationen. Dies ist oft auch auf die längere Operationsdauer, die in vielen 
Studien berichtet wurde, zurückzuführen. Die Evidenz zum Blutverlust war 
uneinheitlich, aber es gab etwas mehr Studien, in denen mit Roboterassistier-
ter Operation signifikant weniger Blutverlust berichtet wurde. 
Zu den Limitationen des vorliegenden Berichts gehört das Fehlen von Strati-
fikation nach chirurgischer Erfahrung. Eine Analyse der Mindestfallzahl und  
zur Erfahrung in der Ausübung der Methode wäre nützlich, da dies erhebliche 
Auswirkungen auf die Wirksamkeit und Sicherheit im Zusammenhang mit der 
Anwendung der Technologie haben dürfte. Um die Leistungsfähigkeit der Chi-
rurgInnen und der Operationsteams aufrechtzuerhalten, sind umfangreiche, 
hochspezialisierte Schulungen und ein ausreichendes Fallvolumen erforder-
lich. Die Entscheidung, nur RCTs mit wenigstens zehn PatientInnen einzu-
schließen und andere Art von Evidenz auszuschließen, kann als eine weitere 
Einschränkung insbesondere bei Aussagen zu Sicherheitsendpunkten angese-
hen werden.  
Jedoch stehen die Schlussfolgerungen des Berichts im Einklang mit systema-
tischen Übersichtsarbeiten und Metaanalysen von Beobachtungsstudien. Die 
Roboterassistierte Chirurgie ist ein sich rasch entwickelndes Aufgabengebiet: 
es gilt die Evidenz ebenso wie die Anbieter (und Kosten) zu beobachten.
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Tabelle 1 gibt einen Überblick über die Ergebnisse zu den wichtigsten Endpunkten der einzelnen Verfahren  
 Mortalität Morbidität/Lebensqualität Komplikationen 
Thoraxchirurgie 
Lobektomie Wirksamkeit unbekannt keine Studien wurden gefunden, die über diesen Endpunkt be-
richteten 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Mediastinalchirurgie Wirksamkeit unbekannt Wirksamkeit unsicher (Evidenzqualität: sehr niedrig) Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Viszeralchirurgie: Ösophagus 
Antireflux-Chirurgie/ Fundoplikatio keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Heller Myotomie keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
Wirksamkeit unbekannt Wirksamkeit unbekannt 
Ösophagektomie Wirksamkeit unsicher (Evidenzqua-
lität: sehr niedrig) 
Roboterassistierte Chirurgie verbessert wahrscheinlich die post-
operative Morbidität/ Lebensqualität im Vergleich zur offenen 
Chirurgie (Evidenzqualität: moderat) 
Roboterassistierte Chirurgie reduziert wahrscheinlich die post-operative 
Komplikationen im Vergleich zur offenen Chirurgie (Evidenzqualität: mode-
rat) 
Roboterassistierte Chirurgie  dürfte die intra-operative Komplikationen re-
duzieren im Vergleich zur offenen Chirurgie (Evidenzqualität: niedrig) 
Viszeralchirurgie: Magen 
Gastrektomie Wirksamkeit unbekannt Wirksamkeit ist unsicher im Vergleich zur Laparoskopie  
(Evidenzqualität: sehr niedrig); nicht berichtet in offener Chirur-
gie  
Roboterassistierte Chirurgie verbessert wahrscheinlich die postoperative 
Komplikationen im Vergleich zur Laparoskopie  
(Evidenzqualität: niedrig);  
Wirksamkeit ist unsicher im Vergleich zur offenen Chirurgie  
(Evidenzqualität: sehr niedrig) 
Bariatrie keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
keine Studien wurden gefunden, die über diesen Endpunkt be-
richteten 
Wirksamkeit unbekannt 
Viszeralchirurgie: Darm 
Kolektomie Wirksamkeit unbekannt (keine In-
formationen über die relative Häu-
figkeit des Ereignisses) 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Rektumresektion Wirksamkeit unsicher (Evidenzqua-
lität: sehr niedrig) 
Roboterassistierte Chirurgie dürfte die Sexualfunktion verbes-
sern, aber Schlafstörungen verschlimmern im Vergleich zur kon-
ventionellen Laparoskopie  
(Evidenzqualität: niedrig) 
Postoperative Komplikationen vor Entlassung und postoperative Komplika-
tionen innerhalb von 30 Tagen: Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Roboterassistierte Chirurgie dürfte intraoperative Komplikationen erhöhen 
und postoperative Komplikationen zwischen 30 Tagen und sechs Monaten 
verringern  
(Evidenzqualität: niedrig) 
Rektopexie keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
Wirksamkeit unbekannt Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Viszeralchirurgie: Gallenblase/ Leber/ Milz 
Cholezystektomie keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
Wirksamkeit unsicher (Evidenzqualität: sehr niedrig) Roboterassistierte Chirurgie dürfte intraoperative Komplikationen verrin-
gern  
(Evidenzqualität: niedrig) 
Roboterassistierte Chirurgie dürfte postoperative Komplikationen nach 30 
Tagen im Vergleich zur Laparoskopie reduzieren  
(Evidenzqualität: niedrig) 
Leberresektion Wirksamkeit unbekannt keine Studien wurden gefunden, die über diesen Endpunkt be-
richteten 
Wirksamkeit unsicher  
(Evidenzqualität: sehr niedrig) 
Hernienreparatur keine Studien wurden gefunden, die 
über diesen Endpunkt berichteten 
keine Studien wurden gefunden, die über diesen Endpunkt be-
richteten 
Wirksamkeit unbekannt 
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SUMMARY OF RELATIVE EFFECTIVENESS OF  
ROBOT-ASSISTED SURGERY IN THORACIC AND VISCERAL INDICATIONS 
Scope 
The aim of this HTA report was to assess the effectiveness and safety of robot-assisted surgery in 
the area of thoracic and visceral indications. The project plan (scope) conceived at the start of the 
project can be found here: Scope. 
 
Introduction 
Description of technology and comparators 
Robotic surgery is a form of minimally-invasive surgery whereby the instruments of the robotic sys-
tem are controlled by a telemanipulator, which is a device for transmitting hand and finger move-
ments to a remote robotic device, allowing the consequent manipulation of objects. The robot has 
a higher degree of dexterity compared to the laparoscopic approach, which allows surgeons to 
operate in very tight spaces in the body (which would otherwise only be accessible through open 
surgery) with the rational of improving clinical outcomes and resource use. 
22 systems have been developed, of which 13 are still in development, 7 are currently commercial-
ly available (da Vinci SI®, da Vinci SP®, da Vinci XI®, da Vinci X®, Freehand v1.2, Surgenius Beta 
and SenhanceTM Surgical System), 1 is available for research purposes only and 1 is only for the 
transoral and transanal approach. The evidence suggests that robot-assisted surgery is more ex-
pensive than conventional surgical methods.  
The aim of the currently available robotic systems is to provide technology to assist surgeons; 
they do not replace surgeons. These devices are a tool that surgeons can choose to use to pro-
vide their patients with a further minimally invasive surgical option. Comparators used in the clini-
cal studies were conventional laparoscopic techniques or open surgery. 
 
Health problem 
This assessment looks at the use of robot-assisted surgery in the area of thoracic and visceral 
surgery. Thoracic surgery is concerned with conditions of the lungs, chest wall and diaphragm and 
is generally dominated by treatment of malignant disease. Thoracic procedures that were exam-
ined in the review included, in accordance with the project plan, pulmonary lobectomy, lung seg-
mentectomy and mediastinal surgery. Visceral surgery deals with all aspects of the surgical treat-
ment of benign and malignant diseases of abdominal organs, the entire gastrointestinal tract, en-
docrine organs, the abdominal wall and the peritoneum. Visceral procedures that were included in 
the review, in accordance with the project plan, were anti-reflux surgery/fundoplication, oesophagec-
tomy or oesophageal repair, heller myotomy, gastrectomy, bariatric surgery, small bowel resection, 
colectomy, rectal resection, cholecystectomy, liver resection/hepatectomy and hernia repair.  
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Methods  
To identify primary studies fulfilling the inclusion criteria outlined in the Scope of the present  
assessment, a systematic literature search in the following databases was performed:  
• The Cochrane CENTRAL Register of Controlled 
• Embase (via Elsevier) 
• Ovid Medline 
Detailed tables on the search strategy are included in Appendix 1. In addition, a hand search, 
supplemented by a Scopus-search, was performed. 
Moreover, the following clinical trial databases were searched to identify ongoing studies:  
• ClincalTrials.gov  
• EU Clinical Trials Register (EU-CTR) 
• The WHO International Clinical Trials Registry Platform (ICTRP).  
Clinical Practice Guidelines (CPGs) were searched in the UptoDate database, through manual 
searching and through consultation with clinical experts, in addition to the systematic search. 
The Cochrane Risk of Bias tool was used for the quality assessment of RCTs and the ROBINS-I 
was used for the assessment of non-randomised studies.  
Randomised controlled studies (RCTs) with ≥ 10 patients were used for assessing the evidence in 
the effectiveness and safety domains. If no relevant RCTs could be identified, prospective non-
randomised controlled studies with ≥ 10 patients were included. Perioperative outcomes and re-
source use were also considered. Potentially relevant studies according to study design were 
therefore included if they provided results on effectiveness, safety or perioperative events/resource 
use outcomes. Comparators were laparoscopic surgery or open surgery.There were no restrictions 
on patient populations; all studies on patients with indications for thoracic or visceral surgery were 
included.  
 
Results 
Available evidence 
The systematic literature search did not identify any RCTs relating to thoracic surgery non-ran-
domised controlled studies (3 for lobectomy/segmentectomy and 1 for mediastinal surgery) were 
included as the next best evidence level.  
Regarding visceral surgery, and specifically surgery in the area of the oesophagus, 5 RCTs (6 pub-
lications) were identified relating to the procedure antireflux/fundoplication and oesphagectomy. 
For Heller myotomy no RCTs were found, hence non-randomised, controlled studies were includ-
ed (two in total).  
Three RCTS were included relating to stomach surgery (2 for gastrectomy and 1 for bariatric sur-
gery) and 7 RCTs were identified relating to bowel procedures (specifically 1 RCT for colectomy, 
1 RCT for rectopexy and 5 RCTs for rectal resection). Lastly in the area of gallbladder/liver/spleen, 
4 RCTS were included for the cholecystectomy procedure whilst for liver resection and hernia 
repair, no RCTS could be identified thus again non-randomised, controlled studies were included 
(2 for liver resection and 1 for hernia repair).  
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All the RCTS identified in the systematic literature search reported on effectiveness, with one ex-
ception [1].The same RCT study pool was used for the safety domain with the addition of one 
study [1]. All the prospective non-randomised controlled studies that were identified as providing 
evidence for the effectiveness domain also reported on safety. 
 
Clinical effectiveness & safety 
The diverse range of surgeries included in this review, combined with the lack of reliable evidence 
for almost all indications, poses difficulties for the analysis and reporting of results. However, the 
following Table 1 provides an overview of the findings on key effectiveness and safety outcomes 
for the individual procedures. Where statements relating to effect can be made, these are also 
summarized below: 
• Oesophagectomy: robot-assisted surgery probably improves post-operative morbidity/QoL 
and reduces post-operative complications compared to open surgery (evidence quality: 
moderate). Intra-operative complications may be reduced with robot-assisted surgery vs. 
open surgery but here the evidence quality is low. 
• Gastrectomy: robot-assisted surgery may reduce postoperative complications vs conven-
tional laparoscopy (evidence quality: low) 
• Rectal resection: robot-assisted surgery may improve sexual functioning but worsen sleep 
disturbances compared with conventional laparoscopy (evidence quality: low); robot-assisted 
surgery may decrease postoperative complications between 30 days and 6 months, but in-
crease intraoperative complications (evidence quality: low) 
• Cholecystectomy: robot-assisted surgery may reduce intraoperative complications and post-
operative complications at 30 days compared to laparoscopy (evidence quality: low)  
For all other outcomes and procedures, the effect of robot-assisted surgery compared to open or 
laparoscopic surgery on the basis of the included study pool was either uncertain (we are uncer-
tain whether robot-assisted surgery improves or reduces the outcome as the quality/certainty of 
the evidence has been assessed as very low), unknown (although included as an outcome in the 
study, relative effect could not be calculated as the study provided no information about the rela-
tive probability of the event, mainly due to missing events in one arm) or the available evidence 
did not measure the outcome. 
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Table 1: Summary of conclusions 
 Mortality Morbidity/QoL Complications 
Thoracic surgery 
Lobectomy Effect unknown No studies were found that considered  
this outcome 
Effect uncertain (evidence quality: very low) 
Mediastinal surgery Effect unknown Effect uncertain (evidence quality: very low) Effect uncertain (evidence quality: very low) 
Visceral surgery: Oesophagus 
Antireflux/ 
fundoplication 
No studies were found that 
considered this outcome 
Effect uncertain (evidence quality: very low) Effect uncertain (evidence quality: very low) 
Heller myotomy No studies were found that 
considered this outcome 
Effect unknown Effect unknown 
Oesophagectomy Effect uncertain (evidence quality: 
very low) 
Robot-assisted surgery probably improves 
post-operative morbidity/QoL compared to 
open surgery (evidence quality: moderate) 
Post-op complications: Probably reduced with robot-assisted 
surgery vs open surgery (evidence quality: moderate) 
Intra-op complications: May be reduced with robot-assisted 
surgery vs open surgery (evidence quality: low) 
Visceral surgery: stomach 
Gastrectomy Effect unknown Effect uncertain in laparoscopy comparison 
(evidence quality: very low); not reported in 
open surgery comparison 
Robot-assisted surgery may reduce postoperative complications 
vs conventional laparoscopy (evidence quality: low); effect 
uncertain in open surgery comparison (evidence quality: very low) 
Bariatric surgery No studies were found that 
considered this outcome 
No studies were found that considered  
this outcome 
Effect unknown 
Visceral surgery: bowel 
Colectomy Effect unknown (no information 
about relative probability of event) 
Effect uncertain (evidence quality: very low) Effect uncertain (evidence quality: very low) 
Rectal resection Effect uncertain (evidence quality: 
very low) 
Robot-assisted surgery may improve sexual 
functioning but worsen sleep disturbances 
compared with conventional laparoscopy 
(evidence quality: low) 
Effect uncertain on postoperative complications to discharge  
and postoperative complications within 30 days (evidence quality: 
very low) 
Robot-assisted surgery may increase intraoperative complications 
and decrease postoperative complications >30 days and ≤ 6 months 
(evidence quality: low) 
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 Mortality Morbidity/QoL Complications 
Rectopexy No studies were found that 
considered this outcome 
Effect unknown Effect uncertain (evidence quality: very low) 
Visceral surgery: gallbladder/liver/spleen 
Cholecystectomy No studies were found that 
considered this outcome 
Effect uncertain (evidence quality: very low) Robot-assisted surgery may reduce intraoperative complications 
(evidence quality: low).  
Robot-assisted surgery may reduce postoperative complications 
at 30 days when compared to single-incision laparoscopic 
cholecystectomy (evidence quality: low) 
Liver resection Effect unknown  No studies were found that considered  
this outcome 
Effect uncertain (evidence quality: very low) 
Hernia repair No studies were found that 
considered this outcome 
No studies were found that considered  
this outcome 
Effect unknown  
Note: “Effect unknown”: although included as an outcome in the study, relative effect could not be calculated as the study provided no information about the relative probability of the event, mainly 
due to missing events in one arm. “Effect uncertain”: in the case of very low quality evidence we are undertain whether robot-assisted surgery improves or reduces the outcome as the quality/certainty 
of the evidence has been assessed as very low 
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Research in progress 
The search within clinical trials databases identified many ongoing or planned trials on the use of 
robotic surgery in the field of thoracic and visceral surgery.  
The procedures for which the largest numbers of ongoing studies were found were rectal resec-
tion (17 studies), gastrectomy (14 studies), hernia repair (8 studies), oesophagectomy (6 studies). 
4 studies were found for lobectomy/segmentectomy, 1 study for antireflux/fundoplication, 3 stud-
ies for colectomy, 2 studies for cholecystectomy and 2 for liver resection/hepatectomy. Most of the 
studies are RCTs comparing the robotic approach with laparoscopic or open surgery. The ongo-
ing or planned studies are recruiting from between 20 to 5,000 patients and they are expected to 
be completed between 2019 and 2024. 
It is of note that there are some particularly large studies which can be expected to add further 
and more relevant evidence. In particular, 5 studies are expected to enroll more than a thousand 
patients. The first results from these ongoing studies could be available from 2021. 
However, not all the indications/procedures considered in this assessment were found to have 
ongoing trials, for instance none could be identified for mediastinal surgery, Heller myotomy/oe-
sophageal repair, bariatric surgery or small bowel resection. 
 
Conclusion 
For 9 of the 13 procedures within the area of thoracic and visceral surgery that we considered in 
this HTA, we conclude that there is insufficient evidence on which a judgement can be made about 
the relative merits of robot-assisted surgery compared to the alternatives (mostly conventional lapa-
roscopic procedures). For 4 of the procedures there was evidence on some of the outcomes, but 
not all. Of the outcomes for which there is evidence we can report that when compared with open 
surgery in oesophagectomy, robot-assisted surgery probably (evidence quality: moderate) has 
advantages in terms of QoL and postoperative complications (although this was not shown for the 
comparison with open gastrectomy); when compared with laparoscopic gastrectomy, there may 
be advantages in terms of postoperative complications with the use of robot-assisted surgery. There 
is some low quality evidence that robot-assisted cholecystectomy may confer advantages in terms 
of reduced complications. The evidence for robot-assisted rectal resection was mixed with some 
areas of improvement and some areas of decline regarding quality of life outcomes and some re-
duced post-operative complications but some increased intraoperative complications. For several 
of the procedures only a single (or no) RCT was available; here further studies are necessary.  
Several of the studies considered cost aspects and most reported higher costs associated with 
robot-assisted surgery. This is often due to the longer operation time necessary, which was re-
ported by many studies; the evidence on blood loss was mixed.  
Limitations of the present report include the lack of stratification according to surgical experience. 
In addition an analysis of the number of cases required to maintain training and knowledge related 
to the method would be useful, as this is likely to have a considerable impact on the effectiveness 
and safety associated with using the technique. Extensive, highly specialized training and an ade-
quate volume of cases are required for surgeons and their surgical teams to maintain proficiency. 
A further limitation related to the decision to include only RCTs ≥ 10 patients where these are 
available, to the exclusion of other types of evidence. However it should be noted, that the con-
clusions drawn here are generally in accordance with systematic reviews and meta-analyses re-
sults of observational studies.  
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1 SCOPE 
The aim of this HTA report was to assess the effectiveness and safety of robot-assisted surgery in 
the area of thoracic and visceral indications. The project plan concievd at the start of the project 
can be found in the table below.  
Description Project scope 
Population  Patients with indication for thoracic surgery: 
• Pulmonary (sleeve) lobectomy [non-small cell lung cancer] 
o International classification of diseases (ICD)-10-CM code:  
e.g. Z90.2 Acquired absence of lung [part of], C34.1/C34.2/C34.3 Malignant 
neoplasm of upper/middle/lower lobe, bronchus or lung 
MeSH Terms: e.g. Lung Neoplasms [C04.588.894.797.520, C08.381.540, 
C08.785.520], Pulmonary Surgical Procedures [E04.928.600] 
• Lung segmentectomy/wedge resection [non-small cell lung cancer] 
o ICD-10-CM code: e.g. Z90.2 Acquired absence of lung [part of], C34.1/C34.2/ 
C34.3 Malignant neoplasm of upper/middle/lower lobe, bronchus or lung 
o MeSH Terms: e.g. Lung Neoplasms [C04.588.894.797.520, C08.381.540, 
C08.785.520], Pulmonary Surgical Procedures [E04.928.600] 
• Mediastinal surgery: e.g. Thymectomy [Myasthenia gravis (pseudoparalytica); 
thymoma]; (posterior) mediastinal lesion resection [(posterior) mediastinal 
mass/tumour, neurogenic tumour]; other mediastinal pathology [e.g.mediastinal 
bronchogenic cyst, lipoma, teratoma or fibrous tumour of the mediastinum] 
o ICD-10-CM code: e.g. G70.0 Myasthenia gravis, D15.0 Benign neoplasms of 
thymus, C37 Malignant neoplasms of the thymus, D15.2 Benign neoplasm of 
mediastinum, D21.3 Benign neoplasm of connective and other soft tissue of 
thorax, C38.1 Malignant neoplasm of anterior mediastinum, C38.2 Malignant 
neoplasm of posterior mediastinum, C38.3 Malignant neoplasm of mediastinum, 
part unspecified, J85.3 Abscess of mediastinum, J98.5 Diseases of mediastinum, 
not elsewhere classified, Q33.0 Congenital cystic lung, Q33.2 Sequestration  
of lung, Q33.5 Ectopic tissue in lung 
o MeSH Terms: e.g. Myasthenia Gravis [C10.114.656, C10.668.758.725, 
C20.111.258.500], Thymoma [C04.557.435.850, C04.588.894.949.500, 
C15.604.861.800], Mediastinum [A01.923.761.800.500], Thymectomy 
[E04.928.770] 
Patients with indication for visceral (abdominal) surgery: 
• Oesophagus: 
o Anti-reflux surgery/fundoplication [gastroesophageal reflux disease (GERD), 
hiatal hernia] 
 ICD-10-CM code: e.g. K21 Gastro-esophageal reflux disease,  
K44 Diaphragmatic hernia 
 MeSH Terms: e.g. Gastroesophageal Reflux [C06.405.117.119.500.484], 
Hernia, Hiatal [C23.300.707.500.467]  
o Oesophagectomy (total or partial)/transhiatal oesophagectomy [benign or 
malignant oesophageal tumours, oesophageal leimyoma, oesophageal diverticula] 
 ICD-10-CM code: e.g. C15 Malignant neoplasm of esophagus, D13.0 
Benign neoplasm of esophagus, K22.1 Ulcer of esophagus, K22.8 Other 
specified diseases of esophagus. K22.9 Disease of esophagus, 
unspecified, K22.5 Diverticulum of esophagus, acquired 
 MeSH Terms: e.g. Esophageal Diseases [C06.405.117], Esophageal 
Neoplasms [C04.588.274.476.205, C04.588.443.353, C06.301.371.205, 
C06.405.117.430, C06.405.249.205], Diverticulosis, Esophageal 
[C06.405.117.136, C06.405.205.282.500.438], Esophagus 
[A03.556.875.500], Esophagectomy [E04.210.346] 
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Description Project scope 
 
o Oesophageal repair1 [oesophageal perforation] 
 ICD-10-CM code: e.g. K22.3 Perforation of esophagus 
 MeSH Terms: e.g Esophageal Perforation [C06.405.117.468, C26.348], 
Esophagus [A03.556.875.500] 
o (Heller) Myotomy [swallowing disorder/achalasia] 
 ICD-10-CM code: e.g. K22.0 Achalasia of cardia 
 MeSH Terms: e.g. Esophageal Achalasia [C06.405.117.119.500.432], 
Myotomy [E04.515] 
• Stomach: 
o Gastrectomy [subtotal for gastric cancer <stage IB, radical for IB-III] 
 ICD-10-CM code: e.g. C16 Malignant neoplasm of stomach 
 MeSH Terms: e.g. Stomach Neoplasms [C04.588.274.476.767, 
C06.301.371.767, C06.405.249.767, C06.405.748.789], Gastrectomy 
[E04.210.419] 
o Bariatric surgery2: e.g. (ROUX-en-Y) gastric bypass, sleeve gastrectomy, 
gastric banding, implantable gastric stimulator, band revision; [obesity] 
 ICD-10-CM code: e.g. E66 Overweight and obesity  
 MeSH Terms: e.g. Obesity [C18.654.726.500, C23.888.144.699.500, 
E01.370.600.115.100.160.120.699.500, G07.100.100.160.120.699.500], 
Bariatric Surgery [E02.570.500.062, E04.062] 
• Bowel: 
o Small bowel resection1 [bleeding, infection, ulcers, blockage, benign tumours, 
precancerous polyps, cancer, injuries, Meckel’s diverticulum] 
 ICD-10-CM code: e.g. K26 Duodenal ulcer, C17 Malignant neoplasm of 
small intestine, D13.2 Benign neoplasm of duodenum, C17.3 Meckel’s 
diverticulum, malignant 
 MeSH Terms: e.g. Intestine, Small [A03.556.124.684], Meckel Diverticulum 
[A03.556.124.684.249.612, A03.556.249.124.612, C01.539.463.199.750.750, 
C06.198.859, C06.405.205.282.750.750, C16.131.314.556, C23.300.415.750], 
Duodenal Diseases [C06.405.469.275], Duodenal Neoplasms 
[C04.588.274.476.411.445, C06.301.371.411.445, C06.405.249.411.445, 
C06.405.469.275.270, C06.405.469.491.445], Jejunal Neoplasms 
[C04.588.274.476.411.523, C06.301.371.411.523, C06.405.249.411.523, 
C06.405.469.491.523, C06.405.469.600.523], Ileal Neoplasms 
[C04.588.274.476.411.501, C06.301.371.411.501, C06.405.249.411.501, 
C06.405.469.420.501, C06.405.469.491.501] 
o Colectomy (total, partial)/hemicolectomy (left, right)/abdominal colectomy/ 
proctocolectomy/sigmoid colectomy/transverse colectomy [bleeding, bowel 
obstruction, cancer, Crohn’s disease, ulcerative colitis, diverticulitis, cancer 
prevention] 
 ICD-10-CM code: e.g. C18 Malignant neoplasm of colon, D12 Benign 
neoplasm of colon, rectum, anus and anal canal, K51 Ulcerative colitis, 
K50 Crohn’s disease [regional enteritis], K56 Paralytic ileus and intestinal 
obstruction without hernia, K57 Diverticular disease of intestine 
 MeSH Terms: e.g. Diverticulitis [C01.539.463.199.375, C06.405.205.282.500], 
Colorectal Neoplasms [C04.588.274.476.411.307, C06.301.371.411.307, 
C06.405.249.411.307, C06.405.469.158.356, C06.405.469.491.307, 
C06.405.469.860.180], Crohn Disease [C06.405.205.731.500, 
C06.405.469.432.500], Colitis [C06.405.205.265, C06.405.469.158.188], 
Colectomy [E04.210.219] 
o Rectal resection (anterior, low anterior, inter sphincteric, total)/colorectal 
resection/polyectomy/proctectomy/rectopexy/total mesorectal excision  
[e.g. rectal cancer, rectal prolapse] 
                                                     
1 Intervention was recommended to be excluded from PICO by one external expert, but not by the manufacturers.  
Thus, the intervention was kept. 
2 Intervention was recommended to be excluded from PICO by one manufacturer (studies are currently underway).  
However, TransEnterix claims that the SenhanceTM Surgical System is intended for use in bariatric surgery. 
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Description Project scope 
 ICD-10-CM code: e.g. C20 Malignant neoplasm of rectal ampulla,  
D12.8 benign neoplasm of rectum, K62.3 Rectal prolapse 
 MeSH Terms: e.g. Rectal Neoplasms [C04.588.274.476.411.307.790, 
C06.301.371.411.307.790, C06.405.249.411.307.790, 
C06.405.469.491.307.790, C06.405.469.860.180.500],  
Rectal Prolapse [C06.405.469.860.800, C23.300.842.624.500] 
• Gallbladder/Liver/Spleen: 
o Cholecystectomy3 [biliary colic, acute cholecystitis, cholangitits (e.g. caused  
by symptomatic gallstones), gallbladder cancer] 
 ICD-10-CM code: e.g. R10.83 Colic, K81 Cholecystitis, K83.0 Cholangitis, 
C23 Malignant neoplasm of gallbladder 
 MeSH Terms: e.g. Colic [C16.614.166], Cholecystitis [C06.130.564.263], 
Cholangitis [C06.130.120.200], Gallbladder Neoplasms [C04.588.274.120.401, 
C06.130.320.401, C06.130.564.401, C06.301.120.401], Cholecystectomy 
[E04.210.120.172] 
o Liver resection (partial, total)/hepatectomy [liver cell carcinoma, hepatocellular 
carcinoma/adenoma, hepatic hemangioma, focal nodular hyperplasia] 
 ICD-10-CM code: e.g. C22 Malignant neoplasm of liver and intrahepatic 
bile ducts, C22.0 Liver cell carcinoma, D13.4 Benign neoplasm of liver, 
D18.09 Hemangioma of other sites 
 MeSH Terms: e.g. Liver Neoplasms [C04.557.470.200.025.255, 
C04.588.274.623.160, C06.301.623.160, C06.552.697.160], Carcinoma, 
Hepatocellular [C04.557.470.200.025.255, C04.588.274.623.160, 
C06.301.623.160, C06.552.697.160], Adenoma, Liver Cell 
[C04.557.470.035.120, C04.588.274.623.040, C06.301.623.040 
C06.552.697.040], Hepatectomy [E04.210.556] 
o Hernia repair3 
 ICD-10-CM code: e.g. K40-K46 Hernia, K40 inguinal hernia 
 MeSH Terms: e.g. Hernia [C23.300.707], Hernia, Abdominal [C23.300.707.374], 
Hernia, Inguinal [C23.300.707.374.875], Herniorrhaphy [E04.680.325] 
Rationale: The population has been defined based on the suggested interventions for 
robot-assisted surgery in recent systematic reviews or studies [2] [3] [4], and informed 
by external experts and manufacturers. Moreover, since the interventions are in the 
focus of the assessment, the individual indications are examples, which the assessment 
is not limited to. 
Intervention  • Robot-assisted surgery 
Comparison • Laparoscopic surgery (or thoracoscopic approach for thoracic surgery) 
• Open surgery 
Rationale: Appropriate comparators have been informed by selected guidelines [5] [6] 
and systematic reviews [7]. 
Outcomes4 Effectiveness (critical outcomes are highlighted in bold): 
• Survival (overall and disease-specific or disease-free) 
• Positive (surgical) margins 
• Recurrence (local, regional or distant) 
• Quality of life (e.g. measured by EQ-5D or SF-36) 
• Other disease-specific effectiveness-related outcomes 
• Conversion to laparoscopic/thoracoscopic/open surgery 
• Length of hospital stay 
• Time to resume work/daily activities 
• Patient satisfaction 
                                                     
3 Intervention was recommended to be excluded from PICO by external experts and one manufacturer. However, Trans-
Enterix claims that the SenhanceTM Surgical System is intended for this intervention (cholecystectomy and inguinal hernia 
repair). Thus, the intervention was kept. 
4 Not all outcomes apply for every single population/indication 
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Safety (critical outcomes are highlighted in bold): 
• Intraoperative complications (e.g. bleeding, procedure-related mortality) 
• Postoperative complications (e.g. 30-day overall complications, pain, infections) 
• Re-operations/additional surgeries  
Perioperative outcomes: 
• Blood loss 
• Operation time 
• Transfusions 
These are a type of outcome but we have not classified these under effectiveness  
as they are not necessarily patient-relevant outcomes but rather proxy outcomes.  
In accordance with the advice of the clinical expert, outcomes were considered at  
the individual procedure level and not across all procedures. 
Rationale: Appropriate clinical outcomes have been informed by systematic reviews [8] 
and the EUnetHTA guidelines [8] [9]. 
Study design Effectiveness: 
• Randomised controlled studies (RCTs) with ≥ 10 patients  
(for effectiveness and safety) 
• Prospective non-randomised controlled studies with ≥ 10 patients  
in the absence of RCTs  
Safety: 
• Randomised controlled studies (RCTs) with ≥ 10 patients  
(for effectiveness and safety), 
• Prospective non-randomised controlled studies with ≥ 10 patients  
in the absence of RCTs  
Prospective studies with ≥100 patients and without a control group are eligible  
for inclusion in the absence of comparative evidence 
Data from good quality non-RCT studies may still be relevant even if RCTs exist 
however given the breadth of this topic the study design to be included was more 
restrictive than might be the case for other HTA topics. 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
The distribution of the responsibilities and the workload between the author and co-authors was as 
follows: 
LBI-HTA (author): 
• Designed first draft of EUnetHTA project plan, amended the draft according to co-author’s, 
dedicated reviewers’, external experts, and manufacturers. 
• Performed the literature search (systematic and by hand, supplemented by a Scopus-search) 
• Performed literature selection for lobectomy, mediastinal and oesophagus  
(fundoplication and anti-reflux, oesophagectomy and heller myotomy)  
• completed the checklist regarding potential ethical (ETH), organisational (ORG), social (SOC) 
and legal (LEG) aspects of the HTA Core Model® for Rapid Relative Effectiveness (REA) 
JOANNEUM RESEARCH (author): 
• Performed literature selection (for stomach, bowel, gallbladder, liver, spleen), data extraction 
for all studies, risk of bias assessment of the selected references, quality assessment of the 
body of evidence (GRADE)  
• Carried out the assessment: answered assessment elements, checked the discrepancies 
with the co-author and reached consensus 
• Compiled draft report, sent “draft versions” to dedicated reviewers and co-authors, compiled 
feedback from reviewers and co-authors and performed changes according to reviewer’s 
comments. 
• Sent “final draft” to external experts, compiled feedback from external experts  
and performed changes according to comments 
• Prepared the final assessment and wrote a final summary of the assessment. 
Azienda Zero Regione del Veneto (co-author): 
• Reviewed and commented on EUnetHTA project plan. 
• Checked and approved all steps (e.g. literature selection of included RCTs, data extraction, 
assessment of risk of bias assessment, quality of the body of evidence assessment). 
• Wrote sections on technology (chapter 3) and ongoing research 
• Reviewed draft assessment, proposed amendments where necessary and provided  
(written) feedback. 
 
2.2 Source of assessment elements 
The selection of assessment elements is based on the HTA Core Model Application for Rapid 
Relative Effectivenes Assessments. The selected issues (generic questions) were translated into 
actual research questions (answerable questions) for the selected domains of the assessment.  
Please note that some research questions were answered together; that is, these questions can 
be listed below each other and the answer can then be provided subsequently. 
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2.3 Search 
To identify recent primary studies fulfilling the inclusion criteria outlined in the Scope of the present 
assessment, a systematic literature search in the following databases was performed:  
• The Cochrane CENTRAL Register of Controlled 
• Embase (via Elsevier) 
• Ovid Medline 
Detailed tables on search strategy are included in Appendix 1. In addition, a hand search of the 
clinical trials database, supplemented by a Scopus-search, was performed.  
Moreover, the following clinical trial databases were searched to identify ongoing studies:  
• ClincalTrials.gov  
• EU Clinical Trials Register (EU-CTR) 
• The WHO International Clinical Trials Registry Platform (ICTRP).  
Clinical Practice Guidelines (CPGs) were searched in the UptoDate database, through manual 
searching and through consultation with clinical experts in addition to the systematic search. 
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2.4 Study selection 
 
Figure 1: Flow chart 
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Exclusion criteria are e.g.: 
• Wrong study design  
(n = 243) 
• Wrong publication type  
(n = 62) 
• Wrong intervention  
(n = 12) 
• Wrong outcome (n = 8) 
• Wrong population (n = 5) 
• Not available (n = 2) 
• Duplicates (n = 5) 
Studies included in qualitative synthesis  
(n = 28 for 30 publications)  
Thorax: RCTs = 0, observational studies = 4 
(lobectomy: n = 3; mediastinal: n = 1) 
Oesophagus: RCTs = 5 (6 publications); 
observational studies = 2,  
(antireflux/fundoplication: RCTs = 4; 
oesophagectomy: RCT = 1;  
Heller myotomy: observational studies = 2) 
Stomach: RCTs = 3 
(gastrectomy: RCT = 2;  
bariatric surgery: RCT = 1) 
Bowel: RCTs = 7 (8 publications) 
(colectomy: RCT = 1; rectal resection:  
RCT = 5; rectal rectopexy RCT = 1) 
Gallbladder/Liver/Spleen:  
RCTs = 4, observational studies = 3 
(cholecystectomy: RCTs = 4;  
liver resection: observational studies = 2; 
hernia repair: observational studies = 1)  
Hand-searching/identified  
by expert (n=5) 
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The systematic searches yielded 3103 records after accounting for duplicates. The author and co-
author independently screened the titles and abstracts and selected studies according to the pre-
defined inclusion as outlined in the Scope for further full-text examination. 2741 records were ex-
cluded at this screening stage, leaving 362 full-text articles which were assessed for eligibility. Of 
these 362 full-text articles, 337 were excluded on the grounds of wrong study design, wrong publi-
cation type, wrong intervention, wrong outcome or wrong population. 7 were either not available or 
turned out to be duplicates. An additional five relevant studies were identified via hand searching 
or contact with experts. For eight procedures (antireflux/fundoplication, oesphagectomy, gastrec-
tomy, bariatric surgery, colectomy, rectal resection, rectal rectopexy, cholecystectomy), RCTs of 
≥10 patients could be identified. For five procedures (lobectomy, mediastinal surgery, Heller myoto-
my, liver resection/hepatectomy, hernia repair), no RCTs ≥10 patients could be identified, hence (in 
accordance with the project protocol) nine non-randomised controlled studies were included (lobec-
tomy:3; mediastinal surgery:1; Heller myotomy:2; liver resection/hepatectomy:2; hernia repair:1).  
 
2.5 Data extraction and analyses 
Data were extracted by the author and checked by the co-author. Evidence tables were created 
based on the predefined outcomes and information about the study. Continuous variables were 
reported using median, interquartile range or overall range, and/or mean with standard deviation, 
according to availability. Categorical variables were reported using frequencies and percentages. 
For the summary of findings table, data from RCTs were pooled, where homogenous outcome 
measures were available, to generate estimates of absolute and relative effect. This took the form 
of relative and absolute risk for categorical variables or mean differences for continuous variables. 
No meta-analysis was performed.  
 
2.6 Quality rating 
For Description and Technical Characteristics of Technology (TEC) and Health Problem and Cur-
rent Use of the Technology (CUR) domains, no quality assessment tool were used; here multiple 
sources were used to generate a narrative description of the results of these domains, chiefly in-
formation from the manufacturer, clinical guidelines and published HTA reports. 
For the Effectiveness (EFF) and the Safety (SAF) domains and following EUnetHTA guidelines, 
risk of bias at the study level was assessed using the Cochrane Risk of Bias tool5 for RCTs and 
the ROBINS-I for non-randomised studies6. The author and co-authors performed the risk of bias 
assessment independently. 
The quality of the body of evidence was assessed using Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE), using the online programme https://gradepro.org/. 
The author performed the GRADE assessment and the co-author checked it. Disagreements were 
resolved by consensus.  
 
                                                     
5 https://handbook-5-1.cochrane.org/  
6 https://www.riskofbias.info/welcome/home  
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2.7 Description of the evidence used 
Table 2: Main characteristics of studies (RCTs) included 
Author  
and year  
Study  
type 
Number  
of patients 
Intervention (s) Comparator (s) Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Oesophagus 
Antireflux/Fundoplication 
Draaisma et al, 
2006 [10] 
Single-centre RCT  
of patients with 
GORD 
50  
(IG: 25, CG: 25) 
Robot-assisted 
laparoscopic Nissen 
fundoplication | da 
Vinci Robotic System 
Laparoscopic 
Nissen 
fundoplication 
Primary endpoints: clinical measures 
and symptoms 
Secondary endpoints: general  
health state (10-point VAS 0-100);  
QoL (Visick scale); self-rated reflux 
symptoms (instrument NR); satisfaction 
with outcome (instrument NR); 
Effective-ness and 
safety 
Morino et al,  
2006 [11] 
Single-centre RCT  
of patients with 
GORD 
50  
(IG:25, CG:25) 
Robot-assisted 
fundoplication | da 
Vinci system 
Laproscopic 
fundoplication 
Primary endpoint: In-hospital cost of 
the procedure 
Secondary endpoints were  
skin-to-skin and total operating time 
Effective-ness and 
safety 
Mueller-Stich  
et al. 2007 &  
Mueller-Stich  
et al. 2009 [12] 
[13] 
Single-centre RCT  
of patients with 
symptomatic GERD 
40  
(IG: 20, CG:20) 
Robot-assisted 
laparoscopic 
fundoplication | da 
Vinci Surgical System 
Laproscopic 
fundoplication 
Primary: Quality of Life in Refux and 
Dsypepsia (QOLRAD); Gastrointestinal 
Symptom Rating Scale (GSRS); 
patient satisfaction; 4-step Likert scale 
for specific symptoms (2009) 
Secondary: Perioperative outcomes 
regarding operative time, perioperative 
complications, length of stay and 
costs (2007) 
Effective-ness and 
safety 
Nakadi et al,  
2006 [14] 
Single-centre RCT  
of patients with 
GERD 
20  
(IG: 9, CG: 11) 
Robot-assisted 
Nissen fundoplication 
| da Vinci system 
Laparoscopic 
Nissen 
fundoplication 
Aims stated as: Feasibility, benefits 
and costs (postoperative complaints, 
satisfaction score, duration of surgical 
procedure, LOS, operative costs) 
Effective-ness 
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Author  
and year  
Study  
type 
Number  
of patients 
Intervention (s) Comparator (s) Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Oesophagectomy 
Van der Sluis  
et al, 2018 [15] 
Single centre RCT  
of patients with 
oesopgaeal cancer 
109  
(IG: 54, CG: 55) 
Robot-assisted 
minimally invasive 
thoracolaparoscopic 
oesophagectomy | da 
Vinci Robotic System 
Open transthoracic 
oesophaegctomy 
Primary: Surgery-related postoperative 
complications. Secondary: mortality 
(in-hospital and within 30 days), 
pulmonary complications, cardiac 
complications, perioperative outcomes, 
quality of life, functioning, pain 
Effective-ness and 
safety 
Stomach 
Gastrectomy 
Pan et al,  
2017 [16] 
Single centre RCT  
of patients with 
gastric cancer 
163  
(IG: 102, CG: 
61) 
Robotic gastrectomy | 
NR 
Laparoscopic 
gastrectomy 
Assessed perioperative outcomes and 
postoperative complications 
Effective-ness and 
safety 
Wang et al,  
2016 [17] 
Single-centre RCT  
of patients with 
gastric cancer 
311  
(IG: 153,  
CG: 158) 
Robotic gastrectomy | 
NR 
Open gastrectomy Primary: duration of hospitalization, 
clinical measures, surgery duration, 
proximal and distal resection margins, 
estimated blood loss, morbidity and 
mortality during the first 30 days after 
the procedure 
Effective-ness and 
safety 
Bariatric Surgery 
Sanchez et al, 
2005 [18] 
Single-centre RCT 50  
(IG: 25, CG: 25) 
Totally robotic laparo-
scopic Roux-en-Y 
gastric bypass | da 
Vinci Surgical System 
Laparoscopic Roux-
en-Y gastric bypass 
Not stated as such but included 
learning curve analysis, safety, 
operative times and length of stay 
Safety 
Bowel 
Colectomy 
Park et al.  
2012 [19] 
Single-centre RCT  
of patients with newly 
diagnosed right-sided 
colonic carcinoma 
71  
(IG: 35, CG: 36) 
Robot-assisted 
colectomy | da Vinci 
Surgical System 
Laparoscopic 
colectomy 
Length of hospital stay 
Secondary endpoints: duration of 
operation, complications, pathological 
completeness of tumour excision and 
postoperative pain 
Effective-ness and 
safety 
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Author  
and year  
Study  
type 
Number  
of patients 
Intervention (s) Comparator (s) Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Rectal resection 
Jayne et al.  
2017 [20] 
International 
multicentre RCT of 
patients with rectal 
adenocarcinoma 
(ROLARR clinical 
trial) 
IG: 237 
randomised;  
(1 withdrew 
before surgery) 
CG: 234 
randomised;  
(4 had no 
surgery after 
randomisation) 
Robot-assisted 
laparoscopic rectal 
cancer resection | da 
Vinci Surgical System 
Laparoscopic rectal 
resection 
Primary endpoint: Rate of conversion 
to open surgery 
Secondary endpoints: 30-day operative 
mortality, duration of operation, compli-
cations, pathological completeness of 
tumour excision, patient-reported bladder 
symptoms (International Prostate Symp-
tom Score, I-PSS) and sexual function-
ing (International Index of Erectile Func-
tion, and Female Sexual Function Index  
Effective-ness and 
safety 
Kim et al.  
2018 [21] 
Single-centre RCT of 
patients with mid to 
low-lying rectal 
cancer 
IG: 81 
randomised,  
66 available for 
analysis 
CG: 81,  
73 available for 
analysis  
Robot-assisted 
laparoscopic rectal 
cancer resection | da 
Vinci Surgical System 
Laparoscopic rectal 
resection 
Primary endpoint: Completeness of 
total mesorectal excision 
Secondary outcomes: circumferential 
and distal resection margin; Global 
Operative Assessment of Laparoscopic 
Skills; bowel function; morbidity; post-
operative pain (Present Pain Intensity 
Index and VAS); QoL (via Korean 
version of EORTC QLQ-C30 and the 
colorectal cancer module QLQ-CR38). 
Effective-ness and 
safety 
Tolstrup et al. 
2018 [22] 
Single-centre RCT  
of patients with rectal 
adenocarcinoma 
(ROLARR clinical 
trial): Denmark centre 
51  
(IG : 25,  
CG : 26) 
Robot-assisted 
laparoscopic rectal 
cancer resection | da 
Vinci Surgical System 
Laparoscopic rectal 
resection 
The aim was to assess perioperative 
pain via numeric rating scale (NRS). 
Length of surgery and complications 
were also assessed. 
Effective-ness and 
safety 
Wang et al.  
2017 [23] 
Single-centre RCT  
of male patients with 
rectal cancer  
137  
(IG: 71; CG 66) 
Robot-assisted total 
mesorectal excision 
(device unspecified)  
Laparoscopic total 
mesorectal excision 
Urinary function and sexual function  
at 12 months 
Effectiveness and 
safety 
Debakey et al. 
2018 [24] 
Single centre RCT  
of patients with rectal 
cancer 
45 (IG: 21, CG 
24) 
Robot-assisted rectal 
cancer resection | da 
Vinci robotic system 
Intuitive  
Laparoscopic rectal 
resection 
Short-term operative outcomes  
(blood loss) and complications 
Oncologic outcomes 
Effective-ness and 
safety 
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Author  
and year  
Study  
type 
Number  
of patients 
Intervention (s) Comparator (s) Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Ventral mesh rectopexy 
Mäkelä-
Kaikonen et al. 
2016 [25], [11] 
Single-centre RCT  
of patients with rectal 
prolapse and 
intussusception 
IG: 16 (total 
relapse 4, intras-
susception 12) 
CG: 14 (total 
relapse 2, intras-
susception 11,  
1 excluded) 
Robot-assisted 
ventral mesh 
rectopexy | da Vinci 
Surgical System 
Laparoscopic 
ventral mesh 
rectopexy 
Perioperative parameters, 
complications and restoration of 
anatomy, postoperative pain via VAS 
Effective-ness and 
safety 
Gallbladder/Liver Spleen 
Cholecystectomy 
Kudsi et al. 
2017 [26] 
International multi-
centre RCT of patients 
with gallbladder 
disease 
136  
(IG: 83, CG: 53) 
Robotic single-site 
cholecystectomy | da 
Vinci Single Site 
Instruments 
Multiport 
laparoscopic 
cholecystectomy 
Patient-perceived cosmesis, patient-
reported satisfaction (BIQ, PSQ) and 
and QoL (SF 12) 
Secondary endpoint: perioperative 
outcomes 
Effective-ness and 
safety 
Pietrabissa  
et al. 2016 [27] 
Single-centre RCT  
of patients with  
gall-bladder lithiasis 
or polyps with  
no evidence of 
choledocholithiasis 
81  
(IG: 40, CG: 41) 
Single incision 
laparoscopic robotic 
cholecystectomy | NR 
Four-port 
laparoscopic 
cholecystectomy 
Primary: Pain at 24 h  
Secondary endpoints: VAS score and 
cosmetic outcome (subjective min  
0-max 10). Further objectives: 
operative times, intra and postoperative 
morbidity, rate of incisional hernia. 
Effective-ness and 
safety 
Grochola et al. 
2018 [28] 
Single centre RCT  
of patients with benign 
gallbladder disease 
60  
(IG 30, CG 30) 
Robot-assisted 
single-site 
cholecystectomy | 
Da Vinci single-site 
TM cholecystectomy 
robotic system  
Single-port 
laparoscopic 
cholecstectomy 
Surgeon’s physical and mental stress 
load. Secondary: intraoperative 
outcomes, complications, health-
related quality of life, cosmesis 
Effective-ness and 
safety 
Ruurda et al. 
2003 [1] 
Single centre RCT  
of patients with 
cholecystolithiasis 
40  
(IG: 20, CG: 20) 
Robot-assisted single-
site cholecystectomy | 
da Vinci telemanipu-
lation system  
Standard 
laparoscopic 
cholecystectomy 
Procedure time Safety 
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Table 3: Main characteristics of studies (non-randomised comparative) included  
Author and 
year or  
study name 
Study  
type 
Number  
of patients 
Intervention (s) Comparator Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Thoracic 
Lobectomy/segmentectomy 
Augustin et al. 
2013 [29] 
Non-randomised 
comparison of all robot-
assisted and consecutive 
conventional minimally 
invasive VATS lobectomies 
52  
(IG: 26, CG: 26) 
Robot-assisted lobectomy 
(5 posterior and 21 anterior 
approach) | da Vinci Surgical 
System (3-arm) 
VATS lung 
lobectomy (anterior 
approach) 
Perioperative events Effective-ness and 
safety 
Gonde et al.  
2017 [30] 
Single-center 1 year 
prospective observational 
cost study 
112  
(IG: 57, CG: 55) 
RATS | da Vinci Surgical 
System (3-arm) 
VATS (modified 
anterior approach) 
Perioperative events & 
resource use 
Effective-ness and 
safety 
Rinieri et al.  
2016 [31] 
Prospective observational 
study  
51  
(IG: 17, CG: 34) 
RATS |da Vinci Surgical 
System (3-arm) 
VATS (anterior 
approach) 
Perioperative events and 
complications 
Effective-ness and 
safety 
Mediastinal surgery 
Balduyck et al. 
2011 [32] 
prospectivenon-
randomised study  
36  
(IG: 14, CG: 22) 
Robot-assisted anterior 
mediastinal mass resection 
| da Vinci robotic system  
Open mediastinal 
mass resection by 
sternotomy 
Quality of life using  
EORTC QLQ-C30  
(cancer core questionnaire) 
and EORTC QLQ-LC-13  
(lung-cancer-specific 
questionnaire module) 
Effective-ness and 
safety 
Oesophagus 
Heller myotomy 
Huffmanm et al. 
2007 [33] 
Single centre prospective 
observational study (conse-
cutive patients over 6 years) 
61  
(IG: 24, CG: 37) 
da Vinci Surgical System 
robot-assisted laparoscopic 
myotomy with partial 
fundoplication 
Laparoscopic 
myotomy with partial 
fundoplication 
Generic and disease-
specific quality of life 
Effective-ness and 
safety 
Sanchez et 
al.2012 [34] 
Single centre, prospective-
comparative study of 
consecutive patients 
31  
(IG: 13, CG: 18) 
da Vinci Surgical System 
robotic assisted laparoscopic 
Heller myotomy 
Laparoscopic Heller 
myotomy 
Efficacy and safety Effective-ness and 
safety 
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Author and 
year or  
study name 
Study  
type 
Number  
of patients 
Intervention (s) Comparator Main  
endpoints 
Included in clinical 
effective-ness and/ 
or safety domain 
Gallbladder/Liver Spleen 
Liver resection/hepatectomy 
Berber et al. 
2010 [35] 
Single centre prospective 
non-randomised study 
32  
(IG: 9, CG: 23) 
Robotic resection of liver 
tumour 
Laparoscopic liver 
resection 
Survival, recurrence, 
perioperative outcomes 
Effective-ness and 
safety 
Lai and Tang 
2016 [36] 
Single centre prospective 
non randomised trial of 
consecutive patients 
130  
(IG: 95, CG:35) 
da Vinci Surgical System 
robot-assisted laparascopic 
partial hepatectomy 
Laparoscopic 
partial hepatectomy 
Survival, perioperative 
outcomes 
Effective-ness and 
safety 
Hernia repair 
Tran et al.  
2011 [37] 
Single centre 
prospectivenon-randomized 
Study 
32  
(IG: 16, CG: 16) 
Robotic Freehand® Robotic 
single-port total extraperi-
toneal inguinal hernia repair 
Laparoscopic 
single-port total 
extraperitoneal 
inguinal hernia repair 
Perioperative outcomes 
and satisfaction 
Effective-ness and 
safety 
Abbreviations: ASA=score American Society of Anesthesiologists; BIQ=body image questionnaire; BMI=body mass index; EORTC QLQ-C30=European Organisation for Research and Treatment  
of Cancer Quality of Life Group; CG=control group; FU=follow-up; GERD=gastroesophageal reflux disease; GORD=gastro-oesophageal reflux disease; GORD HRQOL=Gastro-oesophageal Reflux 
Health-Related Quality of Life scale; GSRS=Gastrointestinal Symptom Rating Scale; ICU=intensive care unit; IG=intervention group; IQR=interquartile range; M=Median; MD=mean difference; 
NR=not reported; ns=not significant; PSQ=photograph series questionnaire; QoL=quality of life; QOLRAD=Quality of Life in Reflux and Dyspepsia; SF-12 (QoL-12)=short form 12; Ø=mean; R=Range; 
RATS=Robot-assisted thoracic surgery; SIRC=single-incision robotic cholecystectomy; TNM=Tumor, nodes, metastasis; VAS=visual analogue scale; VATS=Video-assisted thoracic surgery.  
 
 
2.8 Deviations from project plan 
No deviation has occurred.  
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC) 
3.1 Research questions 
Element ID Research question 
B0001 What is robot-assisted surgery?  
What is open surgery? 
What is laparoscopic/video-assisted thoracoscopic surgery? 
B0002 What is the claimed benefit of robot-assisted surgery in relation to open surgery 
and laparoscopy/VATS? 
B0003 What is the phase of development and implementation of robot-assisted surgery? 
B0004 Who administers robot-assisted surgery?  
In what context and level of care is robot-assisted surgery provided? 
B0008 What kind of special premises are needed to use robot-assisted surgery? 
B0009 What equipment and supplies are needed to use robot-assisted surgery? 
A0020 For which indications/interventions has robot-assisted surgery received 
marketing authorisation or CE marking? 
 
3.2 Results 
Features of the technology and comparators 
[B0001] – What is the technology and the comparator(s)? 
In general, robot-assisted surgery is a form of minimally-invasive surgery. The aim of developing 
robotic surgery was to overcome the limitations (e.g. accessibility of difficult reachable areas) as-
sociated with pre-existing minimally-invasive surgery. The instruments of the robotic system are 
controlled by a direct telemanipulator [38].  
A telemanipulator is a remote manipulator that allows the surgeon to perform the normal move-
ments associated with the surgery, using the robotic arms [39]. 
Robot-assisted surgical systems in development include single-arm units designed to perform sin-
gle-port surgery – also called single-incision surgery – and multi-arm systems typically used for 
multi-port, or multi-incision, procedures. Some manufacturers developing single-port systems de-
signed to access the body via natural orifice describe their systems as allowing “scarless” surgery. 
A comparative potential benefit of multiarm systems over single-arm systems is the ability to per-
form a broader range of surgical procedures due to their allowing for a larger surgical field with cor-
responding greater visualization of the surgical field and their versatility in positioning instruments, 
thus increasing surgeons’ ability to access more anatomy with those instruments. Generally, sin-
gle-port systems may be preferred for less complex surgery, whereas multi-port systems may be 
preferred for more technically challenging procedures7. 
                                                     
7 Emerging Robotic-assisted Surgery Systems, Health Thecnology Forecast, ECRI, 2017 (from: 
https://www.ecri.org/library/general-topics/robotics) 
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Currently there are 17 known manufacturers of robotic systems to aid in surgical procedures (al-
hough one of these is not yet planned for use in thoracic and visceral surgery), of which four are 
currently marketing their products as commercially available in the area of thoracic and visceral 
surgery. These companies are Intuitive Surgical, Inc., Surgica Robotica S.p.A., TransEnterix and 
Freehand 2010 Ltd. 
Intuitive Surgical: da Vinci®: 
Intuitive Surgical, an American corporation and market leader in surgical robots was founded in 
1995 and has launched four generations of robotic surgical systems. The current generation in-
cludes: da Vinci® Xi, SP, and X.  
• The da Vinci® Xi system has four robotic arms. The system includes the most advanced 
instrumentation, vision, and features such as integrated table motion. The Xi is used for a 
variety of complex procedures.  
• The da Vinci® X has the same arm architecture as the Xi, but takes advantage of a number 
of cost-conscious options that reduce the overall price of the system.  
• The da Vinci® SP is designed spefically for single-port accesss. Three multi-jointed instru-
ments and a 3DHD camera are all delivered through a single arm.  
All systems have CE mark and FDA approval. Each system composed of a surgeon console and 
a patient side-cart with boom-mounted robotic arm(s). The surgeon operates at a console (typically 
in the same room as the patient) while viewing a high definition 3D image from inside the patient’s 
body to see anatomical structures in natural colours. The patient side cart(s) is a surgical robotic 
assistant, with multiple arms and detachable instruments, mounted on a cart that can be positioned 
at the surgical site. The system translates the surgeon’s hand, wrist and finger movements into real-
time movements of the wristed surgical instruments. The replaceable wristed instruments (En-
doWrist®) are attached to the arms of the robot. The attached instruments have seven degrees of 
motion and every single instrument available is designed for a specific task (e.g. clamping, cut-
ting, coagulating, dissecting, suturing). Another part of the surgical system is the Vision Cart: posi-
tioned tableside, the system’s central processing unit component includes accessory equipment, 
a surgical video system, and a viewing monitor for the operating team. It is equipped with a high-
definition, 3D endoscope (flexible tube with a camera and light) and image processing equipment 
that provides images of the patient’s anatomy. This 3D HD endoscope is inserted through one of 
the small incisions and is held in place by one of the robotic arms7, 8, 9.  
Surgica Robotica: Surgenius: 
Surgica Robotica, an Italian company, offers one system: Surgenius Beta. The former Alpha Sys-
tem was the first development and it would appear from the manufacturer’s website that this 
product is not commercially available anymore. The Beta version is a further development of the 
Alpha version. The Surgenius Beta is able to cover the entire torso (four abdominal quadrants). 
The robotic tools reach nine degrees of freedom for the surgeon. Beta proved its capabilities with 
operations on the pancreas of mini-pigs and obtained approval in the European Economic Area 
through its CE (Conformité Europeene – European Conformity) Marking Certificate. Presently the 
company is developing the Surgenius Gamma10. 
                                                     
8 https://www.davincisurgerycommunity.com/Systems_I_A/da_Vinci_Si_Si_e  
9 https://www.intuitive.com/about-us/company/legal/safety-information  
10 http://www.surgicarobotica.com/  
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TransEnterix: Senhance™ Surgical System: 
TransEnterix®, an American company, provides the SenhanceTM Surgical System. Initially, the com-
pany marketed another surgical robot (SurgiBotTM System). The FDA rejected the submission for 
SurgiBot system in 2016. In 2015 TransEnterix® also acquired the surgical robot division of SOFAR 
S.p.A with its Telelap ALF-X®. The ALF-X system was renamed the SenhanceTM Surgical System11. 
The new SenhanceTM is a console type robotic platform consisting of a remote control station 
unit, manipulator arms, and a connection node. The robot system comprises three arms, each 
individually mounted on its own cart. It was designed to require only a minimal learning curve with 
familiar laparoscopic motion, trocars and approach. The surgeon sits at a console and telemanipu-
lates the surgical robot. Furthermore, the surgeon has the ability to simultaneously control multiple 
robotic arms, instruments and a camera. Due to its open platform strategy, the SenhanceTM Sys-
tem is compatible with other laparoscopic devices. Moreover, the surgical system provides eye-
tracking that is intended to allow vision control during surgical operations without repositioning the 
camera: this is an evolution of current visualization technologies, such as the da Vinci Surgical 
System’s binocular display controlled by foot-operated switches. Another feature is the haptic feed-
back that provides force feedback: this tactile force feedback translates sensation from an instru-
ment’s distal end to the surgeon’s hand, contrasting da Vinci’s feedback, which is displayed visu-
ally rather than felt by the controller 12 [40].  
Freehand 2010 Ltd Freehand v1.2 
Freehand 2010 Ltd is a company located in the United Kingdom. The company offers a robotic 
camera arm for minimally invasive surgery: this system is composed of a lockable articulating arm, 
an electronic control box, and a robotic motion assembly unit. Mounted on railings around the op-
erating table, the camera can be moved in three dimensions, controlled via operator head move-
ments and laser-pointed guidance. To select the direction of movement, the operator moves his/ 
her head in the desired direction; an LED arrow with the selected direction is then displayed. In 
order to initiate movement, a foot switch is pressed until the camera is in the desired location; 
releasing the switch terminates movement [40]13. 
22 systems have been developed, of which 13 are still in development, 7 are currently commercial-
ly available (da Vinci® Si/Si-e, da Vinci® SP, da Vinci® XI, da Vinci® X, Freehand v1.2, Surgenius 
Beta and Senhance TM Surgical System) and 1 is available for research purposes only. A further 
product Flex® Robotic System is commercially available but is only for transoral and transanal 
surgery. All systems are listed in Table 4. 
  
                                                     
11 https://www.massdevice.com/transenterix-reboots-alf-x-robot-assisted-surgery-platform-senhance/  
12 https://www.senhance.com/us/laparoscopic-surgery-challenges  
13 http://freehandsurgeon.com/Products/Detail/2   
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Table 4: Features of the intervention and development status [40] [41]10, 
Manufacturer Product name Development status Principal 
characteristics/Intended Use 
Applied 
Dexterity 
RAVENTM  
(I, II and III) 
Commercialized as an 
open research platform 
and distributed to 
university clinics and 
research labs 
It was developed with a military’s 
vision (aim: compactness, remote 
control). Multi-arms 
Generic intended use/ 
AVRA Medical 
Robotics 
AVRA Surgical 
Robotic System 
(ASRS) 
In development Semi/autonomous systems 
incorporate artificial intelligence 
for enhanced diagnostic and 
therapeutic capabilities 
Generic intended use 
Cambridge 
Medical Robotics 
Versius In development Multiarms 
Generic intended use 
CAST MIVR (Miniature  
in vivo robot) 
In development Two Arms 
miniaturization of robotic arms and 
the motors that drive them 
DLR Robotics MiroSurge In development Multiarm 
Multipurpose (laparoscopic) 
Haptic fedback 
Freehand® FREEHAND V1.2 FDA approval (2009) 
CE Mark (2009 
There is one robotic video arm, 
which one can be controlled by 
footswitch and a Headset.  
Intuitive Surgical First generation of 
products: da Vinci® 
FDA approval (2003)  
CE Mark (2003) 
da Vinci (IS1200) is no longer on 
the Notified Product List and 
Declaration of Conformity, so  
it is no longer supported as a  
CE-marked product 
Second generation 
of products:  
da Vinci® S 
FDA approval (2009) 
CE Mark (2007) 
da Vinci S (IS2000) is no longer 
on the Notified Product List and 
Declaration of Conformity, so  
it is no longer supported as a  
CE-marked product. 
Third generation of 
products: da Vinci® 
Si or Si-e Surgical 
System 
FDA approval 
(2009/10) 
CE mark (2009/10) 
Four robotics arms (Vinci® Si) 
Three robotic arms (da Vinci® Si-e) 
Multi intended use (for details see 
FDA and CE) 
Fourth generation 
of products: da 
Vinci® Xi; da Vinci® 
X; da Vinci® SP 
Xi: FDA approval (2014); 
CE mark (2014) 
X : FDA approval (2017); 
CE mark (2017) 
SP : FDA approval 
(2018); no CE mark 
Advancement of da Vinci® Si in 
particular arms are thinner and 
instruments longer. 
The Xi’s arms also include a new 
“patient clearance joint” that is 
designed to facilitate intraoperative 
arm adjustments and to provide  
a wider range of motion than is 
possible with the Si and Si-e. 
X is similar to the da Vinci Xi 
architecture but at a lower cost 
Multi intended use (for details  
see FDA and CE) 
Medical Robotic 
Technolgies 
SOFIE (Surgeon’s 
Operating Force-
feedback Interface 
Eindhoven) 
In development Compact, Haptic feedback,  
Multi-arms 
Generic intended use 
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Medrobotics Flex® Robotic 
System14 
FDA clearances (2018) 
CE mark (2014 ) 
highly articulated, serpentine 
scope but only for use in transanal 
or transoral surgery 
Medtronic Hugo In development multiarm, multipurpose  
Meere Company REVO-I  In development 
CE mark  
(planned for 2019)15 
multiarm 
general endoscopic surgery, 
including cholecystectomy and 
prostatectomy  
Nanyang 
Technological 
University and 
National 
University 
Health System 
MASTER In development transluminal endoscopic robot 
two arms 
Surgica 
Robotica S.p.A.16  
Surgenius Beta CE mark (2012) Multiarms  
Generic intended use 
Surgenius Gamma In development Confidential  
Titan Medical17 Single Sport Orifice 
Robotic Technology 
(SPORTTM) 
Surgical System 
In development 
(launch and approval 
planned for 2019) 
Single-port access 
Multiarms 
Generic intended use 
(including general abdominal, 
gynecologic, and urologic 
indications) 
TransEnterix SenhanceTM 
Surgical System 
(Former Telelap 
ALF-X ®)  
FDA approval (2017) 
CE mark (2017) 
Eye-tracking system , haptic 
feedback 
Multi-arms 
indicated for adult use and for 
laparoscopic surgery (although 
different indications for use 
between FDAand CE 
certification18) 
SurgiBot In development Mobile, Single-port access 
Verb Surgical - In development (launch 
planned for 2020) 
Cooperation of Google parent 
Alphabet Inc.’s Verily Life Sciences 
and Johnson & Johnson 
Virtual Incision - In development Single-port 
Intended use abdominal surgery  
 
                                                     
14 Robotic system marketed for transoral and transanal surgery.  
Manufacturer is not commercially active in thoracic and visceral surgery. 
15 REVO-I has Korean FDA-approval so far (2017) 
16 Manufacturer was contacted via e-mail on the 16th May and 12th June 2018. However, no answer was received. 
17 Manufacturer was first contacted on the 16th May via the contact formula on the manufacturers website. After several 
e-mails and phone calls with representatives of the manufacturer the contact was discontinued without any additional 
information from the manufacturer. 
18 FDA: The Senhance Surgical System is intended for use in laparoscopic gynecological surgery, colorectal surgery, chol-
ecystectomy, and inguinal hernia repair. CE: is intended to be used for laparoscopic surgery in the abdomen, pelvis and 
limited uses in the thoracic cavity excluding the heart and greater vessels.   
(from: https://www.senhance.com/us/senhance-indication) 
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What is open surgery? 
Open surgery is a type of surgery in which an incision is made using a scalpel to fully expose the 
area of the body on which the operation will be performed. The surgeon inserts the instruments 
through the incision and conducts the surgery. Selected surgeries are still performed using the 
traditional open incision (especially for the resection of larges masses), but many more are con-
ducted using minimally invasive techniques [42].  
 
What is laparoscopic/video-assisted thoracoscopic surgery? 
Laparoscopic and video-assisted thoracoscopic surgeries (VATS) are minimally invasive approach-
es, meaning that the incision is smaller than the usual open incision. It is also known as keyhole 
surgery. Whereas one incision is required to place the laparoscope (a viewing telescope attached 
to a camera and light source) that allows the surgeon to see the operative area on the video moni-
tor, two or three other small incisions are made to place the surgical instruments [38].  
In laparoscopic surgery, the surgeon performs the procedure holding rigid instruments and views 
the surgical area through an endoscopic camera that is projected onto a monitor. The laparoscopic 
tools move in the opposite direction of the surgeon’s hands due to the pivot point design. Further-
more, the instruments used in traditional laparoscopy normally have four degrees of movement. In 
some cases, a surgery may start out as a minimally invasive procedure, but then convert to the 
larger open incision procedure if the surgeon needs more flexibility of movement or due to an oc-
curring adverse event [38]. 
VATS is a type of minimally invasive surgery, comparable to laparoscopy, which does not require 
the formal thoracotomy incisions, especially the cuts through the ribs or breastbone (sternum). 
VATS is principally performed in the management of pulmonary, mediastinal, and pleural patholo-
gy. The instrumentation for VATS includes the use of a camera-linked optic scope and either con-
ventional thoracic instruments or laparoscopic instruments. In general, VATS and laparoscopic 
surgery are similar surgical approaches. However, unlike with laparoscopy, carbon dioxide insuf-
flation is not generally required with VATS [43]. 
 
[B0002] – What is the claimed benefit of the technology in relation to the comparator(s)? 
Minimally invasive surgery is generally considered superior to open surgery since, assuming sur-
geons are equally skilled in both procedures, the minimally invasive technique is associated with a 
lower risk of infection, shorter recovery times and equally successful outcomes19. These claimed 
benefits of laparoscopic surgery over open surgery also apply for robotic surgery vs. open surgery.  
Nevertheless, robotic surgery is an advanced form of minimally invasive or laparoscopic surgery 
requiring the surgeon to operate a robot. The robot has a higher degree of dexterity compared to 
the laparoscopic approach, allowing surgeons the ability to operate in very tight spaces in the body 
that would otherwise only be accessible through open surgery.  
Robot-assisted surgery is supposed to achieve the safety established with open surgery and the 
reduced patient burden associated with minimally-invasive surgery. However, the robotic approach 
may also confer additional clinical and economic benefits beyond open and laparoscopic surgery. 
The benefits are claimed to relate to improved quality of life, reduction in healthcare resource utiliza-
                                                     
19 https://www.sages.org/publications/patient-information/patient-information-for-laparoscopic-appendectomy-from-sages/ 
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tion, improved perioperative and oncological clinical outcomes. It is also thought to allow surgeons 
to work more ergonomically, resulting in less strain. The degree of improvement varies across mo-
dalities but tends to be most apparent when comparing robot-assisted surgery with open surgery. 
The claimed benefits of robot-assisted surgery compared to open surgery and/or laparoscopic sur-
gery are as follows [39]20 
Healthcare Utilization: 
• Reduced length of stay 
• Fewer Readmissions 
• Reduced ICU Time 
• Fewer post-surgery diagnostic tests 
• Reduction in need for catheters and other accessories  
• Hospital bed utilization 
• Shift to outpatient surgery 
Clinical Outcomes: 
• Reduced blood loss volume 
• Fewer transfusions 
• Lower overall complication rate 
• Fewer conversions to open or laparoscopic surgery 
• Lower Positive Surgical Margins  
• Reduced surgical trauma to tissue 
Improved Quality Of Life: 
• Improvement in patient reported outcomes  
• Faster return to work for patients 
• Reduced burden on caregivers 
• Reduced operative pain and discomfort 
• Less carring and improved cosmesis 
 
[B0003] – What is the phase of development and implementation  
of the technology and the comparator(s)?  
Robotic surgery has been increasingly implemented during the last 10 to 15 years. Minimally-
invasive interventions, performed by laparoscopy, are very common in certain areas (e.g. chole-
cystectomy). However, in more complex surgeries (e.g. prostatectomy) laparoscopy is associated 
with a longer learning curve and surgeons often face technical challenges. It is these challenges 
that surgical robots are intended to assist surgeons in overcoming. Robot-assisted surgery is very 
common in certain interventions (e.g. prostatectomy) whilst the list of eligible surgeries for robotic 
support is growing. The da Vinci Surgical System for example is at present employed most exten-
sively in the areas of urological, visceral, head and neck, and thoracic surgery [39].  
                                                     
20 https://www.intuitive.com/about-us/company/legal/safety-information  
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[B0004] – Who administers the technology and the comparator(s)  
and in what context and level of care are they provided? 
In robot-assisted surgery, performed with the commercially available systems in the European 
Union, a trained surgeon is always in control of the device.  
The aim of the currently available robotic systems is to provide technology to assist surgeons; 
they do not replace surgeons. These devices are a tool that surgeons can choose to use to pro-
vide their patients with a further minimally invasive surgical option. There are no additional per-
sonnel requirements according to the manufacturers; the personnel required is the same as for an 
open or laparoscopic intervention. However, additional training and learning is required to operate 
all systems21, 22 
Other issues associated with robot-assisted surgery are the need for additional pre- and postop-
erative procedures related to preparing, cleaning, and maintaining the system and proprietary 
instrumentation. TransEnterix has stated that switching the reusable surgical instruments for its 
Senhance system is a quick and simple process and that the Senhance system offers per-pro-
cedure costs comparable to those of conventional laparoscopic surgery 10, 14. 
 
[B0008] – What kind of special premises  
are needed to use the technology and the comparator(s)? 
The robotic systems typically consist of a surgeon’s console and a patient-side cart with three to 
four interactive robotic arms controlled from the console. The arms are for tools that hold objects 
and can also act as scalpels, scissors, or graspers. The surgeon uses the console’s master con-
trols to manoeuvre the patient-side cart’s robotic arms. The robotic surgical system is large and 
although it may fit in most operating room suites, renovation or new construction of operating 
rooms may be needed in some cases. In order to justify the cost of robotic systems, hospitals may 
need to apportion its use among several clinical departments10, 14. 
 
[B0009] – What equipment and supplies  
are needed to use the technology and the comparator(s)? 
The capital costs include upgrades and accessories typically purchased with each system (e.g. for 
the da Vinci system these may include da Vinci Skills Simulator, endoscope and Integrated Table 
Motion). There are also specialized surgical instruments designed to offer surgeons better dexteri-
ty and a full range of motion through small incisions. Each interchangeable instrument has a spe-
cific function including grasping, cutting, blunt and sharp dissection, approximation, ligation, sutur-
ing, and electrocautery. 
In the literature there are several studies detailing costs, but the heterogeneity and publication 
bias of the studies make analysis difficult. For example studies report costs incurred at different 
time periods of the learning curve (which may impact staff and material costs), use different tech-
niques in laparoscopic and robotic groups (such as the type of device, hybrid versus totally robotic 
techniques etc.) and have different volumes of patients which may affect the distribution of organ-
isation and related costs. Added to which there is the general variability in costs between hospi-
tals and countries.  
                                                     
21 https://www.intuitive.com/about-us/company/legal/safety-information  
22 https://www.senhance.com/us/laparoscopic-surgery-challenges 
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In a systematic review and meta-analysis of the literature, Fuertes-Guiró et al. [44] reported the 
differences in the total cost of surgery and operative time in traditional laparoscopic surgery and 
da Vinci robotic surgery as follows: da Vinci robot-assisted surgery is associated with signfiicantly 
higher costs compared with traditional laparoscopic surgery (p<0.00001). Robotic surgery takes 
longer (8.0–65.5 min) than traditional surgery (p<0.00001), and this difference represents an av-
erage opportunity cost for robot use of € 489.98, with a unit cost factor/time which varies accord-
ing to the pathology dealt with, from € 8.2 to 18.7/min.  
10 of the studies included in this HTA considered cost aspects, all of which reported higher costs 
with robot-assisted surgery than with the comparator. 2 studies related to the area of thoracic 
surgery [29], [30]. One of these studies found procedural costs to be 44% higher for the robotic 
approach, equating to a difference of € 770.55 per operation [29]. The other study reported a me-
dian cost per procedure of € 10,972 for robot-assisted surgery and € 9,637 for VATS (p<0.01). All 
3 of the antireflux/fundoplication studies that measured costs [14] [11] [12] reported higher costs 
with the robot-assisted technique. In one study, robot-assisted surgery was more than four times 
more expensive than the comparator; individual cost elements that were significantly higher includ-
ed disposable materials, re-usable materials, staffing (nurse) costs, investment and maintenance 
[14]. In another study, mean total costs per procedure were €3244 ± 512 in the robot-assisted fun-
doplication group vs. € 2743 ± 483 in the laparoscopic fundoplication group (p<0.01) [12]. Similarly 
Morino et al [11] reported significantly higher mean total costs per procedure of € 3157 in the ro-
bot-assisted group versus €1527 in the laparoscopic fundoplication group (p<0.001). Two studies 
in the area of bowel surgery reported cost results: in the rectal resection study [20], mean costs 
per procedure in the robot-assisted group were £11,853 vs. £ 10,874 in the conventional laparos-
copy group (mean difference of £980, p<0.05). Main drivers of higher costs in this study were longer 
use of the operating theatre and the cost of instruments. Park et al [19] similarly attributed the higher 
costs associated with robot-assisted surgery (US $12,235 vs. $10,320, p<0.05) to the costs of sur-
gery, primarily consumables. Lastly, robot-assisted cholecystectomy was also found to be more 
expensive than laparoscopic single-incision cholecystectomy (median 9734 CHF vs. 6900 CHF 
respectively, p=0.001) [28]. 
Extensive, highly specialized training and an adequate volume of cases are required for surgeons 
and their surgical teams to maintain proficiency. The surgical team requires training to learn how 
to set-up the system and how to make any necessary adjustments during a procedure. The learn-
ing curve may result in longer surgical times that can reduce the number of procedures that can 
be scheduled in a day until clinical staff gain experience.  
Robot-specific consumables for the da Vinci system also represent a high cost and are significant-
ly more expensive than those required to perform open surgery or conventional minimal invasive 
surgery. For example, the da Vinci system’s EndoWrist instruments – which can be used 10 times, 
after which the system refuses to accept them – are expensive compared to their traditional-sur-
gery counterparts and make up the bulk of the additional consumable cost23. 
Surgeons require training on how to learn to use the system. Some experts advise that new surgeons 
should already have extensive experience in minimally invasive surgery before attempting robot-as-
sisted surgery. If there is a malfunction or emergency during the surgery, the surgeon will need the 
skills to finish the surgery manually. The manufacturer provides onsite and offsite training for surgeons 
and clinical support staff. Offsite training consists of lectures and hands-on sessions that address 
system skills for various applications. Typically, surgeons or hospitals request that a surgeon expe-
rienced in robot-assisted procedures be present to supervise new surgeons for initial cases10, 14. 
                                                     
23 DA VINCI DECISIONS HEALTH DEVICES JANUARY 2013 www.ecri.org 
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Intuitive Surgical recommends different learning programs, which are intended for surgeons who 
seek to develop the knowledge and skills necessary to use da Vinci surgical systems and da Vinci 
technology.24 However, these programs are said to only cover the initial phase of the learning pro-
cess. It is claimed that self-directed study and practice are additionally required to master the tech-
nology. Intuitive Surgical refers to the learning process as the “da Vinci Technology Training Path-
way” (TTP) which consists of the following phases and elements: 
• Phase 1 – Introduction to da Vinci Technology 
• Phase 2 – da Vinci Technology Training 
• Phase 3 – Initial Case Series Plan 
• Phase 4 – Continuing Development 
Whilst acknowledging that the responsibility of developing and updating the training program for 
any surgical area must be led and managed by its respective professional surgical societies, Intui-
tive proffers to provide support and services including simulation, core technology, and skill ad-
vancement. In addition, the company states that there are procedure analytics to help optimize the 
effectiveness of each hospital’s surgical program25. 
TransEnterix established surgical training and innovation centers in Orlando, FL, USA, in August 
2017, and Milan, Italy, in December 2016. 
However, no consensus or recognized standards exist regarding optimal training programs for ro-
bot-assisted surgery. To address this need, some professional organizations have begun develop-
ing guidance to help healthcare facilities address the need for adequate training in robot-assisted 
surgery as it pertains generally to their respective clinical disciplines or to specific surgical proce-
dures. For example, the American Association of Gynecologic Laparoscopists has published guide-
lines for recognising clinicians as proficient in robot-assisted gynecologic laparoscopy [41]. Simi-
larly, the American Urological Association has formulated standard operating practices to guide 
hospitals in granting urologists credentials and privileges to perform robotic surgery at their institu-
tions [41]. The Society of American Gastrointestinal and Endoscopic Surgeons and the Minimally 
Invasive Robotic Association published a consensus statement on robotic surgery, including guide-
lines for training and credentialing, in 2008, which recommends the following [41]: 
• Training in robot-assisted surgery should involve both the acquisition of technical skills and 
practical use of the robot in specific operations. 
• Training programs should involve an expert instructor who provides didactic lessons on the 
“technology, device function, altered functional status, basic troubleshooting, other technical 
issues, and device parameters and limitations.” 
• Instructors should also discuss team interaction and procedure-specific information, includ-
ing “indications, workup, patient selection, instrumentation, preoperative preparation, patient 
and system positioning, port placement, procedural steps, complications, and management.” 
• Didactic training should also include a “discussion of issues related to the learning curve, 
reported outcomes, and expected perioperative course.” 
• Didactic training should be followed by live case observation, including “procedure prepara-
tion, system setup, patient positioning, review of case selection, and intraoperative technical 
aspects.” 
                                                     
24 The learning programs outlined in this section are based on information gathered from Intuitive Surgical.  
Since the other manufacturers did not answer our requests, no further information can be provided. 
25 https://www.intuitive.com/about-us/company/legal/safety-information  
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• After observing at least one complete procedure, trainees should receive hands-on experi-
ence, including “nonclinical simulation encompassing system setup, connections, operation, 
and troubleshooting,” initial skill training to develop procedure-specific skills, and clinical 
simulation. 
However, TransEnterix, Titan Medical, and other manufacturers in earlier development have stat-
ed generally that their robotic systems are designed to take advantage of laparoscopic surgeons’ 
existing skills and experience and will be technically familiar to laparoscopic surgeons10, 14. 
 
[A0020] – For which indications has the technology received marketing  
authorisation or CE marking? 
Please see Table 4 for a summary of the regulatory status.  
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What is the thoracic or visceral surgery and for which diseases  
or health conditions is it used? 
A0003 What are the known risk factors for the diseases or health conditions treated  
by thoracic or visceral surgery? 
A0004 What is the natural course of the diseases or health conditions treated  
by thoracic or visceral surgery? 
A0005 What are the symptoms and the burden of diseases or health conditions  
for the patient? 
A0006 What are the consequences of the diseases or health conditions for the society?  
A0007 What are the target populations in this assessment? 
A0023 How many people belong to the target populations? 
A0024 How are the diseases or health conditions currently diagnosed according  
to published guidelines and in practice? 
A0025 How are the diseases or health conditions currently managed according  
to published guidelines and in practice? 
A0011 How much is robot-assisted surgery utilised? 
Questions A0003-A0006 are answered together since it is beyond the scope of this HTA to detail 
each possible disease – as well as its causes and effects – for which thoracic and visceral surgery 
can be employed as a treatment option.  
 
4.2 Results 
Overview of the disease or health condition 
[A0002] – What is thoracic or visceral surgery and for which diseases  
or health condition is it used? 
This assessment looks at the use of robot-assisted surgery in the area of thoracic and visceral 
surgery. Thoracic surgery is concerned with conditions of the lungs, chest wall and diaphragm and 
is generally dominated by treatment of malignant disease. Visceral surgery deals with all aspects 
of the surgical treatment of benign and malignant diseases of abdominal organs, the entire gastro-
intestinal tract, endocrine organs, the abdominal wall and the peritoneum. 
Within this HTA-assessment of surgical procedures performed with the assistance of robots, the 
following specific disease areas and procedures were included: 
Surgical procedures for thoracic surgery relates to diseases of the lung, ribs and pulmonary pleu-
ra, mediastinum and chest. Often these diseases are specifically related to cancer. Here included 
operative procedures, in accordance with the project plan, were pulmonary lobectomy, lung seg-
mentectomy and mediastinal surgery26.  
                                                     
26 Pleurectomy and pleurla/pulmonary decortication were recommended to be excluded from PICO by manufacturer  
and by external clinical expert 
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Surgical procedures for visceral (abdominal) surgery are related to surgery of the intestinal 
system (gastroenterological surgery), the oesophagus, stomach, small and large intestine, spleen, 
liver and gall bladder system. Here included operative procedures, in accordance with the project 
plan, were anti-reflux surgery/fundoplication, oesophagectomy or oesophageal repair, heller myo-
tomy, gastrectomy, bariatric surgery, small bowel resection, colectomy, rectal resection, cholecys-
tectomy, liver resection/hepatectomy and hernia repair27.  
As defined in the project proposal, diseases and diagnoses for which thoracic surgery was consid-
ered appropriate included lung neoplasms and neoplasms of the thymus, thorax and mediastinum. 
For visceral (abdominal) surgery underlying diseases or conditions for which surgical procedures 
could be deemed relevant included reflux disease, diseases and neoplasm of the oesophagus, 
swallowing disorders/achalasia, stomach neoplasms, obesity, neoplasms of the colon, rectum and 
anus, Crohn’s disease, ulcerative colitis, rectal prolapse, cholecystitis, neoplasm of the gallbladder, 
liver and bile, and hernia. 
 
Effects of the disease or health condition 
[A0003] – What are the known risk factors for the diseases or health conditions treated  
by thoracic or visceral surgery? 
[A0004] – What is the natural course of the diseases or health conditions treated  
by thoracic or visceral surgery?  
[A0005] – What are the symptoms and the burden of disease or health condition  
for the patient? 
[A0006] – What are the consequences of the disease or health condition for the society? 
As stated above, visceral and thoracic surgery covers a variety of individual surgical procedures 
and is employed to treat a wide variety of conditions, both malignant disease and non-cancerous 
disease. 
Lung & chest 
Thoracic surgery (pulmonary lobectomy, lung segmentectomy and mediastinal surgery) is primari-
ly used to treat non-small-cell-lung cancer and small-cell lung cancer28. Primary lung cancer re-
mains the most common malignancy after non-melanocytic skin cancer, and deaths from lung can-
cer exceed those from any other malignancy worldwide. The number of lung cancer-related deaths 
in Europe for 2017 was estimated to represent the leading cause of cancer deaths in both gen-
ders (24% in males and 15% in females) [45]. Non-small cell lung cancer (NSCLC) accounts for 
80%–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency 
in many countries over the past two decades whilst around 70% of lung cancer is attributed to 
tobacco smoking [45]. Aside from lung cancer, conditions requiring thoracic surgery include tuber-
culosis (TB), lung abscess, emphysema, non-cancerous tumors, and fungal infections29.  
 
                                                     
27 Appendectomy was recommended to be excluded by the external expert whilst splenectomy/pancreatectomy  
was recommended to be excluded by both the external clinical expert and by the manufacturer 
28 https://www.nice.org.uk/guidance/cg121/chapter/1-Guidance#treatment 
29 https://www.uabmedicine.org/patient-care/treatments/lobectomy-lung- 
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Mediastinal tumors are benign or cancerous growths that form in the area of the chest that sepa-
rates the lungs and are in general rare. Mediastinal tumors are usually diagnosed in patients aged 
30 to 50 years and almost 40% of people who have mediastinal tumors experience no symp-
toms30. Most of the growths are often discovered on a chest x-ray that is performed for another 
reason31. Thymic epithelial tumours are the most frequent cause of anterior mediastinal mass, ac-
counting for 35% of cases [46]. 
Oesphagus  
Turning to visceral surgery, gastroesophageal reflux disease (GERD) is one of the most fre-
quent benign disorders of the upper gastrointestinal tract. Gastroesophageal reflux disease can 
be defined as troublesome symptoms that are sufficient to impair an individual’s quality of life that 
result from the retrograde flow of gastric contents into the esophagus, oropharynx, and/or respira-
tory tract [47]. The two most frequently reported symptoms of GERD, heartburn or acid regurgita-
tion, are reported by one out of five people on a weekly basis and two out of five people experience 
heartburn or acid regurgitation at least once a month32. Barrett’s esophagus (BE) refers to the en-
doscopic presence, confirmed histologically, of columnar-lined esophagus. This is currently the only 
identifiable complication of GERD that is known to have malignant potential. 
Oesophageal cancer has two main subtypes – oesophageal squamous cell carcinoma – which 
accounts for the vast majority of cases, and oesophageal adenocarcinoma. Oesophageal carcino-
ma is rare in young people and increases in incidence with age; main risk factors for oesophageal 
squamous cell carcinoma in Western countries are smoking and alcohol consumption, whereas 
the rarer subtype predominantly occurs in patients with chronic gastro-oesophageal reflux disease 
and their risk is correlated with the patient’s body mass index with a higher risk among obese 
persons [48]. 
Perforation of the oesophagus results in significant morbidity and potential mortality, depending 
on the cause and location of the injury, as well as time to diagnosis and treatment. It can have in-
strumental causes such as endoscopy and non-instrumental causes such as operative trauma [49]. 
Achalasia is a relatively rare oesophageal motor disorder with an estimated incidence of 0.7 to 
1.6 per 100,000 inhabitants/year [50] whilst oesophageal cancer is the 19th most common cancer 
in the European Union (EU), with around 45 900 new cases diagnosed in 2012 [48]. 
Stomach 
Almost one million new cases of gastric cancer were diagnosed globally in 2012; gastric cancer 
displays significant global variation in incidence with lower rates in North America and Western 
Europe [51]. Risk factors for gastric cancer include male gender, Helicobacter pylori infection, to-
bacco use, atrophic gastritis, partial gastrectomy and Ménétrier’s disease [51]. Tumours of the 
proximal stomach (cardia) are associated with obesity, and tumours of the gastroesophageal junc-
tion are associated with reflux and Barrett’s oesophagus and are more common in non-Asian coun-
tries [51]. 
 
                                                     
30 https://my.clevelandclinic.org/health/diseases/13792-mediastinal-tumor  
31 https://my.clevelandclinic.org/health/diseases/13792-mediastinal-tumor  
32 https://www.aboutgerd.org/prevalence.html  
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One-third of U.S. adults were considered obese in 2009–2010 (BMI ≥30 kg/m2), with obesity 
being associated with an increased hazard ratio for allcause mortality, as well as significant medi-
cal and psychological comorbidity [52]. The prevalence of obesity has tripled since the 1980s in 
many countries of the WHO European Region with overweight and obesity thought to affect 50% 
of the population in many European countries [53]. 
Bowel/small and large intestine 
The incidence of rectal cancer in the European Union is estimated at 125,000 per year, which 
corresponds to 35% of the total colorectal cancer incidence [54]. Risk factors for rectal cancer are 
high BMI, body or abdominal fatness, diabetes type II with longstanding ulcerative colitis and 
Crohn’s disease. Excessive consumption of red or processed meat and tobacco as well as mod-
erate/heavy alcohol act to increase the risk [54]. 
Colorectal cancer is the third most common tumour in men and the second in women, account-
ing for 10% of all tumour types worldwide, and is rare before 40 years of age (nearly 70% of pa-
tients with colon cancer are over 65 years of age) [54]. Mortality has declined progressively in many 
Western countries due to cancer screening programmes, removal of adenomas, early detection of 
cancerous lesions and the availability of more effective therapies for early stage disease [55]. Risk 
factors are lifestyle or behavioural factors (such as smoking, high red meat consumption, obesity, 
physical inactivity) and genetically determinant factors [55]. 
According to the American College of Gastroenterology, benign anorectal disorders include disor-
ders of function such as defecation disorders, fecal incontinence, and proctalgia syndromes, where-
as disorders of structure include rectal prolapse, anal fissure and hemorrhoids [56]. Rectal pro-
lapse is a condition in which the rectum (the last part of the large intestine) loses the normal at-
tachments that keep it fixed inside the body, allowing it to slide out through the anal opening33. 
Rectal prolapse affects mostly adults and women ages 50 and older have six times the risk as 
men. It is a condition that can be very embarrassing and impacts negatively quality of life34. 
Spleen, liver and gallbladder 
Small stones can form in the gallbladder as a result of an imbalance in the substances that make 
up bile which occasionally block the flow of bile and irritate the gallbladder (acute cholecystitis) or 
pancreas (acute pancreatitis). This can cause symptoms such as sudden and intense abdominal 
pain, nausea and jaundice35, however most people with gallstone disease have asymptomatic 
gallbladder stones and the disease – if diagnosed– is often identified as a result of investigations 
for other conditions [57]. In Europe about 10% of all adults have gallstones, with women having 3 
times the prevalence of men during the fertile period; the prevalence rises with age in both sexes 
[58]. 
Liver cancer (or hepatocellular carcinoma) was the fifth most common cancer in men and the 
ninth in women, and the second most common cause of cancer-related death worldwide in 2012 
[59]. In Europe, the estimated incidence rate in 2012 was 10 in men and 3.3 in women per 100,000 
[59]. The incidence of HCC shows a strong male preponderance and increases progressively with 
advancing age in all populations; risk factors include obesity, type 2 diabetes and alcohol consump-
tion [59]. 
                                                     
33 https://www.fascrs.org/patients/disease-condition/rectal-prolapse-0  
34 https://www.fascrs.org/patients/disease-condition/rectal-prolapse-0  
35 https://www.nhs.uk/conditions/gallbladder-removal/  
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 43 
The lifetime occurrence of hernia (viscera or adipose tissue protrusions through the inguinal or 
femoral canal) is reported to be 27–43% in men and 3–6% in women; inguinal hernias are almost 
always symptomatic and the only cure is surgery [60]. Risk factors include inheritance, abnormal 
collagen metabolism, male gender, age, previous prostatectomy and low BMI [60]. 
 
Target population 
[A0007] – What is the target population of this assessment? 
The target population in question is patients requiring surgery for a number of different thoracic 
and visceral conditions.  
 
[A0023] – How many people belong to the target population? 
This question is not answered as several different surgical procedures are included in the HTA 
covering many different target populations, as described earlier in this chapter. However some 
information on epidemiology is provided in the preceding section.  
 
Current clinical diagnosis and management of the disease or health condition 
[A0024] – How is the disease or health condition currently diagnosed  
according to published guidelines and in practice?  
[A0025] – How is the disease or health condition currently managed  
according to published guidelines and in practice? 
Lung & chest 
Starting with the main indication for thoracic surgery, which is lung cancer, symptoms for this dis-
ease occur late in the stage of the disease, so the majority of patients with lung cancer present with 
advanced disease. The cornerstone of treatment of potentially resectable lung cancer is surgical 
removal of the tumour. Whether surgery should be done through standard open thoracotomy, or a 
video-assisted thoracoscopic surgery (VATS) procedure, is probably less important from an onco-
logical perspective, according to the European Society for Medical Oncology [55], since compara-
tive margin clearance and nodal dissection can be achieved with both methods. This organisation 
recommends surgery is offered to all patients with stage I and II NSCLC, and specifically that VATS 
should be the approach of choice in stage 1 tumours. However this recommendation only has a 
grading of V (evidence from studies without control group, case reports, expert opinions) and C 
(Insufficient evidence for efficacy). The guideline makes no mention of whether robotic approach-
es to VATS should be considered [55]. The NCCN guideline recommends that VATS or minimally 
invasive surgery (including robot-assisted approaches) should be strongly considered in patients 
suitable for surgery, however this guideline notes that robotic VATS seems to be more expensive 
and associated with longer operating times than conventional VATS [61]. 
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The treatment used for mediastinal tumors depends on the type of tumor and its location with 
thymic cancers and neurogentic tumors treated surgically36. There is no recognised clinical stag-
ing system and the treatment strategy depends on whether it is possible to resect the tumour up-
front or not [46]. Minimally invasive surgery, including robotic approaches, is considered to be an 
option for presumed stage I and possibly stage II tumours, assuming appropriately trained thorac-
ic surgeons are available; evidence level IV (retrospective cohort studies or case-control studies); 
grade of recommendation C (insufficient evidence for efficacy) [46]. The European Society of Med-
ical Oncology considers robotic surgery might allow a better visualisation of the tumour when com-
pared to VATS although no recommendation level is provided [46]. 
Oesphagus 
Turning to visceral surgery, one of the main indications for non-cancer surgery relates to antireflux 
surgery for an oesophageal GERD syndrome. This is recommended where a patient is intolerant 
of acid suppressive therapy (grade A recommendation) as well as those with persistent, trouble-
some symptoms despite PPI therapy (grade B recommendation). For those with an extraoesoph-
ageal GERD syndrome and persistent, troublesome symptoms despite PPI therapy, the balance 
of benefits and harms is however too close to justify a general recommendation. Generally, patients 
who are well maintained on medical therapy should not be recommended for surgery [62]. At the 
European level, the European Association of Endoscopic Surgery considers laparoscopic fundopli-
cation as one of the most successful surgical operations for GERD [63] although the World Gas-
trological Organisation considers surgical intervention (usually fundoplication) to be rarely indicat-
ed in GERD patients [47]. None of these guidelines mention the use of robot-assisted approaches 
to laparoscopy.  
According to the Society of American Gastrointestinal and Endoscopic Surgeons Guidelines for the 
Surgical Treatment of Esophageal Achalasia [64], laparoscopic Heller myotomy with partial fun-
doplication provides superior and longer-lasting symptom relief with low morbidity for patients with 
achalasia compared with other treatment modalities and should be considered the procedure of 
choice to treat achalasia (high quality of evidence ++++; strong recommendation). This US guide-
line specifically mentions robotic assistance which it considers has been demonstrated to decrease 
the rate of intraoperative esophageal mucosal perforations (low quality of evidence ++; weak rec-
ommendation), although it states that there are no clear described differences in postoperative 
morbidity, symptom relief, or long-term outcomes between robotic and conventional laparoscopic 
techniques [64].  
Surgery is the treatment of choice in limited oesophageal cancer (where local or locoregional 
disease only is present). This can take the form of endoscopic resection or oesophagectomy, de-
pending on the stage of disease and risk criteria [48]. Oesophageal repair is necessary in cases of 
oesophageal perforation [49].  
Stomach 
Surgical resection of gastric cancer, specifically at early stages, is potentially curative with the 
extent of resection necessary determined by the preoperative stage [51]. For stage IB–III gastric 
cancer, radical gastrectomy is indicated. Laparoscopic surgery is becoming one of the recommend-
ed options for patients with early gastric cancer; however, it remains to be shown whether laparo-
scopic surgery can achieve the same results as open surgery in gastric cancers requiring D2 lym-
phadenectomy [51]. 
                                                     
36 https://my.clevelandclinic.org/health/diseases/13792-mediastinal-tumor/management-and-treatment 
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Bariatric surgery has proven to be the most effective mode of treatment for morbidly obese pa-
tients. It is reported that recent long-term studies provide evidence of a substantial reduction in 
mortality among bariatric surgery patients, as well as a decreased risk of developing new health-
related co-morbidities, together with decreased health care utilization and a drop in direct health 
care costs [53]. Patients are indicatd for bariatric surgery if they are 18 to 60 years old with BMI 
≥ 40 kg/m 2 or with BMI 35–40 kg/m 2 with co-morbidities and should have failed to lose weight or 
to maintain long-term weight loss, despite appropriate surgical and/or non-surgical comprehensive 
medical care [53]. Standard bariatric and metabolic procedures include adjustable gastric band-
ing, sleeve gastrectomy, Roux-en-Y gastric bypass, biliopancreatic diversion and duodenal switch 
[53]. The European guideline recommends that a laparoscopic technique should be considered as 
the preferable approach to the operation in bariatric surgery, providing no contraindications for the 
laparoscopic approach are present. However robot-assisted approaches are not mentioned by this 
guideline [53]. The U.S. guideline concurs that in general, laparoscopic bariatric procedures are 
preferred over open bariatric procedures due to lower early postoperative morbidity and mortality 
but again makes no specific mention of robot-assisted techniques [52]. 
Bowel/small and large intestine 
A variety of surgical approaches, depending on the location and extent of disease, are used to treat 
primary rectal cancer lesions, both local procedures, such as transanal endoscopic microsurgery, 
and more invasive procedures involving a transabdominal resection e.g. low anterior resection or 
radical total mesorectal excision [65]. According to the NCCN guideline, conflicting results have 
been documented regarding open surgery versus laparoscopic techniques but the guidelines note 
that studies comparing conventional laparoscopic resection with robot-assisted resection have 
generally seen comparable results [65]. The NCCN Guidelines Panel defined principles by which 
minimally invasive resection of rectal cancer can be considered: the procedure can be considered 
by an experienced surgeon, should include thorough abdominal exploration, and should be limited 
to lower-risk tumors [65]. The European guideline notes that robot-assisted rectal cancer surgery 
provides some technical advantages for surgeons compared with conventional laparoscopy, but is 
still under evaluation [54]. 
Non-metastatic colon cancer is generally treated with curative intent by colectomy [65] where the 
goal of surgery is a wide resection of the involved segment of bowel together with the removal of 
its lymphatic drainage. The laparoscopic approach has now received wide acceptance for several 
types of surgical procedures in major abdominal surgery and laparoscopic colectomy can be safe-
ly carried out for colon cancer, particularly for left-sided cancer laparoscopic approach [55]. How-
ever the European guideline states that the laparoscopic approach should only be carried out if, 
amongst other criteria, technically experienced surgeons are available [55]. 
Surgery should be considered for clinically significant structural abnormalities for example, rectal 
prolapse or large rectocele [56]. 
Spleen, liver and gallbladder 
It is difficult to agree which symptoms are specifically biliary and therefore will be cured by chole-
cystectomy; where there are no symptoms at all, cholecystectomy confirms no benefit in patients 
with asymptomatic gallstones [57]and even in patients with one attack of uncomplicated gallstone 
pain [58]. NICE advises offering early laparoscopic cholecystectomy (to be carried out within 1 week 
of diagnosis) to people with acute cholecystitis and to reconsider laparoscopic cholecystectomy for 
people who have had percutaneous cholecystostomy once they are well enough for surgery [57]. 
Robot-assisted techniques are not mentioned. 
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 46 
Liver resection (also referred to as hepatectomy) is the surgical removal of all or a portion of the 
liver and is one of the potentially curative modalities for patients with HCC, particularly in patients 
with single tumours and well-preserved liver function [59]. Compared with open liver resection, lap-
aroscopic liver resection shows advantages regarding blood loss and faster postoperative recov-
ery and is recommended for liver resection in cirrhosis; robot-assisted techniques are not men-
tioned [59]. 
Worldwide, inguinal hernia repair is one of the most common surgeries, performed on more than 
20 million people annually [60]. Surgical treatment is successful in the majority of cases, but recur-
rences necessitate reoperations in 10–15% and long-term disability due to chronic pain occurs in 
10–12% of patients [60]. Many different repair methods are available, including non-mesh tech-
niques, open mesh techniques and endoscopic techniques (the latter includes robotic repair tech-
niques), which makes the choice of technique challenging [60]. Provided that resources and exper-
tise are available, laparo-endoscopic techniques have faster recovery times, lower chronic pain 
risk and are cost-effective but their use requires the availability of an experienced surgeon [60]. 
 
[A0011] – How much are the technologies utilized?37  
A Belgian HTA into the clinical effectiveness and potential benefit of the currently marketed robot-
ic surgical systems reported that at least 20 robotic surgical systems were in use in Belgium and 
that compared to the rest of the world, Belgium had the second highest number of robotic surgical 
systems per capita, after the US [66]. 
According to a U.S. HTA, as of the first quarter of 2012, 37 da Vinci Surgical Systems had been 
installed in the State of Washington [67]. 
The manufacturer of the da Vinci® surgical system reports that since the year 2007, more than 5 
million minimally invasive procedures have been performed in the U.S. (where it is used in all 50 
states) and 66 countries worldwide. The system is used in over 4,400 hospitals worldwide and 
there are more than 43,000 da Vinci trained surgeons38.  
As of October 2017, TransEnterix reported to have installed seven Senhance systems in five coun-
tries (presumably in Europe) where surgeons continue to gather clinical data, with a goal of ex-
panding FDA-cleared indications in the United States in coming years. In August 2017, the com-
pany established its first Senhance training and surgical innovation center in the United States at 
Florida Hospital (Orlando, FL, USA) to train U.S. surgical teams on its robotic technology [41]. 
                                                     
37 No information could be found regarding the Surgica Robotica (Surgenius) system 
38 https://www.intuitive.com/  
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions 
Element ID Research question 
D0001 What is the expected beneficial effect of robot-assisted surgery on 
mortality/survival? 
D0005 How does robot-assisted surgery affect symptoms and findings (severity, 
frequency) of the disease or health condition? 
D0006 How does robot-assisted surgery affect progression (or recurrence)  
of the disease or health condition?  
D0011 What is the effect of robot-assisted surgery on patients’ bodily functions? 
D0012 What is the effect of robot-assisted surgery on generic health-related quality  
of life? 
D0013 What is the effect of robot-assisted surgery on disease-specific health-related 
quality of life? 
D0016 How does the use of robot-assisted surgery affect activities of daily living? 
D0017 Were patients satisfied with robot-assisted surgery? 
 
5.2 Results 
The inclusion criteria for assessing the clinical effectiveness of robot-assisted surgery were initial-
ly restricted to RCTs with more than or equal than 10 patients or – in the absence of these – non-
randomised prospective studies with control groups of more than or equal to 10 patients. The char-
acteristics of all included studies can be found in Appendix 1. The systematic literature search did 
not identify any RCTs relating to thoracic surgery hence non-randomised controlled studies (3 for 
lobectomy/segmentectomy and 1 for mediastinal surgery) were included as the next best evidence 
level.  
Regarding visceral surgery, and specifically surgery in the area of the oesophagus, 5 RCTs (6 pub-
lications) were identified relating to the procedure antireflux/fundoplication and oesphagectomy. 
For Heller myotomy no RCTs were found, hence non-randomised, controlled studies were included 
(two in total).  
Three RCTS were included relating to stomach surgery (2 for gastrectomy and 1 for bariatric sur-
gery) and 7 RCTs were identified relating to bowel procedures (specifically 1 RCT for colectomy, 
1 RCT for rectopexy and 5 RCTs for rectal resection). Lastly in the area of gallbladder/liver/spleen, 
4 RCTS were included for the cholecystectomy procedure whilst for liver resection and hernia re-
pair, no RCTS could be identified thus non-randomised, controlled studies were included (2 for 
liver resection and 1 for hernia repair).  
All the RCTS identified in the systematic literature search reported on effectiveness, with the ex-
ception of one [1]. The robotic procedure in most of the cases involved the da Vinci Surgical Sys-
tem. In all but three studies, the comparison was laparoscopic surgery. In the oesphagectomy study 
[15], one gastrectomy study [17] and the mediastinal surgery study [32], the comparison was with 
open surgery. 
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Seven procedures (lobectomy, mediastinal mass resection, gastrectomy, colectomy, rectal resec-
tion, liver resection/hepatectomy and oesophagectomy) related to patients undergoing surgical treat-
ment for cancer.  
Lobectomy/segmentectomy for lung cancer: here 100 patients underwent robot-assisted surgery 
in the intervention group and 115 patients underwent videothoracoscopy procedures in the control 
group across the 3 non-randomised, controlled studies [29], [30], [31]. Median age across the 3 
studies was 62 in the IG and 64 in the CG whilst 46% and 42% were female in the IG and CG 
respectively. For mediastinal mass resection for lung cancer, 1 non-randomised, controlled study 
was found [32]. The intervention and control groups in this study differed in median age and sex 
distribution, although this was not statistically significant. The gastrectomy procedure for patients 
with gastric cancer was assessed in 2 RCTs [16], [17] with a total of 255 patients in the IG and 
219 in the CG. These 2 studies differed in the control procedure: Pan et al [16] used a laparoscop-
ic procedure as control, whereas Wang et al [17] used an open gastrectomy procedure, therefore 
the patient data was not pooled. One RCT was identified for oesophagectomy for patients with 
oesophageal cancer [15] with a total of 109 patients (IG 54; CG 55) and with a mean age of 64 in 
the IG and 65 in the CG. A lower proportion of patients in the IG was female compared to the CG 
(15% vs. 24%); the difference was not subjected to statistical testing. Colectomy for colonic carci-
noma was assessed in one study [19] with 35 in the robot-assisted group and 36 in the laparo-
scopically assisted colectomy group. Two non-randomised controlled trials were identified for liver 
resection/hepatectomy [35], [36] with a combined patient pool of 104 in the robot-assisted group 
and 58 in the control group. Both studies included patients with malignant lesions although in one 
study a large proportion of patients had colorectal metastases [35]. Across both studies median age 
in the IG was 64 vs. 62 in the CG and the proportion of women was similar in each arm (40% IG, 
39% CG). Lastly robot – assisted rectal resection for rectal adenocarcinoma was assessed in 5 
studies for a total of 435 patients in the intervention group and 431 patients in the control group 
(undergoing laparoscopic rectal resection). Here the median age (across all studies) was 60.4 in 
the IG and 59.7 in the CG, with 32% female in both treatment allocation groups. 
The other non-cancer related procedures (six) were antireflux/fundoplication, Heller myotomy, chol-
ecystectomy, bariatric surgery, ventral mesh rectopexy and hernia repair.  
Across the 4 antireflux/fundoplication RCTs there were a total of 79 patients in the robot-assisted 
intervention group and 81 in the control group (laparosopic fundoplication). The median age across 
these studies was 46 in the IG and 49 in the CG with 31.5% females in the IG and 32.5% in the 
CG. Two controlled (non-randomised) studies were identified for Heller myotomy with a total of 37 
patients with achalasia in the IG and 55 patients with achalasia in the CG. In Huffmanm et al 
(2007) [33] 58% and 38% of patients in the IG and CG respectively were female (the other study 
did not report on sex characteristics); both intervention and control procedures in this study also 
included a partial fundoplication, in addition to the Heller myotomy (these procedures were never-
theless combined in the summary of findings). Median age in Sanchez et al (2012) [34] was 38 in 
the IG and 40.7 in the CG (Huffmanm only reports a very wide age range). 
Four studies were available for cholecystectomy for gallbladder disease for a total of 163 patients 
in the robot-assisted cholecystectomy (intervention) group and 134 in the laparoscopic cholecys-
tectomy (control) group, although one study used single-port laparoscopic cholecystectomy as con-
trol and was therefore analysed separately from the others in the Summary of Findings table [28]. 
The median age across available studies (Pietrabissa et al, 2016, did not report age and sex 
characteristics and so was excluded from the pooling) was 46.8 in the IG and 51.5 in the CG. 
Overall in the cholecystectomy studies, 78% of patients were female in the IG; the corresponding 
figure for the CG was 80. In 3 studies patients had gallbladder disease and in 1 study patients had 
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cholecystolithiasis. For bariatric surgery, 1 RCT was available with 25 participants in the robot-
assisted gastric bypass (intervention) group and 25 participants in the laparoscopic gastric bypass 
(control) group. One non-randomised controlled study looked at robot-assisted hernia repair with 
16 participants in both intervention and control (conventional single-port inguinal hernia repair) 
groups. The patients (aged 46 in IG; aged 48 in CG; sex unknown) were followed up for 6 months 
and assessed on satisfaction, complications and perioperative outcomes/resource use. Lastly 1 
RCT was included that assessed robot-assisted ventral mesh rectopexy for rectal prolapse and 
intussusception with 16 women in the IG group and 14 women in the laparoscopic ventral mesh 
rectopexy (control) group.  
The critical outcomes to evaluate were effectiveness, safety and perioperative outcomes however 
since the included studies related to different disease areas with often different endpoints, the 
effectiveness of robot-assisted surgery was considered for each operative procedure separately. 
The summary of findings (GRADE) relating to effectiveness (mortality, morbidity/quality of life and 
recurrence) for the individual surgical procedures can be found at the end of this chapter (Table 5).  
 
Included studies 
Thoracic surgery 
Lobectomy 
In the absence of any suitable RCTs, three non-randomised controlled comparisons of robot-as-
sisted and conventional minimally invasive VATS (video-assisted thoracic surgery) were identified, 
which together included a total of 100 subjects in the intervention group and 115 subjects in the 
comparison group. All three studies focused on perioperative events as the main outcome, where-
by Gonde et al, 2017 [30], focused specifically on the costs associated with both procedures (it 
should be noted that one of the co-authors of this paper undertook activities for Intuitive Surgical, 
Inc). The study by Augustin et al, 2013 [29], incorporated two types of robot-assisted lobectomy 
(both the posterior and anterior approach) and also in this study the intervention and control pro-
cedures were not conducted during the same time period (the latter point could also be observed 
by Rinieri et al [31]. In all three studies it is unclear how patients were assigned to the two groups; 
in one study [30], IG and CG were significantly different at baseline regarding sex and the pres-
ence of pulmonary comorbidities. The degree of surgeon’s experience was not consistently report-
ed across the studies. All 3 studies were assessed as having a moderate to critical risk of bias, 
depending on the outcome.  
Mediastinal  
No RCTs and only one non-randomised, controlled study [32] could be identified for mediastinal 
surgery which compared robot-assisted anterior mediastinal mass resection with open mediastinal 
mass resection by sternotomy. This is one of the relatively few studies that focused on quality of 
life using a standardised, valid instrument (although even here the authors note that the EORTC 
questionnaire has only been tested for validity and reliability among stage III and stage IV lung-
cancer patients). The sample size was however small (total 36 participants) and the study was 
assessed as having a moderate to critical risk of bias, depending on the outcome considered  
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Visceral surgery 
Oesophagus 
Antireflux/fundoplication 
Five publications on four RCTS for antireflux/fundoplication operations were included [10], [11], 
[12], [13], [14]. All studies were on patients with gastro-oesophageal reflux disease and all com-
pared robot-assisted laparoscopic fundoplication with conventional laparoscopic fundoplication. In 
total there were 79 in the IG and 81 in the CG. Patients were followed up for a maximum of 6 to 
22 months. Patient characteristics across studies were similar in terms of age; the Mueller-Stich et 
al study [13], [12] had a higher proportionally of female participants than the other studies. Two of 
the studies measured quality of life as an endpoint [10] [12], although quality of life was measured 
in different ways. Two studies focused on costs and perioperative events [11], [14].One study was 
assessed as having a low risk of bias at the study level [11]; the other 3 studies were assessed as 
having a potentially high risk of bias at the study level, principally due to missing information regard-
ing study design.  
Heller myotomy 
Two non-randomised controlled studies were included [33], [34]. Both studies were on patients 
with achalasia but were different in that the intervention and control in one study included a partial 
fundoplication [33]. Both studies were small (61 and 31 participants) and followed patients up for 
at least 6 months. Both studies measured QoL/morbidity: Huffman et al with the SF-36 whilst 
Sanchez et al 2012 looked at relief of symptoms. Intraoperative complications were assessed in 
both studies, as were perioperative events/resource use. Huffman was assessed as having a criti-
cal risk of bias on both the health-related QoL outcomes and the safety & perioperative events 
whilst Sanchez 2012 was also rated as critical for QoL outcome but slightly better (serious risk of 
bias) on the safety & perioperative outcome.  
Oesophagectomy 
One relevant RCT was identified [15] which was conducted in the Netherlands with a total sample 
size of 109 and compared robotic thoracolaparoscopic oesophagectomy with open transthoracic 
oesophagectomy. Median follow up was for 40 months and the main endpoints related to compli-
cations (primary endpoint) as well as mortality and quality of life. Patient characteristics were rea-
sonably similar although there was a higher proportion of women in the control group (25% vs. 
15%), significance testing not reported. The risk of bias at the study level was assessed as low.  
Stomach 
Gastrectomy 
The two RCTS assessing robotic gastrectomy used different comparisons: one used laparoscopic 
gastrectomy as the comparison [16] whilst the other used open gastrectomy [17]; for this reason 
the outcomes were not combined in the summary of findings table. Both studies included over 200 
patients and included patients with gastric cancer. Perioperative outcomes and postoperative com-
plications were the focus of both studies. Both studies failed to report on study design and for this 
reason are considered to have a high risk of bias. 
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Bariatric surgery 
1 RCT was identified [18] which compared robotic laparoscopic Roux-en-Y with laparoscopic Roux-
en-Y gastric bypass in a total of 50 patients (25 in each group) with a focus on safety and resource 
use. This study poses a high risk of bias at the study level as there is unclear information on allo-
cation and blinding, and no sample size calculations were performed. 
Bowel 
Colectomy 
Park et al [19] was the only RCT to consider a robot-assisted colectomy procedure versus laparo-
scopic colectomy in a study sample of 71 patients with newly diagnosed right-sided colonic carci-
noma. Perioperative events and resource use were the main endpoints, alongside completeness 
of tumour excision. This study has a high risk of bias since there is insufficient information on many 
key aspects of the study and the possibility of selective reporting exists (pain score at 72 hours 
was not reported). 
Rectal resection 
Five RCTs [20], [21], [22], [24], [23] compared robot-assisted laparoscopic rectal resection with 
laparoscopic rectal resection for patients with rectal carcinoma. Jayne et al [20] reported on the 
ROLARR clinical trial, which was a multicentre RCT conducted in 10 countries with a total sample 
size of 471 randomised particiapnts. Jayne et al [20] and Kim et al [21] (latter with a sample size 
available for analysis of 139 patients) had clinical endpoints as primary endpoints (rate of conver-
sion to open surgery and completeness of total mesorectal excision respectively) but also consid-
ered QoL and complications whilst Tolstrup et al [22], with a total sample of 51, assessed postoper-
ative pain and complications. The Tolstrup RCT appeared to be the Danish results of the ROLARR 
trial. Wang et al [23] also considered quality of life, focusing on a 12 month assessment of urinary 
and sexual functioning. Debakey et al [24] reported on the results of a single-centre study in Egypt 
(45 patients) focussing on short-term operative and oncologic outcomes and complications. Three 
of the RCTs, Tolstrup et al [22] Debakey et al [24] and Wang et al [23] were assessed as having a 
high risk of bias at the study level.  
Rectopexy 
The RCT published by Mäkelä-Kaikonen et al [25] compared robot-assisted ventral mesh rectopexy 
with laparoscopic ventral mesh rectopexy in 28 female patients with rectal prolapse or intussecep-
tion and looked at perioperative events, complications and pain. This study was judged to have a 
low risk of bias. 
Gallbladder/liver/spleen 
Cholecystectomy 
Three RCTS compared robotic cholecystectomy with multiport or four-port laparoscopic robotic 
cholecystectomy [26] [27] [1], with a total sample size across the studies of 237 patients with a diag-
nosis of gallbladder disease. All RCTs measured perioperative events and quality of life and/or sat-
isfaction. Kudsi et al [26] was classed as having a high risk of bias principally due to missing quality 
of life data, inconsistent reporting of blinding and a high proportion of inexperienced surgeons. Piet-
rabissa al [27] was judged to have a low level of bias at the study level. We inferred that another 
RCT, Ruurda et al [1], compared robotic cholecystectomy with multi-port laparoscopy (although not 
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clearly stated in the publication); here the focus was on procedure time and the study was assessed 
as having a high risk of bias. Grochola et al [28] compared robotic cholecystectomy with single-port 
laparoscopic cholecystectomy in a small trial in Switzerland focusing on surgeon’s physical and men-
tal stress load, but with secondary outcomes relevant to this HTA. This study as a whole was as-
sessed as having a low risk of bias but the risk of bias associated with the QoL outcome was high. 
Liver resection 
Two non-randomised controlled studies (one conducted in the USA and one in China) were avail-
able for analysis [36] [35]. The exact robotic system used is not stated in Berber et al [35]. In both 
studies the control group was operated on usin reported to be laparoscopy (this was the control in 
both studies). Both studies report on survival and recurrence, as well as safety and perioperative 
outcomes. Follow-up was relatively long (mean 14 months in 1 study and 26 or 62 months, de-
pending on allocation group, in the other). Lai and Tang [36] performed a partial hepatectomy whilst 
Berber et al [35] performed a liver tumour resection. As assessed with the ROBINS-I both studies 
have critical risk of bias.  
Hernia repair 
Tran [37] was a small, single-centre, non-randomised, controlled, Australian study comparing the 
Robotic Freehand with laparoscopic hernia repair, focussing on patient satisfaction, safety-related 
outcomes and resource use (length of operation). As assessed with the ROBINS-I it has a critical 
risk of bias.  
The detailed extraction tables and risk of bias tables per study can be found in the Appendix 1. 
 
Mortality 
[D0001] – What is the expected beneficial effect of the technology on mortality/survival? 
 
Thoracic surgery 
Lobectomy 
Three observational studies considered mortality [29], [30], [31]. Results were either non-signifi-
cant or – where the control group had a marginally lower survival rate – there was no statistical 
testing performed [30], [31]. 
Mediastinal  
100% intraoperative survival was reported in both groups [32]. At the outcome level this study was 
assessed to have a critical risk of bias. 
 
Visceral surgery 
Oesophagus 
Antireflux/fundoplication: None of the RCTs assessed mortality. 
Heller myotomy: Not reported by the studies. 
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Oesophagectomy 
Van der Sluis et al [15] did not find any statistically significant differences between the intervention 
and control groups regarding in-hospital mortality, 30-day, 60-day or 90-day mortality. Disease-free 
survival was a median of 26 months in the IG and 28 months in the CG (not statistically signifi-
cant). 
Stomach 
Gastrectomy 
Both gastrectomy RCTs (both with the open gastrectomy and the laparoscopic gastrectomy com-
parisons) reported 100% survival. Both RCTS were assessed as having a high risk of bias at the 
outcome level due to insufficient information and a high risk of bias at the study level.  
Bariatric surgery: Mortality was not assessed.  
Bowel 
Colectomy 
Parks et al [19] reported on a 30-day survival rate of 100% in both groups: this study has a high 
risk of bias.  
Rectal resection 
Three RCTs reported on survival [20], [24], [23]. In Jayne et al [20] 30-day mortality was similar in 
both groups (0.8% IG vs. 0.9% CG). This study was assessed as having a low risk of bias at the 
outcome level. The sample size in Debakey et al [24] was very small and the study was assessed 
as having a high risk of bias; in this study one patient died in the control group and none in the 
intervention group within the 1 month follow-up period. Wang et al [23] reported no deaths in ei-
ther group at 30 days.  
Rectopexy: Not reported. 
Gallbladder/liver/spleen 
Cholecystectomy: None of the studies reported on mortality. 
Liver resection 
In one study survival data was only presented in graphs [35] but it is reported that disease-free 
survival at 14 months was equivalent in both groups (p=ns). Numerical data is reported by Lai and 
Tang [36] which shows 0% mortality in both groups at 90 days but differences between groups in 
5-year survival (overall: IG 65% vs CG 48% and disease-free: IG 42% vs. CG 38%), but these 
were not reported to be statistically significant. Both studies were classed as having a critical risk 
of bias. 
Hernia repair: Not reported. 
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Morbidity 
[D0005] – How does the technology affect symptoms and findings (severity, frequency)  
of the disease or health condition? 
 
Thoracic surgery 
Lobectomy: Symptoms were not assessed in these observational studies.  
Mediastinal  
As reported by Balduyck et al [32] both procedures (robot-assisted and sternotomy) resulted in 
increased thoracic pain at 1 month; this persisted only in the sternotomy group at the 3 month point. 
Sternotomy but not robot-assisted surgery was associated with increased fatigue at 1 month after 
surgery (p<0.01). The robot-assisted group showed an increase in shoulder pain/dysfunction at 3 
months, which was not observed in the sternotomy group (p<0.05). The open surgery group showed 
deterioration on 5 out of 10 QoL/symptom subscales at 1 month; in the robot-assisted surgery group 
there is deterioration in only 1 out of 10 subscales. At the outcome level this study was assessed 
as having a medium risk of bias. 
 
Visceral surgery 
Oesophagus 
Antireflux/fundoplication 
All four RCTs considered symptoms, albeit using different measurement instruments. Draaisma et 
al [10] found no significant difference between the groups in self-rated change in reflux state com-
pared with the preoperative state; Morino et al [11] failed to detect a difference in symptoms or 
oesophagitis between the groups using the Gastro-oesphageal Reflux Health-Related Quality of 
Life scale; Mueller-Stich et al [13] [12] found no significant difference in reflux syndrome measured 
by the GSRS instrument at 12 months after surgery (this was the only RCT judged to have a low 
risk of bias at the outcome level); in Nakadi et al [14] symptoms occurred in a similar proportion in 
both groups after 1 month (in approximately one-third of patients), persisted at 3 months in the IG 
group and were relatively similar in both groups at 12 months after surgery (IG 1/19 vs CG 2/11), 
however no statistical testing was performed.  
Heller myotomy 
Symptoms were measured in Sanchez et al [34]. At 18 months 100% of patients reported relief of 
symptoms in the IG whilst 94.5% reported relief of symptoms at 18 months in the CG (not statisti-
cally significant). No information was given on how symptom relief was assessed. In Huffman et al 
[33], both groups reported statistically significant improvements in the GERD activity index (GRACI) 
at 6 days postoperatively (although no exact results were reported). 
Oesophagectomy 
Postoperative pain at 14 days was significantly lower in the intervention group, as measured by 
the VAS [15].  
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Stomach 
Gastrectomy 
Pan et al [16] reported significantly lower VAS pain scores in the intervention group for up to 3 
days postoperatively (high risk of bias at the outcome level); this outcome was not considered in 
the study by Wang et al [17].  
Bariatric surgery: No results. 
Bowel 
Colectomy 
Park et al [19] reported non-significant results on the VAS assessment for pain (high risk of bias). 
Rectal resection 
Non-significant differences were reported on the prostate symptom score [20]; this study has a 
low risk of bias at the outcome level. Significant differences between treatment groups on the 
same prostate symptom score were reported in another study (with the robotic surgery group 
scoring better than the laparoscopically treated group) however this study has a high risk of bias 
[23]. Non-significant differences on pain were reported by Kim et al, [21] although this study has a 
high risk of bias at the outcome level. Tolstrup et al [22] similarly reported non-significant differ-
ences on pain (using the numerical rating scale).  
Rectopexy 
Mäkelä-Kaikonen [25] [68] (high level of bias at the outcome level) reported non-significant differ-
ences in mean pain scores via the VAS at 2 weeks and no differences in symptom scores (exact 
results are not provided). 
Gallbladder/liver/spleen 
Cholecystectomy 
Pietrabissa et al [27] reported non-significant findings on the VAS pain measurement (low risk of 
bias).  
Liver resection: Not reported. 
Hernia repair: Not reported. 
 
[D0006] – How does the technology affect progression (or recurrence)  
of the disease or health condition?  
Information on recurrence was only available for mediastinal surgery, antireflux/fundoplication and 
liver resection/hepatectomy.  
In the RCT by Draaisma et al [10] on antireflux/fundoplication there was a 12% recurrence of hia-
tal hernia in the CG and 4% recurrence in the IG; statistical significance testing was not reported 
and there is a high risk of bias at the outcome level. In the observational study by Balduyck et al 
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[32], recurrence occurred in 1/22 patients in the control group and none in the intervention group, 
which was reported as non-statistically significant (low to medium risk of bias).  
The positive surgical margin clinical outcome is relevant for all of the cancer-related procedures, 
however the three non-randomised, controlled studies for lobectomy did not report data on this 
outcome (although Rinieri et al [31] stated that all patients undergoing cancer surgery had tumour-
free margins); neither was information on this outcome available on the mediastinal surgery study 
[32] or the liver resection/hepatectomy studies [35], [36]. This outcome was however reported for 
the colectomy procedure [19] where there was a non-significant difference using the proximal mar-
gin and distal margin outcomes. In the rectal resection studies, Jayne et al [20] reported a non-
significant difference on circumferential resection margin positivity between groups and Kim et al 
[21] also reported non-significant differences on this measure as well as on comparisons of prox-
imal and distal resection margins between groups. Tolstrup et al [22] and Wang et al [23] did not 
report results on this outcome. Lastly this is a relevant outcome for the gastrectomy procedures 
for gastric cancers and Wang et al [17] provided results on this outcome: non-statistically signifi-
cant results for proximal resection margins and distal resection margins were reported between the 
intervention and control groups.  
Recurrence occurred in slightly fewer patients in the IG compared to the CG (22% vs. 26% at a 
mean of 14 months) but the difference was not statistically significant [35]. Elsewhere the differ-
ence was more considerable (IG 34% vs. CG 63% after a mean follow-up of 26 months in the IG 
and 62 months in the CG) but this study did not report statistical testing and the difference is likely 
to be attributed to the much later mean follow-up in the control group [36]. Recurrence occurred in 
one patient in the CG but it was not statistically significant (23). 
 
[D0011] – What is the effect of the technology on patients’ body functions? 
[D0016] – How does the use of technology affect activities of daily living? 
These two questions are answered in the next chapter together with quality of life outcomes. 
 
Health-related quality of life 
[D0012] – What is the effect of the technology on generic health-related quality of life and 
[D0013] – What is the effect of the technology on disease-specific quality of life? 
 
Thoracic surgery 
Lobectomy: Not reported. 
Mediastinal  
Functioning deteriorated (statistically significant) in the CG at 1 month (but not thereafter); no de-
terioration was observed in the IG (medium risk of bias in this non-randomised, controlled study), 
[32].  
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Visceral surgery 
Oesophagus 
Antireflux/fundoplication 
One study reported no significant differences in general quality of life at 6 months between the 
groups [10], neither were there any significant differences between groups at 12 months after 
surgery as measured by the QOLRAD, a disease-specific QOL instrument [12] [13]. No pooling 
was possible as different measuring systems and time periods were used. 
Heller myotomy 
All categories of the SF-36 showed statistically significant improvements in the pre-op vs. post-op 
comparison but there were no data on between group comparisons [33]. 
Oesophagectomy 
As measured by the QLQ-C30, the robot-assisted surgery group reported statistically significantly 
better overall health-related quality of life and physical functioning both at discharge and at 6 weeks 
[15]. A statistically significant higher proportion of patients in the intervention group reported func-
tional recovery at 2 weeks: 70% vs. 51% [15]. 
Stomach 
Gastrectomy 
With the exception of pain (reported in morbidity, see question D0005 above), there was no re-
ported data on patient-related outcomes.  
Bariatric surgery: Not reported. 
Bowel 
Colectomy 
With the exception of pain (reported in morbidity, see question D0005 above), there was no re-
ported data on patient-related outcomes.  
Rectal resection 
Here 3 RCTs reported quality of life results however no pooling was possible as different measur-
ing systems and time periods were used. Jayne et al [20] reported no statistically significant dif-
ferences between the groups regarding erectile function or female sexual function at 6 months 
following surgery however Wang et al [23] reported a lower incidence of partial or complete erec-
tile dysfunction post-operatively, compared to the laparoscopically treated group. Kim et al [21] re-
ported no differences between groups after 3 weeks, 3 months or 12 months except for insomnia 
scores at 12 months (IG significantly more sleep disturbances) and sexual functioning at 12 months 
(IG showed significantly better functioning), using the Korean version of the QLQ-C30. Both Jayne 
et al [20] and Kim et al [21] show a low risk of bias at the outcome level.  
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 58 
Rectopexy 
Mäkela-Kaikonen et al [25] (59) reported no significant differences for pain at 2 weeks in compari-
son with pre-surgery for all patients combined and QoL improvements 3 months post-surgery es-
pecially for symptoms and sexual function but there was no comparison between study arms. This 
study has a high risk of bias at the outcome level since data on between group comparisons were 
not presented for any of the measures (data on Pelvic Floor Impact Questionnaire and Prolapse/ 
Incontinence Sexual Questionnaire were missing).  
Gallbladder/liver/spleen 
Cholecystectomy 
Kudsi et al [26] reported no statistically significant results using the SF-12 between the groups at 
2 weeks, 6 weeks or 3 months. Grochola et al [28] similarly reported no statistically significant 
differences at 1 month and 12 months post-operatively on the Gastrointestinal Quality of Life Index. 
Both studies have a high risk of bias at the outcome level. 
Liver resection: Not reported. 
Hernia repair: Not reported. 
 
Satisfaction 
[D0017] – Were patients satisfied with the technology? 
 
Thoracic surgery 
None of the identified thoracic surgery non-randomised, controlled studies reported on patient 
satisfaction.  
 
Visceral surgery 
Oesophagus 
Antireflux/fundoplication 
Draaisma et al [10] reported higher satisfaction in the IG (92% vs. 88%), although this was not 
statistically significant and this study has a high risk of bias, both at study and outcome level. 
Mueller-Stich et al [12] reported no statistically significant differences between the groups regard-
ing self-reported satisfaction with change in condition or satisfaction with operative result (low risk 
of bias at the outcome level, although high risk of bias overall at the study level).  
Heller myotomy: Not reported. 
Oesophagectomy: Not reported. 
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Stomach 
Gastrectomy: Not reported. 
Bariatric surgery: Not reported. 
Bowel 
Colectomy: Not reported. 
Rectal resection: Not reported. 
Rectopexy: Not reported. 
Gallbladder/liver/spleen 
Cholecystectomy 
Kudsi et al [26] reported results for the BIQ (which measures satisfaction with body image) and 
the PSQ (relating to satisfaction with surgical scar) which showed statistically significant differences 
between the two groups in favour of robot-assisted surgery at 2 weeks and 3 months (but not at 6 
weeks) whilst all PSQ results, at all 3 follow-up points, were statistically significantly better for the 
robot-assisted surgery group. Similarly, Pietrabissa et al [27] found that robot-assisted surgery con-
ferred a statistically significant cosmetic advantage. However Grochola et al [28] reported no sta-
tistically significant differences at 1 month and 12 months post-operatively on the Body Image Ques-
tionnaire. Only Pietrabissa et al (18) was assessed as having a low risk of bias at the outcome level.  
Liver resection: Not reported. 
Hernia repair 
The same proportion of patients were highly satisfied and satisfied in both intervention and control 
groups (88% highly satisfied; the rest were satisfied). As assessed with the ROBINS-I, this result 
is associated with a critical risk of bias [37]. 
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Table 5: Summary of findings table regarding effectiveness for robot-assisted surgery in thoracic and visceral indications39 
Thoracic Surgery 
Robot-assisted lobectomy vs. VATS  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperativ
e mortality; 
in-hospital 
mortality 
0 deaths in both arms of all studies except for Gonde et al in 1 arm (2 
deaths in CG) and Rinieri et al in 1 arm (1 death in CG) 
Relative effect cannot be calculated as the study provides no information 
about the relative probability of the event (see Cochrane handbook 5-1, 
section 9.2.2.2) 
164 
(2 RCTs) 
⨁◯◯◯ 
Very low 
Differences in surgery performed and in 
group characteristics; no power 
calculations 
Morbidity Outcome not reported 
 
Robot-assisted mediastinal surgery vs. open mediastinal mass resection  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
In-hospital 
mortality 
0 deaths in both arms 
Relative effect cannot be calculated as the study provides no information 
about the relative probability of the event (see Cochrane handbook 5-1, 
section 9.2.2.2) 
36 
(1 RCT) 
⨁◯◯◯ 
Very low 
unclear how group allocation operated, 
no information on tumour size, no 
sample size calculations  
Morbidity Less short-term deterioration in QoL and symptoms following surgery 
reported in robot-assisted group vs open surgery group 
36  
(1 RCT) 
⨁◯◯◯ 
Very low 
unclear which surgeons conducted 
surgery and with what type of 
experience, unclear how patients were 
assigned to treatment groups 
 
                                                     
39 Relative risk calculations performed via https://www.medcalc.org/calc/relative_risk.php; absolute effect estimates obtained via from GradePro https://gdt.gradepro.org/app/#  
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Visceral surgery 
Oesophagus 
Robot-assisted laparoscopic fundoplication vs. laparoscopic fundoplication  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life 
None of the studies reported significant differences on symptoms 
between the 2 approaches 
160 
(4 RCTs) 
⨁◯◯◯ 
Very low 
Different measurement instruments 
prevents pooling; 3/4 RCTS with high 
risk of bias at the outcome level 
 
Robot-assisted Heller myotomy vs. laparoscopic Heller myotomy  
Outcome Anticipated absolute effects (95% 
CI) 
Relative effect (95% CI) Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life 
Statistically significant improvements in symptoms post-op vs. pre-op in 
both IG and CG groups on the SF-36 (no between group comparisons) 
and symptom relief at 6 days as measured on the GERD (GRACI) index 
in IG and CG. High level of symptom relief in both IG and CG groups at 
18 months (non- statistically significant differences).  
92 
(2 non-randomised 
studies) 
⨁◯◯◯ 
Very low 
Lack of data on between group 
differences. Critical/serious risk of bias 
on ROBINS-I 
 
Robot-assisted thoracolaparoscopic oesophagectomy compared to open transthoracic oesophagectomy 
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality In-hospital mortality: 19 more per 
1,000 (from 15 fewer to 378 more) 
30-day mortality: not estimable  
(0 events in CG) 
60-day mortality: 37 more per 1,000 
(from 12 fewer to 499 more) 
90-day mortality: 74 more per 1,000 
(from 7 fewer to 749 more) 
RR 2.04 (0.19 to 21.81) 
 
- 
 
RR 3.06 (0.33 to 28.47) 
 
RR 5.09 (0.62 to 42.17) 
109  
(1 RCT) 
⨁◯◯◯ 
Very low 
Serious risk of bias; 95% confidence 
intervals around the absolute and relative 
effects includes the possibility of both 
increased postoperative complications 
and reduced postoperative 
complications 
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Robot-assisted thoracolaparoscopic oesophagectomy compared to open transthoracic oesophagectomy 
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Morbidity, 
quality of life 
On QLQ-C30 statistically significant better overall health-related QoL and 
physical functioning at discharge and at 6 weeks. Functional recovery @ 
2 weeks: 70% in IG and 51% in CG (p<0.05) 
109  
(1 RCT) 
⨁⨁⨁◯ 
Moderate 
High risk of bias at the outcome level  
as study not powered to detect QoL 
differences 
 
Stomach 
Robot-assisted gastrectomy vs. laparoscopic gastrectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Intraoperative: 0 deaths in both arms 
Relative effect cannot be calculated as the study provides no information 
about the relative probability of the event (see Cochrane handbook 5-1, 
section 9.2.2.2) 
163  
(1 RCT) 
⨁◯◯◯ 
Very low 
Relative and absolute rates cannot be 
calculated (no events); sample size 
likely to be too small for a reliable 
mortality estimate 
Morbidity, 
quality of life 
Significantly lower VAS scores for pain in IG vs. CG,  
post-operative days 1 to 3 
163  
(1 RCT) 
⨁◯◯◯ 
Very low 
Very serious risk of bias, and serious 
imprecision whilst inconsistency was 
not estimable  
 
Robot-assisted gastrectomy vs. open gastrectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Intraoperative: 0 deaths in both arms 
Relative effect cannot be calculated as the study provides no information 
about the relative probability of the event (see Cochrane handbook 5-1, 
section 9.2.2.2) 
296  
(1 RCT) 
⨁◯◯◯ 
Very low 
Relative and absolute rates cannot be 
calculated (no events); sample size 
likely to be too small for a reliable 
mortality estimate 
Morbidity, 
quality of life Outcome not reported 
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Robot-assisted laparoscopic gastric bypass vs. laparoscopic gastric bypass  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life Outcome not reported 
 
Bowel 
Robot-assisted right colectomy vs. laparoscopic right colectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality at 
30 days 
0 deaths in both groups 
Relative effect cannot be calculated as the study provides no information 
about the relative probability of the event (see Cochrane handbook 5-1, 
section 9.2.2.2) 
70 
(1 RCT) 
⨁◯◯◯ 
Very low 
 
Morbidity, 
quality of life non-significant results on the VAS assessment for pain 
70 
(1 RCT) 
⨁◯◯◯ 
Very low 
Insufficient information and selective 
reporting possible (missing data on pain 
score at 72 hours) 
 
Robot-assisted laparoscopic rectal resection compared to laparoscopic rectal resection  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality 
within 30 
days 
3 fewer per 1,000  
(from 8 fewer to 27 more) 
RR 0.65 
(0.11 to 3.87) 
648  
(3 RCTs) 
⨁◯◯◯ 
Very low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications; 2 studies had high risk  
of bias 
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Robot-assisted laparoscopic rectal resection compared to laparoscopic rectal resection  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Morbidity, 
quality of life 
No statistically significant differences were reported in erectile function or 
female sexual function in the 2 studies with a low risk of bias, but significant 
differences in favour of robotic surgery in one study measuring erectile 
function with a high risk of bias. Some evidence that sexual functioning is 
significantly better in the IG although sleep disturbances at 12 months were 
significantly more prevalent in the IG. One study reporting better prostate 
symptom scores in the robotic surgery group (high risk of bias), which 
was not observed in the other study. No reported differences in pain.  
742  
(3 RCTs) 
⨁⨁◯◯ 
Low 
2 studies are assessed as having a low 
risk of bias; 1 study as having high risk 
of bias 
 
Robot-assisted ventral mesh rectopexy vs. laparoscopic ventral mesh rectopexy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life 
Mäkelä-Kaikonen reported non-significant differences in mean pain 
scores via the VAS at 2 weeks and no differences in symptom scores 
(data not given). 
(1 RCT) ⨁◯◯◯ 
Very low 
high level of bias at the outcome level; 
only 1 study so inconsistency cannot be 
assessed 
 
Gallbladder/liver/spleen 
Single-site laparoscopic robotic cholecystectomy vs. multiport laparoscopic cholecystecomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life 
Non-statistically significant differences in quality of life (SF-12) at 2 weeks, 
6 weeks and 3 months and in VAS (pain) at 24 h, 7 days and 30 days 
196  
(2 RCTs) 
⨁◯◯◯ 
Very low 
High risk of bias with the Kudi (2017) RCT 
that provided QoL assessment via SF-12 
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Single-site laparoscopic robotic cholecystectomy vs. single-incision laparoscopic cholecystecomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life 
Non-statistically significant differences on Gastrointestinal Quality of Life 
Index and Body Image Questionnaire at 1 month and 12 months post-op 
60  
(1 RCT) 
⨁◯◯◯ 
Very low 
No power calculations performed; it is 
possible study is too small to detect 
QoL differences between the arms.  
 
Robot-assisted liver resection/hepatectomy compared to laparoscopic liver resection/hepatectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Recurrence 154 fewer per 1,000 
(from 261 fewer to 5 fewer) 
RR 0.68 
(0.46 to 0.99) 
162  
(2 non-randomised, 
controlled studies) 
⨁◯◯◯ 
Very low 
Critical risk of bias for this outcome at 
the ROBINS-I: much longer follow up in 
CG (Lai and Tang 2016); little information 
on amount of surgical experience and 
type and approach of resection (Berber 
et al, 2010); no power calculations for 
this outcome 
 
Robot-assisted hernia repair vs. laparoscopic single-port inguinal hernia repair  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Mortality Outcome not reported 
Morbidity, 
quality of life Outcome not reported 
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6 SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
C0008 How safe is robot-assisted surgery in relation to open or 
laparoscopic/thoracoscopic surgery? 
C0002 Are the harms related to dosage or frequency of applying robot-assisted surgery? 
C0004 How does the frequency or severity of harms change over time  
or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of robot-assisted surgery? 
C0007 Is robot-assisted surgery associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor  
the use of the robot-assisted surgery? 
 
6.2 Results 
In accordance with the pre-defined HTA project protocol, the study inclusion criteria for assessing 
safety, as with the assessment of clinical effectiveness, defined RCTs with ≥10 patients as rele-
vant for inclusion. In the absence of RCTs, the project plan permitted the inclusion of prospective, 
non-randomised controlled studies with ≥10 patients.  
The critical outcomes used to evaluate the evidence were intraoperative complications, postoper-
ative complications, re-operations/additional surgeries and conversion to laparoscopic/thoracoscop-
ic or open surgery. Several of the studies reported complications using the Clavien-Dindo classifi-
cation which allows comparison across studies. The results of studies reporting Clavien-Dindo 
complications are given in Table 6. The summary of findings (GRADE) tables relating to safety 
can be found at the end of this chapter. In the summary of findings table (Table 7), complications 
relate to the total number of all complications i.e. the analysis is not restricted to complications 
classified by Clavien-Dindo.  
No specific questions regarding perioperative events and resource use were set in the project plan 
but the following indicators were defined: blood loss; operation time; transfusions. Subsequently, 
drain duration (days) and length of hospital stay (days) were also added as potentially relevant 
indicators. No specific study design was stipulated in the project plan hence the same pool of stud-
ies was used as in the EFF and SAF domains.  
 
Included studies 
The same study pool was used as in the effectiveness domain, in addition Ruurda et al was in-
cluded [1]. In Table 6 the studies that presented complications according to the Clavien-Dindo 
classification40 are summarised.  
 
                                                     
40 https://www.baus.org.uk/patients/surgical_outcomes/grading_of_surgical_complications.aspx 
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Patient safety 
[C0008] – How safe is robot-assisted surgery in relation to open or laparoscopic surgery? 
 
Thoracic surgery 
Lobectomy 
The three non-randomised controlled studies for lobectomy all reported non-statistically significant 
differences in total postoperative complications however Gonde et al [30] reported a statistically 
significant difference in conversion to laparoscopic or open surgery, with conversion occurring more 
often in the control group (IG 2% vs. CG 16%, p<0.01) although this finding was not statistically 
significant in the other two studies [29], [31]. None of the studies reported on intraoperative com-
plications and there was no relevant information on reoperations.  
Augustin et al [29] reported significantly more blood loss in the robot-assisted surgery group and a 
significantly longer median operation time. There were non-significant differences in drain duration 
and length of stay but no relevant data on transfusions. Gonde et al [30] did not report on blood 
loss and found non-statistically significant differences in operation time, drain duration and length 
of stay between the groups. Rinieri et al [31] however found a statistically significant difference in 
blood loss between the groups, with the robot-assisted surgery group associated with significantly 
less blood loss (median 50ml compared with median 100ml in the CG); there were no statistically 
significant differences in operation time, drain duration or length of hospital stay. No information on 
transfusions was reported. None of these studies had a low risk of bias at the outcome level.  
Mediastinal  
This single non-randomised, controlled study for mediastinal surgery – using open surgery as the 
comparator – reported non-statistically significant differences between the groups regarding post-
operative complications (IG 3/14 or 22% vs. CG 2/22 or 9%) [32]. Intraoperative complications did 
not occur in either group. Reoperations occurred more often in the CG (IG 0% vs. CG 2/22 or 9%) 
but conversion to laparoscopic/open surgery occurred in the IG but not CG (IG 1/14 or 7% vs CG 0). 
At the outcome level this study was assessed to have a medium risk of bias. 
There were no statistically significant differences between groups in operation time or length of 
hospital stay according to Balduyck et al [32]. No other outcomes were reported. At the outcome 
level this study was assessed to have a medium risk of bias. 
 
Visceral surgery 
Oesophagus 
Antireflux/fundoplication 
There were no intraoperative complications reported in Morino et al [11] and this outcome was not 
reported in Nakadi et al [14]. Draaisma et al [10] reported minor intraoperative complications in 
16% of the IG (4/25) und 28% of the CG (7/25); corresponding figures for the Mueller-Stich study 
[13] [12] were 5% (1/20) and 10% (2/20).  
Postoperative complications were slightly less common in the IG than CG (0% vs. 8%) in the Dra-
aisma [10] study (p=NR), but were not observed in either group in the Morino [11] study. In the 
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Mueller-Stich study (with a low risk of bias at the outcome level and the only study to subject post-
operative complications to inferential statistical testing), there were no significant differences be-
tween the groups regarding minor postoperative complications and no major postoperative com-
plications were observed in either groups [13], [12]. Nakadi et al [14] did not report on postopera-
tive complications.  
As to conversions to laparoscopic or open surgery, Draaisma et al [10] reported more conversions 
in the control group (0% vs 8%), while Morino et al [11] and Nakadi et al [14] reported more con-
versions in the intervention groups (4% vs. 0% and 11% vs. 0% respectively). In Mueller-Stich et al 
(2007) [12] no conversions were reported in either group. No statistical testing was performed on 
this outcome in these studies.  
No significant differences in blood loss were observed by Draaisma [10]. This outcome was not 
reported in the other 3 RCTs. No significant difference in operation time was reported by Draaisma 
[10] however all the other studies did report statistically significant differences on this outcome; in 
2 instances the operation time with robot-assisted surgery was significantly longer [14], [11] and in 
1 RCT robot-assisted surgery was found to be associated with a shorter operation time [13] [12]. 
One of the studies reported on blood loss, but the difference between groups was not statistically 
significant (2). No statistically significant differences were found regarding overall length of stay. 
No information on transfusions or drain duration was reported. The strongest evidence is considered 
to come from Morino et al [11] which showed a low risk of bias at the study and outcome level.  
Heller myotomy 
Intraoperative complications were similar across groups in the Heller myotomy non-randomised 
controlled studies with 0 intraoperative complications in both intervention groups and 3/37 (8%) and 
1/18 (5.5%) in the two control groups [33, 34]. One of the studies [34] reported that statistical test-
ing showed non-significant differences; the other study did not report a p value (25). There were 
no conversions in the Sanchez et al study (25); this outcome was not reported in Huffman et al 
[33]. Neither study reported on postoperative complications.  
Blood loss was reported in one study [33], where less blood loss was observed in the control group 
(no statistical testing performed). Operation time was longer in the robot-assisted group (355 vs. 
287 minutes) but no statistical testing was reported [33]. In Sanchez et al 2012, there was no sig-
nificant difference in operation length between the groups [34]. Overall length of stay was reported 
in one study and the result showed similar length of stays between arms [33]. 
Oesophagectomy 
Intraoperative complications were 13% in the IG group and 16% in the CG (difference was not 
statistically significant) [15]. There were statistically significantly fewer overall surgery-related post-
operative complications (Clavien-Dindo ≥2) RR RR 0.74 CI95% [0.57; 0.96], p<0.05 and overall 
postoperative complications (MCDC grade≥2) RR 0.79 CI95% [0.62; 1.00], p=0.05 in the robotic 
surgery thoracolaparoscopic group compared with open transthoracic oesophagectomy [15]. 
There were more re-operations in the control group (33%) as opposed to the intervention group 
(24%) but this difference was not statistically significant (van der Sluis, [15]). There was significant-
ly less blood loss in the robotic surgery group compared to the open surgery group (IG M 400ml 
vs. CG M 568, p<0.001) however operation time was significantly longer in the robotic surgery 
group (IG Ø 349 minutes vs. CG Ø 296, p<0.001) [15].There was no statistically significant differ-
ence regarding overall length of hospital stay. Conversion to laparoscopic/open surgery was re-
ported only for the IG [15]. 
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Stomach 
Gastrectomy 
There were no intraoperative complications observed in Wang et al [17] and Pan et al [16] did not 
report on this outcome. Both studies reported no statistically significant differences between the 
two groups regarding postoperative complications (Pan et al at 11 months and Wang et al at 30 
days). In the Wang study, a high proportion of patients in both groups required reoperations due 
to anastomotic leakages (IG 4/14 or 29% vs CG 3/15 or 20%); the comparator in this study was 
open surgery. Conversion was not reported in Wang and was an exclusion criterion in Pan. Both 
studies had a high risk of bias at the outcome level. 
Both RCTs found statistically significantly lower blood loss levels in the robot-assisted surgery 
group [16], [17]. Pan et al found no difference in operation time whilst Wang et al found the opera-
tion time for the IG group was significantly longer than the control group. Both found statistically sig-
nificantly shorter hospital length of stay days with the robot-assisted surgery group. Wang report-
ed that 1 transfusion had occurred in each group. No information on drain duration was reported. 
Bariatric surgery 
There were no major intraoperative complications in either groups and 1/25 minor intraoperative 
complications in the IG versus none in the CG (for a high risk of bias at the outcome level) [18]. 
There were no postoperative complications observed. 1 patient of 25 required conversion in the 
IG (none in the CG). Reoperations were not included as an outcome measure [18].  
Sanchez et al (2005) [18] reported that operation time was significantly shorter in the IG (p<0.05) 
but found no overall difference in hospital length of stay. Information on blood loss, transfusions 
and drain duration were not reported. 
Bowel 
Colectomy 
In the only RCT (Park et al, [19] with a low risk of bias at the study level), there were no intraopera-
tive complications observed. There was a statistically non-significant difference between the groups 
in observed post-operative complications (IG 6/35 vs. CG 7/35) and no conversions were per-
formed. Information on reoperations was not included. 
Park et al [19], with a low risk of bias also at the outcome level, reported significantly lower operat-
ing time with robot-assisted surgery but no difference in blood loss or in the length of overall hos-
pital stay. There were no transfusions performed and drain duration was not reported.  
Rectal resection 
Jayne et al [20], with a low risk of study bias, found no statistically significant differences between 
the groups regarding intraoperative complications or post-operative complications (at 30 days, 
and between 30 days and 6 months). Conversion occurred in 19/236 (8%) of the IG and 28/230 
(12%) of the CG, with an unadjusted risk difference of 4.1% (95% CI -1.4% to 9.6%)41. Reopera-
tions were not mentioned in the publication. Kim et al, [21] also with a low risk of bias at the out-
come level, reported non-statistically significant differences in intraoperative and perioperative com-
                                                     
41 In a separate analysis on the ROLARR trial data, multi-level logistic regression (Corrigan et al, 2018)  
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plications (there was no information on postoperative complications). Tolstrup (high risk of bias at 
outcome level) did not report on intraoperative complications or reoperations but reported 10/25 
postoperative complications in the IG and 10/26 in the CG (not statistically significant) [22]. There 
was however a statistically significant difference in the rate of conversions between the groups 
which occurred among 1/25 patients in the IG and 10/26 patients in the CG (p<0.01) [22]. Debakey 
et al (high risk of bias) reported a high rate of postoperative complications within 30 days, although 
this was the same in both groups (29%) and most were grade 1 complications [24]. Conversions 
and re-operations occurred slightly more frequently in the control group (8% in the CG vs. 5% in 
the IG and 4% in the CG vs. 0% in the IG respectively), no statistical testing reported [24]. Wang 
et al [23] reported postoperative complications, but not which time period they related to, so could 
not be included in the GRADE quantitative summary in Table 7. In this study slightly more post-
operative complications were observed in the control group (15%) than in the intervention group 
(1%); conversions and reoperations were not reported [23].  
Jayne reported longer operating times with robot-assisted surgery (no statistical testing performed) 
but no difference in length of stay [20]. Blood loss was not reported. Kim also reported longer 
operating time (p<0.0001) and significantly more blood loss with the robot-assisted surgery group 
(p<0.00001) [21]. Both these studies had a low risk of bias rating at the study and outcome level. 
Debakey et al [24] (high risk of bias at the outcome level) also reported significantly longer operat-
ing time with robot-assisted surgery (p<0.001) but more blood loss in the control group (p=0.05) 
whilst overall length of hospital stay did not differ between the groups. Wang et al [23] similarly 
reported statistically significantly longer operation times with robotic surgery; blood loss and length 
of stay were not reported. Tolstrup [22] reported non-significant differences in operating time and 
did not report on the other outcomes (high risk of bias).  
Rectopexy 
The ventral mesh rectopexy study by Mäkelä-Kaikonen et al [68] reported non-statistically signifi-
cant differences on intraoperative complications and on postoperative complications (low risk of bias 
at outcome level). There were no conversions and information on reoperations was not reported. 
Non-significant differences between the groups were observed regarding operation time and length 
of stay [25]. No other outcomes were reported (low risk of bias at the outcome level).  
Gallbladder/liver/spleen 
Cholecystectomy 
All three RCTs on robot-assisted cholecystectomy that reported on complications [26], [27], [28] 
reported no statistically significant differences between the groups regarding intraoperative or post-
operative complications. Grochola et al [28] reported 10% conversion to conventional laparoscopy 
in the control group and 7% in the intervention group (not statistically significant); in all RCTs [26], 
[27], [1], there were no conversions. No information on reoperations was given. Pietrabissa et al. 
and Grochola et al were classed as having a low risk of bias. 
Kudsi et al [26] and Grochola et al [28] reported on blood loss and found no significant differences 
between IG and CG. Operation time was significantly longer in the robot-assisted surgery group in 
1 RCT [26] but not significantly different between groups in the other RCTs [27] [1] [28] Length of 
hospital stay was reported in three studies [26] [27] [28] and was found not to be (significantly) dif-
ferent between groups in 2 RCTs but statistically significantly shorter in the robot-assisted surgery 
group in Grochola et al [28]. Pietrabissa et al [27] and Grochola et al [28] have a low risk of bias 
whereas the Kudsi et al [26] and Ruurda et al [1] studies are associated with a high risk of bias. 
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Liver resection 
Total complications (intraoperative and postoperative) in the non-randomised, controlled studies 
occurred in 11% and 20% of the robot-assisted group compared with 17% and 20% in the control 
group ( [35], [36] respectively). The differences were not statistically significant [36] or not reported 
[35]. 1 conversion (11%) was needed in the IG group as opposed to none in the CG [35]; 4 con-
versions (4%) were needed in the IG as opposed to 2 in the CG (6%), p=ns [36]. Reoperations 
were observed in Lai and Tang [36]: 5% in IG and 3% in CG and were not reported in Berber et al 
[35]. Both studies were classed as having a critical risk of bias. 
There was no statistically significant difference between the groups regarding blood loss in either 
study. Lai and Tang [36] reported that operation time was statistically significantly longer in the 
robot-assisted group (207 minutes vs. 134 minutes) although Berber et al [35] found no statistically 
significant difference. Length of hospital stay and transfusions were reported by Lai and Tang [36]; 
there were no statistically significant differences on these outcomes and they were not reported in 
the Berber study [35]. Neither study reported on drain duration. Both studies were classed as hav-
ing a critical risk of bias. 
Hernia repair 
There were no wound infections reported in either group [37]. No other complications were con-
sidered. As assessed with the ROBINS-I it has a critical risk of bias  
The operation time was shorter in the robot-assisted group (48 vs. 52 minutes) but there is no 
statistical reporting. As assessed with the ROBINS-I, this study is associated with a critical risk of 
bias [37].  
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Table 6: Frequency and severity of adverse events in studies that used the Clavien-Dindo classification 
Clavien-Dindo classification 
Clavien-Dindo grade 
class/adverse 
events 
Cholecystectomy Rectal resection 
Grochola et al. 2018 [28] Kim et al. 2018 [21] Tolstrup et al. 2018 [22] Debakey et al. 2018 [24] 
IG CG IG CG IG CG IG CG 
Grade I 2/30 (7%) 4/30 (13%) 6/66 (9.1%) 3/73 (4.1%) 1/25 (4%) 4/26 (25%) 4/21 (19%) 5/24 (21%) 
Grade II 2/30 (7%).  1/30 (3%) 11/66 (16.7) 10/73 (13.7%) 6/25 (24%) 1/26 (4%) 1/21 (5%) 1/24 (4%) 
Grade III (Total) NR NR NR NR 2/25 (8%) 4/26 (25%) 1/21 (5%) 0/24 (0%) 
Grade IIIa 0  1/30 (3%) 4/66 (6.4%) 2/73 (2.7%) NR NR NR NR 
Grade IIIb 0 0 2/66 (3.0%) 2/73 (2.7%) NR NR NR NR 
Grade IV (Total) NR NR NR NR 0/25 (0%) 1/26 (4%) NR NR 
Grade IVa 0 0 NR NR NR NR 0/21 (0%) 0/24 (0%) 
Grade IVb 0 1/30 (3%) NR NR NR NR NR NR 
Grade V 0 0 NR NR 1/25 (4%) 0/26 (0%) 0/21 (0%) 1/24 (4%) 
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Clavien-Dindo classification 
 
Lobectomy/Segmentectomy Colectomy Oesophagectomy Gastrectomy 
Rinieri et al. 2016 [31] Park et al. 2012 [19] Van der Sluis et al. 2018 [15] Wang et al. 2016 [17] 
Grade I 2/17 (12%) 2/34 (6%) 5/35 (14%) 
(Grade I and II) 
6/35 (17%) 
(Grade I and II) 
22/54 (41%) 11/55 (20%) 7/14 (50.0%) 6/15 (40.0%) 
Grade II 0/17 (0%) 1/34 (3%) 
32/54 (59%) 
(Grade II to V) 
44/55 (80%) 
(Grade II to V) 
3/14 (21.4%) 4/15 (26.7%) 
Grade III (Total) 1/17 (6%) 4/34 (12%) 
1/35 (3%) 
(Grade III and IV) 
1/35 (3%) 
(Grade III and IV) 
4/14 (28.6%)  4/15 (26.7%) 
Grade IIIa NR NR NR NR 
Grade IIIb NR NR NR NR 
Grade IV (Total) 1/17 (6%) 2/34 (6%) 0/14 (0%) 1/15 (6.7%), 
Grade IVa NR NR NR NR 
Grade IVb NR NR NR NR 
Grade V 0/17 (0%) 1/34 (3%) NR NR NR NR 
Abbreviations: CG= control group; IG=intervention group; NR= not reported 
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Table 7: Summary of findings regarding safety for thoracic and visceral indications 
Thoracic Surgery 
Robot-assisted lobectomy vs. VATS  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Postoperative 
complications  
68 fewer per 1,000 
(from 170 fewer to 77 more) 
RR 0.84 
(0.60 to 1.18) 
215 
(3 RCTs)  
⨁◯◯◯ 
Very low 
unclear which surgeons conducted 
surgery and with what type of experience, 
unclear how patients were assigned to 
treatment groups, small sample size; 
wide CIs around results;  
 
Robot-assisted mediastinal surgery vs. open mediastinal mass resection  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Postoperative 
complications  
124 more per 1,000 
(from 50 fewer to 1,000 more) 
RR 2.36 
(0.45 to 12.38) 
36 
(1 RCT)  
⨁◯◯◯ 
Very low 
unclear which surgeons conducted 
surgery and with what type of experience, 
unclear how patients were assigned to 
treatment groups, small sample size; 
wide CIs around results.  
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Visceral surgery 
Oesophagus 
Robot-assisted laparoscopic fundoplication vs. laparoscopic fundoplication  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
57 fewer per 1,000 
(from 103 fewer to 73 more) 
RR 0.56 
(0.20 to 1.57) 
140 
(3 RCTs) 
⨁◯◯◯ 
Very low 
2 studies with high risk of bias at the 
study level; all 3 studies are small with 
wide CIs around results 
Postoperative 
complications at 
discharge 
57 fewer per 1,000  
(from 157 fewer to 117 more) 
RR 0.80 
(0.45 to 1.41) 
140  
(3 RCTs)  
⨁◯◯◯ 
Very low 
All 3 studies are small with wide CIs 
around results; 2 studies have a high 
risk of bias  
Postoperative 
complications at  
30 days 
18 more per 1,000  
(from 139 fewer to 379 more) 
RR 1.07 
(0.46 to 2.47) 
60 
(2 RCTs) 
⨁◯◯◯ 
Very low 
High risk of bias at the study level (but 
low for this outcome); both studies are 
small with wide CIs around results 
Postoperative 
complications at  
12 months 
119 fewer per 1,000  
(from 224 fewer to 163 more) 
RR 0.59 
(0.23 to 1.56) 
60 
(2 RCTs) 
⨁◯◯◯ 
Very low 
High risk of bias at the study level (but 
low for this outcome); both studies are 
small with wide CIs around results 
 
Robot-assisted Heller myotomy vs. laparoscopic Heller myotomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
IG: 0/37 (0%) vs. CG: 4/55 (7.3%)  
Relative effect cannot be calculated as the study provides  
no information about the relative probability of the event  
(see Cochrane handbook 5-1, section 9.2.2.2) 
92 
(2 non-randomised 
studies) 
⨁◯◯◯ 
Very low 
Critical/serious risk of bias on ROBINS-I  
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Robot-assisted thoracolaparoscopic oesophagectomy compared to open transthoracic oesophagectomy 
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
34 fewer per 1,000 
(from 111 fewer to 160 more) 
RR 0.79 
(0.32 to 1.98) 
109  
(1 RCT) 
⨁⨁◯◯ 
Low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
Postoperative 
complications (overall 
surgery-related, Clavien-
Dindo ≥ grade 2) 
208 fewer per 1,000 
(from 344 fewer to 32 fewer) 
RR 0.74 
(0.57 to 0.96) 
109  
(1 RCT) 
⨁⨁⨁◯ 
Moderate 
Inconsistency uncertain as only 1 study 
Postoperative 
complications (overall, 
MCDC ≥ grade 2) 
168 fewer per 1,000 
(from 304 fewer to 0 fewer) 
RR 0.79 
(0.62 to 1.00) 
109  
(1 RCT) 
⨁⨁◯◯ 
Low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
 
Stomach 
Robot-assisted gastrectomy vs. laparoscopic gastrectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
Outcome not reported 
Postoperative 
complications  
148 fewer per 1,000 
(from 179 fewer to 65 fewer) 
RR 0.25 
(0.09 to 0.67) 
163  
(1 RCT) 
⨁⨁◯◯ 
Low 
High risk of bias 
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Robot-assisted gastrectomy vs. open gastrectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
0 events in both groups 
Relative effect cannot be calculated as the study provides  
no information about the relative probability of the event  
(see Cochrane handbook 5-1, section 9.2.2.2) 
296  
(1 RCT) 
⨁◯◯◯ 
Very low 
High risk of bias at the outcome and 
study level 
Postoperative 
complications  
10 fewer per 1, 000 
(from 57 fewer to 82 more) 
RR 0.90 
(0.45 to 1.79) 
296  
(1 RCT) 
⨁◯◯◯ 
Very low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
 
Robot-assisted laparoscopic gastric bypass vs. laparoscopic gastric bypass  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
Not estimable Relative effect cannot be calculated as the study 
provides no information about the relative probability of the event 
(see Cochrane handbook 5-1, section 9.2.2.2) 
50 
(1 RCT) 
⨁◯◯◯ 
Very low 
0 complications in the control group and 
only 1 complication in the intervention 
group 
Postoperative 
complications  
Not estimable Relative effect cannot be calculated as the study 
provides no information about the relative probability of the event 
(see Cochrane handbook 5-1, section 9.2.2.2) 
50 
(1 RCT) 
⨁◯◯◯ 
Very low 
0 complications in both groups 
 
Bowel 
Robot-assisted right colectomy vs. laparoscopic right colectomy  
Intraoperative 
complications 
Outcome not reported 
Postoperative 
complications  
28 fewer per 1000 
(from 136 fewer to 258 more) 
RR 0.86 
(0.32 to 2.29) 
70 
(1 RCT) 
⨁◯◯◯ 
Very low 
High risk of bias, small sample size, 
wide CI 
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Robot-assisted laparoscopic rectal resection compared to laparoscopic rectal resection  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
13 more per 1,000  
(from 33 fewer to 8 more) 
RR 1.11  
(0.73 to 1.68) 
605 
(2 RCTs) 
⨁⨁◯◯ 
Low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
Postoperative 
complications 
(timeframe unclear) 
39 fewer per 1,000  
(from 105 fewer to 117 more) 
RR 0.74 
(0.31 to 1.77) 
137  
(1 RCT) 
⨁◯◯◯ 
Very low 95% confidence intervals around the absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
Postoperative 
complications to 
discharge 
90 more per 1,000  
(from 35 fewer to 281 more) 
RR 1.33  
(0.87 to 2.03) 
190  
(2 RCTs) 
⨁◯◯◯ 
Very low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications; 1 RCT had a high risk  
of bias 
Postoperative 
complications within  
30 days 
13 more per 1,000  
(from 33 fewer to 8 more) 
RR 1.04  
(0.81 to 1.34) 
511  
(2 RCTs) 
⨁◯◯◯ 
Very low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
Postoperative 
complications > 30 
days and ≤ 6 months 
21 fewer per 1,000  
(from 71 fewer to 55 more) 
RR 0.87  
(0.57 to 1.33) 
466  
(1 RCT) 
⨁⨁◯◯ 
Low 
95% confidence intervals around the 
absolute and relative effects includes the 
possibility of both increased postoperative 
complications and reduced postoperative 
complications 
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Robot-assisted ventral mesh rectopexy vs. laparoscopic ventral mesh rectopexy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
116 more per 1000 
(from 49 fewer to 1000 more) 
RR 2.62 
(0.31 to 22.46) 
30 
(1 RCT) 
⨁◯◯◯ 
Very low 
Single study with small sample size and 
few events. CI around estimates are 
wide, including both beneficial and 
harmful effects. 
Postoperative 
complications  
54 more per 1000 
(from 59 fewer to 1000 more) 
RR 1.75 
(0.18 to 17.30) 
30 
(1 RCT) 
⨁◯◯◯ 
Very low 
Single study with small sample size and 
few events. CI around estimates are 
wide, including both beneficial and 
harmful effects. 
 
Gallbladder/liver/spleen 
Single-site laparoscopic robotic cholecystectomy vs. multiport laparoscopic cholecystecomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
91 fewer per 1000 
(from 124 fewer to 9 more) 
RR 0.37 
(0.14 to 0.94) 
196  
(2 RCTs) 
⨁⨁◯◯ 
Low 
One of the studies constituted a low risk 
of bias (Pietrabissa et al, 2017); the 95% 
confidence interval around the absolute 
effect includes the possibility of both 
increased postoperative complications 
and reduced postoperative complications 
Postoperative 
complications  
29 more per 1000 
(from 13 fewer to 233 more) 
RR 2.20  
(0.46 to 10.65) 
196  
(2 RCTs) 
⨁◯◯◯ 
Very low 
The 95% confidence interval around  
the absolute effect includes the possibility 
of both increased postoperative 
complications and reduced 
postoperative complications 
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Single-site laparoscopic robotic cholecystectomy vs. single-incision laparoscopic cholecystecomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Intraoperative 
complications 
65 fewer per 1,000 
(from 243 fewer to 247 more) 
RR 0.86 
(0.48 to 1.53) 
60  
(1 RCT) 
⨁⨁◯◯ 
Low 
Small sample size; absolute and relative 
risk effects include the possibility of both 
more and fewer events 
Postoperative 
complications at  
30 days 
100 fewer per 1,000 
(from 189 fewer to 175 more) 
RR 0.57 
(0.19 to 1.75) 
60  
(1 RCT) 
⨁⨁◯◯ 
Low 
Absolute and relative risk effects include 
the possibility of both more and fewer 
events 
 
Robot-assisted liver resection/hepatectomy compared to laparoscopic liver resection/hepatectomy  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Total complications 
(intra- and 
postoperative) 
61 fewer per 1,000 
(from 102 fewer to 2 fewer) 
RR 0.68 
(0.46 to 0.99) 
162  
(2 non-randomised, 
controlled studies) 
⨁◯◯◯ 
Very low 
Critical risk of bias for this outcome at  
the ROBINS-I: little information on 
amount of surgical experience and type 
and approach of resection (Berber et al, 
2010); potentially missing complications 
data (Berber et al, 2010) 
 
Robot-assisted hernia repair vs. laparoscopic single-port inguinal hernia repair  
Outcome Anticipated absolute effects  
(95% CI) 
Relative effect  
(95% CI) 
Number of 
participants (studies) 
Quality Comments 
Wound infections O events in both groups 
Relative effect cannot be calculated as the study provides no 
information about the relative probability of the event (see 
Cochrane handbook 5-1, section 9.2.2.2) 
32 
(1 non-randomised 
controlled study) 
⨁◯◯◯ 
Very low 
Critical risk of bias 
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 [C0002] – Are the harms related to dosage or frequency  
of applying robot-assisted surgery? 
This question does not apply to the da Vinci Surgical System or any of the other robotic systems, 
as there is no varying dosage or frequency associated with the device. 
 
[C0004] – How does the frequency or severity of harms change over time  
or in different settings? 
This question is not relevant to the da Vinci Surgical System, as the device is used typically once 
for a given intervention. 
 
[C0005] – What are the susceptible patient groups that are more likely to be harmed 
through the use of robot-assisted surgery? 
No evidence was found to answer this research question.  
 
[C0007] – Is robot-assisted surgery associated with user-dependent harms? 
No evidence was found to answer this research question from the included study pool. Robot-as-
sisted surgery is claimed to be a more ergonomically-friendly method of operating for the surgeon42 
and there is some evidence to support this [69].  
 
[B0010] – What kind of data/records and/or registry is needed to monitor  
the use of the technology and the comparator? 
No evidence was found to answer this research question. 
 
 
                                                     
42 https://www.intuitive.com/about-us/company/legal/safety-information 
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7 DISCUSSION 
Robotic surgery is a form of minimally-invasive surgery whereby the instruments of the robotic sys-
tem are controlled by a direct telemanipulator, which is a remote manipulator that allows the sur-
geon to perform the normal movements associated with surgery. The robot has a higher degree of 
dexterity compared to the laparoscopic approach, which it is claimed allows surgeons to operate 
in very tight spaces in the body that would otherwise only be accessible through open surgery, 
with the rational of improving clinical outcomes and resource use. There are currently 16 manu-
facturers of robotic systems for use in thoracic and visceral surgery; four of these are currently 
actively marketing a total of seven products (da Vinci SI®, da Vinci SP®, da Vinci XI®, da Vinci X®, 
Freehand v1.2, Surgenius Beta, Flex Robotic System and Senhance TM Surgical System). The 
robotic procedure used in most of the studies included in this HTA involved the da Vinci® Surgical 
System. Evidence suggests that robot-assisted surgical methods result in a higher mean cost per 
procedure than conventional surgical methods.  
This HTA had the aim of assessing the effectiveness and safety of robotic surgery applied to the 
areas of thoracic and visceral surgery. Thoracic surgery is concerned with conditions of the lungs, 
chest wall and diaphragm and is generally dominated by treatment of malignant disease. Visceral 
surgery deals with all aspects of the surgical treatment of benign and malignant diseases of ab-
dominal organs, the entire gastrointestinal tract, endocrine organs, the abdominal wall and the 
peritoneum. 
In accordance with the advice of a clinical expert, the evidence on effectiveness and safety was 
assessed for each procedure at the operation level. Different procedures are often associated with 
different outcome categories hence the reporting of results differs according to the procedure un-
der consideration. In total 2 thoracic procedures were assessed, namely lobectomy and mediasti-
nal surgery. Visceral surgery covers a much wider number of organs. Here procedures relating to 
the oesophagus (antireflux/fundoplication, oesophagectomy and Heller myotomy), stomach (gas-
trectomy, bariatric surgery), bowel (colectomy, rectal resection, rectal rectopexy) and gallbladder/ 
liver/spleen (cholecystectomy, liver resection and hernia repair) were assessed.    
There is a serious lack of evidence available from RCTs on the performance of robot-assisted 
surgery compared to open or laparoscopic surgery. Statements of effect were only possible for 
some of the outcomes (but not all) for 4 procedures (oesophagectomy, gastrectomy, rectal resec-
tion, cholecystectomy) and even here the quality of evidence was generally low and at most, mod-
erate. Of these statements of effect, most were in favour of robot-asisted surgery. For all other out-
comes and procedures there are evidence gaps. In terms of ongoing studies, we can report that 
there are many ongoing trials on the use of robotic surgery in the field of thoracic and visceral 
surgery. It is expected that the studies will add further evidence, at least for some of the proce-
dures considered.  
 
7.1 Interpretation of findings/level of evidence 
For eight procedures (antireflux/fundoplication, oesphagectomy, gastrectomy, bariatric surgery, col-
ectomy, rectal resection, rectal rectopexy, cholecystectomy), RCTs of ≥10 patients could be identi-
fied. For five procedures (lobectomy, mediastinal surgery, Heller myotomy, liver resection/hepatec-
tomy, hernia repair), no RCTs ≥10 patients could be identified, hence (in accordance with the pro-
ject protocol) nine prospective studies non-randomised controlled studies were included (lobecto-
my: 3; mediastinal surgery: 1; Heller myotomy: 2; liver resection/hepatectomy: 2; hernia repair: 1). 
All studies included in this HTA were comparative, prospective studies.  
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A total of 28 studies were therefore included; of these 19 were RCTs and 9 were prospective, 
controlled, non-randomised studies. All the RCTS identified in the systematic literature search re-
ported on effectiveness, with the exception of one [1]. In the majority of studies laparoscopy (not 
open surgery) was used as the comparator.  
Seven procedures (lobectomy, mediastinal mass resection, gastrectomy, colectomy, rectal resec-
tion, liver resection/hepatectomy and oesophagectomy) of the total 13 procedures related to pa-
tients undergoing surgical treatment for cancer.  
 
Thoracic surgery: lobectomy 
Intraoperative and in-hospital mortality shows non-significant differences between the arms; rela-
tive risk estimates are not possible since no events are observed in at least one arm. Regarding 
postoperative complications, the point estimate suggests a relative risk reduction but wide confi-
dence intervals include the possibility of both more and fewer complications occurring with robot-
assisted surgery.  
Evidence on blood loss is conflicting (one study found significantly more and one study significant-
ly less blood loss with robot-assisted surgery). 1 out of the 3 studies found statistically significantly 
longer operation times with robot-assisted surgery whilst the other two did not. None of these stud-
ies had a low risk of bias.  
 
Thoracic surgery: mediastinal 
In the non-randomised, controlled study by Balduyck et al (2011) [32], recurrence occurred in 1/22 
patients in the control group and in no cases in the intervention group, which was not statistically 
significant (low to medium risk of bias). The relative effect on intraoperative mortality could not be 
assessed as there were no events in either arm; there was a conversion in the IG (7%) and one 
re-operation in the CG (9%) but no statistical testing was reported. Quality of life and symptoms 
deteriorated significantly in the short-term in several subscales in the open surgery group but much 
less so in the robotic surgery group. There was no statistically significant difference in operation 
time and length of hospital stay. The evidence has been assessed as very low. 
 
Visceral surgery: Oesophagus 
Antireflux/fundoplication 
Up to four RCTs were available for analysis (depending on endpoint), for a total of up to 160 pa-
tients. Mortality associated with the procedure could not be assessed, since it was not reported in 
any of the studies. There were no reported differences in symptoms. In terms of intraoperative and 
postoperative complications, we are uncertain whether robotic fundoplication surgery improves or 
reduces intraoperative and postoperative complications compared to laparoscopic fundoplication 
surgery as the certainty of the evidence has been assessed as very low. Therefore no consistent 
advantage for robot-assisted antireflux surgery has been demonstrated. In one RCT there was a 
12% recurrence of hiatal hernia in the CG and 4% recurrence in the IG but statistical significance 
testing was not reported and there is a high risk of bias at the outcome level. Neither study report-
ing on satisfaction found statistically significant differences.  
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1 study reported on blood loss; no statistically significant differences were reported. The evidence 
on operation time is conflicting: 3 studies reported significant differences but these went in differ-
ent directions (two found robot-assisted surgery took longer and the other reported that it took a 
shorter time than the control procedure) and 1 found a non-significant difference. The strongest 
evidence came from one of the studies reporting a significantly longer operation time.  
Heller myotomy 
2 controlled, non-randomised studies for a total of 92 patients were available for analysis. Mortality 
was not assessed as an outcome. Both the robot-assisted Heller myotomy group and the laparo-
scopic Heller myotomy groups showed post-operative improvements in quality of life and symptoms, 
but no between-group assessments were made in the studies. For this reason we are uncertain 
whether robotic surgery improves morbidity or quality of life compared with laparoscopy for this 
procedure. We cannot infer from the study data whether robotic surgery is associated with more 
or fewer intraoperative complications compared to laparoscopic Heller myotomy. Neither study 
reported significant differences on resource use outcomes. 
Oesophagectomy 
1 RCT was available (109 patients) comparing thoracolaparoscopic oesophagectomy with open 
transthoracic oesophagectomy. Confidence intervals around the absolute and relative effect esti-
mates around the point estimate for mortality include the possibility of both increased postopera-
tive complications and reduced postoperative complications hence we are uncertain whether ro-
botic surgery is associated with more or fewer fatal events. Robotic surgery probably improves 
quality of life and functional recovery and reduces postoperative complications when compared to 
open surgery for this procedure (quality of evidence: moderate). In terms of intraoperative compli-
cations, robotic surgery may reduce intraoperative complications, but the 95% confidence interval 
includes the possibility of both reduced complications and increased complications. This study found 
significantly less blood loss in the robot-assisted surgery arm compared to open surgery but sta-
tistically significantly longer operation time and no statistically significant difference on reoperations.  
 
Visceral surgery: stomach 
Gastrectomy 
2 RCTS were available, each with different comparators (open gastrectomy for a total of 296 pa-
tients and laparoscopic gastrectomy for a total of 163 patients). In both studies, no mortality events 
were reported in either arm. Morbidity and quality of life was not reported in the open gastrectomy 
comparison; in the laparoscopy comparison significant (statistically) lower VAS scores were re-
ported in early post-operative days in the robot-assisted group but the certainty of this evidence is 
assessed as very low. Robot-assisted surgery may reduce postoperative complications compared 
to conventional laparoscopic surgery (low quality/certainty of evidence). The comparison with open 
gastrectomy did not show any clear results in terms of reduction or increase in postoperative com-
plications. There were no statistically significant differences in proximal resection margins (in com-
parison with conventional laparoscopy). Both RCTs found statistically significantly lower blood loss 
levels and significantly shorter hospital length of stay days with the robot-assisted surgery group. 
Operation time was statistically significantly longer for the robot-assisted group compared to the 
conventional laparoscopy arm (there was no difference in the comparison with open surgery).  
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Bariatric surgery/gastric bypass   
Here 1 RCT was available (50 patients), which did not report on mortality or morbidity/quality of 
life. Due to the very few events (only 1 intraoperative complication and 0 postoperative complica-
tions) observed in this study in both arms relative effect estimates were not possible.1 patient re-
quired conversion to traditional laparoscopy in the intervention group (p=NR). We therefore have 
no basis on which to make any statements about effects or safety for this procedure. In terms of 
resource use, the included RCT reported a significantly shorter operation time with robot-assisted 
surgery, although the sample size is small and there was insufficient information on patient char-
acteristics i.e. serious risk of bias.  
 
Visceral surgery: bowel 
Colectomy 
In a single RCT (70 patients) comparing robot-assisted surgery with conventional laparoscopic 
surgery, mortality could not be assessed as there were no events in either arm. Pain assessment 
scores showed no statistically significant results between the groups. Intraoperative complications 
were not reported and postoperative complications showed a relative effect in favour of robot-
assisted colectomy surgery (RR 0. 86), but given the very low quality of this study and the wide CI 
around this effect estimate, we must conclude that we are uncertain whether robot-assisted sur-
gery reduces postoperative complications compared with traditional laparoscopic colectomy. Prox-
imal margin and distal margin outcomes were not influenced by the type of surgery in this study. 
In terms of resource use, significantly shorter operating time was reported with robot-assisted sur-
gery and in terms of perioperative outcomes, there was no stastically significant difference regard-
ing blood loss or length of hospital stay.  
Rectal resection 
5 RCTS were included in this HTA on rectal resection. For the outcome mortality within 30 days 
(2 RCTS; 511 patients) we are uncertain whether robot-assisted surgery reduces mortality com-
pared to conventional laparoscopic surgery. Quality of life results were mixed, with some aspects 
(sexual functioning) better in the IG and others (sleep disturbances) worse (both studies reporting 
on this outcome had a low risk of bias). Intraoperative and postoperative complications were ge-
nereally more prevalent in the robot-assisted group (particularly in the studies with a slightly lower 
risk of bias) but the CI crossed the line of no effect so we are uncertain whether robot-assisted 
surgery increases complications compared with conventional laparoscopic surgery. Proximal mar-
gin and distal margin outcomes were not influenced by the type of surgery in these studies. 
In terms of resource use, 5 RCTs reported on operative time; in 4 studies, robot-assist surgery took 
longer (in 3, significantly so). In terms of perioperative outcomes, 2 studies reported on blood loss 
with conflicting results.  
Rectopexy 
1 RCT was identified that compared robot-assisted ventral mesh rectopexy with laparoscopic 
ventral mesh rectopexy for rectal prolapse and intussusception. We are uncertain whether robot-
assisted rectopexy results in more or fewer intraoperative and postoperative complications as the 
evidence has been assessed as very low. No comparisons between arms were made regarding 
morbidity/quality of life. Regarding resource use, no statistically significant differences were report-
ed on operation time and length of hospital stay. 
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Visceral surgery: Gallbladder/liver/spleen 
Cholecystectomy 
In total 4 RCTs were available with either single-port or muilt-port laparoscopy as the comparator. 
No data was available on mortality. Quality of life and satisfaction results showed no statistically 
significant differences between the arms (3 RCTs, total 256 patients), although the quality of evi-
dence is very low. Robot-assisted surgery may reduce intraoperative complications, but the quali-
ty of evidence is low. Robot-assisted surgery may reduce postoperative complications at 30 days 
when compared to single-incision laparoscopic cholecystectomy (low certainty evidence) however 
the 95% CI includes the possibility of both reduced complications and increased complications. 
Two studies reporting on satisfaction found it was statistically significantly higher with robot-assist-
ed surgery (one of the studies had a low risk of bias) but a third study (also with a low risk of bias) 
reported no statistically significant differences (the overall evidence has been assessed as very 
low). 
Blood loss was reported in 2 studies: both found no significant differences. Operation time was 
significantly longer in 1 of 4 studies but not found to be different in 3 of 4 studies (the evidence 
has been assessed as low).  
Liver resection 
No RCTS were identified for this procedure so non-randomised, controlled studies were identified 
and included (2 in total, 162 patients). There were fewer recurrences with robot-assisted surgery 
compared to conventional liver resection but we are uncertain whether robot-assisted surgery re-
duces recurrences as the quality of the evidence has been assessed as very low. Similarly fewer 
overall complications were reported with robot-assisted surgery compared to conventional liver 
resection but we are uncertain whether robot-assisted surgery reduces complications as the quali-
ty of the evidence has been assessed as very low. Rates of recurrence were either not statistically 
significant in one study or sizable but without statistical testing in another study.  
Neither study found a difference regarding blood loss. Regarding operation time, 1 study found it 
was significantly longer in the robot-assisted surgery group; the other found no difference. 
Hernia repair 
No RCTS were identified for this procedure so non-randomised, controlled studies were identified 
and included (1 in total with 32 patients). Mortality results were not reported, neither were quality of 
life/morbidity results. The study only provides information on wound infections, for which no cases 
were reported in either arm (very low certainty of evidence). Satisfaction rates did not differ between 
the two arms. 
Operation time was shorter in the robot-assisted group but there was no statistical testing reported.  
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7.2 Limitations of the present report 
Limitations of the present report include the lack of stratification according to surgical experience; 
this information was often not available in a way that would enable a structured classification. Also 
an analysis of the number of cases required to maintain training and knowledge related to the 
method would be useful (this was beyond the scope of this HTA). 
Another limitation is the focus on RCTs where these were available, to the exclusion of potentially 
good quality prospective non-randomised studies. This was a decision taken at the project proto-
col stage to enable a manageable evidence pool given the magnitude of the topic (namely the in-
clusion of all procedures existing within the field of thoracic and visceral surgery). Given the range 
of outcomes reported on, which often differed between the procedures, we did not assess whether 
an RCT was available at the outcome level but only at the procedure level. 
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8 CONCLUSION 
There is insufficient evidence to determine whether robot-assisted lobectomy is more effective 
and/or has a better safety profile compared with VATS. 
There is insufficient evidence to determine whether robot-assisted mediastinal surgery is more 
effective and/or has a better safety profile compared with open mediastinal mass resection. 
There is insufficient evidence to determine whether robot-assisted antireflux/fundoplication me-
diastinal surgery is more effective and/or has a better safety profile compared with conventional 
laparoscopic fundoplication. 
There is insufficient evidence to determine whether robot-assisted Heller myotomy is more effec-
tive and/or has a better safety profile compared with conventional laparoscopic Heller myotomy. 
There is insufficient evidence to determine the effect of robot-assisted oesophagectomy upon 
mortality compared with open surgery. Robot-assisted oesophagectomy surgery probably im-
proves post-operative morbidity/QoL compared to open surgery (evidence quality: moderate) and 
robot-assisted oesophagectomy surgery probably reduces postoperative complications compared 
to open surgery (evidence quality: moderate). Intra-operative complications may be reduced with 
robot-assisted surgery compared to open surgery, although the 95% confidence interval includes 
both the possibility of reduced complications and increased complications.  
There is insufficient evidence to determine whether robot-assisted gastrectomy is more effective 
than conventional laparoscopy or open surgery. Robot-assisted gastrectomy may reduce postop-
erative complications compared to conventional laparoscopy (evidence quality: low).  
There is insufficient evidence to determine whether robot-assisted bariatric surgery is more ef-
fective and/or has a better safety profile compared with conventional laparoscopic surgery. 
There is insufficient evidence to determine whether robot-assisted colectomy is more effective 
and/or has a better safety profile compared with conventional laparoscopy. 
There is insufficient evidence to determine the effect of robot-assisted rectal resection upon mor-
tality compared with conventional laparoscopic rectal resection. There is evidence that robot-as-
sisted rectal resection improves some aspects of QoL but worsens others (evidence quality low). 
It may increase intraoperative complications and decrease postoperative complications >30 days 
and ≤6 months (evidence quality: low). 
There is insufficient evidence to determine whether robot-assisted rectal rectopexy is more effec-
tive and/or has a better safety profile compared with conventional laparoscopic rectal rectopexy. 
There is insufficient evidence to determine whether robot-assisted cholecystectomy is more effec-
tive compared with conventional laparoscopy. There is some evidence that robot-assisted surgery 
may reduce intraoperative complications (evidence quality: low) and reduce postoperative compli-
cations at 30 days when compared to single-incision laparoscopic cholecystectomy (evidence quali-
ty: low). 
There is insufficient evidence to determine whether robot-assisted liver resection is more effec-
tive and/or has a better safety profile compared with conventional laparoscopic liver resection. 
There is insufficient evidence to determine whether robot-assisted hernia repair is more effective 
and/or has a better safety profile compared with conventional laparoscopic hernia repair. 
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Several of the studies considered cost aspects and most reported higher costs associated with 
robot-assisted surgery. This is often due to the longer operation time necessary, which was re-
ported by many studies. The evidence on blood loss was mixed but there were more studies re-
porting significantly less blood less with robot-assisted surgery than significantly more blood loss.  
Multicenter studies are needed in order to evaluate the outcomes in a higher number of subjects. 
Pending results from some large studies could contribute to solving at least some of uncertainties. 
For instance, 2 of the ongoing studies with more than a thousand patients will evaluate the long 
term impact on mortality following robot-assisted gastrectomy.  
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A1: Overview of guidelines with specific recommendations regarding robot-assisted 
surgery 
Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/class of 
recommendation 
(I, IIa, IIb, III) 
European Society for 
Medical Oncology 
[54] 
2017 Europe Robot-assisted rectal cancer 
surgery provides some technical 
advantages for surgeons 
compared with conventional 
laparoscopy but it is still under 
evaluation 
No 
recommendation 
level given 
National 
Comprehensive 
Cancer Network [65] 
July 2018 USA Several rectal cancer studies have 
looked at outcomes of 
robot-assisted surgery versus 
conventional laparoscopic 
resection with comparable results 
in terms of conversion to open 
resection, quality of total 
mesorectal excision, 
postoperative complications and 
quality of life 
2a 
National 
Comprehensive 
Cancer Network [61] 
21st Feb. 
2018 
USA VATS or minimally invasive 
surgery (including robotic-assisted 
approaches) should be strongly 
considered for patients with no 
anatomic or surgical 
contraindications, as long as there 
is no compromise of the standard 
oncologic and dissection 
principles of thoracic surgery 
No 
recommendation 
level given 
European Society for 
Medical Oncology 
[46] 
September 
2015 
Europe Minimally invasive surgery 
conducted by trained thoracic 
surgeons (including robotic 
approaches) is an option for 
presumed stage I and possibly 
stage II tumors  
IV, C 
American 
Gastrointestinal and 
Endoscopic Surgeons 
[64] 
May 2011 America Compared with laparoscopy, 
robot- assisted surgery has been 
demonstrated to decrease the rate 
of intraoperative oesophageal 
mucosal perforations but no clear 
differences in postoperative 
morbidity, symptom relief or long-
term outcomes have been 
described. Further evaluation is 
necessary to better establish the 
role of robot-assisted myotomy. 
++, weak 
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Evidence tables of individual studies included for clinical effectiveness and safety 
 
Table A2: Characteristics & risk of bias of randomised controlled studies  
Oesophagus 
 Antireflux/Fundoplication Antireflux/Fundoplication 
Author, year 
[reference number] 
Draaisma et al. 2006 [10] Morino et al. 2006 [11] 
Study design Single-centre RCT of patients with 
GORD 
Single-centre RCT of patients with GORD 
Country The Netherlands Italy 
Funding/Sponsor NR NR 
Intervention (IG) | 
Product 
robot-assisted laparoscopic Nissen 
fundoplication | da Vinci Robotic System 
Robot-assisted fundoplication | da Vinci system 
Comparator (CG) Laparoscopic-assisted laparoscopic 
Nissen fundoplication 
Traditional laparoscopic fundoplication 
Experience of sur-
geon(s), time period 
Surgeons had performed more than 30 
laparoscopic Nissen fundoplications and 
more than 20 robot-assisted laparoscopic 
procedures. Operations were performed 
January 2003-October 2005 
3 surgeons all proficient in laparoscopic 
procedures 
Operations were performed February 2002-
February 2004 
Number of patients IG: 25 
CG: 25 
IG:25 
CG:25 
Inclusion/exclusion 
criteria 
Inclusion: 
• Age >18  
• Diagnosed with GORD via upper 
endoscopy, barium oesophagram 
series, oesophaegeal manometry, 
24-hr pH monitoring 
Exclusion: 
• General contraindications for 
laparoscopy, psychiatric illness, 
previous abdominal surgery 
• 12 patients excluded prior to 
randomisation 
Inclusion: 
• Clinical GORD that necessitated surgery 
according to the criteria of Hinder et al. 
• ASA score I-II 
Exclusion: 
• Giant hiatal hernia (larger than 6 cm on 
preoperative barium meal) 
• ASA score III–IV 
• Previous upper abdominal surgery  
• Contraindications to pneumoperitoneum 
Primary/secondary 
endpoints 
• Primary endpoints: (nadir) end-
expiratory LOS pressure, total 
oesophageal acid exposure time, 
symptom index, symptom 
association probability 
• Secondary endpoints: general 
health state (10-point VAS 0-100); 
QoL (Visick scale); self-rated reflux 
symptoms (instrument NR); 
satisfaction with outcome 
(instrument NR); 
• Primary endpoint: In-hospital cost of the 
procedure 
• Secondary endpoints were skin-to-skin and 
total operating time 
Follow-up (months) 3-6 Ø 22.3 (R 6-32) 
Drop-outs (n (%) IG: 2/25 (8%)  
CG: 0  
none 
Patient characteristics 
Age of patients (yrs.) IG: M 48 (R 20-74) 
CG: M 52 (R 27-71), p=ns 
IG: Ø 43.0 ±12.8  
CG: Ø 46.3 ±11.3, p=ns 
Sex (% female) IG: 36% 
CG: 32%, p=NR 
IG: 24% 
CG: 28%, p=ns 
BMI (kg/m²) IG: M 25.6 (R 19.1-37.2) 
CG: M 28.7 (R 19.5-46.6), p=ns 
IG: Ø 25.5 ±2.9  
CG: Ø 26.1 ±2.3, p=ns 
Clinical classification Los Angeles classification of NR 
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 98 
Oesophagus 
 Antireflux/Fundoplication Antireflux/Fundoplication 
Author, year 
[reference number] 
Draaisma et al. 2006 [10] Morino et al. 2006 [11] 
oesophagitis (IG vs.CG) 
Grade A: 24% vs. 20% 
Grade B: 28% vs. 24% 
Grade C: 12% vs. 0 
Grade D: 8% vs. 4% 
No oesophagitits: 24% vs. 32% 
Unknown: 4% vs. 20% 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR NR 
Recurrence (local, 
regional or distant) 
IG: 1/25 (4%) hiatal hernia 
CG: 3/25 (12%) hiatal hernia, p=NR 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
General quality of life IG vs CG @ 6 
months after surgery, NR CI95% [-
18.1;9.2], p=ns43 : 
IG: M 22.5 (R 12-99) vs. M 72.0 (R21-98) 
CG: M 32.5 (R 0-96) vs. M 76.0 (R 26-
100) 
Self-rated change in reflux symptoms 
compared with preoperative state (IG vs 
CG): 
Resolved: 14/25 (56%) vs. 15 (60%), 
p=ns 
Improved: 9/25 (36%) vs. 9/26 (36%), 
p=ns 
Unchanged: 1/25 (4%) vs. 0, p=ns 
Worsened: 1/25 (4%) vs 1/25 (4%), p=ns 
Self-rated change in general quality of 
life compared with preoperative state (IG 
vs. CG): 
Improved: 22/25 (88%) vs. 20/25 (80%), 
p=ns 
Unchanged: 0 vs. 3/25 (12%), p=ns 
Worsened: 3/25 (12%) vs. 2/25 (8%), 
p=ns 
Symptoms @ 1 month (IG vs. CG), p=NR 
Mild transient dysphagia: 3/25 (12%) vs. 3/25 
(12%),  
@ 6 months, p=NR 
Oesophagitis: 0 vs. 0 
Authors report that no clinical differences between 
the two groups were found using the GORD-
HRQOL at 3, 6 and 12 months. 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction IG: 23/25 (92%) 
CG: 22/25 (88%) 
p=ns, CI95% [-0.13.0.21]1 
NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
Minor complications (IG vs. CG) p=NR: 
• Liver capsule tear: 2/25 (8%) 
vs. 4/25 (16%) 
• Spleen capsule tear: 0 vs. 2/25 
(8%) 
• Pneumothorax: 0 vs. 1/25 (4%) 
• Minor bleeding: 2/25 (8%) vs. 0 
IG: 0 
CG: 0 
Postoperative compli-
cations (e.g. infections) 
IG vs. CG, p=NR: 
Pneumonia: 0 vs. 1/25 (4%) 
IG: 0 
CG: 0 
                                                     
43 No summary statistic reported, only that the CI relates to CG vs. IG 6 months after surgery 
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Oesophagus 
 Antireflux/Fundoplication Antireflux/Fundoplication 
Author, year 
[reference number] 
Draaisma et al. 2006 [10] Morino et al. 2006 [11] 
Urinary tract infection: 0 vs. 1/25 (4%) 
Re-
operations/additional 
surgeries  
@ 6 months FU, p=NR: 
IG: 2/25 (8%), because of dysphagia and 
an incisional hernia 
CG: 2/25 (8%), because of dysphagia 
NR 
Conversion  IG: 0 
CG: 2/25 (8%), p=NR 
IG: 1/25 (4%) because of difficulty in pursuing the 
dissection by robotic techniques with a prolonged 
operating time. 
CG: 0, p=NR 
Perioperative events & resource use 
Blood loss (in ml) IG: M 20 (R 0-200) 
CG: M 45 (R 0-200) 
Mean Difference 25; CI95%[-58.2;8.9], 
pü=ns 
NR 
Operation time in min. IG: M 120 (R 80-180) 
CG: M 95 (R 60-210)  
Mean Difference 25, CI95%[-6.0;32.0] 
IG: Ø 131.3 ±18.3  
CG: Ø 91.1 ± 10.6, p<0.001 
Transfusions NR NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: M 3 (R 2-6) 
CG: M 3 (R 1-13), p=NR 
IG: Ø 2.9 (R 2-6) 
CG: Ø 3.0 (R 2-7), p=ns  
 
Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Mueller-Stich et al. 2007 [12] & Mueller-Stich et al. 2009 [13] 
Study design Single-centre RCT of patients with symptomatic GERD 
Country Germany 
Funding/Sponsor German Research Foundation. 
Intervention (IG) | 
Product 
Robot-assisted laparoscopic fundoplication | da Vinci Surgical System 
Comparator (CG) Conventional laparoscopic fundoplication 
Experience of sur-
geon(s), time period 
All surgeons were reported to be highly experienced in laparoscopy, with at least 30 
conventional laparoscopic fundoplications 
Operations were performed August 2004-December 2005 by 1 surgeon (IG) and 3 surgeons 
(CG) 
Number of patients IG: 20 
CG:20 
Inclusion/exclusion 
criteria 
Inclusion: 
• Age >18  
• History of more than 6 months of symptomatic GERD requiring acid suppressive therapy 
of a minimal standard dosage of the applied proton pump inhibitor (PPI) for at least 3 
months in the preceding year  
• GERD had to be proven endoscopically or by severe clinical symptoms which resolved 
with PPI therapy (positive PPI test)  
Exclusion:  
• Previous major upper abdominal surgery, hiatal hernias with paraesophageal involvement  
• Obesity with a body mass index of over 40 kg/m2 
• Evidence of primary oesophageal disorders such as achalasia, sclerodermia or malignant 
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Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Mueller-Stich et al. 2007 [12] & Mueller-Stich et al. 2009 [13] 
diseases 
12 patients excluded prior to randomisation 
Primary/secondary 
endpoints 
• Primary: Quality of Life in Refux and Dsypepsia (QOLRAD); Gastrointestinal Symptom 
Rating Scale (GSRS); patient satisfaction; 4-step Likert scale for specific symptoms  
• Secondary: Perioperative outcomes regarding operative time, perioperative complications, 
length of stay and costs  
Follow-up (months) 12 (also 1, 3, 6 months) 
Drop-outs (n (%)) none 
Patient characteristics 
Age of patients (yrs.) IG: Ø 49.6 ±12.0 (R 23-71) 
CG: Ø 50.5 ±12.4 (R 25-75), p=ns 
Sex (% female) IG: 50% 
CG: 60%, p=NR 
BMI (kg/m²) IG: Ø 29.2 ±5.8 (R 21-40) 
CG: Ø 26.2 ±3.4 (R 19-31), p=ns 
Clinical classification Los Angeles classification of oesophagitis (IG vs.CG), p=ns: 
Grade A: 45% vs. 55%  
Grade B: 50% vs. 35% 
Grade C: 5% vs. 10% 
Grade D: 0 vs. 0 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
QOLRAD (min. 1-max. 7) before vs. 12 months after surgery: 
IG: Ø 3.7 ±1.3 vs. Ø 1.3 (R 1.0-4.6), p=ns 
CG: Ø 3.7 ±1.2 vs Ø 1.1 (R1.0-2.2), p=ns 
GSRS (reflux syndrome, min. 1-max. 7) before vs. 12 months after surgery: 
IG: Ø 4.0 ±1.7 vs. Ø 1.3 (R 1.0-3.5) 
CG: Ø 4.4 ±1.5, vs. Ø 1.3 (R 1.0-4.0), p=ns 
Time to resume 
work/daily activities 
NR 
Patient satisfaction Change of condition (IG vs. CG): 
Normalised: 11/20 (55%) vs. 5/20 (25%), p=ns 
Improved: 7/20 (35%) vs. 14/20 (70%), p=ns 
Unchanged: 2/20 (10%) vs. 1/20 (5%), p=ns 
Worsened: 0 vs. 0, p=ns 
Operative result (IG vs. CG): 
Excellent: 6/20 (5%) vs. 2/20 (10%), p=ns 
Very good: 7/20 (35%) vs. 9/20 (45%), p=ns 
Good: 6/20 (30%) vs. 8/20 (40%), p=ns 
Sufficient: 0 vs. 1/20 (5%), p=ns 
Would you decide in favour of an operation again? (ratio Yes:No) 
IG: 19:1 
CG: 20:0 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
IG: 1/20 (5%), 1 pneumothorax 
CG: 2/20 (10%), 2 bleedings 
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Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Mueller-Stich et al. 2007 [12] & Mueller-Stich et al. 2009 [13] 
leakage) p=NR 
Postoperative compli-
cations (e.g. infections) 
Minor complications (IG vs. CG): 
• Mild dysphagia at discharge: 16/20 (80%) vs. 18/20 (90%), p=ns 
• Dysphagia 30 days postoperatively: 5/20 (25%) vs. 4/20 (20%), p=ns 
• Mild reflux symptoms 30 days postoperatively: 2/20 (10%) vs. 3/20 (15%), p=ns 
• Reflux score: Ø 1.3 ±0.7 vs. Ø1.6 ±1.3, p=ns 
Major complications (IG vs. CG): 0 vs. 0 
Complications @ 12 months FU (IG vs. CG): 
• Mild reflux symptoms: 0 vs. 2/20 (10%), p=NR 
• Gastritis: 0 vs. 1/20 (5%), p=NR 
• Dysphagia: 0 vs. 0 
• Gas bloat: 3/20 (15%) vs. 2/20 (10%), p=ns 
• Diarrhoea 1/20 (5%) vs. 0, p=ns 
• Impeded vomiting: 0 vs. 1/20 (5%), p=ns 
• Regurgitation: 0 vs. 1/20 (5%), p=ns 
Re-operations/ addi-
tional surgeries  
@ 12 months FU, p=NR 
IG: 1/20 (5%), because of dysphagia 
CG: 0 
Conversion  IG: 0 
CG:0 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in min. IG: Ø 88 ±18  
CG: Ø 102 ±19, p<0.05 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 2.9 ±0.8 
CG: Ø 3.3 ±0.8, p=ns 
 
Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Nakadi et al. 2006 [14] 
Study design Single-centre RCT of patients with GERD 
Country Belgium 
Funding/Sponsor NR 
Intervention (IG) | 
Product 
Robot-assisted Nissen fundoplication | da Vinci system 
Comparator (CG) Laparoscopic Nissen fundoplication 
Experience of sur-
geon(s), time period 
All the procedures were performed by 2 surgeons: 1 digestive surgeon experienced in Nissen 
fundoplication and 1 general surgeon used to laparoscopic techniques. 
Operations were performed between: NR 
Number of patients IG: 9 
CG: 11 
Inclusion/exclusion 
criteria 
Inclusion: 
• Symptoms of pathologic GERD 
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Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Nakadi et al. 2006 [14] 
• Age >16 
• proven complications of GERD like esophagitis, strictures, Barrett without dysplasia and 
extra digestive symptoms 
• Recurrence of symptoms or failure following 3 months of proton pump inhibitor (PPI) 
treatment 
Exclusion: 
• Achalasia and diffuse esophageal spasms  
• Brachyesophagus  
• Recurrence following previous surgery  
• History of previous gastric surgery 
Primary/secondary 
endpoints 
• Aims stated as: Feasibility, benefits and costs (specifically postoperative complaints, 
satisfaction score, duration of surgical procedure, LOS, operative costs) 
Follow-up (months) 1-12 
Drop-outs (n (%)) None 
Patient characteristics 
Age of patients (yrs.) IG: Ø 44 ±4 
CG: 48 ±4, p=ns 
Sex (% female) IG: 27% 
CG: 33%, p=NR 
BMI (kg/m²) IG: Ø 24.8 ±0.7 
CG: Ø 25.3 ±1.2, p=NR 
Clinical classification NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
IG vs. CG, p=NR 
1 month after surgery:  
• Dysphagia for solids: 1/9 (11%) vs. 2/11 (18%) 
• Epigastric pain: 1/9 (11%) vs. 0 
• Flatulence: 1/9 (11%) vs. 2/11 (18%) 
3 months after surgery 
• Dysphagia for solids: 1/9 (11%) vs. 0 
• Epigastric pain: 2/9 (22%) vs. 0 
• Flatulence: 1/9 (11%) vs. 0  
12 months after surgery 
• Dysphagia for solids: 0 vs. 0 
• Epigastric pain: 0 vs. 0 
• Flatulence: 0 vs. 2/11 (18%) 
Soft stools: 1/9 (11%) vs. 0 
Time to resume 
work/daily activities 
NR 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
NR 
Postoperative compli- NR 
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Oesophagus 
 Antireflux/Fundoplication  
Author, year 
[reference number] 
Nakadi et al. 2006 [14] 
cations (e.g. infections) 
Re-
operations/additional 
surgeries  
IG: 1/9 (11%), because of gastric torsion 
CG: 0, p=NR 
Conversion  IG: 1/9 (11%) 
CG: 0, p=NR 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in min. IG: Ø 137 ±12 
CG: Ø 94 ±5, p<0.01 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 4.4 ±0.2 
CG: Ø 4.1 ±0.3, p=ns 
 
Oesophagectomy 
Author, year [reference number] Van der Sluis et al. 2018 [15] 
Study design Single centre RCT 
Country Netherlands 
Funding/Sponsor None (but affiliations to Intuitive Surgical Inc.) 
Intervention (IG) | Product Robot-assisted minimally invasive thoracolaparoscopic oesophagectomy | da 
Vinci Robotic System 
Comparator (CG) Open transthoracic oesophagectomy  
Experience of surgeon(s), time period All surgical procedures were performed by 2 surgeons, who performed at least 
50 of both procedures each.  
January 2012 to August 2016 
Number of patients IG: 54 
CG: 55 
Inclusion/exclusion criteria Inclusion Criteria44: 
• Histologically proven squamous cell carcinoma, adenocarcinoma or 
undifferentiated carcinoma of the intrathoracic esophagus (including 
Siewert I and II). 
• Surgical resectable (T1-4a, N0-3, M0) 
• Age ≥18 and ≤80 years. 
• European Clinical Oncology Group (ECOG) performance status 0,1 
or 2 
• Written informed consent 
Exclusion Criteria: 
• Carcinoma of the cervical esophagus 
• Carcinoma of the gastro-esophageal junction (GEJ) with major tumor 
in the gastric cardia (Siewert III) 
• Prior thoracic surgery at the right hemithorax or thorax trauma 
(rationale: these patients will undergo open resection) 
Primary endpoint Primary: Surgery-related postoperative complications. Secondary: mortality (in-
hospital and within 30 days), pulmonary complications, cardiac complications, 
                                                     
44 Inclusion and exclusion information extracted from the clinical trials website   
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Oesophagectomy 
Author, year [reference number] Van der Sluis et al. 2018 [15] 
perioperative outcomes, quality of life, functioning, pain 
Follow-up (months) M: 40 Months  
Drop-outs (n, %) 41% for quality of life data 
Patient characteristics 
Age of patients (yrs.) Ø 64 (±8.9) CG: Ø 65 (±8.2) p=NR 
Sex (% female) IG: 15% CG: 24% p=NR 
BMI (kg/m²) IG: Ø 26.1 (±4.4) CG: Ø 25.5 (±4.7) p=NR 
Disease Oesophageal Cancer 
Clinical classification Clinical stage, p=NR 
IA: IG 7%; CG 7% 
IIA: IG 9%; CG 6% 
IIB: IG 20%; CG 33% 
IIIA: IG 24% CG 38%;  
IIIB: IG 24%; CG 11% 
IIIC: IG 15%; CG 6% 
Clinical stadium, p=NR 
cT1N0: IG 7%; CG 7% 
cT1N1: IG 2%; CG 4% 
cT2N0: IG 9%; CG 6% 
cT2N1: IG 7%; CG 7% 
cT2N2: IG 2%; CG 0 
cT2N3: IG 2%; CG 0 
cT3N0: IG 11%; CG 22% 
cT3N1: IG 22%; CG 38% 
cT3N2: IG 24%; CG 11% 
cT3N3: IG 11%; CG 4% 
cT4aN2: IG 2%; CG 0 
cT4aN3: IG 0; CG 2% 
Clinically-relevant outcomes45 
Positive surgical margins NR 
Patient-relevant outcomes 
Survival (overall and disease-specific or 
disease-free) 
In-hospital mortality: 
IG: 2/54 (4%); CG: 1/55 (2%), p=ns 
30-day mortality: 
IG: 1/54 (1%); CG 0, p=ns 
60-day mortality: 
IG: 3/54 (6%); CG: 1/55 (2%), p=ns 
90-day mortality 
IG: 5/54 (9%); CG: 1/55 (2%), p=ns 
Disease-free survival: 
IG: M 26 months; CG M 28 months, p=ns46 
Recurrence (local, regional or distant) NR 
Quality of life (e.g. measured by EQ-5D QLQ-C30: 
                                                     
45 Entered as potential endpoint category only in cancer-relevant procedures  
46 Overall survival (Kaplan-Meier) plots are shown but data is unclear 
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Oesophagectomy 
Author, year [reference number] Van der Sluis et al. 2018 [15] 
or SF-36) Health-related quality of life @ discharge: 
IG: Ø 57.9 CI95% [49.9;66.1] vs. Ø CG: 44.6 CI95% [36.7;52.5], p=<0.05 
Health-related quality of life @ 6 wk: 
IG: Ø 68.7 CI95% [61.5;75.9] vs.CG: Ø 57.6 CI95% [50.6;64.6], p<0.05 
Physical functioning @ discharge: 
IG: Ø 54.5 CI95% [45.8;63.3] vs.CG: Ø 41.0 CI95% [32.4;49.6], p< 0.05 
Physical functioning @ 6 wk: 
IG: Ø 69.3 CI95% [61.6;76.9] vs.CG: Ø 58.6 CI95% [51.1;66.0], p=0.05 
Postoperative pain @ 14 days (VAS): 
IG: Ø 1.86 vs. CG: 2.62, p<0.001 
Time to resume work/daily activities Functional recovery within 2 weeks47: 
IG: 38/54 (70%); CG 28/55 (51%), p<0.05 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative complications (e.g. air-
leakage) 
IG: 7/54 (13%) vs. CG: 9/55 (16%) p=ns 
Postoperative complications (e.g. infec-
tions) 
Overall surgery-related postoperative complications (Clavien-Dindo ≥2): 
IG: 32/54 (59%) vs. CG: 44/55 (80%), RR 0.74 CI95% [0.57;0.96], p<0.05 
Overall postoperative complications (MCDC grade≥2) 
IG: 34/54 (63%) vs CG: 44/55 (80%), RR 0.79 CI95% [0.62;1.00], p=0.05 
Pulmonary complications: 
IG 17/54 (32%) vs. CG 32/55 (58%), RR 0.54 CI95%, [0.34;0.85], p = 0.005 
 Pneumonia: IG 15 vs. CG 30, p<0.01 
 Pneumothorax: IG 0 vs. CG 3, p=ns  
 Pulmonary embolism: IG 3 vs. CG 1, p=ns 
 ARDS: IG 0 vs. CG 1, p=ns 
Cardiac complications: 
IG 17/45 (22%) vs. CG 26/55/47%) 0.47 CI95%, [0.27;0.83], p <0.01 
 Atrial fibrillation: IG 12; CG 25, p=0,01 
 Cardia asthma:IG 1; CG 1, p=ns 
Wound infections: 
IG 2/54 (4%) vs. CG 8/55 (15%), p=ns 
 Cervical : IG 2 vs. CG 1, p=ns 
 Thoracic: IG 0 vs. CG 5, p=ns 
 Abdominal: IG 0 vs. CG 2, p=ns 
Anastomic leakage 
 Type I (conservative): IG 0 vs. CG 0 
 Type II (non-surgical intervention) : IG 1 vs. CG 0 
 Type III (surgical intervention) : IG 12 vs. CG 11 
Mediastinitis : IG 12 vs. CG 11, p=ns 
Thoracic epymea: IG 2 vs. CG 3, p=ns 
Gastric conduit necrosis Type III (conduit necrosis extensive, treated with 
resection and diversion): IG 1 vs. CG 2, p=NR 
Chylothorax, p=NR 
 Type I (dietary, low-fat elemental formula gavage): IG 9 vs. CG 6 
 Type II (total parenteral nutrition): IG 6 vs. CG 5 
 Type III (operative): IG 2 vs. CG 1 
Recurrent laryngeal nerve injury 
 Type I (no therapy): IG 5 vs. CG 6, p=NR  
Postoperative bleeding: IG 2 vs. CG 2, p=ns 
Dehiscence of abdominal fascia: IG 0 vs. CG 1, p=ns 
                                                     
47 Defined as: removal of thoracic tubes; no requirement of intravenous fluid resuscitation; tolerance for solid oral intake; 
ability to mobilize independently; adequate pain control with analgesics  
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Oesophagectomy 
Author, year [reference number] Van der Sluis et al. 2018 [15] 
Re-operations/additional surgeries  IG: 13/54 (24%) vs. CG:18/55 (33%), p=ns 
Conversion to laparoscopic/open sur-
gery 
IG: 3/54 (5%) vs. CG: NA 
Perioperative events & resource use 
Blood loss (in ml) IG M 400 (IQR 258–581) vs. CG: M 568 (IQR 428–800), p<0.001 
Operation time in min. IG: Ø 349 (±56.9) vs. CG: Ø 296 (±33.9) p<0.001 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay (days) IG:M 14 (IQR 11–25) 
CG: M 16 (IQR 11–27), p=ns 
 
Stomach 
 Gastrectomy Gastrectomy 
Author, year 
[reference number] 
Pan et al. 2017 [16] Wang et al. 2016 [17] 
Study design Single centre RCT of patients with gastric 
cancer 
Single-centre RCT of patients with gastric cancer 
Country China China 
Funding/Sponsor Supported by the Social Development 
Fund of Jiangsu Province 
National Natural Science Foundation of China 
Intervention (IG) | 
Product 
Robotic gastrectomy | NR Robotic gastrectomy | NR 
Comparator (CG) Laparoscopic gastrectomy Open gastrectomy 
Experience of sur-
geon(s), time period 
The surgical team had experience with 
>550 cases of robotic gastrectomy. 
Operations were performed January 
2015-August 2016 
NR 
Patients were recruited May 2012-December 2014 
Number of patients IG: 102 
CG: 61 
IG: 153 
CG: 158 
Inclusion/exclusion 
criteria 
Inclusion: 
• Endoscopy-considered and biopsy-
proven gastric cancer; clinical stage 
of I, II, or III based on the 7th 
version of the pathologic 
classification of the International 
Union Against Cancer 
• ASA score of ≤2 
Exclusion 
• Serious cardiovascular or 
respiratory disorders; hepatic or 
renal failure; other tumors or 
metastases; surgical failure 
(conversion to open surgery); 
D1/D3/D4 lymphadenectomy 
Inclusion:  
• Patients with gastric cancer, pathologically 
confirmed via gastroscopy 
Exclusion: 
• Patients who had remote metastasis 
• Preoperative chemotherapy 
• A history of abdominal surgery 
• ASA scores above Grade III 
• Patients with detected abdominal cavity 
metastases during surgery or who were 
transferred to open gastrectomy  
• Patients with factors known to influence fast-
track recovery, such as pregnancy, 
cardiopulmonary dysfunction, chronic kidney 
or liver disease, complicated diabetes, or 
anti-cholinergic drug administration,  
Primary/secondary 
endpoints 
• Assessed perioperative outcomes 
and postoperative complications 
• Primary: duration of hospitalization, number 
of nodes retrieved in lymph node dissection, 
resection type, reconstruction type, surgery 
duration, proximal and distal resection 
margins, estimated blood loss, and morbidity 
and mortality during the first 30 days after the 
procedure 
Follow-up (months) 11 NR 
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Stomach 
 Gastrectomy Gastrectomy 
Author, year 
[reference number] 
Pan et al. 2017 [16] Wang et al. 2016 [17] 
Drop-outs (n (%)) None IG: 7/158 (4.43%) 
CG: 8/153 (5.23%) 
Patient characteristics 
Age of patients (yrs.) IG: Ø 65.1 ±11.8 
CG: Ø 65.7 ±13.6, p=ns 
IG: Ø 57.5 ±12.7 
CG: Ø 55.9 ±13.1, p=ns 
Sex (% female) IG: 36% 
CG: 26%, p=ns 
IG: 27.82% 
CG: 38.62%, p=ns 
BMI (kg/m²) IG: Ø 24.1 ±1.7 
CG: Ø 23.9 ±1.6, p=ns 
IG: Ø 22.1 ±2.9 
CG: Ø 21.3 ±2.5, p=ns 
Clinical classification ASA (IG vs. CG), p=ns 
I: 77% vs 77% 
II: 23 vs. 23% 
TNM (IG vs. CG), p=ns 
I: 22% vs. 11% 
II: 46% vs. 64% 
III: 32% vs. 25% 
ASA (IG vs. CG), p=ns 
I: 39% vs. 35% 
II: 54% vs. 53% 
III: 7% vs. 7% 
TNM (IG vs. CG), p=ns 
Ia: 11% vs. 9% 
Ib: 5% vs. 6% 
IIa: 11% vs. 15% 
IIb: 22% vs. 26% 
IIIa: 17% vs. 16% 
IIIb: 27% vs. 25% 
IIIc: 7% vs. 5% 
Clinically-relevant outcomes 
Positive surgical mar-
gins 
NR Proximal resection margin (cm) 
IG: Ø 5.3 ±1.5 
CG: Ø 5.1 ±1.9, p=ns 
Distal resection margin (cm) 
IG: Ø 5.5 ±1.7 
CG: Ø 5.3 ±1.5, p=ns 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
IG: 102/102 (100%) 
CG: 61/61 (100%) 
Intraoperative 
IG: 151/151 (100%) 
CG: 145/145 (100%) 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
VAS for pain (IG vs. CG) 
1st postoperative day:  
Ø 2.6 ±0.7 vs Ø 7.5 ±1.2, p<0.00 
2nd postoperative day:  
Ø 0.8 ±0,8 vs Ø 3.5 ±1.3, p<0.00 
3rd postoperative day:  
Ø 0.1 ±0.3 vs. Ø 1.0 ±1.0, p<0.00 
NR 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
NR IG: 0 
CG: 0 
Postoperative compli-
cations (e.g. infections) 
IG vs. CG during 11-months FU, p=ns: At 30 days (p=ns): 
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Stomach 
 Gastrectomy Gastrectomy 
Author, year 
[reference number] 
Pan et al. 2017 [16] Wang et al. 2016 [17] 
• Ileus: 0 vs. 1/61 (1.6%) 
• Wound infection: 2/102 (2.0%) vs. 
4/61 (6.6%) 
• Pneumonia: 2/102 (1.96%) vs. 
4/61 (6.6%) 
• Oesphago-jejunal anastomosis 
leak: 0 vs. 2/61 (3.3%) 
• Duodenal stump leak: 1/102 
(1.0%) vs. 1/61 (1.6%) 
• None: 97/102 (95.1%) vs. 49/61 
(80.3%) 
 
IG: 14/151 (9.3%) 
CG: 15/145 (10.3%) 
Clavien Dindo classification (IG vs. CG), p=ns 
I: 7/14 (50.0%) vs. 6/15 (40.0%), of these: 
• Surgical site infection: 3/14 (21.4%) vs. 
4/15 (26.7%) 
• Fever: 3/14 (21.4%) vs. 2/15 (13.3%) 
• Fluid collection/abscess: 1/14 (7.1%) vs. 0 
II: 3/14 (21.4%) vs. 4/15 (26.7%) of these: 
• Pneumonia: 2/14 (14.3%) vs. 3/15 (20.0%) 
• Intra-abdominal bleeding: 1/14 (7.1%) vs. 
1/15 (6.7%) 
III: 4/14 (28.6%) vs. 4/15 (26.7%), of these: 
• Fluid collection: 0 vs. 1/15 (6.7%) 
• Anastomotic leakage: 4/14 (28.6%) vs. 
3/15 (20.0%) 
IV: 0 vs 1/15 (6.7%), of these: 
• Acute renal failure: 0 vs. 1/15 (6.7%) 
Re-
operations/additional 
surgeries  
1 patient in the CG group required Braun 
anastomosis on postoperative day 10 
because of jejunal afferent loop 
obstruction.  
IG: 4/14 (28.6%)  
CG: 3/15 (20.0%), p=NR 
(all due to anastomotic leakages). 
Conversion  Conversion as exclusion criterion NR 
Perioperative events & resource use 
Blood loss (in ml) IG: Ø 41.3 ±20.2 
CG: Ø 83.7 ±32.8, p<0.01 
IG: Ø 94.2 ±51.5 
CG: Ø 152.8 ±76.9, p<0.001 
Operation time in min. IG: Ø 153.1 ±16.4 
CG: Ø 152.0 ±23.6, p=ns 
IG: Ø 242.7 ±43.8 
CG: Ø 192.4 ±31.5, p<0.01 
Transfusions NR IG: 1/14 (7.1%) 
CG: 1/15 (6.7%), p=NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: Ø 3.8 ±0.7 
CG: Ø 5.4 ± 1.2, p<0.001 
IG: Ø 5.7 ±2.3 
CG: Ø 6.4 ±2.5, p<0.05 
 
Stomach 
 Bariatric Surgery 
Author, year 
[reference number] 
Sanchez et al. 2005 [18] 
Study design Single-centre RCT  
Country USA 
Funding/Sponsor NR 
Intervention (IG) | 
Product 
Totally robotic laparoscopic Roux-en-Y gastric bypass | da Vinci Surgical System 
Comparator (CG) Laparoscopic Roux-en-Y gastric bypass 
Experience of sur-
geon(s), time period 
Standard Food and Drug Administration mandated training on the da Vinci system 
Operations were performed July 2004-April 2005 
Number of patients IG: 25 
CG: 25 
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Stomach 
 Bariatric Surgery 
Author, year 
[reference number] 
Sanchez et al. 2005 [18] 
Inclusion/exclusion 
criteria 
Inclusion: NR 
Exclusion: NR 
All patients met the minimal criteria for bariatric surgery proposed by the National Institute of 
Health Consensus Development Panel report of 1991 
Primary/secondary 
endpoints 
Not stated as such but included, learning curve analysis, safety, operative times and length of 
stay  
Follow-up (months) NR 
Drop-outs (n (%)) None 
Patient characteristics 
Age of patients (yrs.) IG: M 43.3 (R 27-58) 
CG: M 44.4 (R 20-59), p=ns 
Sex (% female) IG: 92% 
CG: 88%, p=ns 
BMI (kg/m²) IG: M 45.5 (R 35-62) 
CG: M 43.4 (R 37-55), p=ns 
Clinical classification NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR 
Time to resume 
work/daily activities 
NR 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
Complication rate IG vs CG, p=ns 
Minor complications (IG vs. CG): 
Oversewed gastrojejunostomy leak after positive bubble test: 1/25 (4%) vs. 0. 
Major complications (IG vs. CG): 
0 vs. 0 
Postoperative compli-
cations (e.g. infections) 
IG: 0 
CG: 0 
Re-
operations/additional 
surgeries  
NR 
Conversion  IG: 1/25 (4%) required conversion to traditional LRYGB because of exterior anatomy, p=NR 
CG:  0 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in min. IG: Ø 130.8 
CG: Ø 149.4, p<0.02 
Transfusions NR 
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Stomach 
 Bariatric Surgery 
Author, year 
[reference number] 
Sanchez et al. 2005 [18] 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 2.7 (R 2-4) 
CG: Ø 2.7 (R 2-3), p=ns 
 
Bowel 
 Colectomy 
Author, year 
[reference number] 
Park et al. 2012 [19] 
Study design Single-centre RCT of patients with newly diagnosed right-sided colonic carcinoma 
Country Korea 
Funding/Sponsor Supported by the Basic Science Research Programme through the National Research 
Foundation of Korea funded by the Ministry of Education, Science and Technology  
Intervention (IG) | 
Product 
Robot-assisted colectomy | da Vinci Surgical System 
Comparator (CG) Laparoscopically assisted colectomy 
Experience of sur-
geon(s), time period 
Single surgeon 
The operating team had undertaken 30 robotic surgery procedures (including five robotic right 
colectomies) before starting this clinical trial. 
Operations were performed September 2009-July 2011 
Number of patients IG: 35 
CG: 36 
Inclusion/exclusion 
criteria 
Inclusion: 
• Age (≥18 years) with newly diagnosed right-sided colonic carcinoma were potential 
candidates 
Exclusion:  
• Patients who were unfit for operative treatment 
• Patients who presented with an acute surgical emergency, including intestinal obstruction 
or perforation;  
• Patients with distant metastasis on preoperative evaluation 
• Patients with an advanced tumour with adjacent organ invasion requiring en bloc multiple 
organ resection. 
Primary/secondary 
endpoints 
• Length of hospital stay 
• Secondary endpoints: duration of operation, complications, pathological completeness of 
tumour excision and postoperative pain 
Follow-up (months) 24-120 hours 
Drop-outs (n (%)) IG: 0 
CG: 1/36 (2.78%) did not receive intervention due to intraperitoneal chemotherapy  
Patient characteristics 
Age of patients (yrs.) IG: Ø 62.8 ±10.5 
CG: Ø 66.5 ±11.4, p=ns 
Sex (% female) IG: 60% 
CG: 54%, p=ns 
BMI (kg/m²) IG: Ø 24.4 ±2.5 
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Bowel 
 Colectomy 
Author, year 
[reference number] 
Park et al. 2012 [19] 
CG: Ø 23.8 ±2.7, p=ns 
Clinical classification TNM (IG vs. CG) p=ns: 
I: 26% vs. 29% 
II: 46% vs. 46% 
III: 29% vs. 26% 
ASA (IG vs. CG) p=ns: 
I: 43% vs. 60% 
II: 46% vs. 34% 
III: 11% vs. 6% 
Clinically-relevant outcomes 
Positive surgical mar-
gins 
Proximal margin (cm) IG vs CG: 
Ø18.6 ±7.3 vs. Ø18.3 ±9.9, p=ns  
Distal margin (cm) IG vs CG: 
Ø18.0 ±9.0 vs. Ø14.5 ±8.0, p=ns  
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
At 30-day: 
IG: 35/35 (100%) 
CG: 35/35 (100%), p=ns 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
VAS (IG vs. CG) 
24 hours: Ø 6.1 ±2.2 vs. Ø 6.1 ±2.2, p=ns 
120 hours: Ø 2.0 ±1.8 vs. Ø 2.2 ±1.9, p=ns 
 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
IG: 0 
CG: 0 
Postoperative compli-
cations (e.g. infections) 
IG vs. CG 
Total morbidity 6/35 vs 7/35 p=ns: 
• Wound infection: 2/35 (5.71%) vs. 2/35 (5.71%) 
• Anastomosis leakage: 1/35 (2.86%) vs. 0 
• Intra-abdominal abscess: 0 vs. 1/35 (2.86%) 
• Bleeding: 1/35 (2.86%) vs. 3/35 (8.57%) 
• Ileus: 1/35 (2.86%) vs. 1/35 (2.86%) 
Grade of morbidity (Clavien-Dindo (IG vs. CG)) p=ns: 
• I-II: 5/35 (14.29%) vs. 6/35 (17.14%) 
• III-IV: 1/35 (2.86%) vs. 1/35 (2.86%) 
Re-
operations/additional 
surgeries  
NR 
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Bowel 
 Colectomy 
Author, year 
[reference number] 
Park et al. 2012 [19] 
Conversion  IG: 0 
CG:0, p=ns 
Perioperative events & resource use 
Blood loss (in ml) IG: Ø 35.8 ±26.3  
CG: Ø 56.8 ±31.3, p=ns 
Operation time in min. IG: Ø 195 ±41 
CG: Ø 130 ±43, p<0.001 
Transfusions IG: 0 
CG: 0, p=ns 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 7.9 ±4.1 
CG: Ø 8.3 ±4.2, p=ns 
 
Bowel 
 Rectal resection Rectal resection 
Author, year 
[reference number] 
Jayne et al. 2017 [20] Kim et al. 2018 [21] 
Study design International multicentre RCT of patients 
with rectal adenocarcinoma (ROLARR 
clinical trial) 
Single-centre RCT of patients with mid to low-lying 
rectal cancer.  
Country 29 sites across 10 countries (UK, Italy, 
Denmark, US, Finland, South Korea, 
Germany, France, Australia, Singapore)  
South Korea 
Funding/Sponsor Medical Research Council and NIH National Cancer Center 
Intervention (IG) | 
Product 
Robot-assisted laparoscopic rectal 
cancer resection | da Vinci Surgical 
System 
Robot-assisted laparoscopic rectal cancer 
resection | da Vinci Surgical System 
Comparator (CG) Laparoscopic rectal cancer resection Laparoscopic surgery 
Experience of sur-
geon(s), time period 
40 surgeons with minimum 30 previous 
minimally invasive rectal cancer 
resections, of which 10 conventional and 
10 robot-assisted.  
Patients assessed for eligibility January 
2011-September 2014. 
2 surgeons; each had performed laparoscopic 
rectal cancer in over 500 patients and robot-
assisted surgeries in over 30 patients.  
Randomisation occurred February 2012-March 
2015 
Number of patients IG: 237 randomised; 1 withdrew before 
surgery 
CG: 234 randomised; 4 had no surgery 
after randomisation 
IG: 81 randomised, 66 available for analysis (rest 
excluded after randomisation) 
CG: 81, 73 available for analysis (rest excluded 
after randomisation) 
Inclusion/exclusion 
criteria 
Inclusion:  
• Diagnosis of adenocarcinoma of the 
rectum  
Exclusion:  
• Patients with benign lesions of the 
rectum, cancers of the anal canal, 
local advanced cancers not 
amenable to curative surgery or 
synchronous colorectal tumors 
requiring multisegment surgical 
resection  
Inclusion:  
• Patients with mid or low-lying rectal cancer 
without distant metastases  
• All patients had rectal adenocarcinoma 
located within 9 cm of the anal verge 
Exclusion:  
• Cancer invading adjacent organs, distant 
metastases, severe concomitant disease 
• any other malignancy,  
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 Rectal resection Rectal resection 
Author, year 
[reference number] 
Jayne et al. 2017 [20] Kim et al. 2018 [21] 
• pregnant or breastfeeding females, 
• hereditary colorectal cancer,  
• emergency operation. 
• Patients with c3NO-2 tumors received 
preoperative chemoradiotherapy 
Primary/secondary 
endpoints 
• Primary endpoint: Rate of 
conversion to open surgery 
• Secondary endpoints: 30-day 
operative mortality, duration of 
operation, complications, 
pathological completeness of 
tumour excision, patient-reported 
bladder (International Prostate 
Symptom Score, I-PSS) and sexual 
function (International Index of 
Erectile Function, IIEF, and Female 
Sexual Function Index, FSFI)  
• Primary endpoint: Completeness of total 
mesorectal excision 
• Secondary outcomes: circumferential and 
distal resection margin; Global Operative 
Assessment of Laparoscopic Skills; bowel 
function; morbidity (postoperative 
complications using Clavien-Dindo); 
postoperative pain (Present Pain Intensity 
Index and VAS); QoL (via Korean version of 
EORTC QLQ-C30 and the colorectal cancer 
module QLQ-CR38). 
Follow-up (months) 30 days and 6 months (latter for QoL) QOL: postoperative; 3 weeks; 3 months; 12 
months 
Drop-outs (n (%)) IG: 1/236 (0.4%)  
CG: 4/230 (1.7%)  
PROP bladder data available on 351/466 
(75%) 
PROP sexual function data available on 
181/230 men (57%) and 54/15 (36%) 
women 
NR 
Patient characteristics  
Age of patients (yrs.) IG: Ø 64.4 ±10.98 
CG: Ø 65.5 ±11.93, p=NR 
IG: Ø 60.4±9.7 
CG: Ø 59.7±11.7, p=ns 
Sex (% female) IG: 32% 
CG: 32%, p=NR 
IG: 23% 
CG: 29%, p=ns 
 
BMI (kg/m²) IG vs. CG, p=NR 
Underweight/normal (BMI 0-24.9): 39% 
vs 37% 
Overweight (BMI 25.0-29.9): 38% vs. 
39% 
Obese (BMI ≥ 30.0): 23% vs 24% 
IG: Ø 24.1 ± 3.3 
CG: Ø 23.6 ± 3.0, p=ns 
 
Clinical classification T stage (IG vs. CG), p=NR: 
0: 9% vs. 10% 
1: 10% vs. 9% 
2: 27% vs. 27% 
3: 50% vs. 50% 
4: 4% vs. 2% 
Tx or missing: 2% vs. 1% 
N stage: 
0: 62% vs. 65% 
1:27% vs. 25% 
2:11% vs. 9%   
ASA (IG vs. CG), p=ns: 
I: 30% vs. 41% 
II: 70% vs. 59% 
p/ypT classification, p=ns 
T0: 8% vs. 8% 
Tis: 3% vs. 6% 
T1: 12% vs 10% 
T2: 26% vs. 25% 
T3: 46% vs. 49% 
T4a: 3% vs. 1% 
T4b: 3% vs. 1% 
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Bowel 
 Rectal resection Rectal resection 
Author, year 
[reference number] 
Jayne et al. 2017 [20] Kim et al. 2018 [21] 
ASA (IG vs. CG) 
I: 17% vs. 22% 
II: 63% vs. 53% 
III: 19% vs. 22% 
IV: 0% vs. 0.4% 
Missing: 1% vs 2% 
p/ypN classification, p=ns 
N0: 70% vs. 77% 
N1a: 14% vs. 7% 
N1b: 11% vs. 8% 
N1c: 3% vs. 3% 
N2a: 3% vs. 4% 
N2b: 0% vs. 1% 
Clinically-relevant outcomes 
Positive surgical mar-
gins 
Circumferential resection margin 
positivity48: 
IG: 12/235 (5.1%) 
CG: 14/224 (6.3%) 
OR 0.78 CI95% [0.35 ;1.76], p=ns 
Circumferential resection margin positivity1: 
IG:4/66 (6.1%) 
CG: 4/73 (5.5%), p=ns  
Proximal resection margin cm 
IG: M12.3 (R 4.7-35.8) 
CG: M 13.2 (R6.8-29.0), p=ns 
Distal resection margin cm 
IG: M 1.5 (R 0.04-6.7) 
CG: M 0.7 (R 0-2.5), p=ns 
 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
Mortality within 30 days: 
IG: 2/236 (0.8%) 
CG: 2/230 (0.9%), p=ns 
NR 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
IPSS score difference of 0.74 CI95%[-
0.59;2.07], p=ns 
IIEF score difference of 0.80 CI95%[-
4.10;5.70], p=ns 
FSFI score difference of 1.23 CI95%[-
3.54;6.00], p=ns 
 
PPI pain score postoperative day: IG M 1 (R 0-4) 
vs. CG M 1 (R 0-4), p=ns 
VAS score postoperative day: IG M 3(R 1-9) vs. 
CG M 2 (R 0-8), p=ns 
Authors report no difference in scores on QLQ-
C30 after 3 weeks, 3 months and 12 months 
except for insomnia scores, where IG showed 
more sleep disturbances: 
IG Ø 28.3 CI95%[19.6;37] vs. CG Ø 15.7 
CI95%[8.1;23.3], p<0.05 
Reported that there were no significant 
differences on QLQ-CR38 scores except for 
sexual function after 12 months, where IG 
showed better functioning: 
 Ø 35.2 CI95%[26.9;43.5] vs. Ø 23.0 
CI95%[15.7;30.2], p<0.05 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
Safety-related outcomes 
                                                     
48 Defined as tumor cells within 1mm of the circumferential resection margin on histological analysis 
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Bowel 
 Rectal resection Rectal resection 
Author, year 
[reference number] 
Jayne et al. 2017 [20] Kim et al. 2018 [21] 
Intraoperative compli-
cations (e.g. air-
leakage) 
IG: 36/236 (15.3%) 
CG: 34/230 (14.8%), p=ns 
 
Intraoperative (p=ns) 
IG: 5/66 (7.6%) 
CG: 3/73 (4.1%) 
Perioperative complications (p=ns) 
IG: 23/66 (34.8) 
CG: 17/73 (23.3%)  
Clavien-Dindo classification (IG vs. CG), p=ns: 
I: 6/66 (9.1%) vs. 3/73 (4.1%) 
II: 11/66 (16.7) vs. 10/73 (13.7%) 
IIIa: 4/66 (6.4%) vs. 2/73 (2.7%) 
IIIb: 2/66 (3.0%) vs. 2/73 (2.7%) 
Postoperative compli-
cations (e.g. infections) 
Within 30 days: 
IG: 78/236 (33.1%) 
CG: 73/230 (31.7%), p=ns 
>30days and ≤6months: 
IG: 34/236 (14.4%) 
CG: 38/230 (16.5%), p=ns 
NR 
 
Re-
operations/additional 
surgeries  
NR NR 
Conversion  IG: 19/236 (8.1%) 
CG:28/230 (12.2%) 
Unadjusted risk difference 4.1% CI95%[-
1.4%;9.6%] 
IG: 1/66 (1.5%) 
CG: 0, p=ns 
Perioperative events & resource use 
Blood loss (in ml)  IG: M 100 (R 0-1000) 
CG: M 50 (R 0-300), p<0.0001 
Operation time in min. IG: Ø 298.5 ±88.71 
CG: Ø 261.0 ±83.24, p=NR 
Difference in use of operating theatre (IG 
minus CG): Ø 50.88 minutes CI95%[-
20.26;81.56], p=0.001 
IG: Ø 339.2 ±80.1 
CG: Ø 227.8 ±65.6, p<0.0001 
Transfusions NR NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: Ø 8.0 ±5.85 
CG: Ø 8.2 ±6.03, p=NR 
IG: Ø 10.3 ±3.4 
CG: Ø 10.8 ±7.4, p=ns 
 
Rectal Resection 
Author, year 
[reference number] 
Debakey et al. 2018 [24] Wang et al. 2017 [23] 
Study design Single centre RCT Single centre RCT 
Country Egypt China 
Funding/Sponsor Funded by the National Cancer Institute, National Natural Science Foundation of China 
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Rectal Resection 
Author, year 
[reference number] 
Debakey et al. 2018 [24] Wang et al. 2017 [23] 
Cairo University,Egypt. (Grant no. 81500417) 
Intervention (IG) | 
Product 
Robot-assisted rectal cancer resection | 
Da Vinci robotic system Intuitive Surgical 
Inc, (Sunnyvale, CA) 
Robot-assisted total mesorectal excision | device 
unspecified 
Comparator (CG) Conventional laparoscopic rectal 
resection 
Conventional laparoscopic total mesorectal 
excision 
Experience of 
surgeon(s), time period 
Procedures were performed by the same 
surgeon team but no information on 
experience. 
Randomisation performed April 2015 to 
February 2017 
No information on experience of surgeons 
 
Randomisation performed November 2010 to 
September 2013 
Number of patients IG: 21 
CG: 24 
IG: 71 
CG: 66 
Inclusion/exclusion 
criteria 
Inclusion criteria:  
• Histological diagnosis of 
adenocarcinoma of rectum 
located within 15 cm from the 
anal verge. 
• No anesthesiological 
contraindications to minimally 
invasive surgery 
• age ≤ 75 years 
• ASA ≤ 2 
Exclusion Criteria: 
• Metastatic disease 
• Malignant bowel obstruction 
(MBO) 
• Unresectable tumor 
Inclusion criteria 
• Male patients with medium (7-12 cm 
from the anal verge) to low (≤ 7 cm from 
the anal verge) rectal cancer 
Exclusion criteria: 
• Pre-operative sexual dysfunction (n=61) 
• History of: prior rectum or urinary tract 
surgery, abdominal perineal resection, 
partial mesorectal resection, local or 
distant recurrence (n=102) 
• Death within 12 months (n=25) 
• Incomplete follow-up data (n=11) 
Primary endpoint Short-term operative outcomes and 
complications, oncological outcomes 
Urinary function (via International Prostate 
Symptom Score where higher scores indicate 
more severe symptoms) and sexual function (via 
International Index of Erectile Function where 
higher score indicates better functioning)  
Complete erectile dysfuntion defined as domain 
score < 10; partial erectile dysfunction defined as 
domain score <17 but ≥19) 
Follow-up (months) 1 Month  12 months  
Drop-outs (n, %) NR Only patients with follow-up data included in 
analysis 
Patient characteristics   
Age of patients (yrs.) IG: M 53.4 (R 32-67) vs.CG: M 50.3 (R 
36-64) p=ns 
IG: Ø 60.3 (R 36-68) vs. CG Ø 58.7 (R 36-71), 
p=ns 
Sex (% female) IG: 48% vs. CG:46%, p=NR IG: 0% vs CG 0% 
BMI (kg/m²) MBI (kg/m2), p=ns  
MBI< 30 
IG: 48% vs. CG: 33% 
MBI >/= 30 
IG: 11 (52%) vs. CG16 (67%) 
IG: Ø 22.9 (R 19.1-30.1) vs. CG: Ø 22.4 (R 18.3-
30.6), p=ns  
Disease Rectal cancer Rectal cancer 
Clinical classification Clinical stage, p=ns 
I: IG: 1/21 (5%) vs. CG: 4/24 (17%) 
II: IG:15/21(71%) vs 17/24 (71%) 
III: IG: 5/21(24%) vs. 3/24 (13%) 
TNM (tumour, node, metastasis system) 
0/1: IG: 9/71 (13%); CG: 8/66 (12%) 
II: IG: 22/71 (31%); CG 24/66 (36%) 
III: IG 40/71 (56%); CG: 34/66 (52%) 
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Rectal Resection 
Author, year 
[reference number] 
Debakey et al. 2018 [24] Wang et al. 2017 [23] 
Clinically-relevant outcomes  
Positive surgical 
margins 
Proximal margin (cm) 
• IG: M 13 (R 10-20) vs. CG: M 
15 (R 11-239; p=ns 
Distal margin (cm) 
• IG: M 2.8 (R 1.4-4) vs. CG: M 
1.8 (R 1-2.8), p<0.001 
Completeness of resection (% complete) 
• IG: 86% vs. CG: 63%,p=ns 
NR 
Patient-relevant outcomes  
Survival (overall and 
disease-specific or 
disease-free) 
30-day mortality: 
IG: 0/21 (0%) vs. CG: 1/24 (4%) p=NR 
30-day mortality: 
IG: 0/71 (0%); CG: 0/66 (0%) 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR Urinary function 
IG post-op vs pre-op IPSS: 6.79 vs. 4.04, p=ns 
CG post-op vs. pre-op IPSS: 9.66 vs. 4.12, p<0.05 
Total IPSS scores postoperatively: IG 6.79 vs CG 
9.66, p<0.05 
Sexual function 
IG post-op vs. pre-op IIEF: 46.2 vs 56.4, p<0.05 
CG post-op vs. pre-op IIEF: 40.1 vs. 57.9, p<0.05 
Total IIEF scores postoperatively: IG 46.2 vs CG 
40.1, p<0.05 
Incidence of partial and complete erectile 
dysfunction: IG 19/71 (27%); CG 32/66 (48%), 
p<0.05 
Time to resume 
work/daily activities 
NR Return of gastrointestinal function: IG: 37 h vs CG: 
51 h, p<0.05 
Patient satisfaction NR NR 
Safety-related outcomes  
Intraoperative 
complications (e.g. air-
leakage) 
NR NR 
Postoperative 
complications (e.g. 
infections) 
Total number, p=ns: 
IG: 6/21 (29%) vs.CG: 7/24 (29%) 
• Anastomotic leakage: IG 1; CG 
1 
• Ileus (median days): IG: 2; CG 
3 
• Wound problems: IG 2; CG 2 
• Others: IG 1 (DVT); CG 1 
(erectile dysfunction) 
Severity: 
• No complications: IG 15/21 
(71%) vs. 18/24 (75%), p=ns 
• Grade I: IG 4/21 (19%) vs. CG 
5/24 (21%) 
• Grade II: IG 1/21 (5%) vs. CG 
1/24 (4%) 
• Grade III: IG 1/21 (5%) vs. 0 
• Grade IV: IG 0 vs.CG 0 
• Grade v: IG 0 vs. CG 1/24 
IG: 8/71 (11%): 2 anastomic leakages, 2 lung 
infections, 1 urinary tract infection, 1 
intraabdominal abcess, 1 abdominal cavity 
bleeding, 1 incisional wound infection 
CG: 10/66 (15%): 3 anastomic leakages, 3 lung 
infections, 1 urinary tract infection, 3 incisional 
wound infections. 
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Rectal Resection 
Author, year 
[reference number] 
Debakey et al. 2018 [24] Wang et al. 2017 [23] 
(4%) 
Re-
operations/additional 
surgeries  
IG: 0 vs. CG: 1/24 (4%), p=NR NR 
Perioperative events & resource use  
Conversion to 
laparoscopic/open 
surgery 
IG 1/21 (5%) vs. CG: 2/24 (8%), p=NR NR 
Blood loss (in ml) IG: M 200 (R 50-650) vs. CG: M 325 (R 
100-800), p=0.05 
NR per treatment group 
Operation time in min. IG: M 201 (R 140-280) vs. CG: M 134.5 
(R 110-190), p<0.001 
IG: Ø 246.9 (R 210-330) vs CG: 207.3 (R 170-
230), p<0.01 
Transfusions NR NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: M 3 (R 2-14) vs. CG: M 2 (R 2-11), 
p=ns 
NR 
 
Bowel 
 Ventral mesh rectopexy Rectal resection 
Author, year 
[reference number] 
Mäkelä-Kaikonen et al. 2016 (2 
references) [25] [68] 
Tolstrup et al. 201849 [22] 
Study design Single-centre RCT of patients with rectal 
prolapse and intussusception 
Single-centre RCT of patients with rectal 
adenocarcinoma (ROLARR clinical trial): Denmark 
centre 
Country Finland Denmark 
Funding/Sponsor State funding of the Medical Research 
Center Oulu University and Finnish 
Menopause Society 
NR 
Intervention (IG) | 
Product 
Robot-assisted ventral mesh rectopexy | 
da Vinci Surgical System 
Robot-assisted laparoscopic rectal cancer 
resection | da Vinci Surgical System 
Comparator (CG) Laparoscopic ventral mesh rectopexy Laparoscopic rectal cancer resection 
Experience of 
surgeon(s), time period 
3 experienced surgeons performed IG; 4 
(these +1 additional surgeon) performed 
CG. NR: No of prior operations. Operations 
performed February to May 2012 
30 previous minimally invasive rectal cancer 
resections, 10 conventional and 10 robot-assisted. 
Study conducted November 2012 to April 2014.  
Number of patients IG: 16 (total relapse 4, intrassusception 12) 
CG: 14 (total relapse 2, intrassusception 
11, 1 excluded) 
IG : 25 
CG : 26 
Inclusion/exclusion 
criteria 
Inclusion: 
• females;  
• age 18-85;  
• ASA 1-3;  
• symptomatic, uncomplicated, 
isolated, rectal prolapse; 
symptomatic intusseception 
and enterocele 
Exclusion:  
• male; 
• ASA 4-5;  
NR  
                                                     
49 This study reports on a subset of patients from the ROLARR trial pertaining to the Denmark centre. To avoid double-
counting, only those results which are not reported in the main trial publication by Jayne et al are reported here.  
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Bowel 
 Ventral mesh rectopexy Rectal resection 
Author, year 
[reference number] 
Mäkelä-Kaikonen et al. 2016 (2 
references) [25] [68] 
Tolstrup et al. 201849 [22] 
• previous surgery; pregnancy 
now or future; suspicion of 
frozen pelvis 
Primary/secondary 
endpoints 
Perioperative parameters, complications 
and restoration of anatomy, 
postoperative pain via VAS 
The aim was to assess perioperative pain via 
numeric rating scale (NRS). Length of surgery and 
complications were also assessed. 
Follow-up (months) Pain assessment 2 weeks after surgery 
Quality of life (Pelvic Floor Distress 
Inventory, Pelvic Floor Impact 
Questionnaire, Prolapse/Incontinence 
Sexual Questionnaire) also condition-
specific symptom and quality of life 
questionnaires (unspecified) at 3 months 
Discharge from recovery ward 
Drop-outs (n (%) QoL data on total of between 19 and 26 
patients; drop-out 35% to 52%  
NR 
Patient characteristics 
Age of patients (yrs.) IG: Ø 60.8 ±11.5 
CG: Ø 66.0 ±10.1, p=NR 
IG: Ø 63 ±10.9 
CG: Ø 68 ±9.9, p=ns 
Sex (% female) IG and CG: 100%, p=NR IG: 72% 
CG 77%; p=ns 
BMI (kg/m²) IG: Ø 25.6 ±4.5 
CG: Ø 24.3 ±3.0, p=NR 
IG: Ø 27 ±4.5 
CG: Ø 28 ±4.3, p=ns 
Clinical classification ASA (% IG vs. % CG), p=NR 
1: 19% vs. 21% 
2: 63% vs. 36% 
3: 19% vs. 36% 
ASA (% IG vs % CG), p=ns: 
1: 44% vs. 38% 
2: 28% vs. 31% 
3: 0 vs. 4% 
4: 0 
(y)pT-stage (% IG vs. % CG), p=ns: 
0: 12% vs. 12% 
1: 12% vs. 4% 
2: 16% vs. 12% 
3: 52% vs. 58% 
4: 0 vs. 15% 
Clinically-relevant outcomes 
Positive surgical 
margins 
n/a NR 
Patient-related outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR NR 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life or 
symptoms (e.g. 
measured by EQ-5D or 
SF-36) 
VAS @ 2 weeks: 
IG: Ø 2.9 ±1.8 
CG: Ø 2.6 ±1.4, p=ns 
QoL @ 3 months, mean difference (95% 
CI): 
PFDI-20: -61.9 CI95% [40.9 ;82.8%], 
p<0.01 
PFIQ-7: -57.0 CI95% [29.3;84.5%], p<0.01 
PISQ-12: 3.4 CI95% [-6.2;-7.6%], p<0.05 
NRS mean (recovery50): 
IG: 1.800 (0-5) 
CG: 2.000 (0-5), p=ns 
NRS max (recovery): 
IG: 4 ( 0-10) 
CG: 5 ( 0-9), p=ns 
 
                                                     
50 Unclear whether these values relate to actual number, mean or median 
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Bowel 
 Ventral mesh rectopexy Rectal resection 
Author, year 
[reference number] 
Mäkelä-Kaikonen et al. 2016 (2 
references) [25] [68] 
Tolstrup et al. 201849 [22] 
No significant differences were found in 
symptom and condition-specific QoL 
scores in the between-group comparison 
as reported for the PFDI and 2 subscales 
(CRADI and POPDI). No between group 
results reported for PFIQ or PISQ. 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
Perioperative bleeding: 
IG 2/16; CG 0/14, p=ns 
NR 
Postoperative 
complications (e.g. 
infections) 
Vascular complication: IG 1; CG 0, p=ns 
Minor complications, p=ns:  
Haemotoma: IG 1/16; CG 0 
Perineal pain: IG 1/16; CG 0 
Fever: IG 0; CG 1/14  
Not clearly stated but likely to be period until 
discharge: 
Total IG 10/25, CG 10/26 p=ns. Clavien-Dindo 
classification: 
1: IG 1; CG 4 
2: IG 6; CG 1 
3: IG 2; CG 4 
4: IG 0; CG 1 
5: IG 1; CG 0 
Re-operations/ 
additional surgeries  
NR NR 
Conversion  IG 0 
CG 0 
IG: 1/25 
CG: 10/26, p<0.01 
Perioperative events & resource use 
Blood loss (in ml) NR NR 
Operation time in min. IG: Ø 125 ±27 
CG: Ø 130 ±25, p=ns 
IG: 152±43 
CG: 170±57, p=ns 
Transfusions NR NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: Ø 2.2 ±1.5 
CG: Ø 2.5 ±0.9, p=ns 
NR 
 
Gallbladder/Liver Spleen 
 Cholecystectomy Cholecystectomy 
Author, year 
[reference number] 
Kudsi et al. 2017 [26] Pietrabissa et al. 2016 [27] 
Study design International multicentre RCT of patients 
with gallbladder disease 
Single-centre RCT of patients with gallbladder 
lithiasis or polyps with no evidence of 
choledocholithiasis 
Country 7 institutions in the USA and 1 institution 
in Greece 
Italy 
Funding/Sponsor Intuitive Surgical, Inc., Sunnyvale, CA, 
USA in association with the identified 
study investigators under a cooperative 
clinical trial agreement 
None 
Intervention (IG) | 
Product 
Robotic single-site cholecystectomy | da 
Vinci Single Site Instruments 
Single incision laparoscopic robotic 
cholecystectomy | NR 
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 121 
Gallbladder/Liver Spleen 
 Cholecystectomy Cholecystectomy 
Author, year 
[reference number] 
Kudsi et al. 2017 [26] Pietrabissa et al. 2016 [27] 
Comparator (CG) Multiport laparoscopic cholecystectomy Four-port laparoscopic cholecystectomy 
Experience of 
surgeon(s), time period 
At the onset of the study, 8 of the 10 
surgeons were new to the single-site 
technique; however, all 10 surgeons 
were experienced in laparoscopic and 
robot-assisted multiport techniques. 
The RSSC cases include procedures in 
which the surgeons were learning the 
technique 
Enrollment of patients occurred from 
September 2013-August 2015 
Surgeons with prior experience with both 
operation techniques 
Operations were performed September 2011-May 
2013 
Number of patients IG: 83 
CG: 53 
IG: 40 
CG: 41 
Inclusion/exclusion 
criteria 
Inclusion: 
• Age 18–80  
• Diagnosis of symptomatic 
gallbladder disease 
Exclusion: 
• Requirement of emergency 
procedure, acute cholecystitis, 
pregnancy, presence of upper 
midline visible abdominal 
scar(s) or keloid 
• Presence of umbilical hernia or 
prior umbilical hernia repair 
• Inability of patient to tolerate 
Trendelenburg position  
• Pneumoperitoneum 
• Cirrhosis 
• Mental impairment 
Inclusion: 
• Diagnosis of gallbladder lithiasis or 
polyps with no evidence of 
choledocholithiasis 
• Age 18- 80 
• BMI < 30 kg/m2, 
• Ability to adhere to the protocol  
Exclusion 
• Evidence of acute cholecystitis or 
stones in the common duct as assessed 
by liver function tests and abdominal 
ultrasound 
• Gallbladder stone > than 3 cm  
• Previous abdominal surgery through a 
midline or a right subcostal laparotomic 
incision 
• Ongoing pregnancy 
• Liver cirrhosis 
• ASA>II 
• Known allergy to the analgesic drugs 
adopted in the study protocol 
Primary/secondary 
endpoints 
• Patient-perceived cosmesis, 
patient-reported satisfaction 
(BIQ, PSQ) and quality of life 
(QoL-SF 12) 
• Secondary endpoint: 
perioperative outcomes 
• To evaluate the reduction by 50% of 
SIRC patients with moderate to severe 
pain at 24 h after surgery compared to 
the laparoscopy group 
• Secondary endpoints: VAS score and 
cosmetic outcome (subjective min 0-
max 10) of the surgical scars. Further 
objectives: operative times, intra and 
postoperative morbidity, rate of 
incisional hernia. 
Follow-up (months) Max. 3 months IG: M 32.0 IQR [22.4-30.1] 
CG: M 36.8 IQR [26.9-39.5], p=ns 
Drop-outs (n (%)) @ 2 weeks 
IG: 6/83 (7.2%) 
CG: 1/53 (1.9%) 
@ 6 weeks 
IG: 16/83 (19.3%) 
CG: 3/48 (6.3%) 
@ 12 weeks 
IG: 17/83 (20.5%) 
CG: 5/53 (9.4%) 
IG: 10/40 (25.0%) 
CG. 10/41 (24.4%) 
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Gallbladder/Liver Spleen 
 Cholecystectomy Cholecystectomy 
Author, year 
[reference number] 
Kudsi et al. 2017 [26] Pietrabissa et al. 2016 [27] 
Patient characteristics 
Age of patients (yrs.) IG: Ø 46.8 ±15.5 
CG: Ø 46.5 ±17.3, p=ns 
NR, but it was reported “the groups were 
comparable in terms of age, sex and BMI” 
Sex (% female) IG: 78% 
CG: 92%, p<0.05 
BMI (kg/m²) IG: Ø 30.4 ±6.5 
CG: Ø 31.7 ±6.7, p=ns 
Clinical classification ASA (IG vs. CG), p=ns 
I: 20% vs. 21% 
II: 63% vs. 64% 
III: 16 vs. 15% 
IV: 1 vs. 0 
NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR NR 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
SF-12: 
@ 2 weeks, IG vs. CG (Ø±SD): 
39±4.19 vs. 39.5±3.95,p=ns 
@ 6 weeks, IG vs. CG: 
39.23 ±3.79 vs. 40±3.41, p=ns 
@ 3 months, IG vs CG: 
40.45±3.05 vs. 41.18±5.53, p=ns 
VAS (IG vs. CG), p=ns 
@ 24h:  
M 3 IQR [1-8] vs. CG: M 4 IQR [1-9], Δ-1 CI95% 1 [-
5;3] 
@ 7 days: 
M 0 IQR [0-2] vs. M 0 IQR [0-2], Δ 0 CI95% [-2;2], ns 
@ 30 days:  
M 0 IQR [0-0] vs. M 0 IQR [0-0], Δ 0 (NA) 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction BIQ (IG vs. CG) 
@ 2 weeks  
Questions 1-5: Ø 5.5 ±1.0 CI95%[5.3;5.8] 
vs. Ø 6.4 ±1.80 CI95%[5.9;6.9], p<0.01 
Questions 6-8: Ø 20.5 ±3.3 
CI95%[19.8;21.3] vs. Ø18.5 ±4.5 
CI95%[17.3;19.7], p<0.01 
@ 6 weeks  
Questions 1-5: Ø 5.5 ±1.2 CI95%[5.2;5.8] 
vs. Ø 6.2 ±2.2 CI95%[5.5;6.9], p=ns 
Questions 6-8: Ø 21.2 ±3.2 
CI95%[20.4;22.0] vs. Ø 19.8 ±3.8 
CI95%[18.7;21.0], p=ns 
@ 12 weeks  
Questions 1-5: Ø 5.4 ±1.4 CI95%[5.1;5.8] 
vs. Ø 6.1 ±1.5 CI95%[5.6;6.5], p<0.05 
Questions 6-8: Ø 22.3 ±2.3 
CI95%[21.7;22.8] vs. Ø 20.2 ±3.5 
CI95%[19.2;21.2], p<0.01 
 
PSQ (IG vs. CG) 
@ 2 weeks  
Questions 1: Ø 8.3 ±2.0 
CI95%[5.3;5.7] vs. Ø 7.2 ±2.1 
CI95%[5.9;6.9], p<0.01 
Questions 5: Ø 7.8 ±2.7  
Cosmetic outcome (IG vs. CG) 
M 9 IQR [8-10] vs. M 8 IQR [7-8], Δ 1 CI95%[0 to 2], 
p=<0.01 
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Gallbladder/Liver Spleen 
 Cholecystectomy Cholecystectomy 
Author, year 
[reference number] 
Kudsi et al. 2017 [26] Pietrabissa et al. 2016 [27] 
CI95%[7.1;8.4] vs. Ø 6.6 ±2.4 
CI95%[5.9;7.3], p<0.05 
@ 6 weeks  
Questions 1: Ø 8.8 ±1.6  
CI95%[8.4;9.2] vs. Ø 8.1 ±1.9 
CI95%[7.6;8.7], p<0.05 
Questions 5: Ø 8.9 ±1.6  
CI95%[8.6;9.3] vs. Ø 8.2 ±1.8 
CI95%[7.7;8.8], p<0.05 
@ 12 weeks  
Questions 1: Ø 9.2 ±1.1  
CI95%[9.0;9.5] vs. Ø 8.1 ±1.9 
CI95%[7.5;8.6], p<0.01 
Questions 5: Ø 9.4 ±1.1  
CI95%[9.2;9.7] vs. Ø 8.2 ±1.8 
CI95%[7.6;8.7], p<0.01 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
IG: 0 
CG: 0, p=ns 
IG vs. CG, p=ns 
Major adverse events: 0 vs. 0 
Bile spillage: 2/30 (6.7%) vs. 5/30 (16,7%), ns 
Minor bleeding: 3/30 (10.0%) vs. 4/30 (13.3%), ns 
Liver damage at gallbladder fossa: 1/30 (3.3%) vs. 
3/30 (10.0%) 
Postoperative 
complications (e.g. 
infections) 
Total IG 4/83 (5%) vs. CG 2/53 (4%) @ 3 
months, p=ns  
• Bile leakage: 0 vs. 1/53 (1.9%) 
• Wound infection: 2/83 (2.4%) 
vs. 1/53 (1.9%) 
• Inflammatory bowel disease: 
1/83 (1.2%) vs. 0 
• Deep vein 
thrombosis/pulmonary 
embolism: 1/83 (1.2%) vs. 0 
IG vs. CG 
@ 6 months 
• Wound infection: 2/30 (6.7%) (of these 1 
required incisional hernia) vs. 0, p=ns  
Re-
operations/additional 
surgeries  
NR NR 
Conversion to 
laparoscopic/open 
surgery 
IG: 0 
CG: 0 
IG: 0 
CG: 0, p=ns 
Perioperative events & resource use 
Blood loss (in ml) IG: 13.1 
CG: 15.8, p=ns 
NR 
Operation time in min. IG: Ø 61.0 ±27.5 
CG: Ø 44.0 ±19.9, p<0.01 
IG: Ø 98 ±34 
CG: Ø 87 ±30, p=ns 
Transfusions IG: 0 
CG: 0 
NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: 16.7 hours 
CG: 13.9 hours, p=ns 
IG: M 1.2 (R 1-3) 
CG: M 1.2 (R 1-3), p=NR 
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Cholecystectomy 
Author, year 
[reference number] 
Grochola et al. 2018 [28] 
Study design Single centre RCT 
Country Switzerland 
Funding/Sponsor None 
Intervention (IG) | 
Product 
Robot-assisted single-site cholecystectomy | 
da Vinci single-site TM cholecystectomy robotic system ( Intuitive Surgical Inc, Sunnyvale, CA) 
Comparator (CG) Single-port laparoscopic cholecystectomy 
Experience of 
surgeon(s), time period 
Operations performed by three senior surgeons with training and experience in both surgical 
techniques. 
Number of patients IG 30; CG 30 
Inclusion/exclusion 
criteria 
Inclusion: adults with benign gallbladder disease admitted for elective cholecystectomy 
Exclusion: pregnant or breastfeeding, systemic disease, mental or organic disorders affecting 
consent/participation, malignant disease, previous abdominal surgery, obesity (BMI > 35.0 
kg/m2). 
Primary/secondary 
endpoints 
Surgeon’s physical and mental stress load. Secondary: intraoperative outcomes, complications, 
health-related quality of life, cosmesis 
Follow-up (months) 1 year 
Drop-outs (n, %) IG: 0 vs. CG 3/30 (10%) (three patients did not return the HRQoL and BIC questionnaires in the 
CG group at 1-year follow-up and were therefore excluded from the analyses) 
Patient characteristics 
Age of patients (yrs.) IG Ø 52.4 (R 26-82) vs CG Ø 51.5 (R 30-78), p=ns 
Sex (% female) IG 67% vs. CG 53%, p=ns 
BMI (kg/m²) IG Ø 27.3 ± 3.9 vs. CG Ø 27.3 ± 4.2, p=ns 
Disease Cholecystolithiasis: IG 29/30 vs. CG 29/30 
Galbladder polyps: IG 1 vs. CG 1 
Clinical classification NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
Gastrointestinal Quality of Life Index: 
1 month post-op: IG M 123 (R 83-140) vs. CG M 120 (R55-142), p=ns.  
12 months post-op: IG ; 123 (R 105-141) vs. CG ; 128 (94-143), p=ns 
Time to resume 
work/daily activities 
 
Patient satisfaction Body Image Questionnaire: 
1 month post-op: IG M 37 (R 24-40) vs. CG 38 (19-40), p=ns 
12 months post-op: IG M 35.5 (R 20-40) vs. CG M 39 (22-40)NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
EAES grade: 
• No complications: IG 18/30 (60%) vs. CG 16/30 (53%), p=ns 
• Grade I: IG 8/30 (27%) vs. CG 11/30 (37%), p=ns 
• Grade II: IG 4/30 (13%) vs. CG 3/30 (10%), p=ns 
• Grade III-IV: IG 0 vs, CG 0. 
Type of complication, p=ns: 
• Peritoneal tear (EAES Io): IG 8/30 (27%) vs. CG 11/30 (37%) 
• Minor bleeding (EAES IIo): IG 4/30 (13%) vs.CG 3/30 (10%) 
• Major bleeding (EAES > 11o): IG 0 vs. CG 0 
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Cholecystectomy 
Author, year 
[reference number] 
Grochola et al. 2018 [28] 
• Bile duct injury: IG 0 vs. CG 0  
Postoperative 
complications (e.g. 
infections) 
Complications within 30 days: IG 4/30 (13%) vs. CG 7/30 (23%), p=ns 
Dindo-Clavien IG vs. CG, p=NR: 
• No complications: 25/30 (83%) vs. 23/30 (77%) 
• Grade I: 2/30 (7%) vs. 4/30 (13%) 
• Grade II: 2/30 (7%) vs. 1/30 (3%) 
• Grade IIIa: 0 vs. 1/30 (3%) 
• Grade IIIb: 0 vs. 0 
• Grade IVa: 0 vs. 0 
• Grade IVb: 0 vs 1/30 (3%) 
• Grade V: 0 vs. 0 
Type of complication (IG vs. CG), p=ns: 
 Superficial wound infection: 2/30 (3%) vs. 1/30 (3%) 
 Periumbilical hematoma: 1/30 (3%) vs. 0 
 Self-limiting fever episode: 0 vs 1/30 (3%) 
 Bowel paralysis: 0 vs 1/30 (3%) 
 Renal function impairment: 0 vs. 1/30 (3%) 
 Urinary retention: 1/30 (3%) vs. 0 
 Nausea: 0 vs. 1/30 (3%) 
 Common bile duct stones: 0 vs. 1/30 (3%) 
 Multi-organ failure: 0 vs. 1/30 (3%) 
Incisional hernia (within 1 post-op year): IG 2/30 (7%) vs. CG 2/30 (7%), p=ns 
Re-operations/ 
additional surgeries  
Rate of postoperative complications requiring re-intervention (Dindo-Clavien grade ≥IIIa): 
IG: 0 vs CG 2/30, p=ns  
Conversion to 
laparoscopic/open 
surgery 
Conversion to conventional laparoscopy: 
IG 2 (7%) vs. CG 3 (10%), p=ns 
Conversion to open surgery: 
IG 0 vs. CG 0 
Perioperative events & resource use 
Blood loss (in ml) IG: M 5.0 (R 0-150) vs. CG: M 3.5 (R 0-300), p=ns 
Operation time in min. IG: M 85.5 (R 48-148) vs. CG: M 74 (R 31-135), p=ns 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 1.9 (R 1-4) vs. CG Ø 3.06 (R 1-26)  
Median: IG 2 (R 1–4) vs CG: 2 (R 1–26) p<0.05 
 
Cholecystectomy 
Author, year 
[reference number] 
Ruurda et al, 2003 [1] 
Study design Single centre RCT 
Country Netherlands 
Funding/Sponsor NR 
Intervention (IG) | 
Product 
Robot-assisted single-site cholecystectomy | 
da Vinci telemanipulation system ( Intuitive Surgical Inc, Mountain View, CA) 
Comparator (CG) Standard laparoscopy cholecystectomies51  
Experience of 
surgeon(s), time period 
3 experienced surgeons and assisting team with experience of >15 robotic procedures per-
formed IG procedures; 5 surgical residents under supervision of qualified surgeon, performed 
laparoscopic cholecystectomies  
Number of patients IG 10 
CG 10 
Inclusion/exclusion Elective symptomatic cholelithiasis patients with cholecystolithiasis confirmed by ultrasound.  
                                                     
51 Not clearly stated but probably multi-port laparoscopy 
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Cholecystectomy 
Author, year 
[reference number] 
Ruurda et al, 2003 [1] 
criteria 
Primary/secondary 
endpoints 
Procedure time 
Follow-up (months) None 
Drop-outs (n, %) None 
Patient characteristics 
Age of patients (yrs.) IG: M 46 (R 29-72) 
CG: M 54 (R 24-87), p=NR 
Sex (% female) IG: 80% 
CG: 80%, p=NR 
BMI (kg/m²) IG: 2652 (R 18-47) 
CG: 25 (22-30), p=NR 
Disease Cholecystolithiasis (chronic in IG 4/10 and CG 1/20) 
Clinical classification NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR 
Time to resume 
work/daily activities 
NR 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
NR 
Postoperative 
complications (e.g. 
infections) 
NR 
Re-operations/ 
additional surgeries  
NR 
Conversion to 
laparoscopic/open 
surgery 
IG 0, CG: 0 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in min. 53 IG: M 144 (R 111-234) vs. CG M 119 (R 71-189), p=ns 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
NR 
Abbreviations: ASA=score American Society of Anesthesiologists; BIQ=body image questionnaire; BMI=body mass 
index; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Group; 
CG=control group; FU=follow-up; GERD=gastroesophageal reflux disease; GORD=gastro-oesophageal reflux disease; 
                                                     
52 Not stated if mean or median 
53 Defined as time between entry of the patient into the OR and departure from OR 
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GORD HRQOL=Gastro-oesophageal Reflux Health-Related Quality of Life scale; GSRS=Gastrointestinal Symptom Rating 
Scale; ICU=intensive care unit; IG=intervention group; IQR=interquartile range; M=Median; MD=mean difference; NR=not 
reported; ns=not significant; PSQ=photograph series questionnaire; QoL=quality of life; QOLRAD=Quality of Life in Reflux 
and Dyspepsia; SF-12 (QoL-12)=short form 12; Ø=mean; R=Range; RATS=Robot-assisted thoracic surgery; 
SIRC=single-incision robotic cholecystectomy; TNM=Tumor, nodes, metastasis; VAS=visual analogue scale; 
VATS=Video-assisted thoracic surgery.  
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54 Since it impractical for the surgeon to be blinded, we refer here to other healthcare professionals involved 
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Kim et al. 2018 [21] Not defined as outcome 
Mäkelä-Kaikkonen et al, 
2016 x2 [25] [68] Not defined as outcome 
Tolstrup et al, 2018 [22] Not defined as outcome 
Wang et al, 2017 [23] H U 
No infor-
mation 
 
N 
Those not 
providing 
follow-
updata were 
excluded 
before ran-
domisation 
N 
No infor-
mation on 
mortality 
during fol-
low-up 
 
N 
Not powered 
to detect 
mortality 
differences 
H 
 
Debakey et al, 2018 [24] H U   
Insufficient 
information 
for a 
judgement 
Y Y N 
Not powered 
to detect 
survival 
difference 
H 
 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Gallbladder/Liver Spleen 
Kudsi et al. 2017 H U 
No infor-
mation  
U 
No infor-
mation 
N 
Outcomes 
regarding 
quality of life 
just “for 
female 
patients with 
non-missing 
data: con-
trolled for 
age, BMI, 
and prior 
abdominal 
surgery” 
Y H 
 
Pietrabissa et al. 2016 
[27] 
L U 
No infor-
mation 
Y Y Y 
 
L 
 
Grochola et al, 2018 
[28] 
L U 
Insufficient 
information 
for a judge-
ment 
Y Y N 
Study not 
powered to 
detect quali-
ty of life 
difference 
H 
 
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 131 
Ruurda et al, 2003 [1] Not defined as outcome 
Bowel 
Jayne et al. 2017 [20] L U 
Stated that 
blinding of 
assessments 
was con-
ducted 
“where 
possible” 
Y Y Y L 
Kim et al. 2018 [21] L U 
Insufficient 
information 
Y U 
No outcome 
tables  
Y L 
 
Mäkelä-Kaikkonen et al. 
2016 x2 [25] [68] 
L U 
Insufficient 
information 
Y Y U 
No detailed 
reporting of 
condition-
specific  
symptom 
measures 
H 
 
Park et al. 2012 [19] H U 
No infor-
mation 
Y N 
Pain score at 
72 h not 
reported 
Y H 
 
Tolstrup et al. 2018 
[22] 
H U 
Insufficient 
information 
Y N 
(results data 
unclear) 
Y H 
Wang et al, 2017 [23] H U 
No information 
N 
Patients not 
providing 
follow-up 
data were 
excluded 
before 
randomisa-
tion 
N 
No infor-
mation on 
patents not 
providing 
follow-up 
N 
Power of 
study un-
clear 
H 
Debakey et al, 2018 
[24] Not defined as outcome 
SAFETY & PERIOPERATIVE OUTCOMES 
Gallbladder/Liver spleen 
Kudsi et al. 2017 [26] H U 
Insufficient 
information 
for a judge-
ment 
U 
No infor-
mation 
Y Y 
 
H 
 
Pietrabissa et al. 2016 
[27] 
L U 
No infor-
mation 
Y Y Y L 
Grochola et al, 2018 
[28] 
L U Y Y U 
Not powered 
for this 
outcome  
L 
Ruurda et al, 2003 [1] H U 
Insufficient 
information 
for a judge-
ment 
Y Y N 
Limited 
experience 
of surgeons 
in the control 
group could 
affect oper-
ating time; 
unclear if 
sample size 
adequate 
H 
 
   Bowel    
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 132 
Jayne et al. 2017 [20] L U 
Stated that 
blinding of 
assessments 
was con-
ducted 
“where 
possible” 
Y 
 
Y Y L 
Kim et al. 2018 [21] L U 
Insufficient 
information 
for a judge-
ment 
Y Y Y L 
Mäkelä-Kaikkonen et al. 
2016 [25] [68] 
L U 
Insufficient 
information 
for a judge-
ment 
Y Y Y L 
Park et a. 2012 [19] H U 
No infor-
mation 
Y Y Y L 
Tolstrup et al. 2018 [22] H U 
Insufficient 
information 
for a judge-
ment 
Y N  
Results data 
unclear 
Y 
 
H 
Wang et al, 2017 [23] H U 
No infor-
mation 
U 
Unclear   
Y N H 
Debakey et al, 2018 [24] H U  
Insufficient 
information 
for a judge-
ment 
Y Y U 
Unclear if 
sample size 
adequate 
H 
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R
is
k 
of
 b
ia
s 
– 
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e 
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l 
OVERALL MORTALITY 
Oesophagus 
Draaisma et al. 2009 [10] Not defined as outcome 
Mueller-Stich et al. 2007, 
2009 [13] [12] Not defined as outcome 
Morino et al. 2006 [11] Not defined as outcome 
Nakadi et al. 2006 [14] Not defined as outcome 
van der Sluis et al,  2018 
[15] 
L U 
No infor-
mation 
Y Y 
 
N 
Survival 
data un-
clear; not 
powered to 
detect 
survival 
difference 
H 
 
Stomach 
Pan et al. 2017 [16] H U 
No infor-
mation 
U 
No infor-
mation 
U 
Insufficient 
information 
Y H 
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for a judge-
ment 
Sanchez et al. 2005 [18] Not defined as outcome 
Wang et al. 2016 [17] H U 
No infor-
mation 
U 
No infor-
mation 
U 
Insufficient 
information 
for a judge-
ment 
Y H 
 
 
Endpoint 
Trial 
R
is
k 
of
 b
ia
s 
– 
st
ud
y 
le
ve
l 
B
lin
di
ng
 –
 o
ut
co
m
e 
as
se
ss
or
s 
IT
T 
pr
in
ci
pl
e 
ad
eq
ua
-
te
ly
 re
al
iz
ed
  
Se
le
ct
iv
e 
ou
tc
om
e 
re
po
rt
in
g 
un
lik
el
y 
N
o 
ot
he
r a
sp
ec
ts
 
in
cr
ea
si
ng
 ri
sk
 o
f b
ia
s 
R
is
k 
of
 b
ia
s 
– 
ou
t-
co
m
e 
le
ve
l 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Oesphagus 
Draaisma et al. 2009 [10] H U 
Insufficient 
information 
for a judge-
ment 
U 
Insufficient 
information 
on drop-outs 
Y U 
Insufficient 
information 
for a judge-
ment 
H 
 
Mueller-Stich et al. 
2009 [13] 
H Y  U 
No infor-
mation 
Y Y  
 
 L 
Morino et al. 2006 [11] L U U Y  
 
N 
Study not 
powered to 
detect QoL 
differences 
H 
 
Nakadi et al. 2006 [14] Not defined as outcome 
van der Sluis et al, 2018 
[15] 
L U 
Insufficient 
information 
for a 
judgement 
U 
Insufficient 
information 
on drop-
outs 
U 
Data on 
quality of 
life missing 
(“will be 
reported 
extra”) 
N 
Study not 
powered to 
detect 
quality of 
life differ-
ence 
H 
 
  Stomach     
Pan et al. 2017 [16] H U 
No infor-
mation 
U 
No infor-
mation 
Y Y  H 
 
Wang et al. 2016 [17] Not defined as outcome 
Sanchez et al. 2005 
[18] Not defined as outcome 
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SAFETY & PERIOPERATIVE OUTCOMES 
Oesophagus 
Draaisma et al. 2009 [10] H U 
Insufficient 
information 
for a judge-
ment 
U 
Insufficient 
information 
for a judge-
ment 
Y U 
Insufficient 
information 
for a judge-
ment 
H 
 
Mueller-Stich et al. H Y U Y Y L 
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2007 [12] Insufficient 
information 
for a judge-
ment 
Morino et al. 2006 [11] L U 
Insufficient 
information 
for a judge-
ment 
U 
Insufficient 
information 
for a judge-
ment 
Y Y L 
Nakadi et al. 2006 [14] H Y  U 
Insufficient 
information 
for a judge-
ment 
Y Y   L 
van der Sluis, 2018 [15] L U 
Insufficient 
information 
for a judge-
ment 
Y Y Y 
 
L 
 
Stomach 
Pan et al. 2017 [16] H U 
Insufficient 
information 
for a judge-
ment 
U 
Insufficient 
information 
for a judge-
ment 
Y Y  H  
Wang et al. 2016 [17] H U 
Insufficient 
information 
for a judge-
ment 
U 
Insufficient 
information 
for a judge-
ment 
 Y Y  H  
Sanchez et al. 2005 [18] H U 
No infor-
mation 
U 
Insufficient 
information 
for a judge-
ment 
Y Y  H  
 
Table A3: Characteristics & risk of bias of non-randomised studies 
Thoracic surgery 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Augustin et al. 2013 [29] Gonde et al. 2017 [30] 
Study design Non-randomised comparison of all robot-
assisted and consecutive conventional 
minimally invasive VATS lobectomies 
Single-centre 1 year prospective observational 
cost study 
Country Austria France 
Funding/Sponsor None  NR but conflict of interest present 
Intervention (IG) | 
Product 
Robot-assisted lobectomy (5 posterior 
and 21 anterior approach) | da Vinci 
Surgical System (3-arm) 
RATS | da Vinci Surgical System (3-arm) 
Comparator (CG) VATS lung lobectomy (anterior 
approach) 
VATS (modified anterior approach) 
Experience of 
surgeon(s), time period 
RATS was performed by 1 surgeon, who 
had completed formal training in robotic 
surgery. VATS was performed by 3 
surgeons with reported extensive 
experience in minimally invasive surger.y  
RATS procedures undertaken 2001-
2008; VATS procedures undertaken in 
2009 
Minimal invasive surgery for major pulmonary 
resection was established in 2008; in 2012 RATS 
was added; over 100 robotic procedures were 
performed in 2014 before the present study 
Study conducted: 09/2014-09/2015 
Number of patients IG: 26 IG: 57  
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Thoracic surgery 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Augustin et al. 2013 [29] Gonde et al. 2017 [30] 
CG: 26 CG: 55 
Inclusion/exclusion 
criteria 
Inclusion: 
• histologically proven lung 
cancer, centrally located 
solitary lung metastasis, and 
aspergilloma 
• early stage NSCLC cT1-
2N0M0 
Inclusion: 
• Patients who underwent minimally 
invasive lobectomy or segmentectomy 
Exclusion: 
• Wedge resection, sleeve resection, 
pneumonectomy, resection of a tumour 
>8cm. 
Primary/secondary 
endpoints 
Perioperative events and complications Perioperative events, resource use and 
complications 
Follow-up (months) NR 90 days 
Drop-outs (n, %) none none 
Patient characteristics 
Age of patients (yrs.) IG: M 65 (R 47-82) 
CG: M 65 (R 37-79), p=ns 
IG: M 61 (IQR 57-64)  
CG: M 63 (IQR 60-65), p=ns 
Sex (% female) IG: 46%  
CG: 42%, p=ns 
IG: 46% 
CG: 25%, p<0.05 
BMI (kg/m²) NR IG: M 25 (IQR 23-26) 
CG: M 26 (IQR 24-27), p=ns 
Disease Primary lung cancer, p=ns:  
IG: 24/26 (92%)  
CG: 25/26 (96%) 
Of these, clinical stage >1B:  
IG: 0/24  
CG: 6/25 (24%), p<0.05 
Aspergilloma (benign disease):  
IG: 0/26  
CG: 1/26 (3.85%) 
Indication, p=ns 
Lung cancer:  
IG: 44/57 (77%)  
CG: 44/55 (80%) 
Pulmonary metastasis:  
IG: 5/57 (9%)  
CG: 4/55 (7%) 
Benign lesion:  
IG: 8/57 (14%)  
CG 7/55 (13%) 
Clinical classification Pathological stage (UICC 7th edition) IG 
vs. CG, p=ns: 
Ia: 18/24 (75%) vs. 12/25 (48%) 
Ib: 5/24 (21%) vs. 6/25 (24%) 
II: 1/24 (4%) vs. 2/25 (8%) 
III, IV56: 0 vs. 5/25 (20%) 
TNM (IG vs. CG), p=ns 
Ia: 17/39 (44%) vs. 20/44 (45%) 
Ib: 6/39 (15%) vs. 9/44 (20%) 
IIa: 6/39 (15%) vs. 6/44 (14%) 
IIb: 5/39 (13%) vs. 6/44 (14%) 
IIIa: 4/39 (10%) vs. 2/44 (5%) 
IIIb: 1/39 (3%) vs. 0 
IV: 0/39 vs. 1/44 (2%) 
ASA score, p=ns 
1: 8/57 (14%) vs. 7/55 (13%) 
2: 21/57 (37%) vs. 20/55 (36%) 
3: 23/57 (40%) vs. 22/55 (40%) 
4: 4/57 (7%) vs. 6/55 (11%) 
5 and 6: 0 vs. 0 
Unknown: 1/57 (2%) vs. 0 
Clinically-relevant outcomes 
Positive surgical 
margins 
NR NR 
Patient-relevant outcomes 
                                                     
56 Histologically proven bilateral bronchioloalveolar carcinoma confined to the upper lobes 
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Thoracic surgery 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Augustin et al. 2013 [29] Gonde et al. 2017 [30] 
Survival (overall and 
disease-specific or 
disease-free) 
Intraoperative:  
IG: 26/26 (100%) 
CG: 26/26 (100%), p=ns 
In-hospital: 
IG: 26/26 (100%)  
CG: 26/26 (100%), p=ns 
Intraoperative:  
IG: 57/57 (100%) 
CG: 55/55 (100%), p=ns 
In-hospital:  
IG: 57/57 (100%) 
CG: 53/5557 (96%), p=NR 
Survival to 90 days: 
IG: 57/57 (100%) 
CG: 53/55 (96%), p=NR 
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR NR 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
NR NR 
Postoperative 
complications (e.g. 
infections) 
Total complications, p=ns: 
IG: 11/26 (42%) (5 air leaks, 2 atrial 
fibrillations, 1 wound infection, 1 urinary 
tract infection, 1 empyema, 1 colonic 
perforation) 
CG: 10/26 (38%) (4 air leaks, 2 atrial 
fibrillations, 2 pleural fluid collections, 2 
atelectasis)  
Minor complications, p=ns:  
IG: 8/26 (31%)  
CG: 9/26 (35%) 
Major complications, p=ns:  
IG: 3/26 (12%)  
CG: 1/26 (4%) 
IG: 21/57 (37%)  
CG: 29/55 (53%), p=ns 
Minor complications:  
IG: 19/57 (33%)  
CG: 21/55 (38%), p=ns 
Major complications:  
IG: 2/57 (4%)  
CG: 8/55 (15%), p=ns 
Complications requiring readmission: 
IG: 3/57 (5%) 
CG:5/55 (9%), p=ns 
Re-
operations/additional 
surgeries  
NR NR 
Conversion to 
laparoscopic/open 
surgery 
IG: M 5/26 (19%)  
CG: M 2/26 (8%), p=ns 
IG: 1/57 (2%)  
CG: 9/55 (16%), p<0.01 
Perioperative events & resource use 
Blood loss (in ml) Blood loss by comparing hemoglobin 
levels preoperative vs. postoperative: 
IG: Median change 2.40 g/dl vs. CG 1,85 
g/dl, p<0.05 
CG: NR 
NR 
Operation time in min. IG: M 215 (R 162-375) 
CG: M 183 (R 113-379), p<0.05 
IG: M 255 (IQR 225-300)  
CG: M 255 (IQR 217-305), p=ns 
Transfusions 1 patient required transfusion, group was NR 
                                                     
57 During hospital stay: a heart transplant patient because of acute respiratory distress of infectious origin; a second pa-
tient died of multiple organ failure. 
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Thoracic surgery 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Augustin et al. 2013 [29] Gonde et al. 2017 [30] 
not reported 
Drain duration (days) IG: M 7 (R 3-15)  
CG: M 6 (R 3-18), p=ns 
IG: M 4 (IQR 3-5)  
CG: M 4 (IQR 3-7), p=ns 
Length of hospital stay 
(days) 
IG: M 11 (R 7-53)  
CG: M 9 (R 4-23), p=ns 
IG: M 5 (IQR 5-7)  
CG: M 6 (IQR 5-11), p=ns 
 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Rinieri et al. 2016 [31] 
Study design Prospective observational study 
Country France 
Funding/Sponsor None 
Intervention | Product RATS |da Vinci Surgical System (3-arm) 
Comparator VATS (anterior approach) 
Experience of 
surgeon(s), time period 
Surgeons performing VATS (n=?) had performed >100; 1 surgeon performed RATS (no 
information on experience) 
Videothoracoscopy procedures: 2010-06/2014 
Robotic procedures: 2013-06/2014 
Number of patients IG:17  
CG: 34 
Inclusion/exclusion 
criteria 
Inclusion: patients undergoing RATS or VATS segmentectomy 
Primary/secondary 
endpoints 
Perioperative events and complications 
Follow-up (months) NR 
Drop-outs (n, %) None reported 
Patient characteristics 
Age of patients (yrs.) IG:M 62 (IQR 57-67)  
CG: M 64 (IQR 55-69), p=ns 
Sex (% female) IG: 29%  
CG: 50%, p=ns 
BMI (kg/m²) NR 
Disease Benign or infectious lesion: 
IG: 3/17 (17.65%)  
CG: 4/34 (20.59%), p=ns 
Preinvasive lesion or minimally invasive adenocarcinoma:  
IG: 2/17 (12%)  
CG: 10/34 (29%), p=NR 
Invasive adenocarcinoma:  
IG: 4/17 (24%)  
CG: 12/34 (35%) p=NR 
Other lung cancer:  
IG: 2/17 (12%)  
CG: 4/34 (12%) p=NR 
Pulmonary metastasis: 
IG: 6/17 (35%)  
CG: 4/34 (12%) p=NR 
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 138 
Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Rinieri et al. 2016 [31] 
Clinical classification TNM (IG vs. CG), p=ns 
Ia: 4/6 (67%) vs. 12/15 (80%) 
Ib: 1/6 (17%) vs. 2/15 (13%) 
IIa: 1/6 (17%) vs. 1/15 (7%) 
Clinically-relevant outcomes 
Positive surgical 
margins 
No data but reported that all patients had tumor-free margins 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
In-hospital:  
IG: 17/17 (100%)  
CG: 33/34 (97%)58, p=NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR 
Time to resume 
work/daily activities 
NR 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
NR 
Postoperative 
complications (e.g. 
infections) 
Clavien-Dindo classification (IG vs CG), p=ns 
0: 13/17 (76%) vs. 24/34 (71%) 
I: 2/17 (12%) vs. 2/34 (6%) 
II: 0/17 vs. 1/34 (3%) 
III: 1/17 (6%) vs. 4/34 (12%) 
IV: 1/17 (6%) vs. 2/34 (6%) 
V: 0/17 vs. 1/34 (3%) 
Re-
operations/additional 
surgeries  
1 reoperation for air leak, NR which group 
Conversion to 
laparoscopic/open 
surgery 
Lobectomy:  
IG: 1/17 (5.88%)  
CG: 2/34 (5.88%), p=ns 
Thoracotomy:  
IG: 1/17 (5.88%)  
CG: 3/34 (8.82%), p=ns 
Perioperative events & resource use 
Blood loss (in ml) IG:M 50 (IQR 10-100)  
CG: M 100 (IQR 50-200), p<0.05 
Operation time in min. IG: M 140 (IQR 120-170)  
CG: M 150 (IQR 120-180), p=ns 
Transfusions NR 
Drain duration (days) IG: M 3 (IQR 3-4)  
CG: M 3 (IQR 3-4), p=ns 
Length of hospital stay 
(days) 
IG: M 4 (IQR 4-5)  
                                                     
58 this patient died on postoperative day 1 due to cardiac arrest (ventricular fibrillation due to hyperkalemia) 
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Lobectomy/Segmentectomy 
Author, year 
[reference number] 
Rinieri et al. 2016 [31] 
CG: M 5 (IQR 4-759), p=ns 
 
Mediastinal Surgery 
Author, year 
[reference number] 
Balduyck et al. 2011 [32] 
Study design prospective, non-randomised study 
Country Belgium 
Funding/Sponsor NR 
Intervention | Product Robot-assisted anterior mediastinal mass resection | da Vinci robotic system (Intuitive Surgical, 
Inc., Mountain View, CA, USA) 
Comparator Open mediastinal mass resection by sternotomy 
Experience of 
surgeon(s), time period 
NR 
Recruitment: 01/2004-12/2008 
Number of patients IG: 14 
CG: 22 
Inclusion/exclusion 
criteria 
Inclusion: patients with a surgical resectable, anterior mediastinal mass 
Exclusion criteria for robot-assisted surgery: anterior mediastinal mass with maximal diameter 
>4cm, inability to sustain single-lung ventilation, local invasiveness in surrounding great 
vessels  
Primary, secondary 
endpoints 
Quality of life using EORTC QLQ-C30 (cancer core questionnaire) and EORTC QLQ-LC-13 
(lung-cancer-specific questionnaire module 
Follow-up (months) IG: Ø 34.2 ±11.6 
CG: Ø 50.1 ±16.1, p<0.05 
Drop-outs (n, %) 22/36 (61%) returned questionnaires at all 5 time periods. 
Non-response (IG vs. CG) 
6 months questionnaire: 
5/14 (36%) vs. 4/22 (18%) 
12 months questionnaire: 
3/14 (21%) vs. 2/22 (9%) 
Patient characteristics 
Age of patients (yrs.) IG: M 49 (R 18-63) 
CG: M 56 R(23-84), p=ns 
Sex (% female) IG: 71% 
CG: 45% p=ns 
BMI (kg/m²) NR 
Disease Pathological diagnosis after resection, IG vs. CG, p=ns: 
Thymic hyperplasia:  
4/14 (29%) vs. 5/22 (23%) 
Thymic cyst: 
4/14 (29%) vs. 2/22 (9%) 
Thymoma WHO type A: 
1/14 (7%) vs. 1/22 (5%) 
Thymoma WHO type B1: 
2/14 (14%) vs. 2/22 (9%) 
Thymoma WHO type B2: 
1/14 (7%) vs. 5/22 (23%) 
                                                     
59 Postoperative stay 
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Mediastinal Surgery 
Author, year 
[reference number] 
Balduyck et al. 2011 [32] 
Thymoma WHO type B3: 
0 vs. 1/22 (5%) 
Thymoma WHO type AB: 
1/14 (7%) vs. 3/22 (14%) 
Thymic carcinoma: 
0 vs. 1/22 (5%) 
Metastasis of second primary: 
1/14 (7%) vs. 0 
Extragonadal germ cell tumour: 
0 vs. 2/22 (9%) 
Clinical classification NR 
Clinically-relevant outcomes 
Positive surgical 
margins 
NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
Intraoperative 
IG: 22/22 (100%) 
CG: 14/14 (100%), p=NR 
Recurrence (local, 
regional or distant) 
IG: 0 
CG: 1/22 (4.55%), p=ns 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
Measured by EORTC-QLQ-C30 (IG vs CG) 
QoL functioning scores 
Physical functioning @1 month after surgery: Ø 76.9 (p=ns) vs. Ø 66.3 (p=0.001) 
No significant differences at 3, 6 or 12 months after surgery 
Role functioning @ 1 month after surgery: Ø 62.1 (p=ns) vs. Ø 40.8 (p=0.001) 
No significant differences at 3, 6 or 12 months after surgery 
Cognitive functioning: no significant differences at any time period 
Social functioning @ 1 month after surgery: Ø 72.7 (p=ns) vs. Ø 66.7 (p<0.05) 
No significant differences at 3, 6 or 12 months after surgery 
Global QoL: no significant differences at any time period  
QoL symptom scores 
Dyspnoea: no significant differences at any time period  
Coughing: no significant differences at any time period  
Fatigue @ 1 month after surgery: Ø 35.4 (p=ns) vs. Ø 50.5 (p<0.01) 
No significant differences at 3, 6 or 12 months after surgery 
Thoracic pain @ 1 month after surgery: Ø 24.3 (p<0.05) vs. Ø 31.7 (p<0.05) 
3 months after surgery: Ø 23.8 (p=ns) vs. Ø 26.7 (p<0.05) 
No significant differences at 6 or 12 months after surgery 
Shoulder dysfunction @ 3 months after surgery 
3 months after surgery: Ø 30.9 (p<0.05) vs. Ø 11.7 (p=ns) 
No significant differences at 1,6 or 12 months after surgery 
Time to resume 
work/daily activities 
NR 
Patient satisfaction NR 
Safety-related outcomes 
Intraoperative compli-
cations (e.g. air-
leakage) 
IG: 0 
CG: 0 
Postoperative compli-
cations (e.g. infections) 
IG vs CG: 
Cardiac tamponade: 0 vs. 1/22 (5%), p=ns 
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Mediastinal Surgery 
Author, year 
[reference number] 
Balduyck et al. 2011 [32] 
Phrenic paralysis: 2/14 (14%) vs. 0, p=ns 
Deep vein thrombosis: 1/14 (7%) vs. 0,p=ns 
Sternal keloid scarring: 0 vs. 1/22 (5%), p=NR 
Re-
operations/additional 
surgeries  
IG: 0 
CG: 2/22 (9.09%) : 1 re-operation for pleural recurrence and 1 re-operation for sternal 
instability, p=NR 
Conversion to laparo-
scopic/open surgery 
IG: 1/14 (7%) 
CG: 0, p=NR 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in 
min60. 
IG: Ø 224.2 ±66.5 
CG: Ø 243.8 ± 55.5, p=ns 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
IG: Ø 9.6 ±3.9  
CG: Ø 11.8 ± 5.7, p=ns 
 
Oesophagus 
Heller myotomy 
Author, year 
[reference number] 
Huffmanm et al.2007 [33] Sanchez et al. 2012 [34] 
Study design Single centre prospective observational 
Study (consecutive patients over 6 years) 
Single centre, prospective, comparative study of 
consecutive patients 
Country USA, Ohio Venezuela 
Funding/Sponsor NR NR 
Intervention (IG) | 
Product 
da Vinci Surgical System Robot-assisted 
laparoscopic myotomy with partial 
fundoplication 
da Vinci Surgical System Robotic assisted 
laparoscopic Heller myotomy  
Comparator (CG) Laparoscopic myotomy with partial 
fundoplication 
Laparoscopic Heller 
myotomy  
Experience of 
surgeon(s), time period 
Single surgeon for all procedures 
Operations performed between 2004 and 
2006 (intervention); operations 
performed between 2000 and 2004 
(comparator) 
The same surgical team for every case 
Study conducted: January 2008 to November 
2010 
Number of patients IG: 24 
CG: 37 
IG: 13 
CG: 18 
Inclusion/exclusion 
criteria 
Patients suitable for a Heller myotomy 
were included 
Inclusion: patients with achalasia confirmed by 
oesophagogram and manometry  
Primary, secondary 
endpoints 
Generic and disease-specific quality of 
life, perioperative outcomes and 
complications 
Postoperative complications and recurrence of 
symptoms  
Follow-up (months) 1-6 months but: 
CG: M 43 months 
IG: M 15 months 
1 week, 1 month and 4 months after surgery then 
every 6 months (latter by telephone)  
                                                     
60 Total operation room occupation 
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Oesophagus 
Heller myotomy 
Author, year 
[reference number] 
Huffmanm et al.2007 [33] Sanchez et al. 2012 [34] 
Drop-outs (n, %) 0 IG: 0% at 18 Months 
CG: 5.5% at 18 Months 
Patient characteristics 
Age of patients (yrs.) IG: R 22-92  
CG: R 25-85 
IG: M 38.0 
CG: M 40.7, p=ns 
Sex (% female) IG: 58%  
CG:38%, p=NR 
NR 
BMI (kg/m²) NR NR 
Disease Achalasia Achalasia 
Clinical classification NR NR 
Clinically-relevant outcomes 
Positive surgical 
margins 
NR NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR NR  
Recurrence (local, 
regional or distant) 
NR NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
SF-36 general health perceptions post-
op vs. pre-op: 
IG: 53 vs. 34, p<0.05 
CG: 68 vs. 56, p<0.05 
All categories showed improvement 
(post-op vs pre-op) for both groups, 
p<0.05 (data in diagram) 
No data on between group comparisons 
GERD Activity Index (GRACI) showed an 
improvement in severity of symptoms in 
both groups at 6 days postoperatively (P 
<0.05) (no exact results reported). 
At 18 months (method of measurement not 
stated): 
IG: 100% relief of symptoms 
CG: 94.5% relief of symptoms p=NS 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
IG:0 
CG:3/37 (8%) operative oesophageal 
perforations, p=NR 
IG: 0 
CG: 1/18 (5.5%) (oesophageal perforations), p=ns 
Postoperative 
complications (e.g. 
infections) 
NR NR 
Re-operations/ 
additional surgeries  
NR NR 
Conversion to 
laparoscopic/open 
surgery 
NR IG=0 
CG=0 
Perioperative events & resource use 
Blood loss (in ml) IG: 67 ml 
CG: 57 ml p=NR 
NR 
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Oesophagus 
Heller myotomy 
Author, year 
[reference number] 
Huffmanm et al.2007 [33] Sanchez et al. 2012 [34] 
Operation time in min. IG: M 355± 23  
CG: M 287 ± 9, p=NR61 
IG: M 79 ± 20 
CG: M 76 ± 13 p=ns2 
Transfusions NR NR 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
IG: 2.8 days 
CG: 2.6days, p=NR 
NR  
 
Gallbladder/liver/spleen 
Liver resection/hepatectomy 
Author, year 
[reference number] 
Berber et al. 2010 [35] Lai and Tang 2016 [36] 
Study design Single centre prospective non-randomised 
study 
Single centre prospective non randomised 
trial of consecutive patients  
Country USA China 
Funding/Sponsor NR NR 
Intervention | Product Robotic resection of liver tumour da Vinci Surgical System robot-assisted 
laparascopic partial hepatectomy 
Comparator Laparoscopic resection of liver tumour Conventional laparoscopic partial 
hepatectomy  
Experience of 
surgeon(s), time period 
NR 
Robotic procedures conducted October 2008 
to September 2009 
Consultant surgeons with expertise in 
hepatobiliary and laparoscopic surgery 
Procedures undertaken October 1998 to 
February 2015 
Number of patients IG: 9 
CG: 23 
IG: 95  
CG:35 
Inclusion/exclusion 
criteria 
Inclusion: Patients with a peripherally located 
malignant lesion measuring <5 cm 
Exclusion: NR 
Inclusion: 
Patients with hepatocellular carcinoma 
Exclusion: NR 
Primary endpoint Survival, recurrence, perioperative outcomes Survival, perioperative outcomes 
Follow-up (months) Mean (both groups) of 14 months  IG: M 26.4±11.8  
CG: M 61.6±44.5  
Drop-outs (n, %) NR 0 
Patient characteristics 
Age of patients (yrs.) IG: M 66.6 ±6.4 
CG: M 66.7±9.6, p=ns 
IG: M 62.1±10.8  
CG: M 57.9±10.3, p=0.05 
Sex (% female) IG: 22% 
CG:48%, p=ns 
IG: 31% 
CG: 26%, p=ns 
BMI (kg/m²) NR NR 
Disease Tumour type, p=ns 
Colorectal metastasis: 
IG 4/9 (44%) vs CG 14/23 (61%) 
Hepatocellular cancer IG 3/9 (33%) vs. CG 
7/23 (30%) 
Hepatocellular Carcinoma 
                                                     
61 Definition: from induction of anesthesia to extubation 
2 Definition: from incision to closure of the wounds 
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Gallbladder/liver/spleen 
Liver resection/hepatectomy 
Author, year 
[reference number] 
Berber et al. 2010 [35] Lai and Tang 2016 [36] 
Clinical classification NR NR 
Clinically-relevant ouctomes 
Positive surgical 
margins 
NR NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
Data NR (diagram unclear) 
Reported that disease-free survival at 14 
months was equivalent in both groups (p=ns) 
Operative mortality (within 90 days): 
IG: 0% vs. CG: 0% 
5-year overall survival: 
IG: 65% vs. CG: 48%, p=ns 
5-year disease-free survival: 
IG 42% vs. CG: 38%, p=ns 
Recurrence (local, 
regional or distant) 
IG: 2/9 (22%) 
CG: 6/23 (26%), p=ns 
IG: 32/95 (34%) 
CG: 22/35 (63%), p=NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR NR 
Time to resume 
work/daily activities 
NR NR 
Patient satisfaction NR NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
Intra-operative bleeding requiring conversion: 
IG: 1/9 (11%) vs. CG: 0, p=NR 
Not specified if occurred intraoperatively 
Postoperative 
complications (e.g. 
infections) 
Total (intra-operative and post-operative), 
p=NR: 
IG: 1/9 (11%) vs. CG:4/23 (17%) 
All complications/all procedures: 
IG: 20/100 (20%) vs. CG 7/35 (20%), p=NR 
N patients with complications: 
IG: 14/100 procedures (14%) vs CG: 7/35 
(20%), p=ns 
Re-
operations/additional 
surgeries  
NR IG: 5/95 (5.26%) 
CG: 1/35 (2.9%), p=NR 
Conversion to 
laparoscopic/open 
surgery 
IG: 1/9 (11%) vs. CG: 0, p=ns IG 4/100 procedures (4%) vs. CG 2/35 (6%), 
p=ns 
Perioperative events & resource use 
Blood loss (in ml) IG:M 136 ± 61 cc  
CG: M 155 ± 54 cc, p=ns  
IG: M 334.6 (R 5-3500)  
CG: M 336.0 (R 5-2000), p=ns  
Operation time in min. IG: M 258.5 ± 27.9 
CG: M 233.6 ± 16.4, p=ns 
IG:M 207.4±77.1  
CG: M 134.2±41.762, p=0.001 
Transfusions NR IG: 9/100 procedures (9%) 
CG: 4/35 (11.4%), p=ns 
Drain duration (days) NR NR 
Length of hospital stay 
(days) 
NR IG:M 7.3 ± 5.3  
CG: M 7.1 ± 2.6, p=ns  
 
                                                     
62 Defined as time between skin incision and last port skin closure 
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Hernia repair 
Author, year 
[reference number] 
Tran, 2011 [37] 
Study design Single centre prospective, non- randomized, controlled study 
Country Australia 
Funding/Sponsor NR 
Intervention | Product Robotic Freehand® Robotic single-port total extraperitoneal inguinal hernia repair 
Comparator Conventional single-port inguinal hernia 
Repair (laparoscopy) 
Experience of 
surgeon(s), time period 
NR 
Study period October 2010 to December 2010 
Number of patients IG: 16 
CG: 16 
Inclusion/exclusion 
criteria 
Inclusion: Patients listed for LESS TEP inguinal hernia repair 
Exclusion: NR 
Primary endpoint Perioperative outcomes and satisfaction 
Follow-up (months) 6 
Drop-outs (n, %) 0 at 6 months 
Patient characteristics 
Age of patients (yrs.) IG: 46 vs. CG: 48, p=NR 
Sex (% female) NR 
BMI (kg/m²) IG: 28.4 vs. CG 29.2, p=NR 
Disease Inguinal hernia, p=NR 
% Direct:  
IG 6/10 (60%) vs. CG 6/10 (60%) 
Clinical classification ASA: IG 1 vs. CG 1 
Clinically-relevant outcome 
Positive surgical 
margins 
NR 
Patient-relevant outcomes 
Survival (overall and 
disease-specific or 
disease-free) 
NR 
Recurrence (local, 
regional or distant) 
NR 
Quality of life (e.g. 
measured by EQ-5D or 
SF-36) 
NR 
Time to resume 
work/daily activities 
NR 
Patient satisfaction Highly satisfied: 
IG: 14/16 (88%) vs. CG 14/16 (88%), p=NR 
Satisfied: 
IG: 2/16 (13%) vs. CG 2/16 (13%), p=NR 
Safety-related outcomes 
Intraoperative 
complications (e.g. air-
leakage) 
NR 
Postoperative 
complications (e.g. 
infections) 
Wound infections: IG 0 vs. CG 0. 
Re-operations/ NR 
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Hernia repair 
Author, year 
[reference number] 
Tran, 2011 [37] 
additional surgeries  
Conversion to 
laparoscopic/open 
surgery 
NR 
Perioperative events & resource use 
Blood loss (in ml) NR 
Operation time in min IG: 48 (R 35-95) 
CG: 52 (R 40-125), p=NR 
Transfusions NR 
Drain duration (days) NR 
Length of hospital stay 
(days) 
NR 
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Risk of bias – outcome-level of non-randomised studies comparing robot-assisted surgery 
versus open or laparoscopic surgery 
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Thorax 
OVERALL MORTALITY 
Augustin et 
al. 2013 
[29] 
M 
Different 
surgeons 
performed 
surgery;d 
IG 
surgery 
performed 
in 
different 
ways 
C 
Unclear 
how IG 
group was 
defined 
L L L C 
Study 
sample 
very small 
for 
survival 
outcome 
L C 
Gonde et 
al. 2017 
[30] 
S 
Significant 
difference
s in 
groups on 
pulmonar
y 
comorbidit
ies and 
sex 
C 
Unclear 
how 
groups 
were 
constructe
d 
L L L C 
Study 
sample 
likely to 
be too 
small for 
assessme
nt of 
survival 
C 
No 
statistical 
testing on 
mortality 
result 
C 
Rinieri et al. 
2016 [31] 
C 
Long 
study 
period, no 
informatio
n how 
many 
surgeons 
conducted 
VATS or 
experienc
e level of 
RATS 
surgeon, 
some 
patients 
chosen 
specificall
y for 
VATS 
C 
Unclear 
how 
groups 
were 
constructe
d 
L L L C 
Sample 
size too 
small for 
outcome 
L C 
Balduyck et 
al. 2011 
[32] 
C 
Unclear 
how 
participant
s were 
assigned 
to group 
and NI 
about 
C 
No 
informatio
n and no 
comparab
le 
characteri
stics for 
tumour 
L L L C 
Sample 
size too 
small for 
outcome 
and only 
short 
follow-up 
for 
L C 
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surgeon 
experienc
e 
size recurrenc
es 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Augustin et 
al. 2013 
[29] 
Not defined as outcome 
Gonde et 
al. 2017 
[30] 
Not defined as outcome 
Rinieri et al. 
2016 [31] 
Not defined as outcome 
Balduyck et 
al. 2011 
[32] 
M 
See 
above 
NI L L L NI L M 
SAFETY & PERIOPERATIVE OUTCOMES 
Augustin et 
al. 2013 
[29] 
M 
See 
above 
C 
See 
above 
L L L 
 
M 
Small 
sample 
size 
M 
Missing 
results on 
blood loss 
in CG 
M 
Gonde et 
al. 2017 
[30] 
S 
See 
above 
C 
See 
above 
L L L L L S 
Rinieri et al. 
2016 [31] 
C 
See 
above 
C 
See 
above 
L L L L L C 
Balduyck et 
al. 2011 
[32] 
M 
See 
above 
M 
No 
informatio
n and no 
comparab
le 
charateris
tics for 
tumour 
size 
L L L L L M 
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Heller myotomy         
OVERALL MORTALITY 
Huffmanm et al. 2007 
[33] 
Not defined as outcome 
         
Sanchez et al. 2012 
[34] 
Not defined as outcome 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Huffmanm et al. 2007 
[33] 
C 
Unclear 
for how 
long 
follow- up 
was 
per-
formed 
C 
2 groups 
were 
treated at 
different 
times 
L L C 
Missing 
numerical 
data on 
GERD 
activity 
index 
GRACI 
 
C 
No 
informatio
n on data 
collection 
and small 
sample 
size 
 
C 
Missing 
data for 
GERD 
and 
GRAC 
C 
Sanchez et al. 2012 
[34] 
H 
No infor-
mation on 
sex or 
BMI 
L L L L C 
No 
informatio
n on 
measure
ment of 
symptom
s and 
small 
sample 
size 
 
L C 
SAFETY & PERIOPERATIVE OUTCOMES 
Huffmanm et al. 2007 
[33] 
C 
See 
above 
C 
See 
above 
L L L NI 
Unclear if 
sample 
size 
adequate 
 
L  
 
C 
Sanchez et al. 2012 
[34] 
S 
Insufficie
nt 
informatio
n on 
patient 
characteri
L L L L  NI  
Unclear if 
sample 
size 
adequate 
L S 
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stics 
Liver resection/ 
hepatectomy 
        
OVERALL MORTALITY 
Berber et al, 2010 [35]  C 
Experienc
e of 
surgeons 
not 
reported, 
insufficien
t 
informatio
n on 
inclusion/
exclusion 
criteria, 
on clinical 
and 
pathologi
c 
variables 
M  
NI on 
type and 
approach 
of 
resection  
L L S  
Data not 
clearly 
reported 
C 
Small 
sample 
size for 
survival, 
no power 
calculatio
n 
L C 
Lai & Tang, 2016 [36] C 
Experienc
e of 
surgeons 
with 
robotic 
procedur
e unclear, 
insufficient 
informatio
n on 
inclusion/
exclusion 
criteria 
NI L S 
Cross-
over of 
procedur
es and 
multiple 
procedur
es 
performe
d 
L C 
No 
sample 
size 
calculatio
ns, 
sample 
too small 
for 
outcome, 
NI on loss 
to follow-
up 
L C 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Berber et al, 2010 [35] Not defined as outcome 
Lai & Tang, 2016 [36] Not defined as outcome 
SAFETY & PERIOPERATIVE OUTCOMES 
Berber et al, 2010 [35] S 
See 
above 
NI L L C 
Not all 
complicati
ons data 
reported 
L 
 
C 
Compli
cations 
data 
missing 
C 
Lai & Tang, 2016 [36] S 
See 
above 
NI L S 
See 
above 
L 
 
C 
Reported 
on 
complicati
ons per 
L C 
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procedur
es not 
patients 
Hernia repair         
OVERALL MORTALITY 
Tran, 2011 [37] Not defined as outcome 
PATIENT-ASSESSED OUTCOMES (QoL, symptoms, satisfaction) 
Tran, 2011 [37] C 
NI on 
experienc
e of 
surgeons,
insufficien
t 
informatio
n on 
inclusion/
exclusion 
criteria 
and on 
clinical 
and 
pathologi
cal 
variables 
C 
Unclear 
how 
selection 
performe
d  
L L L 
 
C 
No 
informatio
n on how 
satisfactio
n was 
measured 
L C 
SAFETY & PERIOPERATIVE OUTCOMES 
Tran, 2011 [37] C 
See 
above 
C 
See 
above 
L L C 
Only 
informatio
n on 
wound 
infection 
given 
 S  
Only 
informatio
n on 
wound 
infection 
given  
 S 
Only 
informa
tion on 
wound 
infectio
n given 
C 
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Applicability tables 
Table A4: Summary table characterising the applicability of a body of studies 
Thoracic surgery: lobectomy and mediastinal surgery 
Domain Description of applicability of evidence 
Population All thoracic surgery procedures included in this HTA were performed due to lung cancer. 
The enrolled populations in the studies do not differ substantially from the target population; 
therefore the findings are generalizable to the target population. 
Intervention Lobectomy/segmentectomy studies used robot-assisted lobectomy (RATS) with the da 
Vinci system whilst the mediastinal surgery study used robot-assisted anterior 
mediastinal mass resection, again with the da Vinci system.  
Comparators Videothoracoscopy (VATS) was the control procedure for the lobectomy studies and open 
mediastinal mass resection by sternotomy was the control procedure for the mediastinal 
surgery study.  
Outcomes The main outcomes considered were perioperative events, complications and resource 
use. All four observational studies (3 for lobectomy/segmentectomy and 1 for mediastinal 
surgery) were included in the effectiveness and safety domains. The 3 lobectomy/ 
segmentectomy studies considered perioperative events, perioperative events and 
resource use, and perioperative events and complications. One study had a follow-up for 1 
year but this was primarily a cost study; information on endpoints relevant for this HTA was 
only available for up to 90 days. None of the lobectomy studies considered quality of life. 
The mediastinal surgery study considered quality of life using a standardized and valid 
instrument although the sample size was small.  
Setting All the lobectomy/segmentectomy studies were conducted in Europe. In 2 studies the 
intervention and control procedures were undertaken in different time periods. In one of the 
studies there was no information on the level of experience or training of the surgeon.   
The mediastinal surgery study was also conducted in Europe. No information was provided 
on the training or experience of the surgeon. 
Visceral surgery: Oesophagus 
Domain Description of applicability of evidence 
Population (i) Antireflux/fundoplication: patients had gastro-oesophageal reflux disease.  
(ii) Heller myotomy: patients had achalasia. 
(iii) Oesophagectomy: patients had carcinoma.  
The enrolled populations in the studies do not differ substantially from the target population; 
therefore the findings are generalizable to the target population. 
Intervention (i) One of the Heller myotomy studies used a partial fundoplication in addition to the robot-
assisted laparoscopic Heller myotomy, the other only used robot-assisted laparoscopic 
Heller myotomy  
(ii) robotic fundoplication was used in the antireflux/fundoplication studies  
(iii) robotic thoracolaparoscopic oesophagectomy was used in the oesophagectomy RCT.  
All of the studies, regardless of specific procedure, used the da Vinci robotic system as the 
intervention. 
Comparators (i) conventional laparoscopic fundoplication  
(ii) laparoscopic Heller myotomy (in one study partial fundoplication was added to this)  
(iii) open transthoracic oesophagectomy 
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Domain Description of applicability of evidence 
Outcomes Antireflux/fundoplication. 3 studies contributed to the effectiveness and safety domains 
whilst one study provided evidence on effectiveness only. Mortality associated with the 
procedure could not be assessed, since it was not reported in any of the studies. Morbidi-
ty/quality of life was reported by all 4 studies although different instruments were used 
which makes comparison difficult.  
Oesophagectomy. The single RCT reported on both safety and effectiveness parameters 
including mortality, quality of life and functional recovery as well as providing data on 
perioperative events/resource use.  
Heller myotomy. Neither observational study considered mortality or recurrence but both 
measured quality of life (with a follow-up of up to 6 months) whereby one of the studies 
used a standardized, valid instrument (although no results on between group comparisons 
were reported). Most information relates to perioperative events/resource use.  
Two of the studies in this area considered outcomes relating to patient satisfaction whilst 
one considered time to work/daily activities. 
Setting Both the antireflux/fundoplication and the oesophagectomy studies were conducted in 
Europe whilst the Heller myotomy studies were conducted outside of Europe (USA and 
Venezuela). Neither the oesophagectomy study nor the Heller myotomy studies provided 
information on surgical training or experience. In one antireflux study, surgeons had 
undertaken 20 robotic surgery procedures whilst in 3 studies no information was given on 
the experience with robotic surgery.  
Visceral surgery: Stomach 
Domain Description of applicability of evidence 
Population Gastric cancer patients were included in the gastrectomy studies; the samples relate to 
Chinese patients. No patient details were given for the bariatric surgery study. 
Intervention The specific device used for robotic gastrectomy was not reported whilst for the bariatric 
surgery, robotic laparoscopic Roux-en-Y gastric bypass with the daVinci Surgical System 
was implemented. 
Comparators For the gastrectomy studies, one used laparoscopic gastrectomy whilst the other used 
open gastrectomy as the comparator. 
In the bariatric surgery study laparoscopic Roux-en-Y gastric bypass was the comparator. 
Outcomes Bariatric. Only information relating to the safety domain was provided but here there were 
very few events so relative effect estimates were not possible. Resource implications– 
notably operation time– was reported although the sample size was small and there was 
insufficient information on patient characteristics i.e. serious risk of bias.  
Gastrectomy. In the comparison with open gastrectomy, morbidity and quality of life was 
not reported; in the laparoscopy comparison the certainty of the evidence was assessed as 
very low. Both studies reported complications and perioperative events/resource use, 
namely blood loss, length of stay and operation time.  
Setting In one study, surgeons were very experienced with robotic gastrectomy; in the other study 
no information was given. Both gastrectomy studies took place in China. The bariatric 
surgery study took place in the USA; surgeons were reported to have had mandatory FDA 
training in the da Vinci system. 
Visceral surgery: Bowel 
Domain Description of applicability of evidence 
Population (i) Colectomy: colonic carcinoma patients for colectomy 
(ii) Rectal resection: rectal cancer patients 
(iii) Rectal rectopexy: rectal prolapse/intrasusception patients.  
The enrolled populations in the studies do not differ substantially from the target population; 
therefore the findings are generalizable to the target population. 
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Domain Description of applicability of evidence 
Intervention (i) Robot-assisted colectomy with the da Vinci system  
(ii) robot-assisted laparoscopic rectal cancer resection with the da Vinci system  
(iii) robot-assisted ventral mesh rectopexy with the da Vinci system 
Comparators (i) Laparoscopically-assisted colectomy 
(ii) laparoscopic rectal resection  
(iii) laparoscopic ventral mesh rectopexy 
Outcomes Colectomy: follow-up was for a maximum of 30 days (not clearly stated); outcomes were 
positive surgical margins, pain scores (VAS), complications and perioperative 
events/resource use. 30-day mortality was reported but the sample size was too small for 
this outcome. 
Rectal resection: outcomes related to survival, clinically-relevant outcomes, quality of life 
(measured with different instruments), pain and complications. One was an international 
mutlicentre RCT. The longest follow-up was 12 months. 2 studies were of a low risk of bias. 
Rectal rectopexy: This RCT only considered pain, complications and perioperative 
outcomes with a maximum follow-up of until discharge.  
Setting (i) RCT took place in Korea; the operating team had previously undertaken 30 robotic 
procedures (5 specifically of this type)  
(ii) the RCTs covered a number of European and international countries; 3 of 4 studies 
reported on the existence of surgeon experience with robot-assisted surgery  
(iii) study took place in Finland with “experienced” surgeons (no details reported).  
Visceral surgery: Gallbladder/Liver/Spleen 
Domain Description of applicability of evidence 
Population (i) Cholestectomy: patients had benign gallbladder disease and in one study, gallstones.  
(ii) Liver resection: patients with liver tumours (no details on exclusion criteria). 
(iii) Hernia repair: patients recommended for hernia repair (no details on exclusion 
criteria). 
As far as could be assessed, the enrolled populations in the studies do not differ 
substantially from the target population, therefore the findings are generalizable to the 
target population. 
Intervention (i) Single-site cholecystectomy with da Vinci (in 1 trial the product type was not specified)  
(ii) robot-assisted laparoscopic hepatectomy/liver resection (in 1 study da Vinci system was 
used; in 1 study product was not reported)  
(iii) robotic single-port total extraperitoneal inguinal hernia repair with the Freehand system 
was used 
Comparators (i) Single-port, four-port or multiport laparoscopic cholecystectomy  
(ii) laparoscopic resection/partial hepatectomy  
(iii) laparoscopic single-port inguinal hernia repair 
Outcomes Cholecystectomy: follow-up varied between none (only operation itself considered) to 
around a maximum of 3 years. 3 RCTs considered QoL (using SF-12 or gastrointestinal 
quality of life index) and 2 studies measured satisfaction (using Body Image Questionnaire). 
Pain, complications, and perioperative events/resource use were also reported.  
Liver resection: follow-up was long (> 1 year) but variable. Survival, recurrence, 
complications and perioperative events/resource use were assessed. 
Hernia repair: 6 month follow-up looking at satisfaction and complications. 
Setting (i) RCTs were conducted in 4 different European countries; surgeons often had prior expe-
rience but also included surgeons who were learning the robotic technique 
(ii) studies took place in USA and China; no information on experience with robot-assisted 
surgery  
(iii) study took place in Australia; no information on the experience of surgeons  
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DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Strategies for identifying literature on robotic thoracic and visceral surgery (systematic 
search)  
1. Robotic (Pulmonary) Lobectomy:  
Search strategy for Medline (Ovid MEDLINE(R) <1946 to June Week 3 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<June 25, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <June 25, 2018>, Ovid MEDLINE(R) Daily 
Update <June 25, 2018>). Date of search: 26.06.2018 
1     ((pulmonar* or lung*) adj5 (segmentectom* or lobectom*)).mp. (3776) 
2     ((excis* or resect*) adj5 (lobe* or lung*)).mp. (20369) 
3     1 or 2 (22911) 
4     exp Robotic Surgical Procedures/ (3932) 
5     robot*-assisted*.mp. (9971) 
6     (robot* adj5 (surger* or surgical*)).mp. (12260) 
7     4 or 5 or 6 (16830) 
8     3 and 7 (193) 
9     limit 8 to (clinical trial, all or randomized controlled trial) (10) 
10  ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug       therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3665363) 
11     8 and 10 (41) 
12     9 or 11 (47) 
13     remove duplicates from 12 (47) 
Search strategy for Embase (via Elsevier). Date of search: 26.06.2018  
No.  Query                                            Results       
#14. #10 OR #12 OR #13                                           57   
#13. #9 AND ('clinical trial'/de OR 'randomized                  26   
     controlled trial'/de OR 'randomized controlled  
     trial (topic)'/de) 
#12. #9 AND #11                                                  47   
#11. 'crossover procedure':de OR 'double-blind            2,247,422   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#10. #4 AND #8 AND ([controlled clinical trial]/lim OR           15   
     [randomized controlled trial]/lim) 
#9.  #4 AND #8                                                  545   
#8.  #5 OR #6 OR #7                                          66,212   
#7.  ((excis* OR resect*) NEAR/5 (lobe* OR                   57,124   
     lung*)):ti,ab,de 
#6.  ((pulmonar* OR lung*) NEAR/5 (segmentectom* OR          18,430   
     lobectom*)):ti,ab,de 
#5.  'lung lobectomy'/exp                                     9,251   
#4.  #1 OR #2 OR #3                                          26,594   
#3.  robot* NEAR/5 surg*                                     26,594   
#2.  'robotic surgical procedure'/exp                         2,001   
#1.  'robot assisted surgery'/exp                             6,055   
 
Search strategy for Cochrane (CENTRAL). Date of search: 26.06.2018 
ID Search  
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot*-assisted*  (Word variations have been searched) 
#3 robot* near surg*  (Word variations have been searched) 
#4 #1 or #2 or #3 
#5 (pulmonar* or lung*) near (segmentectom* or lobectom*)  (Word variations have been searched) 
#6 (excis* or resect*) near (lobe* or lung*)  (Word variations have been searched) 
#7 #5 or #6  
#8 #4 and #7 in Trials (Word variations have been searched) 
 
21 Hits 
 
2. Robotic Mediastinal Surgery (incl. Thymectomy): 
  
Search strategy for Medline (Ovid MEDLINE(R) <1946 to June Week 4 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<July 02, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <July 02, 2018>, Ovid MEDLINE(R) Daily 
Update <July 02, 2018>). Date of search: 04.07.2018 
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1     exp Mediastinum/su [Surgery] (850) 
2     (mediastin* adj5 (surg* or resect*)).mp. (4209) 
3     exp Thymectomy/ (7687) 
4     thymectom*.mp. (10046) 
5     exp Thymus Gland/su [Surgery] (470) 
6     (thymus adj5 (surg* or resect* or excis* or remov*)).mp. (770) 
7     1 or 2 or 3 or 4 or 5 or 6 (15261) 
8     exp Robotic Surgical Procedures/ (3961) 
9     robot*-assisted*.mp. (9982) 
10     (robot* adj5 (surger* or surgical*)).mp. (12294) 
11     8 or 9 or 10 (16863) 
12     7 and 11 (187) 
13     limit 12 to clinical trial, all (6) 
14   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3667967) 
15     12 and 14 (31) 
16     13 or 15 (35) 
17     remove duplicates from 16 (35) 
Search strategy for Embase (via Elsevier). Date of search: 04.07.2018 
No.  Query                                                 Results        
 
#19. #14 OR #16 OR #18                                           34    
#18. #17 AND ('clinical trial'/de OR 'randomized                 15    
     controlled trial'/de OR 'randomized controlled  
     trial (topic)'/de) 
#17. #13                                                        345    
#16. #13 AND #15                                                 29    
#15. 'crossover procedure':de OR 'double-blind            2,251,819    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#14. #4 AND #12 AND ([controlled clinical trial]/lim             10    
     OR [randomized controlled trial]/lim) 
#13. #4 AND #12                                                 345    
#12. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11                22,143    
#11. (thymus NEAR/5 (surg* OR resect* OR excis* OR            1,804    
     remov*)):ti,ab,de 
#10. 'thymus'/exp/dm_su                                         178    
#9.  thymectom*:de,ti,ab                                     12,113    
#8.  'thymectomy'/exp                                        10,168    
#7.  (mediastin* NEAR/5 (surg* OR resect*)):ti,ab,de          9,026    
#6.  'mediastinum'/exp/dm_su                                    263    
#5.  'mediastinum surgery'/exp                                   25    
#4.  #1 OR #2 OR #3                                          26,691    
#3.  robot* NEAR/5 surg*                                     26,691    
#2.  'robotic surgical procedure'/exp                         2,027    
#1.  'robot assisted surgery'/exp                             6,096   
Search strategy for Cochrane (CENTRAL). Date of search: 04.07.2018 
ID Search  
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot*-assisted*  (Word variations have been searched) 
#3 robot* near surg*  (Word variations have been searched) 
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Mediastinum] explode all trees and with qualifier(s): [Surgery – SU] 
#6 mediastin* near (surg* or resect*)  (Word variations have been searched) 
#7 MeSH descriptor: [Thymectomy] explode all trees 
#8 thymectom*  (Word variations have been searched) 
#9 MeSH descriptor: [Thymus Gland] explode all trees and with qualifier(s): [Surgery – SU] 
#10 thymus near (surg* or resect* or excis* or remov*)  (Word variations have been searched) 
#11 #5 or #6 or #7 or #8 or #9 or #10  
#12 #4 and #11 in Trials (Word variations have been searched) 
11 Hits 
3. Oesophageal Surgery 
 
3.1. Robotic Fundoplication (Anti-reflux surgery) 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to July Week 3 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<July 31, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <July 31, 2018>, Ovid MEDLINE(R) Daily 
Update <July 31, 2018>). Date of search: 01.08.2018 
1     exp Robotic Surgical Procedures/ (4119) 
2     robot*-assisted*.mp. (10146) 
3     (robot* adj5 (surger* or surgical*)).mp. (12496) 
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4     1 or 2 or 3 (17130) 
5     exp Gastroesophageal Reflux/ (25014) 
6     gastro?esophageal reflux.mp. (30221) 
7     gastro-?esophageal reflux.mp. (1488) 
8     GER.mp. (3281) 
9     GERD.mp. (7602) 
10     GORD.mp. (791) 
11     5 or 6 or 7 or 8 or 9 or 10 (33322) 
12     surgery.fs. (1840672) 
13     (plication* or fundic wrap*).mp. (3415) 
14     12 or 13 (1841448) 
15     11 and 14 (8318) 
16     ((anti?reflux or reflux) adj3 (surg* or management)).mp. (3983) 
17     exp Gastroesophageal Reflux/su [Surgery] (5022) 
18     15 or 16 or 17 (10463) 
19     exp FUNDOPLICATION/ (4170) 
20     fundoplication*.mp. (6573) 
21     18 or 19 or 20 (12997) 
22     4 and 21 (187) 
23     limit 22 to clinical trial, all (18) 
24   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3687346) 
25     22 and 24 (46) 
26     23 or 25 (55) 
27     remove duplicates from 26 (55) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 02.08.2018 
 
No.  Query                                                  Results          
#29. #24 OR #26 OR #28                                           67    
#28. #23 AND #27                                                 53    
#27. 'crossover procedure':de OR 'double-blind            2,266,299    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#26. #25 AND ('clinical trial'/de OR 'controlled                 42    
     clinical trial'/de OR 'randomized controlled  
     trial'/de OR 'randomized controlled trial  
     (topic)'/de) 
#25. #23                                                        370    
#24. #4 AND #22 AND ([controlled clinical trial]/lim             14    
     OR [randomized controlled trial]/lim) 
#23. #4 AND #22                                                 370    
#22. #5 OR #6 OR #19 OR #20 OR #21                           22,366    
#21. fundoplication:ti,ab,de                                 10,812    
#20. 'stomach fundoplication'/exp                             9,762    
#19. #15 AND #18                                             13,359    
#18. #16 OR #17                                              18,421    
#17. plication* OR 'fundic wrap*'                             5,390    
#16. #15 AND 'surgery'/lnk                                   13,214    
#15. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14       64,050    
#14. gord:ab,ti                                               1,308    
#13. gerd:ab,ti                                              14,624    
#12. ger:ab,ti                                                3,630    
#11. 'gastro-oesophageal reflux':ab,ti,de                     5,035    
#10. 'gastro-esophageal reflux':ab,ti,de                      2,793    
#9.  'gastrooesophageal reflux':ab,ti,de                        545    
#8.  'gastroesophageal reflux':ab,ti,de                      52,805    
#7.  'gastroesophageal reflux'/exp                           57,419    
#6.  ((antireflux OR 'anti reflux' OR reflux) NEAR/2          5,183    
     (surg* OR management)):ti,ab,de 
#5.  'antireflux operation'/exp                              11,662    
#4.  #1 OR #2 OR #3                                          26,978    
#3.  robot* NEAR/5 surg*                                     26,978    
#2.  'robotic surgical procedure'/exp                         2,091    
#1.  'robot assisted surgery'/exp                                     6,220 
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 02.08.2018 
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ID Search  
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot*-assisted*  (Word variations have been searched) 
#3 robot* near surg*  (Word variations have been searched) 
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Gastroesophageal Reflux] explode all trees and with qualifier(s): [Surgery – SU] 
#6 gastro*esophageal reflux  (Word variations have been searched) 
#7 GER:ti,ab,kw  (Word variations have been searched) 
#8 GERD:ti,ab,kw  (Word variations have been searched) 
#9 GORD:ti,ab,kw  (Word variations have been searched) 
#10 #6 or #7 or #8 or #9  
#11 MeSH descriptor: [General Surgery] explode all trees 
#12 surg* or operat*  (Word variations have been searched) 
#13 #11 or #12  
#14 #10 and #13  
#15 (anti*reflux or reflux) near (surg* or operat* or management)  (Word variations have been searched) 
#16 MeSH descriptor: [Fundoplication] explode all trees 
#17 fundoplication*  (Word variations have been searched) 
#18 plication* or fundic wrap*  (Word variations have been searched) 
#19 #5 or #14 or #15 or #16 or #17 or #18  
#20 #4 and #19 in Trials (Word variations have been searched) 
 
24 Hits 
 
 
3.2. Robotic Oesophagectomy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to July Week 4 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 07, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 07, 2018>, Ovid MEDLINE(R) 
Daily Update <August 07, 2018>). Date of search: 08.08.2018 
 
1     exp Robotic Surgical Procedures/ (4178) 
2     robot*-assisted*.mp. (10167) 
3     (robot* adj5 (surger* or surgical*)).mp. (12570) 
4     1 or 2 or 3 (17192) 
5     exp Esophagectomy/ (8641) 
6     Oesophagectom*.mp. (1464) 
7     Esophagectom*.mp. (11939) 
8     (Trans?hiat* adj3 (Oesophagectom* or Esophagectom*)).mp. (725) 
9     ((oesophag* or esophag*) adj3 (remov* or excis* or resect*)).mp. (5787) 
10     5 or 6 or 7 or 8 or 9 (15424) 
11     4 and 10 (188) 
12     limit 11 to clinical trial, all (10) 
13   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3690476) 
14     11 and 13 (39) 
15     12 or 14 (45) 
16     remove duplicates from 15 (45) 
 
Search strategy for Embase (via Elsevier). Date of search: 08.08.2018 
 
No.  Query                                                  Results          
#16. #12 OR #13 OR #15                                           45    
#15. #11 AND #14                                                 33    
#14. 'crossover procedure':de OR 'double-blind            2,268,330    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#13. #11 AND ('clinical trial'/de OR 'clinical trial             31    
     (topic)'/de OR 'randomized controlled trial'/de  
     OR 'randomized controlled trial (topic)'/de) 
#12. #4 AND #10 AND ([controlled clinical trial]/lim              9    
     OR [randomized controlled trial]/lim) 
#11. #4 AND #10                                                 297    
#10. #5 OR #6 OR #7 OR #8 OR #9                              24,210    
#9.  ((oesophag* OR esophag*) NEAR/2 (remov* OR excis*       22,584    
     OR resect*)):ti,ab,de 
#8.  ((transhiat* OR 'trans hiat*') NEAR/2                      989    
     (oesophagectom* OR esophagectom*)):ti,ab,de 
#7.  esophagectom*:ab,ti,de                                  12,057    
#6.  oesophagectom*:ab,ti,de                                  2,077    
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#5.  'esophagus resection'/exp                               18,631    
#4.  #1 OR #2 OR #3                                          27,005    
#3.  robot* NEAR/5 surg*                                     27,005    
#2.  'robotic surgical procedure'/exp                         2,091    
#1.  'robot assisted surgery'/exp                             6,236      
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 08.08.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot* NEAR assisted* 
#3 robot* NEAR surg* 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Esophagectomy] explode all trees 
#6 Oesophagectom* 
#7 Esophagectom* 
#8 (Transhiat* OR Trans-hiat*) NEAR (Oesophagectom* OR Esophagectom*) 
#9 (oesophag* OR esophag*) NEAR (remov* OR excis* OR resect*) 
#10 #5 OR #6 OR #7 OR #8 OR #9 
#11 #4 AND #10 in Trials 
 
13 Hits 
 
 
3.3. Heller Myotomy (Robotic oesophageal repair) 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 2 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 21, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 21, 2018>, Ovid MEDLINE(R) 
Daily Update <August 21, 2018>). Date of search: 22.08.2018 
 
1     exp Robotic Surgical Procedures/ (4274) 
2     robot*-assisted*.mp. (10223) 
3     (robot* adj5 (surger* or surgical*)).mp. (12657) 
4     1 or 2 or 3 (17300) 
5     exp Esophageal Perforation/ (4092) 
6     ((oesophag* or esophag* or Heller*) adj3 (repair* or perforat* or myotom*)).mp. (7221) 
7     exp Heller Myotomy/ (37) 
8     LHM.ti,ab. (268) 
9     exp Esophageal Achalasia/ (6437) 
10     achalasia*.mp. (7954) 
11     ((oesophag* or esophag*) adj3 (swallow* adj3 (disorder* or difficult* or problem* or impair*))).mp. (64) 
12     ((oesophag* or esophag*) adj3 dysphagia*).mp. (1267) 
13     5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (15841) 
14     4 and 13 (83) 
15     limit 14 to clinical trial, all (9) 
16   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3702283) 
17     14 and 16 (21) 
18     15 or 17 (28) 
19     remove duplicates from 18 (28) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 22.08.2018 
 
#21. #17 OR #18 OR #20                                           21   
#20. #16 AND #19                                                 16   
#19. 'crossover procedure':de OR 'double-blind            2,273,818   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#18. #16 AND ('clinical trial'/de OR 'randomized                 12   
     controlled trial (topic)'/de) 
#17. #4 AND #15 AND ([controlled clinical trial]/lim              4   
     OR [randomized controlled trial]/lim) 
#16. #4 AND #15                                                 193   
#15. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #13 OR #14         30,237   
#14. ((oesophag* OR esophag*) NEAR/2                         11,166   
     dysphagia*):de,ab,ti 
#13. #11 AND #12                                              1,448   
#12. oesophag*:de,ab,ti OR esophag*:de,ab,ti                284,072   
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#11. (swallow* NEAR/2 (disorder* OR difficult* OR             7,781   
     problem* OR impair)):ti,ab,de 
#10. achalasia*:ti,ab,de                                     11,603   
#9.  'esophagus achalasia'/exp                               10,777   
#8.  lhm:ti,ab                                                  397   
#7.  'cardioesophagomyotomy'/exp                              1,628   
#6.  'esophagus perforation'/exp                              6,612   
#5.  ((oesophag* OR esophag* OR heller*) NEAR/2              11,545   
     (repair* OR perforat* OR myotom*)):ti,ab,de 
#4.  #1 OR #2 OR #3                                          27,092   
#3.  robot* NEAR/5 surg*                                     27,092   
#2.  'robotic surgical procedure'/exp                         2,115   
#1.  'robot assisted surgery'/exp                             6,281    
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 22.08.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot* NEAR assisted* 
#3 robot* NEAR surg* 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Esophageal Perforation] explode all trees 
#6 (oesophag* OR esophag* OR Heller*) NEAR (repair* OR perforat* OR myotom*) (Word variations have been 
searched) 
#7 MeSH descriptor: [Heller Myotomy] explode all trees 
#8 (LHM):ti,ab,kw (Word variations have been searched) 
#9 MeSH descriptor: [Esophageal Achalasia] explode all trees 
#10 (achalasia*) 
#11 ((oesophag* OR esophag*) NEAR (swallow* NEAR (disorder* OR difficult* OR problem* OR impair*))) 
#12 ((oesophag* OR esophag*) NEAR dysphagia*) 
#13 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
#14 #4 AND #13 in Trials 
 
2 Hits 
 
 
4. Stomach Surgery 
 
4.1. Robotic Gastrectomy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 3 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 23, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 23, 2018>, Ovid MEDLINE(R) 
Daily Update <August 23, 2018>. Date of search: 24.08.2018 
 
1     exp Robotic Surgical Procedures/ (4282) 
2     robot*-assisted*.mp. (10237) 
3     (robot* adj5 (surger* or surgical*)).mp. (12668) 
4     1 or 2 or 3 (17316) 
5     exp Gastrectomy/ (32564) 
6     Gastrectom*.mp. (41938) 
7     Pylorectom*.mp. (71) 
8     ((stomach or pylor*) adj3 (remov* or excis* or resect*)).mp. (3395) 
9     5 or 6 or 7 or 8 (43701) 
10     4 and 9 (314) 
11     limit 10 to clinical trial, all (19) 
12   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3702513) 
13     10 and 12 (113) 
14     11 or 13 (122) 
15     remove duplicates from 14 (120) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 24.08.2018 
 
No.  Query                                                 Results          
#15. #11 OR #13 OR #14                                          198   
#14. #10 AND ([controlled clinical trial]/lim OR                 30   
     [randomized controlled trial]/lim) 
#13. #10 AND #12                                                156   
#12. 'crossover procedure':de OR 'double-blind            2,274,392   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
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     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#11. #10 AND ('clinical trial'/de OR 'clinical trial            122   
     (topic)'/de OR 'controlled clinical trial'/de OR  
     'randomized controlled trial'/de OR 'randomized  
     controlled trial (topic)'/de) 
#10. #4 AND #9                                                1,092   
#9.  #5 OR #6 OR #7 OR #8                                    97,081   
#8.  ((stomach* OR pylor*) NEAR/5 (surg* OR resect* OR       52,698   
     excis* OR remov*)):ti,ab,de 
#7.  pylorectom*:ab,ti,de                                        62   
#6.  gastrectom*:ab,ti,de                                    59,831   
#5.  'gastrectomy'/exp                                       55,460   
#4.  #1 OR #2 OR #3                                          27,104   
#3.  robot* NEAR/5 surg*                                     27,104   
#2.  'robotic surgical procedure'/exp                         2,117   
#1.  'robot assisted surgery'/exp                             6,287   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 28.08.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot* NEAR assisted* 
#3 robot* NEAR surg* 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Gastrectomy] explode all trees 
#6 (Gastrectom*) 
#7 (Pylorectom*) 
#8 (stomach OR pylor*) NEAR (remov* OR excis* OR resect*) 
#9 #5 OR #6 OR #7 OR #8 
#10 #4 AND #9 in Trials 
 
36 Hits 
 
 
4.2. Robotic Bariatric Surgery 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 4 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 29, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 29, 2018>, Ovid MEDLINE(R) 
Daily Update <August 29, 2018>. Date of search: 30.08.2018 
 
1     exp Robotic Surgical Procedures/ (4316) 
2     robot*-assisted*.mp. (10256) 
3     (robot* adj5 (surger* or surgical*)).mp. (12704) 
4     1 or 2 or 3 (17343) 
5     exp Bariatric Surgery/ (21860) 
6     bariatric*.mp. (17322) 
7     (Gastric adj3 (bypass* or band* or stimul*)).mp. (18304) 
8     Roux*.mp. (12538) 
9     RYGB.ti,ab. (2197) 
10     (sleeve* adj3 gastrectom*).mp. (4077) 
11     5 or 6 or 7 or 8 or 9 or 10 (40294) 
12     4 and 11 (258) 
13     limit 12 to clinical trial, all (9) 
14   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3704848) 
15     12 and 14 (62) 
16     13 or 15 (67) 
17     remove duplicates from 16 (67) 
 
Search strategy for Embase (via Elsevier). Date of search: 30.08.2018 
 
No.  Query                                                  Results          
#19. #15 OR #16 OR #18                                           72   
#18. #14 AND #17                                                 54   
#17. 'crossover procedure':de OR 'double-blind            2,276,938   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
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#16. #14 AND ('clinical trial'/de OR 'clinical trial             47   
     (topic)'/de OR 'controlled clinical trial'/de OR  
     'randomized controlled trial'/de OR 'randomized  
     controlled trial (topic)'/de) 
#15. #4 AND #13 AND ([controlled clinical trial]/lim             16   
     OR [randomized controlled trial]/lim) 
#14. #4 AND #13                                                 616   
#13. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12         61,691   
#12. (sleeve* NEAR/2 gastrectom*):ti,ab,de                   11,248   
#11. 'sleeve gastrectomy'/exp                                10,141   
#10. rygb:ti,ab                                               4,976   
#9.  roux*:ti,ab,de                                          22,907   
#8.  'gastric bypass surgery'/exp                            19,963   
#7.  (gastric NEAR/2 (bypass* OR band* OR                    31,140   
     stimul*)):ti,ab,de 
#6.  bariatric*:ti,ab,de                                     33,770   
#5.  'bariatric surgery'/exp                                 35,121   
#4.  #1 OR #2 OR #3                                          27,132   
#3.  robot* NEAR/5 surg*                                     27,132   
#2.  'robotic surgical procedure'/exp                         2,121   
#1.  'robot assisted surgery'/exp                             6,308   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 30.08.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 robot* NEAR assisted* 
#3 robot* NEAR surg* 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Bariatric Surgery] explode all trees 
#6 (bariatric*) (Word variations have been searched) 
#7 (Gastric*) NEAR (bypass* OR band* OR stimul*) (Word variations have been searched) 
#8 (Roux*) (Word variations have been searched) 
#9 (RYGB):ti,ab,kw 
#10 (sleeve* NEAR gastrect*) (Word variations have been searched) 
#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10 
#12 #4 AND #11 in Trials 
 
21 Hits 
 
 
5. Stomach Surgery 
 
5.1. Robotic Small Bowel Resection 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 4 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 30, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 30, 2018>, Ovid MEDLINE(R) 
Daily Update <August 30, 2018>). Date of search: 31.08.2018 
 
1     exp Robotic Surgical Procedures/ (4320) 
2     robot*-assisted*.mp. (10262) 
3     (robot* adj5 (surger* or surgical*)).mp. (12711) 
4     1 or 2 or 3 (17354) 
5     exp Intestine, Small/ (156220) 
6     ((small bowel* or small intestine*) adj3 (remov* or excis* or resect*)).mp. (3762) 
7     5 or 6 (157794) 
8     4 and 7 (135) 
9     limit 8 to clinical trial, all (3) 
10  ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3705798) 
11     8 and 10 (11) 
12     9 or 11 (13) 
 
Search strategy for Embase (via Elsevier). Date of search: 03.09.2018 
 
No.  Query                                                  Results          
#13. #9 OR #10 OR #12                                            53    
#12. #8 AND #11                                                  48    
#11. 'crossover procedure':de OR 'double-blind            2,278,078    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
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     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#10. #8 AND ('clinical trial (topic)'/de OR                      16    
     'randomized controlled trial (topic)'/de) 
#9.  #8 AND ([controlled clinical trial]/lim OR                   5    
     [randomized controlled trial]/lim) 
#8.  #4 AND #7                                                  307    
#7.  #5 OR #6                                                28,403    
#6.  (('small bowel*' OR 'small intestine*') NEAR/5           9,044    
     (remov* OR excis* OR resect*)):ti,ab,de 
#5.  'small intestine resection'/exp                         22,983    
#4.  #1 OR #2 OR #3                                          27,157    
#3.  robot* NEAR/5 surg*                                     27,157    
#2.  'robotic surgical procedure'/exp                         2,126    
#1.  'robot assisted surgery'/exp                             6,326 
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 03.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Intestine, Small] explode all trees 
#6 (small bowel* OR small intestine*) NEAR (remov* OR excis* OR resect*) (Word variations have been searched) 
#7 #5 OR #6 
#8 #4 AND #7 in Trials 
 
7 Hits 
 
 
5.2. Robotic Colectomy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 4 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<August 31, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <August 31, 2018>, Ovid MEDLINE(R) 
Daily Update <August 31, 2018>). Date of search: 04.09.2018 
 
1     exp Robotic Surgical Procedures/ (4324) 
2     robot*-assisted*.mp. (10264) 
3     (robot* adj5 (surger* or surgical*)).mp. (12718) 
4     1 or 2 or 3 (17362) 
5     exp Colectomy/ (18986) 
6     colectom*.mp. (21602) 
7     procto?colectom*.mp. (4501) 
8     hemi?colectom*.mp. (3636) 
9     sigmoidectom*.mp. (923) 
10     transversectom*.mp. (25) 
11     ((colon* or hemi*colon* or sigmoid*) adj3 (remov* or excis* or resect*)).mp. (8878) 
12     5 or 6 or 7 or 8 or 9 or 10 or 11 (33558) 
13     4 and 12 (341) 
14     limit 13 to clinical trial, all (20) 
15   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3706833) 
16     13 and 15 (101) 
17     14 or 16 (113) 
18     remove duplicates from 17 (113) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 04.09.2018 
 
No.  Query                                                  Results          
#19. #15 OR #16 OR #18                                          112    
#18. #14 AND #17                                                 91    
#17. 'crossover procedure':de OR 'double-blind            2,278,584    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#16. #14 AND ('clinical trial'/de OR 'randomized                 57    
     controlled trial (topic)'/de) 
#15. #4 AND #13 AND ([controlled clinical trial]/lim             19    
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     OR [randomized controlled trial]/lim) 
#14. #4 AND #13                                                 755    
#13. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12         60,627    
#12. ((colon* OR hemi*colon* OR sigmoid*) NEAR/5             45,392    
     (remov* OR excis* OR resect*)):ti,ab,de 
#11. transversectom*:ti,ab,de                                    40    
#10. sigmoidectom*:ti,ab,de                                   3,519    
#9.  hemi*colectom*:ti,ab,de                                  9,415    
#8.  procto*colectom*:ti,ab,de                                6,440    
#7.  'proctocolectomy'/exp                                    5,454    
#6.  colectom*:ti,ab,de                                      17,766    
#5.  'colon resection'/exp                                   38,801    
#4.  #1 OR #2 OR #3                                          27,173    
#3.  robot* NEAR/5 surg*                                     27,173    
#2.  'robotic surgical procedure'/exp                         2,134    
#1.  'robot assisted surgery'/exp                             6,335   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 04.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Colectomy] explode all trees 
#6 colectom* (Word variations have been searched) 
#7 procto*colectom* (Word variations have been searched) 
#8 hemi*colectom* (Word variations have been searched) 
#9 sigmoidectom* (Word variations have been searched) 
#10 transversectom* (Word variations have been searched) 
#11 (colon* OR hemi*colon* OR sigmoid*) NEAR (remov* OR excis* OR resect*) (Word variations have been 
searched) 
#12 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
#13 #4 AND #12 in Trials 
 
31 Hits 
 
 
5.3. Robotic Rectal Resection 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 5 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<September 06, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <September 06, 2018>, Ovid MED-
LINE(R) Daily Update <September 06, 2018>). Date of search: 07.09.2018 
 
1     exp Robotic Surgical Procedures/ (4345) 
2     robot*-assisted*.mp. (10297) 
3     (robot* adj5 (surger* or surgical*)).mp. (12761) 
4     1 or 2 or 3 (17417) 
5     polypectom*.mp. (4528) 
6     proctectom*.mp. (1131) 
7     rectopex*.mp. (805) 
8    ((rect* or colo?rect* or meso?rect* or polyp* or sphincter*) adj3 (remov* or excis* or resect*)).mp. (21331) 
9     colo?rectom*.mp. (20) 
10     rectom*.mp. (43) 
11     5 or 6 or 7 or 8 or 9 or 10 (26117) 
12     4 and 11 (498) 
13     limit 12 to clinical trial, all (37) 
14   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3709558) 
15     12 and 14 (169) 
16     13 or 15 (187) 
17     remove duplicates from 16 (186) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 07.09.2018 
 
No.  Query                                                 Results          
#21. #17 OR #18 OR #20                                          214    
#20. #16 AND #19                                                178    
#19. 'crossover procedure':de OR 'double-blind            2,280,161    
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
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     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#18. #16 AND ('clinical trial'/de OR 'controlled                127    
     clinical trial'/de OR 'randomized controlled  
     trial'/de OR 'randomized controlled trial  
     (topic)'/de) 
#17. #4 AND #15 AND ([controlled clinical trial]/lim             54    
     OR [randomized controlled trial]/lim) 
#16. #4 AND #15                                               1,309    
#15. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12         65,349    
     OR #13 OR #14 
#14. ((rect* OR colo*rect* OR meso*rect* OR polyp* OR        55,886    
     sphincter*) NEAR/5 (remov* OR excis* OR  
     resect*)):ti,ab,de 
#13. 'mesorectal excision'/exp                                   46    
#12. rectopex*:ti,ab,de                                       1,367    
#11. 'proctopexy'/exp                                         1,348    
#10. proctectom*:ti,ab,de                                     1,796    
#9.  'rectum resection'/exp                                  14,722    
#8.  polypectom*:ti,ab,de                                    12,108    
#7.  'polypectomy'/exp                                        7,815    
#6.  rectom*:ti,ab,de                                            74    
#5.  colo*rectom*:ti,ab,de                                       46    
#4.  #1 OR #2 OR #3                                          27,214    
#3.  robot* NEAR/5 surg*                                     27,214    
#2.  'robotic surgical procedure'/exp                         2,141    
#1.  'robot assisted surgery'/exp                             6,354   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 07.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 colo*rectom* (Word variations have been searched) 
#6 rectom* (Word variations have been searched) 
#7 polypectom* (Word variations have been searched) 
#8 proctectom* (Word variations have been searched) 
#9 rectopex* (Word variations have been searched) 
#10 (rect* OR colo*rect* OR meso*rect* OR polyp* OR sphincter*) NEAR (remov* OR excis* OR resect*) 
#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10 
#12 #4 AND #11 in Trials 
 
73 Hits 
 
 
6. Gallbladder, Liver and Spleen Surgery 
 
6.1. Robotic Cholecystectomy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to August Week 5 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<September 10, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <September 10, 2018>, Ovid MED-
LINE(R) Daily Update <September 10, 2018>). Date of search: 11.09.2018 
 
1     exp Robotic Surgical Procedures/ (4354) 
2     robot*-assisted*.mp. (10309) 
3     (robot* adj5 (surger* or surgical*)).mp. (12776) 
4     1 or 2 or 3 (17436) 
5     ((gallbladder* or gall bladder*) adj3 (remov* or excis* or resect*)).mp. (1641) 
6     exp Cholecystectomy/ (27234) 
7     cholecystectom*.mp. (36376) 
8     5 or 6 or 7 (36960) 
9     4 and 8 (329) 
10     limit 9 to clinical trial, all (25) 
11   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3711921) 
12     9 and 11 (71) 
13     10 or 12 (81) 
14     remove duplicates from 13 (81) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 11.09.2018 
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No.  Query                                                  Results          
#14. #10 OR #11 OR #13                                           90   
#13. #9 AND #12                                                  75   
#12. 'crossover procedure':de OR 'double-blind            2,280,988   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#11. #9 AND ('clinical trial'/de OR 'controlled                  58   
     clinical trial'/de OR 'randomized controlled  
     trial'/de OR 'randomized controlled trial  
     (topic)'/de) 
#10. #4 AND #8 AND ([controlled clinical trial]/lim OR           29   
     [randomized controlled trial]/lim) 
#9.  #4 AND #8                                                  716   
#8.  #5 OR #6 OR #7                                          54,211   
#7.  ((gallbladder* OR 'gall bladder*') NEAR/5 (remov*        3,007   
     OR excis* OR resect*)):ti,ab,de 
#6.  cholecystectom*:ti,ab,de                                53,072   
#5.  'cholecystectomy'/exp                                   47,382   
#4.  #1 OR #2 OR #3                                          27,238   
#3.  robot* NEAR/5 surg*                                     27,238   
#2.  'robotic surgical procedure'/exp                         2,146   
#1.  'robot assisted surgery'/exp                             6,366   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 11.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Cholecystectomy] explode all trees 
#6 Cholecystectom* (Word variations have been searched) 
#7 (gallbladder* OR gall bladder*) NEAR (remov* OR excis* OR resect*) (Word variations have been searched) 
#8 #5 OR #6 OR #7 
#9 #4 AND #8 in Trials 
 
51 Hits 
 
 
6.2. Robotic Herniorrhaphy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to September Week 1 2018>, Ovid MEDLINE(R) Epub Ahead of 
Print <September 13, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <September 13, 2018>, Ovid 
MEDLINE(R) Daily Update <September 13, 2018>). Date of search: 14.09.2018 
 
1     exp Robotic Surgical Procedures/ (4350) 
2     robot*-assisted*.mp. (10290) 
3     (robot* adj5 (surger* or surgical*)).mp. (12747) 
4     1 or 2 or 3 (17399) 
5     exp Herniorrhaphy/ (7050) 
6     herniorrhaph*.mp. (8906) 
7     hernioplast*.mp. (1561) 
8     (hernia* adj3 repair*).mp. (12237) 
9     5 or 6 or 7 or 8 (18213) 
10     4 and 9 (184) 
11     limit 10 to clinical trial, all (4) 
12   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3709223) 
13     10 and 12 (45) 
14     11 or 13 (47) 
15     remove duplicates from 14 (47) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 14.09.2018 
 
No.  Query                                                  Results          
#16. #12 OR #13 OR #15                                           34   
#15. #11 AND #14                                                 23   
#14. 'crossover procedure':de OR 'double-blind            2,283,132   
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     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#13. #11 AND ('clinical trial'/de OR 'controlled                 18   
     clinical trial'/de OR 'randomized controlled  
     trial'/de) 
#12. #11 AND ([controlled clinical trial]/lim OR                 14   
     [randomized controlled trial]/lim) 
#11. #4 AND #10                                                 423   
#10. #5 OR #6 OR #7 OR #8 OR #9                              27,239   
#9.  (hernia* NEAR/5 repair*):ti,ab,de                       19,833   
#8.  herniorrhaph*:ti,ab,de                                   5,516   
#7.  'herniorrhaphy'/exp                                      4,521   
#6.  hernioplast*:ti,ab,de                                   15,087   
#5.  'hernioplasty'/exp                                      14,351   
#4.  #1 OR #2 OR #3                                          27,289   
#3.  robot* NEAR/5 surg*                                     27,289   
#2.  'robotic surgical procedure'/exp                         2,154   
#1.  'robot assisted surgery'/exp                             6,393   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 14.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 MeSH descriptor: [Herniorrhaphy] explode all trees 
#6 Herniorrhaph* (Word variations have been searched) 
#7 Hernioplast* (Word variations have been searched) 
#8 hernia* NEAR repair* (Word variations have been searched) 
#9 #5 OR #6 OR #7 OR #8 
#10 #4 AND #9 in Trials 
 
22 Hits 
 
 
6.3. Robotic Hepatectomy 
 
Search strategy for Medline (Ovid MEDLINE(R) <1946 to September Week 1 2018>, Ovid MEDLINE(R) Epub Ahead of 
Print <September 12, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <September 12, 2018>, Ovid 
MEDLINE(R) Daily Update <September 12, 2018>). Date of search: 13.09.2018 
 
1     exp Robotic Surgical Procedures/ (4343) 
2     robot*-assisted*.mp. (10281) 
3     (robot* adj5 (surger* or surgical*)).mp. (12734) 
4     1 or 2 or 3 (17381) 
5     ((liver* or hepat*) adj3 (remov* or excis* or resect*)).mp. (24484) 
6     exp Hepatectomy/ (27346) 
7     Hepatectom*.mp. (34628) 
8     5 or 6 or 7 (46729) 
9     4 and 8 (230) 
10     limit 9 to clinical trial, all (9) 
11   ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug therapy.fs. or 
randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3708257) 
12     9 and 11 (43) 
13     10 or 12 (48) 
14     remove duplicates from 13 (48) 
 
 
Search strategy for Embase (via Elsevier). Date of search: 13.09.2018 
 
No.  Query                                                  Results          
#14. #10 OR #11 OR #13                                           46   
#13. #9 AND #12                                                  33   
#12. 'crossover procedure':de OR 'double-blind            2,282,498   
     procedure':de OR 'randomized controlled trial':de  
     OR 'single-blind procedure':de OR  
     random*:de,ab,ti OR factorial*:de,ab,ti OR  
     crossover*:de,ab,ti OR ((cross NEXT/1  
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     over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl*  
     NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1  
     blind*):de,ab,ti) OR assign*:de,ab,ti OR  
     allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#11. #9 AND ('clinical trial'/de OR 'clinical trial              23   
     (topic)'/de OR 'randomized controlled trial  
     (topic)'/de) 
#10. #9 AND ([controlled clinical trial]/lim OR                   6   
     [randomized controlled trial]/lim) 
#9.  #4 AND #8                                                  424   
#8.  #5 OR #6 OR #7                                          74,835   
#7.  hepatectom*:ti,ab,de                                    28,837   
#6.  'liver resection'/exp                                   51,090   
#5.  ((liver* OR hepat*) NEAR/5 (remov* OR excis* OR         65,195   
     resect*)):ti,ab,de 
#4.  #1 OR #2 OR #3                                          27,285   
#3.  robot* NEAR/5 surg*                                     27,285   
#2.  'robotic surgical procedure'/exp                         2,154   
#1.  'robot assisted surgery'/exp                             6,388   
 
 
Search strategy for Cochrane (CENTRAL). Date of search: 13.09.2018 
 
ID Search 
#1 MeSH descriptor: [Robotic Surgical Procedures] explode all trees 
#2 (robot* NEAR assist*) (Word variations have been searched) 
#3 (robot* NEAR surg*) (Word variations have been searched) 
#4 #1 OR #2 OR #3 
#5 (liver* OR hepat*) NEAR (remov* OR excis* OR resect*) (Word variations have been searched) 
#6 MeSH descriptor: [Hepatectomy] explode all trees 
#7 Hepatectom* (Word variations have been searched) 
#8 #5 OR #6 OR #7 
#9 #4 AND #8 in Trials 
 
11 Hits 
 
 
Search strategies for the identification of ongoing clinical trials (trial register search) 
 
1. Robotic (Pulmonary) Lobectomy 
Date of search: 28.06.2018 
 
ClinicalTrials.gov (Advanced Search Mode) 
( robotic OR robot ) AND ( pulmonary segmentectomy OR pulmonary lobectomy OR lung segmentectomy OR lung lobec-
tomy OR lung excision OR lung resection OR pulmonary resection OR pulmonary excision ) [DISEASE] 
10 Hits 
 
WHO ICTRP (Advanced Search Mode) 
robot* in the Title 
segmentectomy OR lobectomy OR pulmonary segmentectomy OR pulmonary lobectomy OR lung segmentectomy OR 
lung lobectomy OR lung excision OR lung resection OR pulmonary resection OR pulmonary excision in the Intervention 
5 (3 additional) Hits 
 
EU-CTR 
robot* AND (segmentectomy OR lobectomy OR pulmonary OR lung) 
No studies identified 
 
 
2.  Robotic Mediastinal Surgery (incl. Thymectomy): 
      Date of search: 04.07.2018 
 
ClinicalTrials.gov  
No studies identified 
 
WHO ICTRP (Advanced Search Mode) 
robot* in the Title 
thymus OR thymectomy OR mediastinal OR mediastinum in the Intervention 
12 Hits 
 
EudraCT (Basic Search Mode) 
robot* AND (segmentectomy OR lobectomy OR pulmonary OR lung) 
No studies identified 
 
 
3.  Oesophageal Surgery 
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3.1. Robotic Fundoplication (Anti-reflux surgery): 
        Date of search: 03.08.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot* ) AND ( Antireflux OR Anti-reflux OR reflux OR Fundoplication ) 
3 Studies identified  
 
WHO ICTRP (Advanced Search Mode) 
robot* in the Title 
(Antireflux OR Anti-reflux OR Fundoplication) in the Intervention 
2 further studies identified 
 
EudraCT (Basic Search Mode) 
robot* AND (Antireflux OR Anti-reflux OR reflux OR Fundoplication) 
No studies identified 
 
 
3.2. Robotic Oesophagectomy 
        Date of search: 10.08.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot* ) AND ( Esophagectomy OR Oesophagectomy OR ( remov* OR excis* OR resect* ) AND ( Esoph-
agectomy OR Oesophagectomy ) ) [TREATMENT]  
5 Studies identified  
 
WHO ICTRP (Basic Search Mode) 
robot* AND Esophagectomy 
18 (15 further) studies identified 
 
EudraCT (Basic Search Mode) 
robot* AND (Esophagectom* OR Oesophagectom*) 
No studies identified 
 
 
3.3. Heller Myotomy (Robotic oesophageal repair) 
        Date of search: 28.08.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot* ) AND (Myotom* OR Heller* OR Achalasia* OR oesophageal repair* OR esophageal repair*) ) 
[TREATMENT]  
No Studies identified  
 
WHO ICTRP (Basic Search Mode) 
robot* AND Myotom*     No results 
robot* AND Heller*          No results 
robot* AND (o)esophageal repair*  No results  
robot* AND Achalasia*       1 Study identified 
 
EudraCT (Basic Search Mode) 
(robotic OR robot*) AND (Myotom* OR Heller* OR Achalasia* OR oesophageal repair* OR esophageal repair*) 
No studies identified 
 
 
4.  Stomach Surgery 
 
4.1. Robotic Gastrectomy: 
 
ClinicalTrials.gov (Expert Search Mode, Date of search: 28.08.2018) 
( robotic OR robot ) AND gastrectomy [DISEASE] 
24 Studies identified  
 
WHO ICTRP (Basic Search Mode, Date of search: 30.08.2018) 
robot* AND gastrectom* 
47 (29 additional) studies identified 
 
EudraCT (Basic Search Mode, Date of search: 30.08.2018) 
robot* AND gastrectom*   No studies identified 
robot AND gastrectom*   No studies identified 
robot* AND gastrectomy   No studies identified 
robot AND gastrectomy   No studies identified 
robotic AND gastrectom*  No studies identified 
robotic AND gastrectomy  No studies identified 
robotic gastrectom*   No studies identified 
robotic gastrectomy   No studies identified 
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4.2. Robotic Bariatric Surgery 
        Date of search: 31.08.2018 
 
ClinicalTrials.gov. (Expert Search): 
( robotic OR robot ) AND ( bariatric OR roux OR gastric bypass OR gastric stimul* OR gastric band* OR sleeve gastrec-
tom* ) [TREATMENT] 
8 Studies identified 
 
WHO-ICTRP (Basic Search Mode): 
robot* AND bariatric    3 studies identified 
robot* AND roux*   No studies identified 
robot* AND gastric bypass  3 studies identified 
 
robot* AND sleeve*   1 study identified 
 
3 (1 additional) studies identified 
 
EU Clinical Trials (Basic Search Mode): 
robot* AND bariatric    No relevant studies identified 
robot* AND roux*   No relevant studies identified 
robot* AND gastric bypass  No relevant studies identified 
robot* AND stomach bypass  No relevant studies identified 
robot* AND sleeve*   No relevant studies identified 
robot* AND gastric   No relevant studies identified 
 
 
5.  Bowel Surgery 
 
5.1. Robotic Small Bowel Resection 
         Date of search: 03.09.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( small bowel OR small intestine ) [TREATMENT] 
2 Studies identified  
WHO ICTRP (Basic Search Mode) 
robot* AND small bowel 
2 further (potentially relevant) studies identified 
EudraCT (Basic Search Mode) 
robot* AND ("small intestine" OR "small bowel") 
No studies identified 
5.2. Robotic Colectomy 
        Date of search: 06.09.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( colectomy ) [TREATMENT] 
21 Studies identified  
WHO ICTRP (Basic Search Mode) 
robot* AND colectom* 
16 (9 further) studies identified 
EudraCT (Basic Search Mode) 
robot* AND colectom* 
1 additional study identified 
5.3. Robotic Rectal Resection 
        Date of search: 10./11.09.2018 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( colorectal OR rectal OR mesorectal OR polypectomy OR proctectomy OR rectopexy OR rec-
tomy OR colorectomy OR mesorectomy OR sphincter OR polyp ) [TREATMENT]  
45 Studies identified  
WHO ICTRP (Basic Search Mode) 
robot* AND colorect*     28 Studies identified 
robot* AND colo-rectal      2 Studies identified 
robot* AND rectal    37 Studies identified 
 
 67 (38 further) studies identified 
 
EudraCT (Basic Search Mode) 
robot* AND (colorectal OR color-ectal OR rectal OR mesorectal OR meso-rectal OR polypectom* OR proctectom* OR 
rectopex* OR rectom* OR colorectom* OR mesorectom* OR sphincter OR polyp*)  
5 (1 further) studies identified 
6.  Gallbladder, Liver and Spleen Surgery 
 
6.1. Robotic Cholecystectomy 
        Date of search: 12.09.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( Cholecystectomy OR gallbladder OR gall bladder ) [TREATMENT] 
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12 Studies identified  
 
WHO ICTRP (Basic Search Mode) 
robot* AND cholecystectomy     
13 (5 further) Studies identified 
 
EudraCT (Basic Search Mode) 
robot* AND (cholecystectom* OR gall bladder OR gallbladder) 
No studies identified 
6.2. Robotic Herniorrhaphy 
         Date of search: 14.09.2018 
 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( herniorrhaphy OR hernioplasty OR hernia repair ) [TREATMENT] 
13 Studies identified  
 
WHO ICTRP (Basic Search Mode) 
robot* AND hernia repair     13 Studies identified 
robot* AND herniorrhaphy NOT hysterectomy  13 Studies identified 
robot* AND hernioplasty    13 Studies identified 
 
 13 (0 further) studies identified 
 
EudraCT (Basic Search Mode) 
robot* AND (hernia* OR herniorrhaph* OR hernioplast*)  
No studies identified 
6.3. Robotic Hepatectomy 
        Date of search: 13.09.2018 
ClinicalTrials.gov (Expert Search Mode) 
( robotic OR robot ) AND ( hepatectomy OR liver OR hepatic ) [TREATMENT] 
10 Studies identified  
WHO ICTRP (Basic Search Mode) 
robot* AND hepatectomy *      3 Studies identified 
robot* AND hepatic      8 Studies identified 
robot* AND liver         7 Studies identified 
 
 18 (6 further) studies identified 
 
EudraCT (Basic Search Mode) 
Robot* AND (hepatectom* OR liver OR hepatic) 
3 (0 further) studies identified 
Search strategies for Guidelines  
Search date: 23.10.2018 
G-I-N Guideline Search 
Search term(s) entered: Robot*, Robotic 
1 Hit  
Trip-database (advanced search mode) 
Searchstring: (robot* OR robotic ) 
42 Hits (in category “Guidelines”) 
N.B.: The National Guidelines Clearinghouse (NGC) has ceased compiling/making accessible Guidelines on 16th July 
2018. Archived contents have been incorporated into the TRIP-Database 
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APPENDIX 2 : LIST OF ONGOING AND PLANNED STUDIES 
List of ongoing and planned studies 
Lobectomy/Segmentectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT02804893 Not date 
given 
(status 
unknown) 
Prospe
ctive 
rando
mized 
study, 
Paralle
l 
assign
ment 
 
300 VATS  RATS • Age older than 18 years old 
• Known or suspected lung 
cancers 
• Patients in clinical stage T1-T2, 
N0-N1 candidate to surgery 
lobectomy or anatomical 
segmentectomy 
• ASA-1-2 
Primary endpoints 
• Intraoperative complications: conversion rate, defined as 
procedures that start with minimally invasive access and are 
converted to open surgery due to different reasons (bleeding, 
anatomical reasons, oncological reasons, technical reasons, 
other) [ Time Frame: date of Surgery ] 
• Postoperative complications: surgical complications, higher or 
equal grade II assessed by Clavien-Dindo scale, within 90 
days [ Time Frame: within 90 days ] 
NCT03134534 January 2020 rando
mized 
study, 
Paralle
l 
assign
ment 
300 RATS 
lobectomy 
VATS 
lobectomy 
• surgical indication for 
lobectomy; 
• minimal invasive surgery;  
• ASA (American Society of 
Anesthesiologists) stage: I-III;  
• signed informed consent 
Primary endpoints 
• 3-year overall survival (OS) [ Time Frame: 3 year after surgery 
] OS at 3 year after surgery 
 
NCT02617186 March 2018 
(recruiting) 
RCT 186 Robotic 
thoracic 
surgery 
Video-
assisted 
thoracoscopic 
surgery 
• Age > 18 years 
• clinical stage I, II or IIIa non-
small cell lung cancer (NSCLC) 
• Candidates for minimally 
invasive pulmonary lobectomy, 
as determined by the operating 
surgeon. 
• Difference in HRQOL scores between the treatment groups, 
as measured by the EQ-5D-5L questionnaire at week 12 
weeks. [ Time Frame: Assessed at 12 weeks, presented 
average 1 year from end of study ] 
NCT01933828 June 2015 
(status 
unkown, no 
Rando
mized 
prospe
176 VATS 
lobectomy  
Robot-
open 
lobectomy 
• Non-small cell lung carcinoma, 
pathologically confirmed or 
strong suspicion based on 
Primary endpoints 
• Quality of life (EQ5D) [Time Frame: up to12 month ] Primary 
endpoints include Quality of life assessed by EQ5D for VATS 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
publication 
identified) 
ctive 
trial, 
Paralle
l 
Assign
ment 
assisted 
lobectomy 
imaging. 
• T1 or T2a (≤ 5 cm) on computer 
tomography (CT). 
• Primary aim is lobectomy. 
• Tumor not in close relation to 
the hilar structures 
(bronchus,vessels) based on 
CT. 
• Clinically staged N0 (no 
regional lymph node 
metastasis) or N1 (metastasis 
to ipsilateral, hilar, interlobar- 
and/or intrapulmonary lymph 
nodes), M0 (no distant 
metastasis) after clinical 
staging according to the current 
Dutch guideline (may 2011). 
versus open lobectomy in patients with early stage non small 
cell lung carcinoma. 
• Hospital length of stay [Time Frame: day of discharge from 
hospital after surgery (expected within 2 weeks). ] 
. 
Mediastinal Surgery 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
No relevant ongoing trials were identified  
Antireflux/Fundoplication 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
DRKS0001469
0 
Not date 
given 
(ROLAF 
Trial) 
RCT 40 Robotic 
fundoplication 
Conventional 
laparoscopic 
fundoplication 
• Age > 18 years 
• Male and female 
Primary endpoints 
• Quality Of Life in Reflux and Dyspepsia (QOLRAD) 
questionnaire [Time Frame: 10 years after initial surgery] 
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Heller Myotomy/Oesophageal Repair 
Study 
Identifier 
Estimated 
completio
n date 
Study 
type 
Number  
of 
patients 
Interventio
n 
Comparato
r 
Patient population Endpoints 
No relevant ongoing trials were identified 
Oesophagectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT02292914 November 
2017 
(Status 
unknown) 
Rando
mized 
prospe
ctive 
trial, 
Paralle
l 
Assign
ment 
1120 Robot-
assisted: 
esophagecto
my; 
gastrectomy; 
pancreatecto
my;rectal 
resection; 
radical 
cistectomy; 
prostatectomy
; Partial 
Nephrectomy; 
hysterectomy; 
Resection of 
malignant 
tumors of the 
mouth and 
orofaringolarin
ge; lung 
lobectomy 
Procedure: 
Conventional 
Surgery 
Thoracoscopi
c 
oesophagecto
my; Open 
rectal 
resection and 
rectal 
laparoscopy 
resection; 
Open radical 
cistectomy; 
Open 
prostatectomy
; Open Partial 
Nephrectomy; 
Laparoscopic 
hysterectomy; 
Laparoscopic 
lung 
lobectomy 
• Patients eligible for robot-
assisted surgery 
Primary endpoints 
• Postoperative Complications [ Time Frame: 30 days .] The 
postoperative complications will be measured by clavien-
dindo scale 
 
NCT03094351 December 
2024 
RCT 300 Robot-
assisted 
Thoraco-
laparoscopic 
Esophagecto
Conventional 
Thoraco-
laparoscopic 
oesophagecto
my 
• Histologically proven squamous 
cell carcinoma of the 
intrathoracic esophagus. 
• Surgical resectable (T1b-3, N0-
2, M0) 
Primary endpoints 
• Overall Survival Rate [ Time Frame: 5 years ] 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
my • Age ≥ 18 and ≤ 75 years 
• European Clinical Oncology 
Group performance status 0, 1 
or 2 
• Written informed consent 
ChiCTR-IIR-
17012851   
June 2020 RCT 272 Robot- 
assisted 
minimally 
invasive 
esophagecto
my (RAMIE) 
conventional 
open surgery 
(OE) 
• squamous cell carcinoma was 
diagnosed by gastroscopy or 
cytologic examination; 
• primary tumor in thoracic 
oesophageal cancer,  
• according to the inspection, 
confirmed the preoperative 
clinical stage cT3-4aN0-1M0 
(AJCC/UICC eighth) of the 
patients with oesophageal 
cancer  
• Aged 18 to 75 years, physical 
condition, ECOG score of 0 to 
1, expected survival time more 
than 12 months; 
• subjects without major organ 
dysfunction, blood, lung, liver, 
kidney function and heart 
function  
• informed consent 
Primary endpoints 
• 3-year overall survival 
 
ChiCTR-INR-
16009408   
December 
2019 
RCT 300 Robot-
assisted 
oesophagecto
my 
Conventional 
minimally 
invasive 
thoraco-
laparoscopic 
oesophagecto
my 
• Aged 20 to 80 years; 
• Karnofsky score above 80; 
• Histologically proven squamous 
cell carcinoma of the 
intrathoracic oesophagus; 
• Primary tumor located in the 
thoracic oesophagus.  
• Surgically resectable (T1-3, N0-
Primary endpoints 
• 3-year overall survival 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
3, M0, excluding T4) based on 
the 7th UICC-TNM 
classification.  
• No prior treatment of 
chemotherapy or radiation 
therapy against any other 
malignancies.  
• No prior lateral thoracotomy (or 
thoracoscopic surgery) on the 
right side or no prior lobectomy 
or more extended surgery on 
the left side has been 
performed; 
• Sufficient organ functions 
• R0 oesophagectomy is 
expected; 
• Written informed consent. 
ChiCTR-TRC-
13003318 
2015-07-16   RCT 200 three-field 
robot-assisted 
esophagecto
my 
three-field 
thoracic-
laparoscopic 
esophagecto
my 
• Patients with esophageal 
cancer (Age from 18 to 75); 
• No chemotherapy or 
radiotherapy was performed 
before operation; 
• Understood the experiment, 
informed consent. 
• Pulmonary infection 
• Anastomotic leak 
• Anastomotic stricture 
• Chylothora 
ChiCTR-TRC-
13003312 
2015-07-16   RCT 200 three-field 
robot-assisted 
esophagecto
my 
three-field 
thoracic-
laparoscopic 
esophagecto
my 
• Patients with oesophageal 
cancer (Age from 18 to 75); 
• No chemotherapy or 
radiotherapy was performed 
before operation; 
• Understood the experiment, 
informed consent. 
• Pulmonary infection 
• Anastomotic leak 
• Anastomotic stricture 
• Chylothora 
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Gastrectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT03313700 August 2022 RCT 300 Robot-
assisted 
Distal 
Gastrectomy 
Laparoscopic 
Assisted 
Distal 
Gastrectomy 
• Age from over 18 to under 75 
years 
• Primary gastric 
adenocarcinoma  
• cT1-4a(clinical stage tumor), N-
/+, M0  
• expected to perform distal 
gastrectomy  
• Performance status of 0 or 1 on 
Eastern Cooperative Oncology 
Group scale 
• American Society of 
Anesthesiology class I to III 
• Written informed consent 
Primary endpints 
• 3-year disease free survival rate [ Time Frame: 36 months ] 
the rate of 3-year disease free survival 
 
NCT03524300 November 
2022 
RCT 220 Robotic 
Assisted Total 
Gastrectomy 
Laparoscopic 
Assisted Total 
Gastrectomy 
• Age from over 18 to under 75 
years 
• Primary gastric 
adenocarcinoma  
• The tumor is on the upper or 
middle third stomach and 
expected to perform total 
gastrectomy  
• Performance status of 0 or 1 on 
Eastern Cooperative Oncology 
Group scale 
• American Society of 
Anesthesiology class I to III 
• Written informed consent 
Primary endpoints 
• 3-year disease free survival rate [ Time Frame: 36 months ] 
the rate of 3-year disease free survival 
 
NCT02413476 May 2018 
(Status 
Non-
rando
120 Robot-
assisted 
Laparoscopic-
assisted 
• Pathologically proven gastric 
cancer (early or advanced) 
Primary endpoints 
• Five-year disease free survival rate [ Time Frame: Up to 5 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
unknown) mized, 
prospe
ctive 
study, 
Paralle
l 
Assign
ment 
gastrectomy Gastrectomy • Age: >18 and <80 
• cT1-4a(surgically resectable 
tumor), N0-3,M0  
• No obvious surgical 
contraindications 
• American Society of 
Anesthesiology score class I, II, 
or III 
• Written informed consent. 
years post-operative ] 
 
NCT03273920 September 
2022 
RCT 1110 Robotic 
gastrectomy 
Laparoscopic 
gastrectomy 
• Pathologically proven gastric 
adenocarcinoma. 
• Tumor located in the lower third 
of the stomach, and is possible 
to be curatively resected by 
subtotal gastrectomy. 
• Preoperative stage of cT2-
4aN0-3M0  
• Eastern Cooperative Oncology 
Group performance status of 0 
or 1 
• American Society of 
Anesthesiology  score of class I 
to III 
• informed consent  
Primary endpoints 
• 3-year relapse-free survival [ Time Frame: 3 years ] Relapse-
free survival is defined as days from surgery to recurrence or 
death from any cause, and it is censored at the latest day 
when the patient is alive without any evidence of recurrence 
 
NCT03500471 December 
2019 
Non-
rando
mised, 
prospe
ctive 
study 
150 Robot-
assisted Total 
Gastrectomy 
Laparoscopic-
assisted Total 
Gastrectomy 
• Pathologically proven gastric 
adenocarcinoma; 
• Age: >18 and <80 
• Tumor located in the upper 
third of the stomach or 
esophagogastric junction or 
other location, and is possible 
to be curatively resected by 
Primary endpoints 
• Overall postoperative morbidity rates [ Time Frame: 30 days ]. 
Refers to the incidence of early postoperative complications. 
The early postoperative complication are defined as the event 
observed within 30 days after surgery. 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
total gastrectomy; 
• Preoperative stage of cT2-
4aN0-3M0; 
• American Society of 
Anesthesiology  score of class I 
to III; 
• Eastern Cooperative Oncology 
Group  performance status of 0 
or 1; 
• informed consent  
NCT02751086 December 
2024 
Non-
rando
mised, 
prospe
ctive 
cohort 
study 
5000 Robot-
assisted 
surgery 
 
Laparoscopic 
surgery  
 
Open surgery 
- • Histologically proven gastric 
cancer 
• Preoperative staging work-up 
performed by upper endoscopy 
and/or endoscopic ultrasound, 
and CT scan and in 
accordance to international 
guidelines 
• Early Gastric Cancer 
• Advanced Gastric Cancer 
• Patients treated with curative 
intent in accordance to 
international guidelines 
Primary endpoints 
• Rate of patients with intraoperative adverse events [ Time 
Frame: During surgery ] events other than the normal course 
of the surgery  
• Mean of retrieved lymph nodes [ Time Frame: Within 30 days 
after surgery ] Count of retrieved lymph nodes at the 
histopathological examination of the surgical specimen  
• Rate of patients alive [ Time Frame: 1 year after surgery ] 
subjects alive at the planned endpoint  
• Rate of patients alive [ Time Frame: 2 year after surgery ] 
subjects alive at the planned endpoint  
• Rate of patients alive [ Time Frame: 3 year after surgery ] 
subjects alive at the planned endpoint  
• Rate of patients alive [ Time Frame: 4 year after surgery ] 
subjects alive at the planned endpoint  
• Rate of patients alive [ Time Frame: 5 year after surgery ] 
subjects alive at the planned endpoint 
 
R000013738 No date 
given 
(no longer 
recruiting) 
Non-
rando
mised, 
prospe
ctive 
650 Robotic 
gastrectomy 
 
Conventional 
laparoscopic 
gastrectomy 
• Age > 18 years 
• Male and female 
• Primary gastric cancer for 
Primary endpoints 
• Morbidity 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
study, 
Paralle
l 
Assign
ment 
 which surgical treatment was 
applicable (cStageI-III) 
R000011407 No date 
given 
(no longer 
recruiting) 
Non-
rando
mised, 
uncont
rolled 
phase 
II study 
100 robot assisted 
gastrectomy 
- • Age 20-80 years 
• Male and female 
• adenocarcinoma 
• Diagnosed as Stage IA or IB 
gastric cancer  
• Curative resection is expected 
by distal gastrectomy or total 
gastrectomy 
• Eastern clinical oncology group 
performance status is 0 or 1 
• BMI < 30 
• no prior upper abdominal 
surgery or intestinal resection 
other than appendectomy 
• No previous chemotherapy or 
radiation including those for 
other cancers 
Primary endpoints 
• The incidence of post-operative intra-abdominal infectious 
complications (anastomotic leakage, pancreas related 
infection, and intra-abdominal abscess)  
 
R000019689 No date 
given 
(open public 
recruiting) 
Non-
rando
mised, 
uncont
rolled 
study 
120 Robot-
assisted 
laparoscopic 
gastrectomy 
-  • Age > 20 years 
• Male and female 
• Histologically confirmed gastric 
cancer; clinically diagnosed T1 
or T2N0 
• Enough main organ functions 
to perform operation 
• informed consent obtained from 
the patient 
Primary endpoints 
• The incidence of postoperative complication during 30 days 
after surgery 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
R000017904 No date 
given 
(open public 
recruiting) 
historic
ally 
controll
ed 
prospe
ctive 
cohort 
study 
330 Robotic 
gastrectomy 
- • Operable patients under 
general anesthesia 
• Histologically diagnosed gastric 
adenocarcionoma 
• cStage I or II disease curably 
treated with total, distal, or 
proximal gastrectomy  
• Not indicated for endoscopic 
resection 
• Age over 18 
• Informed consent is obtained 
Primary endpoints 
• Postoperative complications greater than Grade III according 
to Clavien-Dindo classification 
 
R000036007 No date 
given 
(preinitiation) 
Rando
mised 
phase 
III 
study, 
Paralle
l 
Assign
ment 
240 Robotic 
gastrectomy 
Conventional 
laparoscopic 
gastrectomy 
• Age 20-80 years 
• Histologically proven gastric 
carcinoma, resectable gastric 
cancer, excluding esophageal 
invasion  
• Eastern clinical oncology group 
performance status is 0 or 1 
• BMI < 35 
• No history of gastrointestinal 
surgery 
• No history of chemotherapy or 
radiotherapy 
• Normal function of the major 
organs 
• Proven written informed 
consent 
Primary endpoints 
• Incidence of intra-abdominal infectious complications 
(pancreatic fistula, intra-abdominal abscess, and anastomotic 
leakage) with more than Clavien-Dindo grade 2 
 
R000024081 No date 
given 
(open public 
recruiting) 
historic
ally 
controll
ed 
non-
110 Robotic 
gastrectomy 
- • Age > 20 years 
• Male and female 
• Pathologically confirmed gastric 
Primary endpoints 
• Intraoperative complication 
• Postoperative complication (within 30 days) 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
rando
mised 
study 
cancer 
• Amenable to curative resection 
• ECOG Performance Status 0/1 
• Written informed consent 
• Operative mortality 
 
ChiCTR-TRC-
13003301 
2015-07-01 RCT 200 robot surgery laparoscopic 
surgery 
• Patients with esophagogastric 
junctional adenocarcinoma 
• Anastomotic leak 
• Pulmonary infection 
• Anastomotic stricture 
• Wound infection 
 
ChiCTR-INR-
17010404 
2017-12-31 RCT 100 da Vinci 
robotic 
surgery group 
Laparoscopic 
surgery group 
• Patients with gastric cancer • Recent clinical outcome measures  
• Markers of inflammat  
• immunologic function 
 
Bariatric Surgery 
Study 
Identifier 
Estimated 
completio
n date 
Study 
type 
Number  
of 
patients 
Interventio
n 
Comparato
r 
Patient population Endpoints 
No relevant ongoing trials were identified 
Colectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT02642978 September 
2019 
RCT 100 robot-
assisted, 
simultaneous 
Traditional 
open 
simultaneous 
• Age ≥ 18 and ≤ 75 years; 
• Primary tumor has undergone 
Primary endpoints 
• Disease-free survival(DFS) [ Time Frame: 3 years disease-
Robot-assisted surgery for thoracic and visceral surgery 
Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 183 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
radical 
resection of 
both 
colorectal 
cancer and 
liver 
metastasis 
(RSRCLM) 
radical 
resection of 
both 
colorectal 
cancer and 
liver 
metastasis 
histologically confirmed colon 
adenocarcinoma 
• Together with clinical or 
radiological evidence of Stage 
II (T3-4, N0, M0) or Stage III 
(T1-4, N1-2, M0) disease  
• Performance status 0~1 
• Adequate haematological, 
hepatic, renal function:  
• informed consent  
• liver resectability  
free survival ] DFS was defined as from the date of 
randomization to the date of tumor recurrence or death from 
any cause 
 
ChiCTR18000
17146   
June 2026 RCT 746 Robot-
assisted 
surgery 
Laparoscopic 
surgery 
• Aged 18 to 80 years; 
• Pathologic biopsy confirmed 
the right-sided colon 
adenocarcinoma; 
• Preoperative clinical stage: 
locally advanced right-sided 
colon adenocarcinoma（cT2-
4,N0-2,M0AJCC-8); 
• R0 results are expected from 
right hemicolectomy and 
regional lymph node dissection; 
• Preoperative ECOG physical 
state score: 0/1; 
• Preoperative ASA score: I-III; 
• informed consent. 
Primary endpoints 
• 3-year disease-free survival 
 
NCT03650517 December 
2021 
Prospe
ctive, 
parallel 
cohort 
study 
1200 Robot-
assisted Right 
Colectomy 
with ICA and 
with ECA 
 
-  Primary endpoints 
• Surgical wound infection [ Time Frame: 30 days ] (CDC 
definition) 
• Clavien Dindo Complication [ Time Frame: 30 days ] 
Complications according to Clavien Dindo Classification. 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
Laparoscopic 
Right 
Colectomy 
with ICA and 
with ECA 
 
 
 
Small Bowel Resection 
No relevant 
ongoing 
trials were 
identified  
Estimated 
completio
n date 
Study 
type 
Number  
of 
patients 
Interventio
n 
Comparato
r 
Patient population Endpoints 
No relevant ongoing trials were identified  
Rectal Resection 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT01130233 December 
2014 
(status 
unknown) 
RCT 98 robotic 
assisted rectal 
resection 
laparoscopic 
rectal 
resection 
• Histologically proven new case 
of rectal cancer with the lower 
border within 15 cm from anal 
verge 
• Age >18 years 
• Informed consent obtained 
• American Society of 
Anesthesiologist class 1-3 
• No contraindication to 
laparoscopic surgery 
• Acceptable operating risk 
Primary endpoints 
• Bladder function [ Time Frame: one year ] Urodynamic 
Questionnaire 
•  
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT02673177 May 2019 Rando
mised, 
prospe
ctive 
study 
225 Robot-
assisted total 
mesorectal 
excision 
Laparoscopic 
total 
mesorectal 
excision 
• Patients who agree to both 
procedures  
• Match the diagnostic criteria; 
• Aged 18-70 years old; 
• Preoperative TNM staging (CT, 
laparoscopic exploration): cT1-
3N0-3M0 (excluding M1, T4); 
• Preoperative ASA 3 scores; 
• no history of malignancy 
• no prior radiotherapy, 
chemotherapy or 
immunotherapy; 
• normal sexual function 
Primary endpoint 
• Incidence of sexual and urinary dysfunction [ Time Frame: 
One years after surgery ] 
 
NCT01736072 June 2018 
(status 
unknown) 
RCT 520 Robotic-
assisted 
Resection of 
Rectal Cancer 
Laparoscopic 
Resection of 
Rectal Cancer 
• Aged ≥ 18 years 
• written informed consent 
• Diagnosis of rectal cancer 
amenable to curative surgery  
• Rectal cancer suitable for 
resection by either standard or 
robot-assisted laparoscopic 
procedure 
• Fit for robot-assisted or 
standard laparoscopic rectal 
resection 
• American Society of 
Anesthesiologists (ASA) 
physical status ≤ 3 
• Capable of completing required 
questionnaires at time of 
consent  
Primary endpoints 
• End of Conversion to Open Surgery [ Time Frame: 1 day ] 
The primary end point is the rate of conversion to open 
surgery as an indicator of surgical technical difficulty. 
Conversion is defined as the use of a laparotomy wound for 
any part of the mesorectal dissection. The use of a limited 
laparotomy wound to facilitate a low stapled anastomosis 
and/or specimen extraction is permissible and not defined as 
an open conversion. 
 
NCT01591798 December rando 146 Robot- Laparoscopic • mid or low rectal cancer (within Primary endpoints 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
2017 
(status 
unknown) 
mised 
phase 
II trial 
assisted rectal 
resection 
assisted rectal 
resection 
9cm from anal verge) 
• pathologically proven as 
adenocarcinoma 
• written informed consent 
• no severe functional disability 
in lung and heart 
• Quality of mesorectal excision [ Time Frame: 7days after 
surgery (Pathologic report) ] Evaluating the quality of 
mesorectal excision in rectal specimen  
NCT01346436 May 2020 RCT 50 Roboti-
assisted 
approach 
Laparoscopic 
approach 
• Aged ≥ 18 years 
• women 
• proven pelvic floor dysfunction 
• informed consent 
Primary endpoints 
• Perioperative outcomes [ Time Frame: up to 30 days ] 
Including: blood loss, operative time, conversion rate, quality 
of dissection, pain, complications, hospital stay. 
 
NCT03597126 September 
2020 
RCT 100 Robot-
assisted 
Intersphincteri
c Resection 
Laparoscopic-
assisted 
Intersphincteri
c Resection 
• 18 years to 80 years 
• Match diagnostic criteria; 
• tumor located 3 cm from anal 
verge 
• Clinically diagnosed cT1-3N0-2 
M0 lesions 
• Tumor size of 4 cm or less 
• ASA 1-3 scores; 
• ECOG score is 0-1; 
• Adequate preoperative 
sphincter function 
Primary endpoints 
• Change in urinary function [ Time Frame: 6 months ] The days 
of indwelling catheter after operation The overall efficiency of 
urination function  
• Change in International Index of Erectile Function [IIEF] score 
[ Time Frame: 18 months ]  
• Change in FIQL scores [ Time Frame: 18 months ] Alterations 
in Fecal Incontinence Quality of Life Instrument (FIQL) scores 
from baseline up to 18 months postoperatively  
• Change in Female Sexual Function Index [FSFI] [ Time 
Frame: 18 months ]  
NCT02642978 September 
2019 
RCT 100 robot-
assisted, 
simultaneous 
radical 
resection of 
both 
colorectal 
cancer and 
liver 
metastasis 
Traditional 
open 
simultaneous 
radical 
resection of 
both 
colorectal 
cancer and 
liver 
• Age ≥ 18 and ≤ 75 years; 
• Primary tumor has undergone 
histologically confirmed colon 
adenocarcinoma;  
• Together with clinical or 
radiological evidence of Stage 
II (T3-4, N0, M0) or Stage III 
(T1-4, N1-2, M0) disease  
Primary endpoints 
• Disease-free survival(DFS) [ Time Frame: 3 years disease-
free survival ] DFS was defined as from the date of 
randomization to the date of tumor recurrence or death from 
any cause 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
(RSRCLM) metastasis • Performance status 0~1 
• Adequate haematological, 
hepatic and renal function:  
• Written informed consent  
• liver resectability  
NCT01985698 October 2019 RCT 402 Robot-
assisted 
resection 
Laparoscopic 
resection 
 
Open Surgery 
• Age 18-75 years 
• Histologically proven rectal 
adenocarcinoma 
• Inferior edge of the tumor 
located within 5 cm from the 
anal verge  
• No evidence of distant 
metastases  
• Tumor assessed as cT1-T3 or 
ycT1-T3  
• No other malignancies  
• Suitable for both robot-
assisted, laparoscopic and 
open surgery 
• American Society of 
Anesthesiologists (ASA) class I 
- III 
• No other preoperative 
treatment except neoadjuvant 
chemoradiotherapy 
• Informed consent 
Primary endpoints 
• operative complications [ Time Frame: 30 days post 
operatively ] intra, and postoperative complications related to 
operation 
• assessed using a self-rating scale "International Index of 
Erectile Function" (IIEF-5).  
• self reported sexual function for female patients [ Time Frame: 
at postoperative 3, 6 and 1 2 months ] This section is 
assessed using a self-rating scale "Female Sexual Function 
Index" (FSFI). 
NCT03209076 December 
2020 
Prospe
ctive, 
rando
mised 
study 
120 Robot-
assisted low 
anterior 
resection 
Laparoscopic 
low anterior 
resection 
• Age 18-70 years 
• Mid or low Rectal 
Adenocarcinoma 
• Performance Status (ECOG) 0 
Primary endpoints 
• Urinary dysfunction [ Time Frame: Change from Before 
surgery to 3 months after surgery ] Urodynamic test 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
- 2 
NCT03574493 June 2022 Prospe
ctive 
cohort 
study 
1300 Open 
laparotomy 
 
Laparoscopic 
surgery 
 
Robot-
assisted 
surgery 
 
Transanal 
surgery 
through the 
anus 
- • Age ≥ 18 years old 
• Rectal adenocarcinoma  
• High risk operative patients  
• Patients with adequate 
performance status  
• informed consent  
Primary endpoints 
• Efficacy of surgical method (success determined by 
composite of Oncologic, morbidity and functional outcomes) [ 
Time Frame: up to 4 years ] completeness of resection, TME 
grade III, The absence of clavien dindo grade III-IV 
complications within 30 days post op 
NCT02817126 October 2023 RCT 680 Robot-
assisted 
resection 
Laparoscopic 
resection 
• Age 18-80 years 
• histologically proven rectal 
adenocarcinoma 
• inferior edge of the tumor 
located within 12 cm from the 
dentate line as determined by 
rigid rectoscopy 
• no evidence of distant 
metastases 
• tumor assessed as cT1-T3  
• no other malignancies  
• suitable for both robot-assisted 
and laparoscopic surgery 
• informed consent 
Primary endpoints 
• Disease-free survival [ Time Frame: 3 years ] 
 
NCT01423214 December 
2018 
Prospe
ctive, 
540 robot-assisted 
surgery 
Laparoscopic 
surgery 
• Eligibility rule of enrollment 
• Rectal adenocarcinoma that 
Primary endpoints 
• Surgical quality based on pathological examination [ Time 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
rando
mised 
study, 
Paralle
l 
assign
ment 
were 10 cm or less from the 
anal verge 
• 18 -80 years old 
• Clinically diagnosed cT3N0-2 
disease 
• adequate hepatic, renal, and 
bone marrow function 
Frame: up to 4 weeks after operation ] A comparison of 
completeness of total mesorectal excision 
 
ISRCTN14574
075 
February 
2019 
RCT 70 Robot-
assisted rectal 
surgery 
laparoscopic 
rectal surgery 
• Patients with a diagnosis of 
rectal cancer  
• Male aged 18 years and over 
• informed consent 
• Fit enough to undergo 
minimally invasive surgery 
(ASA≤3) 
• Deemed suitable for minimally 
invasive surgery by local MDT 
• Elective case 
• Sexually active  
Primary endpoints 
• Urological function is measured using the International 
Prostatic Symptoms Score (IPSS) pre-operatively and 3, 6 
and 12 months after surgery 
• Sexual function is measured using the International Index of 
Erectile Function (IIEF) pre-operatively and 3, 6 and 12 
months after surgery 
• Urodynamics (urine flow rate and post micturition residual 
urine volume) are assessed by a uroflow meter and a bladder 
scanner pre-operatively and 3, 6 and 12 months after surgery 
ChiCTR-ICR-
15007040   
September 
2020 
RCT 215 Robot-
assisted 
radical 
resection for 
rectal cancer 
Laparoscopic-
assisted 
radical 
resection for 
rectal cancer 
• Patients who agree to both 
surgical procedures  
• Match diagnostic criteria; 
• Aged 18-70 years old; 
• Preoperative TNM staging (CT, 
laparoscopic exploration): cT1-
3N0-3M0 (excluding M1, T4); 
• Preoperative ASA 3 scores; 
• no history of malignancy 
• no definitive treatment, such as 
radiotherapy, chemotherapy 
Primary endpoints 
• The overall efficiency of urination function 
• The overall efficiency of sexual function 
• Sphincter-preserving rate of low rectal cancer 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
• normal sexual function 
DRKS0001132
8 
No date 
given 
(recruiting) 
Non-
rando
mised 
controll
ed 
study, 
Paralle
l 
Assign
ment 
100 Robot-
assisted rectal 
resection 
Laparoscopic-
assisted rectal 
resection 
 
Open rectal 
resection 
• Age 18-80 years 
• Patients with rectal cancer  
• informed consent 
• BMI<=30 kg/m2 
• No medical contraindication 
that exclude laparoscopy  
• Preoperatively normal bowel, 
bladder and sexual function  
Primary endpoints 
• Functional outcome 6 and 12 months after surgery. Stool, 
urinary and sexual function as assessed by Wexner-score, 
EORTC QLQ-CR29 and EORTC QLQ-C30 
 
NCT01196000 
 
July 2013 RCT 0 (Study 
withdrawn
) 
Standard 
conventional 
laparoscopic 
resection 
Robot-
assisted 
laparoscopic 
resection 
• •Able to provide written 
informed consent 
• •Diagnosis of rectal cancer 
amenable to curative surgery  
• ASA =< 3 
• •Capable of completing 
required questionnaires at time 
of consent 
• Rate of conversion to open surgery as an indicator of surgical 
technical difficulty 
 
Cholecystectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT02485392 July 2017 
(status 
unknown) 
RCT 60 Single-Site 
robot-assisted 
cholecystecto
my 
Single-
incision 
laparoscopic 
cholecystecto
my 
• Patient compliance and 
geographic proximity  
• Written informed consent  
• Women who are not 
breastfeeding and are not 
pregnant 
• Age ≥18 years 
Primary endpoints 
• Surgeon's comfort as measured by LED and SMEQ 
questionnaires [ Time Frame: 1 Day ] 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
• Symptomatic cholecystolithiasis 
• Chronic cholecystitis 
• Benign gallbladder polyps 
NCT03160157 December 
2020 
Prospe
ctive, 
rando
mised 
cohort 
study 
200 Robotic 
Cholecystecto
my 
Laparoscopic 
Cholecystecto
my 
• 18 years or older 
• Any of the pre-operative 
diagnoses including chronic 
cholecystitis, acute 
cholecystitis, benign neoplastic 
disease of the gallbladder or 
pre-cancerous conditions of the 
gallbladder (polyps, 
adenomyomatosis), 
symptomatic cholelithiasis, 
porcelain gallbladder and biliary 
dyskinesia. 
Primary endpoints 
• Determine which minimally invasive (small incisions) surgical 
approach is associated with the best outcomes when 
performing the removal of the gallbladder (cholecystectomy): 
laparoscopic or robotic? [ Time Frame: 2 years ] Outcome: 
open conversion  
• Determine which minimally invasive (small incisions) surgical 
approach is associated with the best outcomes when 
performing the removal of the gallbladder (cholecystectomy): 
laparoscopic or robotic? [ Time Frame: 2 years ] Outcome: 
biliary injuries  
• Determine which minimally invasive (small incisions) surgical 
approach is associated with the best outcomes when 
performing the removal of the gallbladder (cholecystectomy): 
laparoscopic or robotic? [ Time Frame: 2 years ] Outcome: 
biliary anomalies  
• Determine which minimally invasive (small incisions) surgical 
approach is associated with the best outcomes when 
performing the removal of the gallbladder (cholecystectomy): 
laparoscopic or robotic? [ Time Frame: 2 years ] Outcome: 
blood loss  
Liver resection/Hepatectomy 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT03297099 June 2020 Non-
rando
mised, 
prospe
ctive 
60 Robot-
assisted 
Laparoscopic 
operation 
Open surgery • Age 18-70 years 
• Patients with intrahepatic bile 
duct stones or hepatolithiasis. 
Primary endpoints 
• initial stone clearance rate [ Time Frame: during the operation 
] rate of the removal of the stones from intrahepatic bile duct 
identified by ultrasonic or computed tomography or magnetic 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
cohort 
study 
• Liver function > Child-pugh 
level B, no severe biliary 
cirrhosis 
• Age: Between 18 to 70 years 
• Combined with severe liver 
atrophy hypertrophy syndrome, 
hepatic portal transposition or 
hilar biliary fibrosis/stenosis 
• Patients with good general 
condition,  
• Other organ lesions and 
previous biliary tract operation 
is not the absolute exclusion 
criteria 
• Written informed consent 
resonance 
 
ChiCTR-IOR-
17011298   
December 
2020 
RCT 20 Robot-
assisted living 
donor 
hepatectomy 
laparoscopic 
living donor 
hepatectomy 
• healthy people without 
infectious disease,tumor and 
cardiopulmonary disorders; 
• Age over 18 years and under 
55 years; 
• No history of upper abdominal 
surgery. 
• Normal liver function, normal 
coagulation function,no mental 
disease; 
• Voluntary donation of liver and 
in accordance with medical and 
ethics criteria; 
• Three generations lineal 
consanguinity   
Primary endpoints 
• Intraoperative blood loss 
• Operation time 
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Hernia Repair 
Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
NCT03283982 September 
2020 
Registr
y-
Based, 
prospe
ctive, 
RCT 
74 Robotic 
Ventral Hernia 
Repair with 
IPOM 
Laparoscopic 
Ventral Hernia 
Repair with 
IPOM 
• Adult patients (>18 years old) 
• Primary or Incisional Ventral 
Hernia 
• informed consent 
• Considered eligible for 
minimally invasive ventral 
hernia repair 
• Willing to undergo mesh-based 
repair 
• Fascial closure is presumed to 
be achieved 
Primary endpoints 
• Postoperative Pain Scores [ Time Frame: Pain scores will be 
assessed on baseline, on postoperative days 1,7 and 30 and 
365. ] Pain scores will be assessed using the Numeric Pain 
Rating Scale (NRS-11) 
NCT03007758 December 
2019 
RCT 100 Robot-
assisted 
ventral hernia 
repair 
open ventral 
hernia repair 
• Age >18 years 
• Ventral or incisional hernia 
measuring ≥ 7 cm and ≤ 15 cm. 
• At least one of the following risk 
factors: Body Mass Index > 30, 
Chronic Obstructive Pulmonary 
Disease, Diabetes Mellitus, 
current smoker (within 1 month) 
Primary endpoints 
• Composite outcome of diagnosis of surgical site occurrence or 
infection, hospital readmission, or hernia recurrence [ Time 
Frame: Through study completion, an average of 2 years ] A 
composite outcome of events which are clinically significant 
including but not limited to seroma requiring procedural 
intervention, skin dehiscence, cellulitis, hematoma, skin 
necrosis, and surgical site infections which may require 
interventions such as wound care or antibiotic therapy. 
 
NCT02816658 May 2019 RCT 100 laparoscopic 
inguinal 
hernia surgery 
repair 
Robot-
assisted 
inguinal 
hernia repair 
• 21 years or older 
• No prior open abdominal 
surgery at or below the 
umbilicus 
• Primary or recurrent unilateral 
inguinal hernia repair 
• No previous preperitoneal 
mesh placement 
• BMI less than or equal to 
Primary endpoints 
• Pain Score [ Time Frame: 2 Years ] Differences in 
postoperative pain between those patients who undergo 
robotic inguinal hernia repair versus laparoscopic inguinal 
hernia repair. 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
40kg/m2 
NCT03490266 April 2023 RCT 120 Robot-
assisted 
Repair 
Laparoscopic 
Repair 
• 18 years and older 
• All patients undergoing elective 
ventral hernia repair deemed 
appropriate for minimally 
invasive repair. 
Primary endpoints 
• Total number of days in the hospital [ Time Frame: 90 days 
post-operative ] Total number of days spent in the hospital.  
NCT02715622 May 2021 Prospe
ctive 
cohort 
study 
900 Open hernia 
repair 
 
Laparoscopic 
Hernia Repair 
 
Robotic 
Hernia Repair 
- • Age 18 years and older 
• All patients undergoing either 
an open, laparoscopic or robot-
assisted 
• Incisional or Inguinal Hernia 
repair procedure 
• Non-Emergent Incisional or 
Inguinal Hernia Repair cases 
Primary endpoints 
• Number of complications observed intraoperatively through 30 
days [ Time Frame: 30 days ] Number of intraoperative and 
short-term complications related to hernia repair.  
• Number of patient reported complications post 30-days 
through 3 years post procedure [ Time Frame: 30 days post-
procedure to 3 years post-procedure ] Number of long-term 
complications related to hernia repair directly reported by 
patients 
NCT03133533
Note: Principal 
Investigator on 
an extended 
leave of 
absence 
June 2023 RCT 0 (Study 
withdrawn
) 
Surgical 
inguinal 
hernia repair 
using 
laparoscopic 
approach 
Surgical 
inguinal 
hernia repair 
using robot-
assisted 
approach 
 
laparoscopic 
laparoscopic 
inguinal 
hernia repair 
robot-assisted 
robot-assisted 
inguinal 
hernia repair 
• Surgeon determined need for 
inguinal hernia repair 
• Age 18 Years to 99 Years 
Primary endpoints 
• Operative time 
 
NCT03133715
Note: Study 
not approved 
by Institutional 
Review Board 
June 2023 RCT 0 robot-assisted 
ventral hernia 
laparoscopic 
ventral hernia 
repair 
• Surgeon determined need for 
ventral hernia repair 
• Age 18 Years to 99 Years 
Primary endpoints 
• Operative time 
 
NCT00908193 
Note: No 
June 2012 RCT 70 robot-assisted 
coelioscopy 
conventional 
coelioscopy 
• over 18 years • Evaluate the reduction in morphine consumption 
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Study 
Identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of 
patients 
Intervention Comparator Patient population Endpoints 
Publication 
identified 
although study 
completed 
• with indication of hernia repair 
• a collar with a diameter of less 
than 10cm 
• no antecedent of hernia 
treatment with poses plate 
• agreeing coelioscopy 
• agreeing to participate the 
clinical study, having sign an 
informed consent 
• agreeing a regular monitor 
• Pain patient 
• Quality of life (questionary SF-36) 
• Length of stay in hospital, percentage return home to 24 hours 
of surgery 
• Morbidity 
• Resumption of work 
 
 
Abbreviations: VATS =Video-assisted thoracoscopic surgery;RATS=Robot-assisted thoracoscopic surgery;ASA =American Society of Anaesthesiologists; EORTC QOL-30 =European Organisation 
for Research and Treatment of Cancer Quality of Life Group;OS= overall survival; LOS =length of stay;QOL= quality of life;DFS =disease free survival;NSCLC =non-small cell lung cancer;HRQOL= 
health-related quality of life;QOLRAD =Quality Of Life in Reflux and Dyspepsia;GSRS =Gastrointestinal Symptom Rating Scale;QLQ-C30 =Quality-of-Life-Questionnaire;CTCAE v4.0= Common 
Terminology Criteria for Adverse Events;FISI =Fecal Incontinence Severity Index;I-PSS =International Prostatic Symptom Score;IIEF =International Index of Erectile Function;FSFI= Female Sexual 
Function Index;MSKCC =Memorial Sloan Kettering Cancer Centre Bowel Function Instrument;ECOG =Eastern Cooperative Oncology Group;NCCN =National Comprehensive Cancer Network;ICA 
=intracorporeal anastomosis;ECA =extracorporeal anastomosis;VAS= Visual analogue scale;SSI =surgical site infection;SSO =surgical site occurrence;HerQLes =Hernia-Related Quality-of-Life 
Survey to Assess Abdominal Wall Function 
Sources: ClinicalTrials.gov; WHO ICTRP; EU Clinical Trail (EudraCT) Register 
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APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL AND LEGAL ASPECTS 
1 Ethical  
1.1 Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any new ethical issues? 
Potentially, yes 
This has been discussed in the literature. Surgical robotics present challenges in the realm of law and 
ethics [70] 
  
1.2 Does comparing the new technology to the defined, existing comparators point to 
any differences that may be ethically relevant? 
No 
If answered with ‘yes’, please provide a short statement explaining why.  
 
2 Organisational  
2.1 Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) require organisational changes? 
Yes 
If answered with ‘yes’, please provide a short statement explaining why.  
 
Introduction of robot-assisted surgery requires the device and adequate training of staff. If a hospital 
plans to purchase a robot, an adequate infrastructure is also required (e.g. room/space for robots). 
 
2.2 Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be organisationally relevant? 
Yes 
If answered with ‘yes’, please provide a short statement explaining why.  
 
Some infrastructural changes may be needed to accommodate the equipment in the operating room. 
3 Social  
3.1 Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any new social issues? 
No 
If answered with ‘yes’, please provide a short statement explaining why.  
  
3.2 Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be socially relevant? 
No 
If answered with ‘yes', please provide a short statement explaining why.  
  
4 Legal  
4.1 Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any legal issues? 
Yes 
If answered with ‘yes’, please provide a short statement explaining why.  
 
In case of any malfunction of the robotic system the question of liability could arise. 
 
4.2 Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be legally relevant? 
No 
If answered with ‘yes’, please provide a short statement explaining why. Note: The assessment should 
not address patent-related issues. 
 
